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Abstract
The natural history of Chlamydia trachomatis infection in
women: a multi-parameter evidence synthesis
Malcolm J Price,1 AE Ades,2* Kate Soldan,3 Nicky J Welton,2
John Macleod,2 Ian Simms,3 Daniela DeAngelis,3,4
Katherine ME Turner2 and Paddy J Horner2,5
1Institute of Applied Health Research, University of Birmingham, Birmingham, UK
2School of Social and Community Medicine, University of Bristol, Bristol, UK
3Public Health England (formerly Health Protection Agency), Colindale, London, UK
4Medical Research Council Biostatistics Unit, Cambridge, UK
5Bristol Sexual Health Centre, University Hospital Bristol NHS Foundation Trust, Bristol, UK
*Corresponding author T.Ades@bristol.ac.uk
Background and objectives: The evidence base supporting the National Chlamydia Screening
Programme, initiated in 2003, has been questioned repeatedly, with little consensus on modelling
assumptions, parameter values or evidence sources to be used in cost-effectiveness analyses. The purpose
of this project was to assemble all available evidence on the prevalence and incidence of Chlamydia
trachomatis (CT) in the UK and its sequelae, pelvic inflammatory disease (PID), ectopic pregnancy (EP)
and tubal factor infertility (TFI) to review the evidence base in its entirety, assess its consistency and,
if possible, arrive at a coherent set of estimates consistent with all the evidence.
Methods: Evidence was identified using ‘high-yield’ strategies. Bayesian Multi-Parameter Evidence
Synthesis models were constructed for separate subparts of the clinical and population epidemiology of
CT. Where possible, different types of data sources were statistically combined to derive coherent
estimates. Where evidence was inconsistent, evidence sources were re-interpreted and new estimates
derived on a post-hoc basis.
Results: An internally coherent set of estimates was generated, consistent with a multifaceted evidence
base, fertility surveys and routine UK statistics on PID and EP. Among the key findings were that the risk of
PID (symptomatic or asymptomatic) following an untreated CT infection is 17.1% [95% credible interval
(CrI) 6% to 29%] and the risk of salpingitis is 7.3% (95% CrI 2.2% to 14.0%). In women aged 16–24 years,
screened at annual intervals, at best, 61% (95% CrI 55% to 67%) of CT-related PID and 22% (95% CrI
7% to 43%) of all PID could be directly prevented. For women aged 16–44 years, the proportions of PID,
EP and TFI that are attributable to CT are estimated to be 20% (95% CrI 6% to 38%), 4.9% (95% CrI
1.2% to 12%) and 29% (95% CrI 9% to 56%), respectively. The prevalence of TFI in the UK in women at
the end of their reproductive lives is 1.1%: this is consistent with all PID carrying a relatively high risk of
reproductive damage, whether diagnosed or not. Every 1000 CT infections in women aged 16–44 years, on
average, gives rise to approximately 171 episodes of PID and 73 of salpingitis, 2.0 EPs and 5.1 women with
TFI at age 44 years.
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Conclusions and research recommendations: The study establishes a set of interpretations of the major
studies and study designs, under which a coherent set of estimates can be generated. CT is a significant
cause of PID and TFI. CT screening is of benefit to the individual, but detection and treatment of incident
infection may be more beneficial. Women with lower abdominal pain need better advice on when to seek
early medical attention to avoid risk of reproductive damage. The study provides new insights into the
reproductive risks of PID and the role of CT. Further research is required on the proportions of PID, EP and
TFI attributable to CT to confirm predictions made in this report, and to improve the precision of key
estimates. The cost-effectiveness of screening should be re-evaluated using the findings of this report.
Funding: The Medical Research Council grant G0801947.
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Plain English summary
Chlamydia trachomatis (CT) infection is a cause of pelvic inflammatory disease (PID), ectopic pregnancy(EP) and infertility but is usually asymptomatic. The National Chlamydia Screening Programme (NCSP)
offers sexually active young men and women annual screening for CT, but its effectiveness and value
for money have not been definitely established. There has been no consensus on how much reproductive
damage untreated CT infection can cause or on the best methods for estimating this.
The purpose of this project was to assemble all the evidence on CT infection, PID, EP and tubal factor
infertility (TFI) to see if a consistent picture could be formed of the role of CT in causing reproductive
damage. We looked at the worldwide literature on the risks of these outcomes following CT, and also
at the UK evidence on CT prevalence, and routinely reported PID and EP seen in general practitioner
surgeries, hospitals and sexually transmitted disease clinics, and at evidence on infertility from UK surveys.
We found a way of interpreting all this evidence which provided a single consistent set of estimates.
It was confirmed that untreated CT infection posed a significant threat to reproductive health. Our findings
show that screening is beneficial to the individual, but a focus on treating infections at the time they are
acquired may have greater benefit.
The cost-effectiveness of the NCSP now needs to be reassessed, using these new estimates of how much
reproductive damage CT infection can cause.
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Scientific summary
Background and objectives
The National Chlamydia Screening Programme (NCSP) was initiated in 2003 and was operational
throughout England by 2008. It offers screening for Chlamydia trachomatis (CT) infection annually, and
on partner change, to sexually active men and women under 25 years attending general practitioner (GP)
surgeries and other services. In 2012, over 1.7 million chlamydia tests were carried out in England among
young people aged 15–24 years old. Assuming one test per person, this approximates to 35% of
young women and 16% of young men being tested for chlamydia. The objectives of the programme
(see www.chlamydiascreening.nhs.uk/ps/overview.asp) are to:
l prevent and control CT through early detection and treatment of infection
l reduce onward transmission to sexual partners
l prevent the consequences of untreated infection, principally pelvic inflammatory disease (PID), which
can result in ectopic pregnancy (EP) and tubal factor infertility (TFI).
The effectiveness and cost-effectiveness of the programme has yet to be clearly established.
Treatment of current CT infection is considered to be both safe and effective, and screening has been
proposed because the majority of incident CT remains asymptomatic. However, the cost-effectiveness and
clinical effectiveness of screening depends primarily on the precise extent of reproductive morbidity caused
by untreated CT, chiefly PID, EP and TFI, and on the proportion that can be prevented by screening.
The work reported here was funded by the Medical Research Council. The premise for the project was that
there was no consensus on the quantitative risks of PID, EP and TFI following a CT infection, or on how to
derive estimates from the evidence available, or even on what kind of evidence should be used. The
objective, therefore, was to comprehensively assemble all the available evidence on the incidence and
prevalence of CT in the UK, and the evidence from the various prospective and retrospective study designs
from which quantitative relationships between CT, PID, EP and TFI can be derived, as well as routine
sources of evidence on PID, EP and TFI in the UK, in order to assess the consistency of the different types
of evidence, and, if possible, to provide a coherent, unified account of the clinical and population
epidemiology of CT in the UK and its reproductive consequences in women.
Methods
Evidence sources were identified using ‘high-yield’ strategies, based on citations in recent cost-effectiveness
analyses, reviews and research papers, and on the advice of the multidisciplinary group of investigators.
New formal systematic reviews were not undertaken. Where routine UK data were used, this was from
2002, prior to the introduction of the NCSP.
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In the interests of transparency and simplicity, the problem was broken down into separate but interlinked
subproblems. These were: duration of asymptomatic CT; incidence, prevalence and duration of CT
considered together; the risk of PID following CT infection; the incidence of PID and the proportion of PID
attributable to CT; the cumulative incidence of PID, of repeat episodes and the prevalence of previous
salpingitis; the relation between salpingitis and EP; the relation between salpingitis and TFI; and the
relation between CT and TFI from serological case–control studies. Under each of these headings, multiple
sources of evidence were assembled and their interpretation was reviewed. Models were estimated from
the assembled data following a Multi-parameter Evidence Synthesis (MPES) approach, using Bayesian
Markov chain Monte Carlo.
Where appropriate, we combined the evidence from multiple sources to form a single coherent set of
estimates for multiple parameters (such as incidence, prevalence and duration). Wherever possible, we
assessed the consistency of estimates derived from alternative evidence sources. Where evidence sources
were in conflict, we attempted to identify alternative sets of assumptions, or alternative interpretations of
the data sources, under which the different sources of data could be regarded as making consistent
predictions for the model parameters. In such cases, where models and interpretations were based on
post-hoc reasoning, this was highlighted, and any conclusions were considered as tentative and requiring
further confirmation.
Results
The key results from each of the analyses are as follows.
Duration of asymptomatic Chlamydia trachomatis infection in women
(see Chapter 4)
Evidence on CT duration in women was extraordinarily heterogeneous. However, the heterogeneity can be
explained if studies of incident and prevalent infection are distinguished, and if one assumes that ‘passive’
infections clear over approximately 1 week. A model including such passive and ‘real’ infections gave an
adequate fit. The evidence was also compatible with a three-rate model which includes fast clearing real
infection as a result of a protective immune response in addition to passive infection and slow clearing
real infection.
Incidence, prevalence, and duration of Chlamydia trachomatis in the UK
(see Chapter 5)
It was shown that available evidence on CT incidence in the UK (infection rates and re-infection rates),
appropriately calibrated to apply to the general population, was consistent with evidence on duration and
prevalence. Key findings were:
l Approximately 77% [95% credible interval (CrI) 68% to 84%] of incident CT in women
is asymptomatic.
l An asymptomatic CT infection has an average duration of 1.31 years (95% CrI 1.06 to 1.56 years).
l A CT infection (symptomatic and asymptomatic) has an average duration of 1.03 years (95% CrI 0.82
to 1.25 years).
l CT prevalence in women ranges from 8.4% per year in 16- to 17-year-olds to 0.8% in 30- to 44-year-olds.
It was 5.2% (95% CrI 3.8% to 6.9%) in 16- to 24-year-olds and 2.1% (95% CrI 1.6% to 2.7%) in 16- to
44-year-olds.
l CT incidence ranges from 8.2 per 100 person-years in 16- to 18-year-olds to 0.8 in 30- to 44-year-olds.
It was 5.0 per 100 person-years (95 CrI 3.5 to 7.1) in 16- to 24-year-olds and 2.1 per 100 person-years
(95% CrI 1.5 to 2.8) in 16- to 44-year-olds.
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Risk of pelvic inflammatory disease following Chlamydia trachomatis
infection (see Chapter 6)
A Markov model was constructed which allowed for CT clearance as a ‘competing risk’ alongside the
development of PID. Estimates of the proportion of incident CT that progresses to PID were generated,
based on synthesised data from three trials, as well as estimates of the proportion of CT-related PID that
could be prevented by screening on an annual basis. We explored the possibility that rates of progression
to PID could be higher in the 3 months following infection, but the data available could not distinguish
between one- and two-rate models:
l 14.9% (95% CrI 4.8% to 24.8%) of incident CT infections progress to symptomatic PID
l 17.1% (95% CrI 5.6% to 28.9%) of incident CT infections progress to PID (symptomatic
and asymptomatic)
l 7.3% (95% CrI 2.3% to 14%) of incident CT infections progress to salpingitis
l In women aged 16–24 years who undergo screening at annual intervals, at best, 61% (95% CrI 55%
to 67%) of CT-related PID and 22% (95% CrI 7% to 43%) of all-cause PID can be directly prevented.
Incidence of pelvic inflammatory disease and proportion of pelvic
inflammatory disease attributable to chlamydia (see Chapter 7)
We established that the all-cause PID incidence as observed in the Prevention of Pelvic Infection (POPI) trial,
taking account of the proportion that is asymptomatic (13%), is consistent with routinely collected data on
PID from hospital, GP and genitourinary medicine clinic returns, taking account of the overlap between
these data sets and the proportion of PID that is undiagnosed (64%).
l A pooled estimate of PID incidence in 16- to 24-year-olds, including diagnosed and undiagnosed PID,
is 2.5 per 100 person-years (95% CrI 1.8 to 3.4), and in 16- to 44-year-olds is 1.8 per 100 person-years
(95% CrI 1.3 to 2.5).
l 62.9% (95% CrI 57.8% to 67.4%) of PID episodes are in women aged > 24 years.
Several estimates of the proportion of PID due to CT, the Population Excess Fraction (PEF) (see Chapter 3),
were compared:
l the PEF is four to six times higher in 16- to 19-year-olds than in 35- to 44-year-olds
l the preferred estimate of the PEF was 35.3% (95% CrI 10.5% to 68.5%) in 16- to 24-year-olds,
and 19.7% (95% CrI 5.9% to 38.1%) in 16- to 44-year-olds, based on estimates of CT incidence,
CT-related PID incidence and the CT-to-PID progression risk
l this is consistent with estimates derived from case–control studies, adjusted for under-ascertainment of
CT infection, and with estimates of relative risk reduction from the POPI trial although uncertainty
is high.
Cumulative incidence of Chlamydia trachomatis-related and non-Chlamydia
trachomatis-related pelvic inflammatory disease and salpingitis
(see Chapter 8)
Based on a Markov model of PID and salpingitis incidence and repeat episodes:
l A total of 42.9% (95% CrI 25.5% to 61.2%) of incident PID would be confirmed as salpingitis
on laparoscopy.
l In women aged 35–44 years, 33.6% (95% CrI 25.4% to 43.1%) have experienced at least one
episode of PID (all causes, diagnosed and undiagnosed), and 16.1% (95% CrI 9.0% to 24.7%) have
experienced at least one episode of salpingitis (all causes, diagnosed and undiagnosed).
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Comparison of ectopic pregnancy rates predicted from the Lund study with
UK data on ectopic pregnancy incidence (see Chapter 9)
Although conception rates peak between the ages of 20 and 30 years, the proportion of conceptions that
are EPs rises sharply with age, indicating its sensitivity to cumulative exposure to risk factors. The proportion
of EP that is due to salpingitis was derived from two French case–control studies.
l 1.13% of all pregnancies in the UK are EPs
l an estimated 27% (95% CrI 11% to 46%) of EPs are due to salpingitis
l an estimated 4.9% (95% CrI 1.2% to 12.1%) of EPs are due to CT.
We derived predictions for UK EP conception rates based on the salpingitis-to-EP risks observed in the
Lund study, and a parallel set of predictions were made for TFI. It was concluded, however, that the
salpingitis-to-EP risks observed in the Lund study were too high to be consistent with UK data on EP,
possibly because of changes in interuterine device use.
Comparison of tubal factor infertility rates predicted from the Lund study
with UK infertility surveys (see Chapter 10)
l Prevalence of primary and secondary TFI in women aged 44 years was 1.08% (95% CrI 0.79% to
1.54%), based on UK infertility surveys.
l This is consistent with the salpingitis-to-TFI risks observed in the Lund study, if it is assumed that the TFI
risks associated with all salpingitis, whether diagnosed or not, is the same as, or slightly lower than,
the salpingitis-to-TFI risk observed in the Lund study.
l An estimated 29% (95% CrI 9% to 56%) of TFI is attributable to CT.
Proportion of tubal factor infertility attributable to Chlamydia trachomatis,
based on serological case–control studies (see Chapter 11)
We developed a method for estimating the proportion of TFI cases due to CT from serological studies, with
adjustment for the sensitivity and specificity of the serological assays. This was applied to a case–control
study from the Netherlands. It was estimated that 45% (95% CrI 28% to 62%) of TFI was attributable
to CT in this study, but this is likely to be an overestimate. There is a large body of evidence clearly
demonstrating that CT is a significant cause of TFI.
Conclusions
The study has generated a set of estimates on chlamydia epidemiology, from its incidence, prevalence and
duration of infection, all the way through to its role in PID, EP and TFI. These estimates are not only
consistent with an extensive body of literature, and with fertility surveys and routine statistics on PID and
EP, but they are also internally coherent. To achieve this, the study has produced a coherent set of
interpretations of the key study designs.
Public health significance
l Our findings confirm that CT is an important cause of PID and TFI.
l The findings support the view that screening of prevalent cases prevents PID, but suggest that a greater
emphasis should be placed on detection and treatment of incident CT infection, as part of an
integrated programme for sexually transmitted infection treatment and control.
l Current guidance on PID management, regarding a low threshold for presumptive treatment with
broad-spectrum antibiotics, should not be changed.
l Women with lower abdominal pain require advice on when to seek early medical attention to avoid
risk of reproductive damage.
l Every 1000 CT infections in women aged 16–44 years, on average, gives rise to approximately
171 episodes of PID and 73 of salpingitis, 2.0 EPs and 5.1 women with TFI at age 44 years.
SCIENTIFIC SUMMARY
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Limitations
The study has a limited scope: it has not covered dynamic models of CT transmission, and therefore cannot
by itself fully inform cost-effectiveness analyses of screening. Neither costs nor impact on quality of life
have been addressed. Chronic pelvic pain, CT infection in pregnancy, and the role of CT in neonatal
pneumonia and conjunctivitis have not been covered.
Within its scope, the main limitations relate to the large number of assumptions that have been made,
although these are assumptions that have been commonly made in the previous literature, in particular:
l the proportion of PID that is undiagnosed is the same, regardless of age and whether or not the PID is
CT related
l the proportion of PID that would be confirmed as salpingitis on laparoscopy is the same, whether or
not it is CT related
l the proportion of PID that would be confirmed as salpingitis on laparoscopy is the same, whether or
not it is diagnosed
l the reproductive damage caused by salpingitis is the same whether it is CT related or not.
Recommendations for further research
Further research is recommended as follows:
l A suite of serological studies, based on routine health service activity, should be undertaken to estimate
the causal role of CT in PID, EP and TFI, and how this might vary with age.
l Such studies would also offer the opportunity to gain up-to-date information on: PID referral patterns,
leading to better estimates of PID incidence; the proportion of PID causing reproductive damage that is
diagnosed, and the proportion that is silent; whether or not the CT-related PID is more or less likely to
be associated with reproductive damage, and is more or less likely to diagnosed. Microbiological
studies of the aetiology of reproductive damage following salpingitis could also be undertaken.
l Further dynamic modelling, within a MPES framework, so that all sources of evidence can be
incorporated and checked for consistency, with appropriate uncertainty propagation. Further research
may be required to develop methods of Bayesian computation capable of incorporating sexual network
dynamics in disease transmission models.
Funding
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Chapter 1 Background
Objectives
1. To set out the background to this research, and the context in which it was conceived.
2. To describe its motivation, objectives and the analytic strategy that has been adopted.
3. To set out the structure of the monograph.
Introduction
We begin with a brief description of the National Chlamydia Screening Programme (NCSP) in England,
and the decision-making processes that led to it. Our account suggests that, at the time it began,
Chlamydia trachomatis (CT) screening in the UK was not based on clear evidence of its effectiveness or
cost-effectiveness. The present study, the questions it seeks to answer and the methodology it uses,
originate in the early history of NCSP, and in the way in which evidence was used in the two UK studies1,2
of the cost-effectiveness of screening for CT, published in 2007.
The National Chlamydia Screening Programme in England
The early history of the programme
The NCSP was set up in 2003 and was implemented in some way in every region of England by 2008. It is
an opportunistic approach involving a combination of health and non-health screening venues, targeted
at sexually active young people aged 15–24 years.3 The objectives of the programme include both
individual and population benefit.
1. Reduce CT incidence (population benefit). Detection and treatment of CT directly lowers CT prevalence
and this will reduce the incidence of new cases in future.
2. Treat CT and prevent sequelae (individual benefit). Detection and early treatment of CT should prevent
progression to sequelae.
3. Treat sexual partners of index cases.
The website (www.chlamydiascreening.nhs.uk/) provides further information on how the programme operates.
The precise evidence base for the NCSP has been controversial both before4 and since its introduction.5
In the UK, new screening programmes are normally examined by the National Screening Committee (NSC),
based on a specifically commissioned systematic review and cost-effectiveness analysis (CEA) of candidate
proposals for screening. The committee applies a set of criteria (see www.screening.nhs.uk/criteria) derived
from the Wilson and Junger criteria for screening,6 and considers the infrastructural implications of the
screening and diagnostic tests, training in counselling and other services. In the case of CT, the decision to
go ahead with a screening programme was originally based on the report from the Chief Medical Officer’s
Expert Advisory Group on Chlamydia trachomatis.7 This group considered that the proposed programme
met the necessary criteria, although others5 have found otherwise. Although the report recommended
screening in sexually active women aged < 25 years, women aged 25 years or over with a new partner in
the previous 12 months, and high-risk men, there was a recognition that data on the costs, feasibility and
acceptability of the programme were lacking, and these were to be addressed by pilot studies to be
initiated the following year, in 1999. An early dynamic modelling study undertaken during this period by
the Department of Health8 may also have influenced the decision. It had concluded that screening could
be cost neutral within 4 years.
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In the event, following supportive experience during the pilot studies, CT screening formed an important
plank in the English government’s 2001 sexual health strategy9 and has continued to do so ever since. The
NSC reviewed the population-based screening programme in 2006 but did not recommend it.10 The NSC
may revisit this, or it may review opportunistic screening as currently practiced in England, in the future.
Sheringham et al.11 recently provided an insightful analysis of the development of policy leading to
the NCSP.
Evaluating the benefits of Chlamydia trachomatis screening
As with any screening programme, evaluation of its effects can be undertaken in two ways: one method is
experimental studies in which individuals are randomised to either screening and early treatment or to no
screening, with outcomes assessed at appropriate later time points. At the time when the NCSP was set
up, two randomised controlled trials (RCTs) had been conducted,12,13 one of which, a large-scale study13
on women considered to be at higher risk in the USA, appeared to show that the frequency of pelvic
inflammatory disease (PID) could be approximately halved in the screened group. This trial13 has been
criticised by a number of commentators,14–16 although the US Task Force for Prevention did not see fit to
adjust the estimates of benefit17 and we return to consider this more closely in later chapters. A second
study, by Ostergaard et al.,12 was relatively small. Both of these trials12,13 studied an intervention and target
population somewhat different from that proposed and implemented in England. Further RCTs have been
published since the NCSP was introduced.
By 2009 there had been more reviews of the trial evidence than there had been trials.18 Once again,
although there was good evidence that screening could be effective in lowering the incidence of PID in
high-risk populations, and also in high school students, some felt that there was a lack of evidence
that screening would be successful in the general population.18 Since then, the Prevention of Pelvic
Infection (POPI) trial19 has studied whether or not screening can lower the PID rate in women in higher
education. The findings of this trial19 were again positive. However, the results were considered to be
less than definitive: the trial was somewhat underpowered because of difficulties with recruitment
and lower-than-expected rates of PID.20,21
There have also been trials that have sought to estimate the effect of screening on population prevalence,
rather than its effect on morbidity in the recruited population. Studies published to date have not delivered
convincing results.18 A stepped-wedge pilot in the Netherlands has reported no substantial fall in positivity
among those screened over three screening rounds. The intended primary outcome of impact on
population prevalence was aborted as a result of difficulties obtaining this measure.22 A Danish trial23
randomised women to a single postal invitation to be screened compared with no intervention, and
followed up to PID, EP and infertility outcomes over a 9-year period. In view of the uptake of testing in
both arms as part of routine care, and the low uptake of the offer of testing in the treatment arm, the
result is not surprising.24 In addition, the length of follow-up is likely to lead to considerable dilution of the
relative risk (see Chapter 3, Population Excess Fraction). Results from the large-scale ACCEPt trial
(Australian Chlamydia Control Effectiveness Pilot)25 in Australia are still awaited.
A second approach to evaluation is by systematic review of the evidence and CEA. CEA applied to
screening decisions can be informed directly by randomised studies, but is more often based on putting
together the wide range of evidence on the population epidemiology of the condition, its clinical natural
history with and without treatment, and – in the case of infectious disease programmes – models of the
dynamic effects of interventions on future incidence. With sexually transmitted diseases (STDs), dynamic
models must also make a range of assumptions about sexual partnership formation rates, duration of
partnerships, their concurrency, and the impact of screening on partner recall and subsequent sexual
behaviour, and so on. The advantage of evaluation by modelling, compared with RCTs, is that it is possible
to consider the longer-term outcomes, beyond the trial, such as EP and tubal factor infertility (TFI). One can
also study the expected dynamic effects of reducing prevalence. In 2007, two major CEAs of CT screening
in the UK context were published.1,2,15
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The results from the two CEAs were very different: one2 concluded that screening was highly unlikely to be
cost-effective (ClaSS, Chlamydia Screening Studies project), whereas the other concluded that screening
was likely to be cost-effective, and most clearly so in men and women aged < 20 years if the risk of PID
attributable to chlamydia was 10% or more. The fact that the two models produced different results is,
in itself, not at all surprising. They were not examining exactly the same screening protocol, different
structural assumptions were made about the natural history and different parameter values were assumed,
particularly touching on transmissibility and sexual behaviour.26,27
However, what is surprising, particularly given the wide acceptance of systematic review as the methodology
for analysing problems of this type, is that the disagreement between the two UK cost-effectiveness analyses1,2
was not only about the parameter values, or even about how parameter values should be estimated from the
available data, but also went as far as a conflict about what kinds of data should be used to inform parameters.
Later in this chapter we illustrate the extent of the controversy concerning just one single parameter.
Population and individual benefits of screening
There are two distinct aspects to the epidemiological model underlying CEA of CT screening programmes:
the dynamic effects on future incidence and prevalence of lowering prevalence by screening and treating
a large proportion of the population, and the expected effect of screening and treatment of CT on
progression to PID, EP and TFI. The two topics are not necessarily completely independent of each other,
although it is important to establish that the two topics can be studied independently.
Although findings from the two UK screening models differed,1,2 one clear finding that emerged from both
CEAs was that the cost-effectiveness of CT screening was highly dependent on what was assumed to be
the frequency of sequelae in untreated infection. The issue needs to be stated in two slightly different
ways, each relating to the two objectives of screening:
1. If CT incidence is lowered by a given amount, how many PIDs, EPs and TFIs are prevented in the
population as a whole?
2. In each case of CT detected by screening and treated, how much is the risk of PID, EP and TFI lowered?
The two questions are fundamentally different, and this has not always been fully appreciated. The first
question invites us to consider how many further CT infections are prevented by treating each infected
woman, recognising that each prevented CT infection can be associated with a number of averted
sequelae. The second question relates to the benefits to the individual of detecting and successfully
treating CT infection. This is the question that can be evaluated by randomising individuals in RCTs of
screening versus no screening.
One way in which the questions of population benefit and individual benefit differ is that the former
concerns incident infection, whereas the latter concerns prevalent infection. Women whose infection is
picked up on screening are almost all asymptomatic (otherwise they would most likely have sought
treatment already) and have already been infected for an unknown period. Trials of screening versus no
screening show that treatment of asymptomatic prevalent infection does prevent subsequent PID. The
issue of incident versus prevalent infections impacts on the interpretation of all the prospective studies of
CT (see Chapters 4 and 6), as well as on the potential benefits of screening.
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Difficulties with the evidence base for screening
In this section, we illustrate the extent of the controversy concerning what evidence should be used to
inform models of CT screening and how it should be used.
Cost-effectiveness analysis models have agreed that the probability of PID following a CT infection is a key
parameter in forming public health decisions on CT prevention and control. Although not all PID is caused
by CT, the probability that an (untreated) episode of CT causes an episode of PID directly controls the
downstream benefit of preventing a CT infection through screening or other preventative measures.
Further, PID occupies a pivotal position among the various sequelae of infection in women because the
consensus view1,28–34 is that PID is a necessary precursor to a significant proportion of ectopic pregnancy
(EP) and to virtually all TFI,35 whether or not the PID is causally attributable to CT. Thus, increasing the
probability that CT causes PID in any model should also lead to predictions of higher incidence of EP and
TFI. (Although, this assumption was not built into the ClaSS study.2) The relationships between the clinical
entities are shown in Figure 1.
Once again, given the central role of this parameter, it comes as a surprise that the two UK studies1,2
sourced parameter estimates in completely different ways.
The ClaSS study2 based their estimates on analyses of the Uppsala cohort,36 a data linkage study involving
all women aged 15–39 years, resident in Uppsala County, Sweden, in a 5-year period from 1985. Screening
was offered by general practitioners (GPs), and laboratory screening records for the period were linked to
hospital records of PID, EP and TFI. Setting aside the precise details of how estimates of progression rates
were derived from the study, several difficulties can be enumerated, perhaps the most important of which is
that women who were screened and found to be CT infected were treated. It is therefore not possible to
draw conclusions about the progression rate to PID, EP and TFI in untreated women.
A very different approach was taken by the Health Protection Agency (HPA) study.1 Here the investigators
carried out scenario analyses around three estimates of the probability that an incident CT causes a PID:
1%, 10%, and 30%. The investigators proposed that the 10% PID rate should be considered the most
plausible on the basis of an analysis of retrospective data. Their argument has two parts: first, overall PID
incidence was between 1.5% and 2.4% per year, based on analyses of the General Practice Research
Database (GPRD). Second, the proportion of total PID that could be attributed to chlamydia infection was
approximately 30% according to studies that looked at evidence of current exposure in PID cases.37
The HPA investigators then compared the supposed numbers of CT-related PIDs presenting to GPs
with data on the number of incident CT cases. Whatever the validity of this approach, the use of
retrospective data and the chain of reasoning via more than one type of study, contrasts with the use of
a data linkage study in the ClaSS2 model.
PID
EP
CT Salpingitis
TFI
Other
infections
Other
causes
FIGURE 1 Relationships between CT infection and its major sequelae.
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Subsequently, an authoritative series of papers on CT clinical and population epidemiology and the
potential for CT screening appeared in the Journal of Infectious Diseases in 2010.38 These were based on
reports from an expert group set up by the US Centers for Disease Control and Prevention (CDC). Among
them was a review of the research on the relation between CT and PID, co-authored by some of the authors
of the ClaSS analysis. The review focused its attention not on linkage studies, nor on retrospective studies,
but on a third type of study: prospective follow-up of untreated women with CT. Register linkage studies
were recognised as possible sources of information, but were discounted for the reasons given above.
Even this does not exhaust the list of types of data that have been proposed. Another type of data was
brought into play by van Valkengoed et al.39 This was not prospective, retrospective or a linkage study, but
simple routine statistics on the numbers of PIDs, EP and infertility being reported in routinely collected data.
These estimates have been criticised,40 and the reasoning behind them is questionable (see Appendix 9).
However, although unconventional from a traditional Hierarchy of Evidence viewpoint,41 the use of routine
statistics to support inferences about causal effects is valid. Given an estimate of CT incidence in a
population of known size, a register study of the number of PID episodes can put effective constraints on
the CT-to-PID progression rate.
Summary of aims and objectives
Hopefully, our previous comment on the background to the NCSP, the way it was introduced and the
difficulties that respected experts have had, not only in providing a CEA of screening, but even in
identifying an appropriate methodology, explains the motivation behind this project. The aims of the
proposed research, as they were stated at the outset, were to generate:
1. a consensus view of what existing data tell us about the natural history of untreated CT
2. a quantitative model of the natural history of CT, providing internally coherent and externally validated
estimates of the prevalence and incidence of the complications of CT in the absence of treatment,
suitable for modelling cost-effectiveness of interventions in the UK.
This monograph focuses attention on CT and its sequelae in women aged between 16 and 44 years of
age, corresponding approximately to the period of reproductive activity. Many of the data sources relate to
England, some to Great Britain and some to the UK. However, our general presumption is that, in the
absence of any evidence to the contrary, there is no reason to believe that we would reach different
conclusions for different nations within the UK, and conclusions are therefore intended to be relevant to
the UK as a whole.
Any estimates of incidence and prevalence, both of CT and of its sequelae, must refer to a specified time,
as well as a specified place. We have targeted the year 2002, which is immediately before the beginning
of the NCSP. Where possible, routine data have been from that year, and, although it has not been
possible to source all evidence from that year, we have interpreted evidence as being relevant to that year,
unless otherwise stated.
We now explain the analytic strategy we adopted to achieve these aims.
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Analytic strategy
In a previous section we have just picked out a single parameter, the risk of PID following CT, to show first
that previous investigators have not simply inferred different parameter values from the same set of
available data, but that they have sourced their parameter estimates from completely different kinds
of data. This is by no means the only example that could be cited. These fundamental divergences of
approach between previous investigators lie behind the analytic strategy we have adopted, which is
essentially to look at all the sources of evidence, to see if they are consistent with each other, and to
produce a set of internally consistent and coherent estimates, based on all the data sources – or at least all
of those that we believe provide unbiased estimates of their target parameters. This is a large and complex
undertaking, not only because of the range of types of study that could bear on each parameter, but also
because the parameters are all related. For example, if we were to entertain the belief that CT incidence
was at the high end of its credible interval (CrI), we should be committed to also believing that CT
prevalence is higher and/or duration of infection is lower; also that there is a higher incidence of
CT-related PIDs, a higher incidence of CT-related EP episodes and a higher prevalence of CT-related TFI.
Therefore, when we examine the evidence about any one of these parameters we should examine the
evidence about all of them, because we can learn about each one by looking at any of the others.
The relationships between the key clinical entities are shown in Figure 1.
To meet this challenge we have adopted the following analytic strategy:
1. work through the natural history of CT and its sequelae in a logical sequence, starting with CT
incidence, prevalence and duration, and ending with TFI
2. at each stage, review the different kinds of evidence available, prospective, retrospective and routine
data, and review previous approaches to deriving parameter values from these evidence types
3. formulate a model for the evidence at each stage, and synthesise the evidence under that model,
examining the consistency of estimates with the data
4. examine the consistency of the entire set of estimates overall.
Statistical combination of evidence
To carry out this programme, we have relied on Multi-parameter Evidence Synthesis (MPES). This is an
approach to model building and evidence synthesis42,43 that has properties that will prove valuable in the
present context. It recognises that epidemiological studies do not necessarily generate direct evidence on
the parameters of interest, but instead can inform functions of parameters. It has the technical means to
combine information on parameters and functions of parameters within a single coherent structure;
it offers standard statistical approaches to checking model fit, and specifically for determining whether
or not different sources of evidence are in conflict regarding the information they contribute to any
specified parameter; all data sources are formally incorporated via their likelihood, and parameter
uncertainty, sampling uncertainty, and variation owing to heterogeneity is readily propagated through the
evidence network.
Multi-parameter Evidence Synthesis is an essentially Bayesian methodology and it has been implemented
using the popular Bayesian Markov chain Monte Carlo (MCMC) package WinBUGS version 1.4.3 (Medical
Research Council Biostatistics Unit, Cambridge, UK).44 But we emphasise that the use of Bayesian MCMC is
not a necessary feature of our approach to evidence synthesis. Bayesian MCMC in WinBUGS makes it
relatively easy for investigators to fit complex models, and the adoption of simulation-based Bayesian
computation also greatly facilitates uncertainty propagation. However, similar results could be achieved, in
principle, though perhaps with some difficulty, using Frequentist methods.
The idea of statistical combination of information on different functions of parameters appears to have
been independently rediscovered a number of times in the last 80 years, with applications in physics,
environmental risk control, deterministic dynamic models of population change, and in a range of
computational frameworks, in both Frequentist and Bayesian forms.45–48 The term ‘multi-parameter
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
synthesis’ was coined by Victor Hassleblad,49 one of the originators of the Confidence Profile Method,50 a
programme of research in clinical and descriptive epidemiology that was the immediate precursor to MPES
and which made particular use of bias adjustment.
Besides review papers,42,43,51 there are a number of applications of MPES to infectious disease
epidemiology, often oriented to screening problems.52–56 A relatively simple application, and perhaps the
best introduction, setting out all of the main properties of MPES, is a stylised application to prenatal
human immunodeficiency virus (HIV) testing.57
Multi-parameter Evidence Synthesis can be viewed as a purely technical extension of the single parameter
meta-analysis, as described in numerous textbooks and tutorial papers,58–60 to multi-parameter problems.
But it is probably more accurate to see it as a philosophically different approach to evidence and
evidence synthesis.
Coherence of estimates
An important property of this approach to synthesis is its internal coherence. The generation of
epidemiological evidence tends to be fragmented: separate studies are made of CT prevalence, CT
incidence and CT duration, and separate estimates are published. But, in truth, these three quantities are
known to be related: prevalence= incidence × duration. Estimates of any one of these parameters need to
be consistent with estimates of the other two and with whatever data inform any of them. In the same
way, studies of CT incidence, progression rates to PID, EP and TFI should produce results that are
mathematically related to the results from retrospective studies of the role of CT in PID, EP and TFI, and to
routine statistics. MPES is simply a methodology in which these relationships can be explored in a formal
way, while taking account of the full extent of uncertainty due to sampling variation, additional sources of
variation and any concerns that might come under the heading of ‘data quality’.
There is, in fact, nothing very new or original about putting different pieces of information together to see
if they ‘add up’. Many chlamydiologists have carried out ‘back of the envelope’ calculations with exactly
this objective in mind, to see whether information on incidence and prevalence, put together with
information on progression to PID, EP or TFI could be consistent with routine data or not. Or asking
whether routine data, put together with information on the proportion of PID, EP or TFI attributable to CT
could be consistent with CT incidence and prevalence information or not. Indeed, many calculations of this
type have been published.5,39,40,61,62 The programme of work described in this monograph uses MPES to
examine exactly the same ideas, but within the framework of a formal statistical method, and perhaps in a
more complete and systematic way.
Role of interpretation
Note, however, that MPES is not simply a ‘synthesis exercise’. The synthesis is carried out under a very
specific model of how the different data sources were generated. There is, therefore, as in any scientific
exercise, an element of interpretation, and therefore of judgement. This arises in several ways. First,
goodness-of-fit tests may not be able to distinguish between alternative models, forcing investigators to
use their judgement. But a far more serious element of subjectivity lies in the fact that our overall
judgement about the mechanisms that generate a set of data may depend greatly on our interpretation of
just one or two studies. It is notoriously difficult, for example, to know if confounding variables or effect
modifiers are present, or how great their impact is. Although conflicts between evidence sources may alert
us to the presence of confounders and effect modifiers, the use of MPES does not remove the problems
they create. We have therefore been explicit about where there is a subjective element to model choice,
and particularly where there is an element of data-driven (post hoc) re-interpretation of evidence. In these
instances, we follow the usual practice of describing the results as ‘hypothesis generating’, and we
prioritise research recommendations in this light.
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Overview of this monograph
In Chapter 2 we present a brief account of the natural history and epidemiology of CT and its sequelae.
The objective is to explain the relationships between the clinical entities, and the definitions we have
adopted. Chapter 3 sets out the methodology used throughout the monograph. This covers methods for
literature identification, and gives some further details of the MPES approach, such as sensitivity to priors,
technical aspects relating to the use of WinBUGS software, and our methods for assessing model fit and
model selection.
The rest of the monograph takes the successive aspects of the natural history of CT and PID in turn and
delivers a ‘mini-synthesis’ of specified subsets of the data. This approach allows us to gather together and
synthesise all the direct evidence on each parameter, and then to build it incrementally into the overall
model. We adopt an incremental strategy, in preference to putting every piece of evidence straight into a
single overarching model. It may seem at first sight that this defeats the very advantages of MPES.
However, the advantage of the incremental approach is that it commits us to a view on each parameter
that can be examined and debated in reference to the existing literature. If we had combined all the data
from the outset, it would be much more difficult to understand conflicts between the results and
previous work.
Figure 2 provides a simple schematic guide to the contents of Chapters 4–12, in terms of the relationships
between the clinical entities (see Figure 1). We begin at the start of the natural history process with a
synthesis of data on the duration of CT in asymptomatic women (see Chapter 4). This is followed
(see Chapter 5) by a synthesis of information of prevalence and incidence in the UK with the duration data.
PID
TFI EP
Other
infections
Salpingitis Other causes
(a)
CT
PID
CT
TFI EP
Other
infections
Salpingitis
(b)
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TFI EP
Other
infections
Salpingitis
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FIGURE 2 Guide to Chapters 4–12 of the report. (a) Chapters 4 and 5, incidence, prevalence and duration;
(b) Chapter 6, CT to PID progression; (c) Chapter 7, CT and PID; (d) Chapter 8, cumulative PID and salpingitis;
(e) Chapter 9, salpingitis and EP; (f) Chapter 10, salpingitis and TFI; (g) Chapter 11, TFI and CT; and
(h) Chapter 12, summary. (continued )
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FIGURE 2 Guide to Chapters 4–12 of the report. (a) Chapters 4 and 5, incidence, prevalence and duration;
(b) Chapter 6, CT to PID progression; (c) Chapter 7, CT and PID; (d) Chapter 8, cumulative PID and salpingitis;
(e) Chapter 9, salpingitis and EP; (f) Chapter 10, salpingitis and TFI; (g) Chapter 11, TFI and CT; and
(h) Chapter 12, summary.
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This allows us to establish the consistency of incidence, prevalence and duration data, and to go forward
with a coherent analysis of these parameters. The next chapter (see Chapter 6) examines and re-analyses
information from prospective studies, particularly randomised studies, following women with untreated CT
forward to observe the occurrence of PID. This is used to generate estimates of the probability a CT episode
causes PID. In Chapter 7, we examine the relationship between CT and PID from a retrospective viewpoint:
how much PID is caused by CT. This requires us also to consider the incidence of PID.
There is strong evidence that the women with PID, who have an elevated risk of EP and TFI, are those in
whom salpingitis can be confirmed by laparoscopy. In these women, EP and TFI risk increases with the
number of PID episodes. Chapter 8 presents a Markov model in which information on PID incidence and
CT re-infection rates is used to generate predictions on the proportion of women who have experienced
salpingitis followed by further episodes of PID. In Chapter 9 we use these together with data from
prospective and retrospective studies of salpingitis and PID to compare the predicted occurrence of EP to
the rates of EP observed in the UK. Chapter 10 takes the same form as Chapter 9, but deals with TFI rather
than EP. Chapter 11 derives sensitivity and specificity estimates for some new CT serology assays to adjust
reported CT seroprevalence in a study comparing TFI cases and controls. We then derive estimates of the
proportion of TFI attributable to CT. Finally, in Chapter 12 we review the previous chapters, identifying
where inconsistencies between estimates exist, and suggesting how these might be resolved.
Chapters 8–12 should be considered to be somewhat more tentative than Chapters 4–7. There has been
little previous work looking at these different evidence sources, and the aetiological mechanisms relating
CT and PID to EP and TFI are less well studied. As a result, there is a larger element of post-hoc reasoning
as we attempt to identify what assumptions need to be made about the evidence sources in order to make
them consistent, rather than the preferred more objective approach of assembling evidence and then
checking consistency under a well-understood model of how the evidence sources are generated. Chapter 12
ends with a tentative set of final estimates, an outline of study limitations, and research priorities.
Summary
1. At the time the NCSP was introduced, the evidence base for the cost-effectiveness of CT screening
against its aims of reducing infection rates and reducing sequelae was mixed and questionable.
2. Two major UK studies1,2 of the cost-effectiveness of CT screening sourced critical parameter estimates
from completely different types of study, indicating a lack of consensus about what kinds of evidence
should be used to inform natural history parameters.
3. Our analytic strategy is to look at all sources of evidence: retrospective, prospective and routine data.
4. MPES is used to assess the consistency of different types of evidence, and to develop an internally
coherent model of the natural history and population epidemiology of CT.
5. The use of MPES does not remove the subjective elements in model choice and evidence interpretation.
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Chapter 2 Natural history and epidemiology of
Chlamydia trachomatis
Objectives
To:
l provide an introductory account of CT, and its natural history, clinical and population epidemiology in
the UK in women
l explain what is known about the relations between CT, PID, salpingitis, EP and TFI, explaining features
of their clinical and descriptive epidemiology in the UK
l provide definitions of clinically diagnosed PID and salpingitis, and to explain the concepts of
undiagnosed symptomatic PID, and asymptomatic or silent PID.
Chlamydia trachomatis infection
Chlamydia trachomatis is an intracellular bacterial pathogen and a major cause of genital and eye disease.
It comprises three human biovars. One causes trachoma, the most common form of blindness worldwide,
and particularly prevalent in Africa. A second is the cause of lymphogranuloma venereum, a sexually
transmitted infection (STI), mainly of gay men, in the developed world. The third biovar, consisting of
serovars D to K, is the topic of this monograph. It is a major cause of PID, EP and TFI in women,
epididymitis in men, and neonatal conjunctivitis and neonatal pneumonia in newborns.3,28,63,64
Chlamydia trachomatis is transmitted by oral, vaginal or anal sex, and can also be transmitted from mother
to newborn during a vaginal delivery.3,63,64 Diagnosis is generally based on nucleic acid amplification
tests (NAATs) carried out on cervical or vaginal swabs in women, urethral swabs in men or on urine
samples.3,63,64 NAAT has largely replaced culture or enzyme immunoassays for diagnostic testing.3,63,64
However, culture played a key role in earlier epidemiological studies, and the lower sensitivity of culture,
60–80%,64,65 needs to be taken into account when interpreting the earlier research results.
The infection can be treated effectively by antibiotics, such as azithromycin or doxycycline, but it is often
asymptomatic, especially in women.3,63,64 Re-infection by the same partner is an important issue in
prevention: partner notification rates can be improved and risks of re-infection reduced by providing index
cases with prescriptions intended for their partners, or with the medication itself.66–71
Control and prevention
There appears to be little consensus on approaches to control and prevention. In the USA screening is
recommended for non-pregnant women aged < 25 years, and for older women with risk factors
(e.g. those who have a new sex partner or multiple sex partners).63 The technical report from the European
Centre for Disease Control 2008 lists the chlamydia-control activities in Europe, ranging from none to an
organised CT screening programme.16 In Sweden, a change in infectious disease laws in 1988 required
doctors to offer testing and treatment to those with suspected chlamydia. This policy continues in five
other countries. It should probably be considered as opportunistic testing for selected asymptomatic
individuals, rather than as a formal screening programme.5,16 Only two countries are detailed as having an
organised CT screening programme: England and the Netherlands.16 The opportunistic screening approach
adopted in England is described in Chapter 1. In the Netherlands, a pilot register-based screening
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programme for people aged 16–29 years was recently undertaken (2007–10).72 Participation rates were
low, < 20%, and decreased over three rounds of register-based screening.22
Natural history and epidemiology
Chlamydia trachomatis infection
Approximately 75% of incident infections in women are asymptomatic.73 Although studies of the duration
of asymptomatic infection have produced a wide range of estimates – between 1 and 18 months
(see Chapter 4) – it is evident that the infection can clear spontaneously in the absence of treatment
as a consequence of the adaptive and innate immune responses.38,74
The risk of transmission of infection from one episode of sexual intercourse is estimated to be between
10% and 20%.75,76 Given the high sensitivity of current NAATs for detecting CT,8–10 and the fact that
non-host DNA and sperm can be recovered from the female genital tract up to 7 days following sexual
intercourse, this strongly implies that at least some women who test CT positive (CT+) are probably only
passively infected.77,78 This is consistent with the observations of Joyner et al.79 and Geisler et al.80 that a
proportion of women testing CT+ without treatment become CT NAAT-negative within 2 weeks.
Prevalence of CT can be studied by population surveys, using NAATs on genitourinary specimens. As with
most STIs, incidence and prevalence are highest among young people, and decline steeply with age.81
Infection is more common among the more sexually active individuals, with the greatest number of
sexual partners.8–10,81
Pelvic inflammatory disease
Definition of pelvic inflammatory disease
Pelvic inflammatory disease comprises a spectrum of upper genital tract inflammatory disorders among
women, which includes any combination of endometritis, salpingitis, tubo-ovarian abscess and pelvic
peritonitis.82 The principal clinical and economic significance of CT lies in the fact that it is a causal agent
of PID and the further damage to reproductive health that follows from salpingitis.33,83,84 Confusion can
arise with the term PID. Historically, it was often used interchangeably with the term ‘acute salpingitis’ as
detected at laparoscopy, which, historically, was the gold standard for diagnosing PID.85,86 More recently
endometritis, which is associated with salpingitis but can be detected by endometrial sampling, has been
equated with PID because of the unacceptability of performing laparoscopy on large numbers of women
with minimal symptoms.85–87
Pelvic inflammatory disease is not easy to diagnose and the criteria for a clinical diagnosis of PID have
changed over time.33 In the original Lund studies33 the minimum criteria for diagnosis were: (1) lower
abdominal or pelvic pain of < 3 weeks; (2) a purulent vaginal discharge diagnosed on microscopy or
painful intermenstrual bleeding; and (3) increased motion tenderness of the uterus and adnexa on
bimanual examination. In the UK national PID guideline 2011,83 recent onset of lower abdominal pain in
association with local tenderness on bimanual examination is now considered sufficient to establish a
diagnosis and initiate treatment. This is because it is now recognised that many women with salpingitis
have subtle or mild symptoms.63,83 Even when present, the clinical symptoms and signs of PID lack
sensitivity and specificity for detecting women with salpingitis.83 Because of the difficulty of diagnosis and
the potential for damage to the reproductive health of women (even by apparently mild PID) and the
benefit of early antimicrobial therapy, health-care providers are now advised to maintain a low threshold
for the diagnosis of PID.83
Laparoscopic diagnosis of PID, which identifies women with salpingitis, is no longer undertaken in women
with a clinical diagnosis of PID. However, clinical information can be used to classify PID as ‘possible’,
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‘probable’ and ‘definite’ PID, based on Hager’s criteria.88,89 Table 1 details the clinical definitions adopted
by Taylor-Robinson et al.,88 based on a modified version of the Hager criteria, and which were used to
estimate the proportion of women with salpingitis following a clinical diagnosis of PID. This classification is
often used in clinical trials such as POPI, and in studies of patient data such as the GPRD database,
although in recent work using GPRD ‘probable’ PID includes chronic disease as well.19,88,90 As the
probability that patients diagnosed with PID based on clinical presentation have salpingitis decreases, the
likelihood of other diagnoses, such as endometriosis, irritable bowel syndrome and functional
pain, increases.
For the purposes of this report we define clinically diagnosed PID as women with ‘probable’ and ‘definite’
diagnostic criteria. Women with ‘possible’ diagnostic criteria may be treated for PID depending on to
where they present, which is probably less likely in primary care compared with departments of
genitourinary medicine (GUM) as there is greater expertise in managing PID in the latter setting. Diagnostic
thresholds have changed over time as the role of PID in reproductive damage has been recognised.
Accordingly, the proportion of women with PID regarded as having ‘probable/definite’ or ‘possible’ PID
diagnostic criteria is likely to have increased over time, with fewer women remaining symptomatic and
undiagnosed.19,90 This probably began in the mid to late 1990s in the UK.
Infections associated with pelvic inflammatory disease
Pelvic inflammatory disease is not exclusively caused by CT, with about 30–40% of PID cases being
CT+37,82 (see Chapter 7). A range of STIs have been implicated, particularly gonorrhoea and, more recently,
Mycoplasma genitalium.63,83,91 It is also likely that PID can be caused by micro-organisms associated with
bacterial vaginosis (BV), which is commonly present in women with PID.63,83,92 These micro-organisms
include Gardnerella vaginalis and anaerobes (including Prevotella, Atopobium and Leptotrichia),83,93 which
are probably sexually transmissible but would not be classed as STIs.92,93 Anaerobes are isolated more often
from women with severe PID. As a consequence, broad-spectrum antibiotic therapy is recommended for
PID to cover Neisseria gonorrhoeae, CT, and a variety of aerobic and anaerobic bacteria commonly isolated
from the upper genital tract in women with PID.83
Bacterial vaginosis is a common condition affecting women of reproductive age.94,95 It is a condition
characterised by vaginal flora imbalance, in which the normal plentiful lactobacillus is scarce and other
anaerobic bacteria abundant.94–96 It is present in between 12% and 25% of women.94,95 Women are
usually asymptomatic and if symptoms are present these consist of vaginal discharge with or without an
odour.63 Only some BV-associated bacteria have been associated with PID, and it remains to be established
whether or not these bacteria are indeed causally implicated in reproductive damage.63
TABLE 1 Definition of clinical diagnosis of PID
PID diagnosis Definition
Definite Recent-onset lower abdominal pain; cervical excitation with or without uterine/tenderness, with adnexal
tenderness with or without mass, and clinically unwell, and LGTI
Probable Recent-onset lower abdominal pain with (1) cervical excitation/uterine tenderness and adnexal
tenderness or (2) cervical excitation/uterine tenderness or adnexal tenderness with evidence, LGTI or
clinically unwell
Possible Recent-onset lower abdominal pain and only one of the following: (1) cervical excitation/uterine
tenderness or (2) adnexal tenderness
or
Chronic lower abdominal pain, not clinically unwell and no evidence of LGTI and only one of the
following: (1) cervical excitation/uterine tenderness or (2) adnexal tenderness
LGTI, lower genital tract infection.
Definitions based on Taylor-Robinson et al.88
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Undiagnosed pelvic inflammatory disease and asymptomatic pelvic
inflammatory disease
Over 50% of PID episodes in the UK are treated in primary care, but it is also treated in STI clinics and in
hospital. Data from the GPRD, Hospital Episode Statistics (HES), and KC-60 returns from STI clinics for
2002 are shown in Table 2, which is based on the ‘definite/probable PID’ definition.90 We have assumed
that women admitted for inpatient treatment of PID in the HES data, and women diagnosed at
departments of GUM by clinicians trained in diagnosing PID, are ‘probable’ or ‘definite’ cases. An
unknown proportion of diagnosed PID episodes meeting these definitions will be recorded under more
than one of these locations, although the study by Nicholson et al.97 using the GPRD database suggests
that approximately one-third of cases of probable or definite PID diagnosed in primary care have been
treated elsewhere.
These figures on diagnosed PID incidence certainly underestimate the true incidence of PID episodes.
It is widely accepted that a relatively high proportion of PID is undiagnosed. This is inferred from historical
studies of TFI. PID is considered to be a necessary precursor of TFI,98 and yet a high proportion of women
with TFI have no history of clinical PID.99–102 Wolner-Hanssen103 found that only 34% of TFI cases reported
a previous diagnosis of PID. However, only 11% reported never having had clinical symptoms.103 The
implication is that a large proportion of the PID that causes TFI is undiagnosed, but it is relatively unusual
for PID which causes reproductive damage to be completely asymptomatic. We therefore distinguish
diagnosed PID, by which we mean PID meeting the ‘probable/definite’ criterion, undiagnosed symptomatic
PID and asymptomatic or silent PID (see Chapter 7).
Therefore, even if we maintain a single diagnostic criteria, such as ‘probable/definite’, across all studies,
and these definitions were consistently applied – which we know is not the case – it would still be the case
that the proportions of PID that would be ascertained would depend on the study design. For example,
the routine PID statistics in Table 2 depend on patient self-referral, whereas in a prospective study of
women attending a STI clinic, or in the context of a screening trial, a higher proportion of PID meeting the
same definition may come to light (see Chapter 7).
Current guidance on pelvic inflammatory disease management
Recognising the difficulty of achieving a definitive diagnosis, the British Association for Sexual Health and
HIV (BASHH) guidelines83 emphasise a low threshold for empiric treatment, to lower the risk of subsequent
EP and infertility. The same advice is seen in primary care guidelines and the National Institute for Health
and Care Excellence (NICE) Clinical Knowledge Summaries.104,105 However, the latter cites multiple partners,
a recent new partner, young age and previous history of PID or a STI as risk factors for PID. The NICE
Clinical Knowledge Summary104 explicitly states that ‘PID is almost always due to a sexually transmitted
disease’. This contrasts somewhat with BASHH guidelines,83 which acknowledge that only 25% of cases of
can be accounted for by CT or N. gonorrhoeae. US guidelines highlight young age as a risk factor but
avoid citing any behavioural risk factors.63 All guidance advocates early use of broad-spectrum antibiotics.
TABLE 2 Number of incident cases of PID in England, 2002
Age (years) HES GPRDa GUMb Female population
16–19 1233 5083 3212 1,199,600
20–24 3101 8842 4399 1,519,100
25–34 9756 14,932 3919 3,502,100
35–44 10,526 9609 1388 3,795,600
GPRD, General Practice Research Database; GUM, genitourinary medicine; HES, Hospital Episode Statistics.
a Definite and probable PID as defined in French et al.90
b Data by age not available for 2002, so we assume that the age distribution for these data was the same in 2002 as
in 2009.
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Age profiles of Chlamydia trachomatis and pelvic inflammatory disease
In this section we briefly compare the age profiles of CT and PID, to draw attention to an important, but
generally overlooked, issue in the natural history of CT. Estimates of CT prevalence are approximately
fourfold higher in women aged 16–24 years than women aged 25–44 years.106 The age profile of incident
PID is very different. HES show an increasing trend in PID incidence rates with age (see Table 2). Evidence
from the GPRD shows incidence rates that are higher in the age group 20–24 years, but the difference in
PID incidence rates across ages is far less than the difference in chlamydia prevalence. The age profile
in PID presenting in STI clinics is more similar to the age profile of incident CT, in that there is a relatively
high proportion of young women. However, of the three sources, these make up the smallest proportion
of diagnosed cases.
There are three plausible contributory reasons for these discrepancies in age profile. First, the PID diagnosis
rates may increase with age. There is some evidence that the severity of PID might increase with the
number of previous PID episodes. The proportion of women who become infertile because of tubal
scarring from adhesions, and the proportion of pregnancies that are ectopic, appears to increases
multiplicatively with number of previous PID episodes,33 which is likely to be positively correlated with age,
and it is likely that more severe PID has a higher chance of being diagnosed and hospitalised. This
hypothesis is supported by the dramatic increase with age of hospital-diagnosed PID.
A second possibility is that the probability that a case of CT causes an episode of PID may be higher in
older women, perhaps owing to more previous episodes of CT, other STIs and PID.107
Finally, the proportion of PID that is caused by CT may decline with age (see Chapter 7), possibly because
of differences in the age distributions of the other risk factors for PID. Facultative and anaerobic bacteria
are frequently isolated from women with PID; although often present in the normal vaginal flora, they
occur more often and in increased concentrations, in women with BV,82 which has been associated with
PID. Interestingly, isolation of endogenous bacteria from the upper genital tract appears more common in
older women and may be associated with severe suppurative disease, including tubo-ovarian abscess and
recurrent PID.82,108 Although BV does not appear to be associated with age, it is associated with increasing
lifetime number of sexual partners.94,109
These three different explanations would have quite different public health implications. Analyses in
subsequent chapters throw some light on the issues, but we do not believe it can be resolved on the basis
of existing evidence, and this is addressed in the research recommendations in Chapter 12.
Salpingitis
Much of our knowledge of the impact of PID on reproductive health is based on the Swedish Lund
study,33,34,84,110 which recruited PID cases admitted to hospital between 1960 and 1984, and followed
them forward to observe reproductive outcomes over a median 8-year period. The study was based on
laparoscopic examination. Women with macroscopic inflammation of the fallopian tubes, ‘salpingitis’, were
distinguished from PID cases with no macroscopic inflammation at laparoscopy. The more severe the
macroscopic salpingitis, the greater the risk of adverse reproductive outcomes. Remarkably, the incidence
of TFI and EP in the control group, those admitted to hospital with PID but with no salpingitis on
laparoscopy, appeared to be no different from the general population, even though a lower genital tract
infection was identified in the majority of cases.33 It is likely that many of these women would have had
endometritis or microscopic inflammation of the fallopian tubes but some will have had other pathology
or causes for their pelvic pain.83,111,112 Incidence of EP and TFI among women with salpingitis depended on
age, the number of clinical PID episodes – and thus presumably on the number of salpingitis episodes –
and on the severity of the salpingitis on admission (see Chapters 9 and 10).
These results raise the question: what proportion of clinically diagnosed PID is accompanied by an
underlying macroscopic salpingitis? Unfortunately for our purposes, laparoscopy is no longer a routine
procedure in examination of PID, so it is not possible to match up the definitions of PID and salpingitis
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employed in the Lund study33,34,84,110 to current practice or to recent research studies. However, we can
deduce from the fact that they were hospitalised that the cases of PID recruited into the Lund study33,34,84,110
would be at the more severe end of the spectrum. What is known is that the proportion of clinical PID cases
with salpingitis fell during the course of the Lund study33,34,84,110 from an initial 80% down towards 60%
among those recruited at the end of the study.110 In the analyses we present in Chapters 10 and 11, we have
assumed that the proportion of PID cases with salpingitis has continued to fall.
Finally, there is little quantitative information on whether the organism causing PID impacts on the
probability or extent of reproductive damage. In the Lund study33,34,84,110 it was observed that the severity of
CT salpingitis at laparoscopy was generally greater than would be expected from the relatively benign
clinical picture.101 For PID with salpingitis (including that caused by CT), delay of treatment for more than
3 days from onset of symptoms increases the likelihood of tubal damage.84 Therefore, if the clinical
symptoms of CT-related PID appear to be less severe than gonococcal PID, it is possible that women with
chlamydia PID may present later than women with gonococcal PID,101,113–115 and as a result suffer more
reproductive damage. The same comments apply to women with asymptomatic PID.
Ectopic pregnancy
In a normal pregnancy the fertilised egg implants in the uterus, where it divides and develops into an
embryo and, eventually, a fetus. An ectopic pregnancy is one in which the egg implants outside the uterus,
most often in the Fallopian tubes. EP is an important cause of maternal morbidity and, occasionally,
mortality.116 It usually presents with acute symptoms including pelvic pain and vaginal bleeding, although
increasingly EPs are diagnosed before the onset of symptoms, allowing early, conservative treatment.
Prevention of maternal morbidity and mortality relies on early diagnosis and appropriate management,
which is almost invariably in a specialist setting.116
Among the common causes of EP are fallopian tube damage because of salpingitis, surgery and smoking.116
In a normal pregnancy, cilia in the Fallopian tubes carry the fertilised egg towards the uterus. If the cilia are
damaged, the egg may become lodged in the tube. PID is an inflammatory process that can result in the
development of scar tissue in the tubes. If both tubes become entirely blocked then fertilisation cannot take
place at all. This constitutes a single common pathway leading from salpingitis to both EP and to TFI (which
will be exploited in the modelling in Chapters 9 and 10).98,116
Data on overall EP rates in England are based on HES (HES code O00).117 If these are compared with
conception rates (maternities plus abortions),118 it is evident that the EP rate, defined as the number of
EPs divided by the number of conceptions, has remained remarkably constant between 2000 and 2009
(Figure 3), at around 1% of conceptions. Similar rates have been reported in France, although there was
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evidence that a fall in intrauterine device (IUD)-related EPs had masked a rise in EPs caused by salpingitis.119
EP rates reported in the USA have been somewhat lower, but, again, have remained stable over
recent years.120
Although the overall conception rate falls steeply from the age of 30 years onwards, the proportion of
conceptions that are EPs rises with age (see Figure 3). The same phenomenon has been observed many
times.120–122 This points to the role of cumulative exposure to the causal factors, whether these are smoking
or tubal damage, which can only increase with age.
The fact that EP risk links to cumulative exposure to risk factors, including salpingitis, rather than to, say,
incident exposure, is critical to understanding the role of PID.123 Egger et al.121 report an ecological analysis
of EP rates and CT prevalence by age and location in Uppsala county, Sweden. They establish that the
correlation between CT prevalence and EP rates is strongest in 20- to 24-year-olds, and that it becomes
increasingly weak in the 25- to 29-year-old, 30- to 34-year-old, and finally the 35- to 39-year-old groups.
At the same time the regression of EP rate against CT prevalence becomes increasingly steep, which
would not be expected if variation in EP rates was driven by variation in CT incidence. However, these
phenomena can be readily explained if cumulative salpingitis incidence is the variable determining EP rates.
Most CT occurs in the younger age groups, but current incidence and prevalence become increasingly
poor predictors of cumulative exposure to CT as age increases. On the other hand, the regression against
recent incidence becomes increasingly steep with age – although with increasing error about the
regression – because cumulative incidence is higher per unit of current prevalence. These ecological
observations provide further support for the conclusions we draw from Figure 3 in the previous paragraph.
Another important feature of the relation between salpingitis and EP is the strong ‘dose–response’
relationship reported in prospective studies following women with salpingitis. The Lund studies,33,110,124 in
particular, followed women for an average of approximately 8 years from hospitalisation for PID. The
proportion of women whose first subsequent pregnancy was an EP increased systematically with severity
as determined by laparoscopy, and also with the number of previous salpingitis episodes.124 Among the
women who subsequently conceived, those with two, or three or more previous episodes of salpingitis had
a non-linear increase in risk of EP (see Chapter 9). A similar pattern of findings was reported for TFI.33 A
record linkage study in the USA following high-risk women with a diagnosed CT infection over an average
6-year period again reported a similar increase in risk of EP, but this time in relation to the number of
previous CT infections rather than the number of PID episodes.107 These studies constitute some of the
strongest evidence for a causal link between salpingitis (PID) and EP. Of particular significance is the fact
that the dose–response relation is exactly what would be expected on the basis of cumulative exposure to
risk factors. In addition, the similarity of the ‘dose–response’ effect attaching to CT and salpingitis suggests
that the risk of EP may be approximately the same whatever the cause of the salpingitis, although the
agreement could be coincidental if the aetiology changes with age in a way that approximately cancels out
any differences.
Tubal factor infertility
Women are usually considered ‘infertile’ if they have tried to have a baby for ≥ 1 year and have been
unsuccessful. Defined in this way, infertility is clearly not an absolute condition, as only 85% of couples
succeed in conceiving within 1 year, whereas 95% may succeed within 3 or 4 years.125 This immediately
reveals a major difficulty in the study of infertility, as apparently minor changes in definition readily
generate threefold changes in the number considered infertile.
Infertility is a complex construct: the infertile population includes both couples who are sterile, and couples
who are subfertile. The former cannot conceive, but the latter can, if given enough time. Population
surveys of infertility in the UK126–128 distinguish between primary unresolved failure to conceive, between
2% and 3.5%, representing women who have not conceived at the end of their reproductive life, and
secondary infertility, which includes women who have conceived at least once, but who subsequently
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experience difficulty in conceiving. Secondary infertility must be included in our study because it is quite
possible for salpingitis to be acquired by women who have already had children.
Surveys reporting secondary infertility have reported the numbers who have experienced at least two years
of being unable to conceive.126–128 According to one study,126 the secondary infertility group included
women who had already had one or two, and in one case eight, previous children. The 2–3.5% estimates
of secondary infertility from these surveys are therefore probably an overestimate, but the extent of the
overestimate depends on the distribution of duration of infertility.
A further problem is the difficulty of estimating the proportion of women who are infertile at any
particular age. Not only is it necessary to ensure that their infertility has lasted sufficiently long to meet a
specified definition, but infertility can only manifest itself, and thus be diagnosed, in women who are
trying to become pregnant, although the underlying condition may have been present for a long time.
This contrasts with the study of EP where reliable age-specific incidence data are available from routine
hospital statistics.
To avoid these problems in this monograph we have followed a strategy that has been adopted in a
number of epidemiological studies of infertility in the UK,126–129 which is to focus attention on the
proportion of the population who are infertile, which specifically means unable to conceive, at the end of
their reproductive life, which we take to be the age of 44 years (see Chapter 10).
Tubal factor infertility is one of several causes of female infertility (Figure 4).130 According to a 2006 survey
by the Human Fertilisation and Embryology Authority (HFEA), 22% of those being treated by in vitro
fertilisation (IVF) have TFI (Table 3), but a further 30% of infertility in women undergoing treatment
is unexplained.131
The Lund studies124 established the key relationship between PID and TFI, which parallels the relationship
between EP and TFI. A higher rate of TFI was observed only in PID cases with confirmed salpingitis on
laparoscopy, and the risk increased with the number of subsequent PID episodes. Critically, none of the
601 control group women with PID who were not confirmed as having salpingitis went on to have TFI.
A difference between EP and TFI, however, is that TFI can occur only following an infective process,35
namely salpingitis; EP on the other hand has a multifactorial aetiology.
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There is an extensive literature on the role of CT in TFI. Much of it consists of retrospective studies
demonstrating a higher prevalence of serum antibody to CT in TFI cases compared with non-TFI controls.
Because of the poor sensitivity and specificity of the assays, the imprecise characterisation of their
diagnostic accuracy, and the variation in cut-offs, these studies have not generated reliable quantitative
estimates of the role of CT in TFI. However, a number of these retrospective studies have reported marked
differences in the titre distributions in antibody-positive TFI cases and controls (see Chapter 11). The higher
prevalence of high titres in TFI cases constitutes powerful evidence of the causal role of CT.
Chronic pelvic pain
Chronic pelvic pain is a well-recognised complication of PID, which has a significant morbidity.33,132 It is
defined as non-menstrual pain of ≥ 6 months’ duration that is severe enough to cause functional disability
or require medical or surgical treatment. Chronic pelvic pain is common in women, with an estimated
prevalence of 3.8% in women aged 15–73 years in the USA. Often the aetiology is not clear. There are
many physical disorders of the reproductive tract, gastrointestinal system, urological, musculoskeletal
system and psychoneurological system that may be associated with chronic pelvic pain in women,132 and
these may often co-exist. Although adhesions resulting from pelvic inflammatory disease are diagnosed
in about 25% of women undergoing investigation, it is not clear whether these are always the cause of
the pain.132 The prevalence of adhesions in women with chronic pelvic pain will vary depending on the
population studied. Most information is obtained from women attending secondary and tertiary care, who
are likely to experience more severe forms and may not be representative of women with chronic pelvic
pain in the community. An accurate diagnosis of pelvic adhesions is only possible following laparoscopy
and, even then, it is not possible to ascertain the cause, as the infectious agent will have usually resolved
prior to investigation.
We have therefore chosen not to investigate chronic pelvic pain because of the paucity of data on the role
of PID, and the lack of evidence on the contribution of CT.
Premature delivery, neonatal pneumonia and conjunctivitis
There is conflicting evidence that CT may result in miscarriage and/or premature labour. One hypothesis is
that adverse pregnancy outcomes may only occur following primary infection. No studies have investigated
this since 1990. In view of the limited and conflicting data on adverse pregnancy outcomes, we decided
not to include this in our work plan.
TABLE 3 Tubal factor infertility by age, 2002
Age
(years)
Number of
cycles in
women
with TFI
(B)
Average
number of
cycles per
woman
with TFI
(C)
Number of
women
with TFI
adjusted for
mean
number
of cycles:
(D)= (B)/(C)
Number of
cycles in
women
with other
cause
infertility (E)
Average
number of
cycles per
woman with
other-cause
infertility (F)
Number of
women with
other-cause
infertility
adjusted
for mean
number
of cycles:
(G)= (E)/(F)
Proportion of
women treated
in HFEA with TFI:
(H)= (D)/((D)+ (G))
18–34 4550 2.20 2071 16773 2.43 6916 0.23
35–37 2247 2.51 896 8618 2.80 3076 0.23
38–39 1192 2.70 442 4404 2.92 1508 0.23
40–42 858 2.81 305 3663 3.13 1171 0.21
43–44 216 2.97 73 1102 3.07 359 0.17
45–50 86 3.37 26 767 3.17 242 0.10
Source: HFEA.
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Chlamydia trachomatis is transmitted to approximately half of children of mothers infected with CT and
about 10–50% of these develop neonatal conjunctivitis and/or pneumonia. This was recently reviewed by
Thorne133 for the NSC. Data in the UK are based on those presenting to hospital and thus biased towards
severe and prolonged cases. Neonatal infection with chlamydia is usually asymptomatic, and the most
common manifestations (conjunctivitis and pneumonia) are non-specific. Furthermore, chlamydial disease is
usually of a mild to moderate nature and easily treated or is often self-limiting. For these reasons, perinatal
and neonatal outcomes have not been included in this study.
Summary of clinical definitions and assumptions
1. The monograph focuses on:
i. the mean duration, incidence, and prevalence of CT
ii. the causal relationship between CT and PID
iii. the relation between PID and salpingitis, by which we mean macroscopic inflammation of the
fallopian tubes
iv. the relationships between salpingitis and EP, between salpingitis and TFI, and between TFI and CT.
2. Premature delivery, neonatal outcomes and chronic pelvic pain are not covered in this report.
3. When referring to clinically diagnosed PID, we are referring to ‘probable’ and ‘definite’ PID as
previously defined.88,90
4. We distinguish between diagnosed PID, undiagnosed symptomatic PID, and asymptomatic or
silent PID.103
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Chapter 3 Methods
Objectives
To set out methods used for:
1. evidence identification
2. Population Excess Fractions (PEFs)
3. evidence synthesis
4. model critique and model choice.
Introduction
This chapter sets out the methods used in evidence identification, evidence synthesis modelling and model
critique. We provide only generic descriptions of our approach to these components of the project. The
actual statistical synthesis models themselves, and the specific forms that the model critique took, are set
out in detail in each of the subsequent chapters. We also include a section defining PEF and outlining the
different ways PEFs can be estimated, because these feature in several chapters.
Evidence identification
The task of identifying data sources to inform the full range of CT natural history parameters from CT
incidence through to EP incidence and TFI prevalence more closely resembles the task faced by
investigators populating a decision-analytic model in a limited period of time than the task of systematic
review. Although systematic review methods are considered ideal, it is uncommon for them to applied
comprehensively in a multiple-parameter setting.134 We have therefore relied on ‘high-yield’ and
‘snowballing’ strategies135 that efficiently identify a large number of relevant data sources from a small
number of cited references rather than on exhaustive systematic review. It is recognised that this
introduces a risk of missing relevant sources. However, there is limited evidence comparing the sensitivity
of the two approaches, particularly in the context of natural history parameters.135 Nor is it clear that
‘sensitivity’ is an appropriate criterion, as the issue is not whether absolutely every literature source
has been identified, but whether further searching would reveal anything that would change
the conclusions.135,136
The search strategy was therefore to identify relevant literature cited in a series of dynamic modelling and
cost-effectiveness analyses,1,2,20,74,98,106,137–145 and review papers.20,61,62,74,98,106,139,142–147 Cost-effectiveness
analyses were used because their authors are obliged to have parameters with specified values, and must
therefore cite the sources they used. A second tier of identification was based on a citation search on
selected epidemiology papers identified in the first round. In addition the collaborative group undertaking
the project included epidemiologists and STD clinicians with a very wide range of research experience in
most aspects of chlamydia epidemiology, treatment and referral pathways in the UK, and routine and
ad-hoc surveys on chlamydia and its sequelae in the UK. This formed an ‘in-house’ expert group who were
consulted on the completeness of the literature identification, as well as on the interpretation of the data.
Finally, in our study of the duration of CT infection (see Chapter 4) we consulted a panel of internationally
recognised experts to ask if they knew of further papers that we had missed.
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An important series of review papers published in Journal of Infectious Disease 201038 provided a
particularly valuable resource. These were from an expert group set up by the CDC, Atlanta, Georgia,
which included many of the world’s acknowledged leaders in various fields of chlamydia research. The
CDC expert group employed a more formal systematic review methodology. We have not made a formal
study of whether or not these reviews identified papers that had not been identified by our searches, and
we therefore cannot claim that the CDC project validates our approach. However, we believe that their
work minimises the risk that we have overlooked information that is capable of having a material effect on
the analyses we have produced.
The MPES approach, explained below, allows us to combine many different types of information in order
to draw conclusions. For example, as we shall see in subsequent chapters, studies of different types may
form a ‘chain of evidence’,50 which can be put together to inform a prospective relation between CT and
TFI. The results can then be compared with retrospective evidence on the relation between CT and TFI,
which can also be derived by combining several kinds of data source. The question of which is most likely
to provide an accurate estimate must be viewed with an open mind, bearing in mind both the relevance of
the studies and their internal validity.
This contrasts somewhat with standard systematic review methodology, which tends to favour prospective
over retrospective studies, and is not obviously compatible with reasoning via chains of evidence. For
example, a systematic review of the causal effect of CT on TFI trawled through several thousand abstracts
and identified a single study, which was then deemed to be inadequate, with the conclusion that no
quantitative estimates could be derived.145 This conclusion seems unwarranted as it would effectively rule
out both retrospective evidence and estimates derived from a chain of evidence. In addition, systematic
review would not allow certain kinds of evidence which are essential to our project, such as routine
statistics, to be considered at all.
As noted above, a risk of missing sources of evidence would still remain even if we attempted to devise a
formal systematic review on each parameter in every model. The strength of the MPES methodology,
described below, is that it can combine direct evidence on model parameters with independent evidence
on functions of model parameters. This raises further questions on whether or not evidence sources have
been missed, as we know of no formal methods to define all the functions of parameters on which data
might exist, let alone search strategies that could efficiently identify literature on each function.
However, it will become clear in subsequent chapters that, whatever the advantages and disadvantages
of our approach to literature identification, we have combined and cross-checked many times more
information on chlamydia, its incidence, prevalence and sequelae than previous researchers. Although we
cannot be certain that every piece of relevant information has been incorporated, we believe that it is
unlikely that anything has been missed that could have a material impact on our conclusions. It is in any
case easy to incorporate further data within the framework we have created.
Details of included studies and reasons for study exclusion are set out separately for each chapter or in the
appendices. Where appropriate, appendices are also used to explain how the data used in our analyses
were derived from the published information. Further appendices set out the actual data as it was used in
the data analyses, as well as the program code used to analyse it.
Population Excess Fractions
Population Excess Fractions feature in several places in the monograph. We outline the definition and
estimation methods, as this has been an area of confusion in epidemiological and lay literature.148 The PEF
is the proportional reduction in disease risk that would be achieved by eliminating the exposure of interest
from the population, assuming the exposure is causally related to the disease.149 A number of formulae
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have been derived by which the PEF can be estimated from epidemiological data. The formula giving an
estimate from case–control or prospective studies is:
PEF =
π.(RR−1)
π.(RR−1)+1
(1)
Here, RR is the relative risk of the disease in exposed groups relative to unexposed groups, and π is the
prevalence of the exposure in the population of interest. Strictly RR should be an incidence ratio, or hazard
ratio (HR), but the formula is a reasonable approximation where a relative risk is used, as long as incidence
is low during the period under consideration. If the incidence is high enough to reduce the risk set by
more than say 20%, the approximation will become poor.
There are several further points to note. First, the formula can be applied to case–control studies,
substituting the odds ratio (OR) in place of the RR, if the study recruits an incidence density sample or if
the disease is sufficiently rare for the OR to be a reasonable estimate of the RR. Second, the presence of π
in the formula reminds us that the PEF has only a ‘local’ interpretation: it is not only a property of the
disease and the exposure, but also of the time and place where the data were collected.
The most important caveat is that the formula is correct only when there are no confounding factors.
Suppose, for example, we were considering the proportion of PID that is attributable to CT infection.
We could estimate the OR in studies comparing CT prevalence in PID cases and non-PID control subjects.
Typically, an OR of ≥ 6 is found in such studies (see Chapter 7). However, PID can be caused by other STIs
as well as CT, and we can anticipate that women infected with CT are also more likely to be infected with
other STIs as well. In the extreme case it would therefore be possible to observe a high PEF, even if there
was no causal relation between CT and PID. Because of this, in the presence of positive confounders,
we would have to consider the estimated PEF to be an upper bound. However, RRs adjusted for
confounders can be used in Equation 1.
A simpler formula can be used in situations where there are no confounding variables:148
PEF =
IPPopn− IPUnExp
IPPopn
(2)
In this case IPPopn and IPUnExp are the cumulative proportions of the total population and the unexposed
group developing the disease in a specified time period. (The comments above about rates and risks apply
equally in this case.) Here the PEF can be interpreted as the proportional reduction in incidence in the
population if the exposure was removed.
In the context of a randomised trial this corresponds to the idea of relative risk reduction (RRR),
the proportion of incidence in the control group that can be eliminated by treatment:
RRR =
IPCo− IPTrt
IPCo
(3)
In CT screening trials (see Chapter 7), the outcome is incident PID in a 1-year period, the control group is
the untreated population, and the treated group is screened and treated for CT. If we assume that the
treatment is 100% effective, the RRR is therefore a trial-based estimate of the PEF.
Note, however, the importance of follow-up time in this calculation for these single screen studies.
Screening and treatment for CT ‘work’ by preventing CT that is prevalent at the onset of the study from
developing into PID during the 1-year follow-up. As the follow-up time is extended to 2, 3 or more years,
women in both arms will experience more episodes of PID, and the RRR will converge towards zero.
Further, this will be case whether the further PID episodes are CT related or not.
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It is necessary, therefore, to consider models of PID incidence over a relatively long term, and compare
scenarios in which (1) CT is a contributing cause of PID, and (2) CT does not exist. Estimates of the PEF
taking the form of Equation 2 can be computed from these models of long-term effects.
Because we estimate a number of PEFs in the report, we use the notation PEF (risk factor←disease) to
stand for the PEF of the disease attributable to the risk factor.
Statistical methods
Bayesian Markov chain Monte Carlo in WinBUGS
We have adopted Bayesian methods throughout this monograph.150 Bayesian inference seeks to find the
probability distribution of parameters (the posterior distribution) given the data (likelihood) and a prior
distribution representing beliefs before the data were available. Classical inference (maximum likelihood)
considers the parameter values at which the probability of obtaining the data is greatest. The Bayesian
viewpoint is generally considered to be the more ‘natural’, in that people want to know what they can say
about parameters given the data, not what they can say about the data given specific parameter values.
However, it has been considered to have two disadvantages: the ‘subjectivity’ of the prior distribution and
the computational difficulty of carrying out the high-dimensional integration required. We have avoided
the subjectivity issue by using vague priors wherever possible (but see below). Advances in statistical
theory151 and computing power, and the development of highly flexible programming packages, such as
WinBUGS,44 have not only solved the computational problems, but also have made Bayesian methods the
common choice for complex synthesis.42
The general principles of Bayesian MCMC are set out in standard texts,152 and the procedures for
Bayesian MCMC using WinBUGS are to be found in the WinBUGs on-line user manual.44 The WinBUGS
user is required to specify a model in algebraic terms. The model consists of (1) specification of prior
distribution for ‘basic‘50 parameters; (2) definitions of ‘functional’ parameters in terms of basic parameters,
effectively the ‘model’; and (3) specification of data likelihoods. Each item of data informs either a basic or
a functional parameter.
Given some starting values for the basic parameters, parameter distributions converge to the joint posterior
distribution. The WinBUGS 1.4.3 software makes use of a number of different MCMC algorithms. The
most commonly used is Gibbs sampling,153,154 in which samples are drawn from the conditional distribution
of each parameter in turn, conditioning on the other parameters and on the data. Eventually, the marginal
distributions of the parameters converge to their true marginal posterior distribution. In essence, all the
parameters are uncertain: the marginal distribution expresses the uncertainty in each parameter, averaging
over the distributions of all the other parameters.
Users find out about the posterior distributions of parameters of interest by sampling from them. Posterior
means or medians are commonly cited, along with 95% CrIs or posterior standard deviations (SDs). CrIs
have the interpretation that many people attribute to classical confidence intervals (CIs): namely that they
express the probability that the parameter lies within that range, given the model, priors and data.
Posterior SDs have the same interpretation as standard errors of estimates in classical statistics.
Because of the need for the process to converge, MCMC users must pay careful attention to a number of
technical issues. First, diagnostics must be used to assess whether or not the process has converged. The
Brooks–Gelman statistics155 are commonly used as these are available in WinBUGS. The initial samples –
the ‘burn-in’ – are discarded. Second, a large number of posterior samples may be needed to obtain
accurate summary statistics. It is usually recommended that the process is run until the Monte Carlo error
in the mean is < 5% of the posterior SD. It is also good practice to base posterior inference on more than
one MCMC chain, because occasionally chains converge to different posteriors. Our practice here is to
use two chains, to check they converge to the same point, to use a conservatively large burn-in period,
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and also conservatively large numbers of posterior samples. In all the analyses in the monograph
convergence has been achieved within about 25,000 samples, and we discard the first 50,000 as ‘burn-in’.
Posterior inference is based on 200,000 samples, 100,000 from each of two chains.
Sensitivity analyses
A further issue arising in Bayesian analysis is sensitivity to prior distributions.150 Our general approach has
been to introduce all information through likelihoods, and to put vague priors on all the basic parameters.
When data are relatively sparse, or when the number of parameters to be estimated is large in relation to
the amount of data informing them, results can be sensitive to the distributional form of the priors.
Sensitivity analyses are therefore included wherever this is the case. The main findings from sensitivity
analyses and their implications for the conclusions are discussed in the main text, but the full details are
provided in the appendices.
In some cases it is preferable to fix parameters at a range of set values, to see the impact on the final
results, rather than give the parameters a distribution. This, again, may generate a series of sensitivity
analyses that are reported in full only in the appendices.
Model diagnostics and model selection
Our methods for assessing goodness of fit are based on Spiegelhalter et al.156 The key statistic is the
posterior mean residual deviance D, corrected for the saturated model. This is the familiar residual deviance
statistic from classical statistics, except that it is computed on each MCMC cycle rather than at the
maximum likelihood values of the parameters. As a result a distribution of samples is generated and the
mean is taken as a measure of goodness of fit. In a good-fitting model, the summed residual deviances
should approximate to the number of data points.156,157 When comparing models with different numbers
of parameters a common approach in classical statistics is the Akaike Information criterion,158 in which the
models are ‘penalised’ by adding the number of parameters to the deviance statistic. We adopt this
approach where appropriate using the Bayesian Deviance Information Criterion (DIC):156,159 DIC = D + pD,
where pD represents the effective number of parameters. This statistic is calculated by WinBUGS and is
available through the DIC tool. In models lacking any hierarchical elements, pD is simply the number of free
parameters in the model. With hierarchical models it reflects the degree of shrinkage. We make sparing
use of hierarchical models in this monograph because of difficulties of interpretation (see Chapter 4),
and they play no role in our final estimates.
D and DIC can be examined as measures of global model fit, or the contributions of individual data points
to D and DIC can be examined in order to locate more precisely the particular data points that are in
conflict with the other data under the model. It should be emphasised that these statistics are sensitive to
prior distributions. This is one of the reasons why we tend to put vague priors on all parameters and
introduce all of the information through data likelihoods. In this way, we can use residual deviance to
assess conflict between different data sources.
There are exceptions to this rule, however, where we introduce evidence through informative priors.
This is done where the parameter’s role is local to a source of data, or when it is not central to the issues
under study. In these cases, we may also use the WinBUGS ‘Cut Function’.44 This is a special function in
WinBUGS that allows users to impose a prior distribution on a set of parameters that is not updated by the
likelihood (the posterior is equal to the prior). The flow of information from elsewhere back to those
parameters is blocked. This is done in cases when we wish to impose a belief (probability distribution) on a
set of parameters, which we do not want to be altered by the data, or more pertinently, when we want
the key parameters to be estimated conditional on a set of specific assumptions over which we have
complete control.
An example that illustrates the reasoning behind this is the duration of symptomatic CT infection in
women. It was difficult to source evidence for this parameter from formally collected data, and we turned,
instead, to expert clinical opinion. The duration of symptomatic infection is the sum of the ‘incubation
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time’ between infection and the appearance of symptoms; the time from symptoms until treatment is
obtained; and the time from treatment to clearance of infection. It was considered by clinicians that a
uniform distribution between 4 and 8 weeks would represent clinically informed belief about this
parameter, and this was the chosen prior. This information was combined with information on incidence,
prevalence, duration of asymptomatic infection, and the proportion of infections that are symptomatic,
all of which had been based on formal consideration of likelihoods of data sourced in a reproducible way.
If all the evidence was combined without the ‘cut’ function, the incidence and prevalence information
would have changed our view of the duration of symptomatic infection.
In our view, this was not appropriate. We therefore used the ‘cut’ function to prevent this flow of
information between sets of parameters. This allows us to estimate the other parameters, conditional on
the assumption that this duration parameter is 4–8 weeks. This is clear and reproducible. If we built a full
probability model with feedback, we would have to report that the parameter estimates were conditional
on having a prior of 4–8 weeks on the duration parameter, but leading to a posterior distribution for
duration that was somewhat different. We do, of course, assess the sensitivity of the results on incidence,
prevalence, and other parameters to this assumption.
WinBUGS Development Interface and WinBUGS Differential Interface
WinBUGS itself has a limited repertoire of mathematical functions and statistical distributions. However,
WBDev (WinBUGS Development Interface)160 allows users to specify their own mathematical subroutines in
the Component Pascal programming language. Although the functions must be evaluated on every
MCMC iteration, the programming is ‘hard wired’ in a way that allows for very efficient computation.
WBDev is used in to solve the discrete time Markov chain for repeat PID in Chapter 8.
A second WinBUGS ‘add-on’, WBDiff (WinBUGS Differential Interface)161 allows users to specify systems of
first-order ordinary differential equations, which are solved on each MCMC iteration using the Runge–Kutta
method. WBDiff is used to solve the equations relating transition rates to transition probabilities in the
continuous time Markov model fitted in Chapter 6.
When these add-ons are used, the WBDev and WBDiff code are provided in the appendices.
Directed acyclic graphs (influence diagrams)
The directed acyclic graph (DAG), or influence diagram, is a way of portraying the relationships between
the data and the model parameters. The DAG is a formal entity in Bayesian statistics, and, in the WinBUGS
language,44 it is in fact possible to specify a model as a DAG rather than write WinBUGS code. In this
monograph, following the previous work in Bayesian evidence synthesis,42,50,52 we use schematic DAGs to
show how all of the data sources ‘fit together’ around the synthesis model.
The schematic DAG in Figure 5 illustrates how they are used and how they should be interpreted. The
figure shows four numbered data items in rectangles, and five model parameters α, β, γ, δ, θ in ellipses.
Data 1
(a)
Data 2
Data 4
Data 1
α
α
β
β
δ
γ =
γN
δθ =
Data 1
(b)
Data 2
Data 4
Data 1
α
α
β
β
δ
γ =
γN
δθ =
FIGURE 5 Directed acyclic graph. (a) Two sources of evidence on a parameter; and (b) one source is blocked from
influencing the parameter.
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The direction of ‘influence’ is shown in the direction of the arrows. The model is said to generate the data,
so that the data are always pointed to. (In cases where information is introduced via informative priors,
rather than as data, the information is shown in a rectangle, with an arrow pointing to the parameter.)
Three of the five parameters, α, β, δ have no ‘parents’, that is, no arrows point to them, only from them.
These are called ‘basic’ parameters,50 and they are the parameters that must be assigned prior distributions.
The remaining two parameters γ, θ are ‘functional’ or ‘logical’ parameters, and they can always be defined
in terms of the basic parameters. The functional relationships between parameters are shown as equations
in the ellipses, and these equations would be exactly those in the WinBUGs code.
Note that data can inform either basic or functional parameters. Also, the same model can be
parameterised in many different ways, with different parameters defined as basic or functional. As long as
the data are not too sparse in the relation to the number of parameters, this should not have any material
impact on estimates.
Methods to examine evidence conflict
There are effectively two evidence groups in Figure 5a, each representing a different source of information
on the parameter θ. One source of information is from Data item 4, the other is a combination of
information from Data items 1, 2 and 3. Figure 5a represents a DAG in which both sources of information
are combined to give a pooled estimate of θ. In this situation the inclusion of Data 4 not only informs θ,
but it also feeds back to impact on the estimates of all the other parameters. We can examine conflict
between the two groups of evidence by simply blocking Data item 4, to obtain an estimate of θ in its
absence (see Figure 5b). Similarly, we can block out the other data to see what the estimate of θ would be
if informed from Data item 4 alone. This technique is a version of ‘node splitting’.162,163
A very useful way of assessing conflict between different sources of evidence visually is to plot the
posterior densities. In this way, the posterior distributions of the parameter based on separate sources of
evidence can be compared. The posterior density when the different sources are pooled can also be
plotted on the same graph. This approach has been used by Dias et al.164 in the context of splitting nodes
in mixed treatment comparison evidence networks. A further refinement is to generate ‘significance tests’
based on Bayesian p-values: these test the hypothesis that one source of evidence generates a posterior
distribution that is different from the other source.
Summary
1. Literature identification has been based on a high-yield strategy and snowballing, not on
systematic review.
2. PEF is the proportion of incident cases in the population that would be eliminated by removing
the exposure.
3. The synthesis models are fitted in a Bayesian MCMC framework using WinBUGS.
4. Global measures of goodness of fit, DIC and D, are used to assist model selection.
5. Vague prior distributions are used throughout, so that conflict between evidence sources can be
assessed by goodness of fit.
6. ‘Node-splitting’ methods are also used to assess conflict between different sources of data.
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Chapter 4 Duration of asymptomatic Chlamydia
trachomatis infection
Objective
To estimate the mean duration of asymptomatic infection in women, based on duration studies alone.
Introduction
There have been several attempts to estimate the duration of asymptomatic CT infection. It is intrinsically
difficult to measure because, although one can determine whether an individual is infected by bacterial
culture or DNA amplification, it is not possible to determine for how long the infection has been present.
Further, infected individuals would now normally be treated, so it is not possible to observe the natural life
course of the infection. Studies do exist, however, of untreated women. Previous reviewers have all noted
that the published studies have produced a highly diverse set of estimates but have responded to the
heterogeneity in different ways. Golden et al.139 presented no summary estimate at all, whereas Geisler
et al.74 cited a median of approximately 1 year, based on an essentially narrative review. Korenromp et al.142
derived an estimate of 1.4 years. This was based on an unweighted average of the study-specific estimates,
in order to avoid giving a higher weight to larger studies.
Models of the transmission dynamics of CT have to make assumptions about its duration. Turner et al.,141
citing the reviews by Korenromp et al.,142 and Golden et al.,139 drew somewhat different conclusion from
the evidence, and assumed a 0.5-year duration. Roberts et al.2 chose 0.56 years, citing the well-known
modelling study of Kretschmar et al.,137 which used the results from a duration study by Rahm et al.165
More recently, Althaus et al.166 based their estimate on a single study. It is worth emphasising that,
although these authors have not used exactly the same evidence base, there is considerable agreement
between them on the core studies that need to be included in a review.
In this chapter we compare fixed-effect (FE) and random-effects (RE) models for the duration of CT
infection in a somewhat more formal way than previous authors, using statistical measures of goodness of
fit. But we also re-examine the diverse study designs that constitute the evidence base. This leads us to
propose a latent class analysis of the data, in which there are, in effect, two or three classes of infection,
or apparent infection, each with a different expected duration. We assume that clearance rates within
each class are constant over time, giving us a mixture of two or three exponentials.167 Unlike the standard
FE and RE models, which can be estimated relatively directly from the data, under the latent class models
the study-specific proportions of individuals in each class represent an additional form of sampling
variation. In the methods section (see below), we explain how the patient recruitment and sampling
mechanisms engaged by each study design impact on the data likelihood. In the discussion section
(see below), we consider other survival models and meta-regression models that could have been used,
and briefly assess the scientific plausibility of the mixture-of-exponentials models we propose. The work in
this chapter has been published.168
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Methods
Evidence identification
Our target parameter is the mean duration of an episode of untreated, asymptomatic CT in women.
Studies in any country on any population were included, as long as they reported sufficient information to
determine: numbers at risk of clearing infection, numbers who cleared infection, and total time at risk.
We define an episode of CT as the time from infection to the time that the infection has cleared, in the
absence of treatment. Studies of CT duration have the inherent limitation that patients may clear infection
and be re-infected during the follow-up period. For this reason we consider same-partner re-infections,
which microbiological evidence suggest comprise the great majority of re-infections169 to be part of a
continuous episode. Symptomatic infection is defined as infection that is diagnosed and treated.
We identified studies through three recent reviews,74,139,142 reference searches of published economic
and population transmission models,1,2,8,29,140,141,170–174 and consultation with an expert panel (see
Acknowledgements). A 2012 search identifying papers that had cited the three reviews revealed no
further studies of duration of asymptomatic infection in women. The recent review paper by Geisler
et al.74 was part of an authoritative review of CT epidemiology set up by an expert group of the CDC.38
Two studies175,176 were excluded because patients were treated for CT or other infection soon before
recruitment175 or during follow-up.176 Three were excluded because they provided insufficient
information.177–179 Results from the 11 studies73,79,165,169,180–186 included are shown below (see Table 4).
Initial consideration of the data: study design
The studies differed in their design with some being set in STD clinics, and others based on women
identified as infected by population screening (Table 4). Two were set in antenatal clinics, where women
were screened for CT at a prenatal visit. In most studies, patients were followed forward from an initial
examination, when samples were collected, until they returned for a second visit, when CT status was
assessed again; patients attended for the second test after different intervals but each patient was retested
only once. In other studies,169,180 the same patients were tested repeatedly over several follow-up periods:
those at risk in subsequent periods had already ‘survived’ the previous period without clearing infection.
A preliminary analysis is presented in Table 4, showing the numbers clearing infection during each follow-up
period i of study j with mean follow-up time tij. (Where this was not reported, we estimated it from the data
at hand: details in Appendix 1.) We assume that in each study the clearance of infection in each woman is
the result of an independent Bernoulli trial, and that the number clearing infection in each period is
therefore binomially distributed with parameter θ(tij), and a constant clearance rate λij. As the observations
are interval censored, the exact clearance times are unobserved, but we can obtain an estimate of the
clearance rate λi and CIs through the relation θ(tij)= 1– exp(–λijtij).This is the complementary log–log (cloglog)
link commonly assumed for binomial data generated in this way.187 The mean CT duration Δij in that
segment is estimated by Δij= 1/λij.
The crude estimates of mean duration vary by over 40-fold, varying between studies and also within.
Although it is possible to fit either FE or RE models to these data, neither would capture the strong
association between clearance rate, length of follow-up and study design. The studies based in STD clinics
tend to have much shorter follow-up periods, and have a higher clearance rate than the longer-term
studies, which tend to be screening studies. In the STD studies, women were recruited only if they were
both asymptomatic at first attendance and had no indicators, such as a sexual partner with CT, that would
trigger immediate treatment. Our interpretation is that women who attend STD clinics in the absence of
any symptoms are most likely to be seeking to assess their infection status following a possible recent
sexual exposure to CT. Those found to be infected in this setting might therefore have their first sample
collected within a few days of the date of infection, and thus represent incident cases of infection.
In screening studies, observations are left truncated as well as interval censored: those found to be
infected have already ‘survived’ clearance for an unknown period prior to screening. Screening studies
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TABLE 4 Studies of the duration of asymptomatic CT infection in women: the study design, the numbers at risk,
the numbers clearing infection, and the follow-up period over which they were observed.168 Reproduced from:
Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis
infection. Stat Med 2013;32:1547–60, under the Commons Attribution-NonCommercial license 3.0:
http://creativecommons.org/licenses/by-nc/3.0/
First author
Study
design
Number
clearing CT
Number
tested at
follow-up
Follow-up
period
Estimated
mean
follow-up,
years
Mean duration,
years (95% CI)
Johannisson183 Clinic 10 23 0–2w 0.038 0.07 (0.04 to 0.15)
7 14 0–3w 0.058 0.08 (0.05 to 0.22)
6 14 0–4w 0.077 0.14 (0.07 to 0.39)
6 8 0-(5–8)w 0.125 0.09 (0.05 to 0.29)
Joyner79 Clinic 2 12 0-(2–7)d 0.012 0.07 (0.03 to 0.58)
7 28 0-(8–14)d 0.030 0.10 (0.06 to 0.27)
1 4 0-(15–21)d 0.049 0.17 (0.05 to 7.72)
0 8 0-(22–42)d 0.088
3 6 0-(43–231)d 0.274 0.39 (0.18 to 2.14)
Geisler73 Clinic 23 129 0-(4–59)d 0.045 0.23 (0.16 to 0.36)
Paavonen184 Clinic 3 15 1m 0.083 0.36 (0.15 to 1.80)
Rahm165 Screened 17 85 3m 0.250 1.12 (0.74 to 1.93)
0 1 6m 0.500
0 1 9m 0.750
Sorensen185 Screened 8 13 (2–24)m 1.000 1.05 (0.6 to 2.62)
McCormack186 Screened 3 7 (16–17)m 1.375 2.46 (1.11 to 13.3)
Morre180 Screened 2 20 1m 0.083 0.79 (0.29 to 6.66)
2 5 6m 0.500 0.98 (0.4 to 9.21)
4 15 1+ 5m 0.417 1.34 (0.63 to 5.12)
0 1 1+ 11m 0.917
2 13 6+ 6m 0.500 2.99 (1.12 to 25.4)
Molano169 Screened 44 82 1y 1.000 1.32 (1.00 to 1.86)
23 37 1+ 1y 1.000 1.03 (0.72 to 1.68)
7 14 2+ 1y 1.000 1.44 (0.80 to 3.81)
2 6 3+ 1y 1.000 2.47 (0.97 to 22.6)
Sheffield181 Antenatal 16 52 (1–5w) 0.058 0.16 (0.10 to 0.28)
45 88 (6–13w) 0.183 0.24 (0.18 to 0.34)
Alexander182 Antenatal 12 15 6w 0.115 0.07 (0.05 to 0.16)
d, days; m, months; w, weeks; y, years.
Follow-up time: 0–Xw indicates follow-up for X weeks of women who were observed to be infected at time zero; 0–(X–Y)d
indicates between X and Y days‘ follow-up from time zero; 3m indicates a 3-month period of observation with an
unknown starting date; 1+ 1y indicates a 1-year period of observation of women who had already been followed for
1 year without having cleared infection. CrIs based on the binomial distribution (see text).
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therefore reflect prevalent infection. This, together with the apparently slower clearance rate seen in
screening studies, provides a prima facie case for believing that CT infections may clear at different rates:
screening studies may generate apparently longer clearance rates because they selectively oversample
the longer-lasting infections, as short-duration infections are more likely to clear before screening,
a phenomenon known as length-biased sampling.188
The high rates of clearance reported at the shortest follow-up times are consistent with observations made
in Chapter 2 on the likelihood of ‘passive infection’ (see also Joyner et al.79), according to which CT is
recoverable from the female genital tract for several days after sexual intercourse, but without leading to
an active infection.
This provides a basis, independent of the evidence in Table 4, for a two-class model comprising passive
and true infections. However, examination of Table 4 suggests that, even within the screening studies,
longer follow-up times seem to be associated with lower average clearance rates. We have therefore also
considered a three-class model, comprising passive infection, and fast- and slow-clearing infections. These
alternative conceptions of the natural history of transmission, infection and clearance can be captured by
mixture-of-exponentials models. We return to a consideration of the a priori scientific plausibility of both the
two- and three-class models in the discussion, where the role of alternative survival models is also considered.
We begin by describing the standard FE and RE models for these data. We then describe the parameters of
the mixture of exponentials models and develop expressions for their functional relationship to the
parameters in the likelihood.
Statistical models for studies of the duration of Chlamydia
trachomatis infection
Random-effects model
The RE model assumes a single clearance rate λj within each study j, drawn from a distribution of clearance
rates. We assume that the log study-specific rates are normally distributed, with a mean µ and variance σ2
to be estimated from the data: log(λj)= αj, αj∼N(µ,σ2).
In studies reporting the numbers clearing infection in more than one period of follow-up, the same rate
applies in each time period, so that the number clearing infection during the ith period in study j is
binomially distributed: rij∼Bin(θ(tij),nij), where θ(tij)= 1 – exp(–λjtij).
Fixed-effect model
The FE model follows immediately from setting λj= λ, for all j.
Mixture of exponentials model
In both FE and RE models described above, within every study, each woman has the same clearance rate.
We now develop the three-class mixture model. This allows women within every study to have one of
three different rates. It is the same three rates that are present in every study. We then introduce the
two-class model as a special case. As we now show, there are three types of data: each provides
information on a different function of a common set of parameters. For each type of data we define the
likelihood and explain the relation between the parameters in the likelihood and the common set of rate
and probability parameters in the model.
We assume that incident infections are in one of three categories (‘passive’, fast-clearing and slow-
clearing). The proportion of incident infections in each of the three classes is p1, p2, p3; p3= 1 – p1 – p2,
and the clearance rates are λ1, λ2, λ3, with each rate having a fixed effect across studies. It can readily be
established that the two-class model is a special case of the three-class model, in which p3= 0, and that
the FE model is a one-class model in which p2= 0 and p3= 0. We henceforth refer to the latter as the
one-class FE model. The schematic DAG (Figure 6) clarifies the relationships between the shared rate and
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proportion parameters, and the likelihoods generated by the sampling and recruitments schemes
represented by the three study designs, under the mixture-of-exponentials models.
Sexually transmitted disease clinic studies
We interpret clinic studies as studies of incident infection, as explained above, and the infections observed
are therefore a mixture of the three types of infections, the clearance rates of which are exponentially
distributed. In any given sample, the denominator number of infections ‘at risk’ of clearing is an
unobserved mixture of infection types. The proportions recruited from each class k will vary by chance
around the population mean proportions p1, p2, p3. For each observation i in study j, the number of
infections zi,j,k in class k at risk of clearing will be drawn from a multinomial distribution, with probabilities
p1, p2, p3 and denominator nij: zi,j,k=1,2,3∼Multinomial (p1, p2, p3, nij).
The expected clearance probability in follow-up period tij is therefore a weighted average of the clearance
probabilities for the three classes with the zijk as weights:
θ(ti j) =
zi, j,1
ni j
. 1− exp(−λ1.ti j)
 
+
zi, j,2
ni j
. 1− exp(−λ2.ti j)
 
+
zi, j,3
ni j
. 1− exp(−λ3.ti j)
 
(4)
Screening studies: follow-up from the initial screen
The expected proportion of incident infections of each type is p1, p2, p3. But screening studies must
over-sample longer lasting infections. The prevalence πk of infection of type k can be derived from the
relationship: prevalence = incidence × duration:
πk =
η.pk
λk
(5)
(tij) = (1 – e  k
tij)λ (1 – e–  ktij)λk∑
Studies of incident infection
pk
Studies of prevalent infection
h
pk
k
∑
kλnij
nij
tij
tij, Tij
rij ~ Bin(  (tij), nij)θ
rij ~ Bin(  (tij, Tij), nij)θ
zijk ~ Multi(wk, nij)
zijk ~ Multi(pk, nij)
wk = λ
ph
hλ
θ (tij, Tij) = k∑θ
zijk
nij (e–  ktij)λk∑
z1 jk
n1 j
(e–  kTij)λ
z1 jk
n1 j
FIGURE 6 Directed acyclic graph of the CT duration synthesis. Subscripts: i, observation; j, study; k, class; n, number
followed up; pk, proportion of infections in class k; r, number of patients clearing infection; tij, duration of
follow-up period; Tij, duration of previous segments; wk, expected proportion of infections in class k; zijk, number of
infections in class k at risk of clearing in time interval ij; θ(), probability of clearance; λk, clearance rate of class
k infections.
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where η is the incidence of CT. Thus the expected proportion wk of women in each group k in a prevalent
population is:
wk =
pk
λk
 
=
p1
λ1
+
p2
λ2
+
p3
λ3
 
(6)
Again, to take account of the chance variation between the proportions in the general population and the
proportions sampled for each observed group, we take the data collected in each observation as a
multinomial sample, now with parameters wk. For the first observation (i= 1) in study j we may now use
the same expression (see equation 4) for the probability of clearance, with weights:
Z1, j,k=1,2,3∼Multinomial(w1,w2,w3,ni j) (7)
Screening studies: subsequent follow-up periods
In the Molano et al.169 and Morre et al.180 studies, after the first observation period, patients who are ‘at
risk’ of clearance in the subsequent follow-up segments should be considered to have ‘survived’ both the
original period between infection and screening, and the previous follow-up segments, of duration say
Tij, since screening. This is shown in Table 4. For example in the Molano et al.169 study, 2 out of 6 cleared
CT during a 1-year period of observation, having already ‘survived’ a further Tij= 3 years since their
recruitment to the study. This leads to another, rather complex, sampling structure. The proportion zi,j,k in
each category k for each observation i in study j is determined by two factors. First, a single multinomial
sample at the start of the first time period (the time of screening) determines the numbers wk in each
group, exactly as in equation 6. Second, in subsequent time periods there is no further multinomial
sampling. Instead, each original sample in category k must be depleted by a further exp(–λk Tij), so that,
through substitution into equation 5, and then equation 4, the observed number of women clearing CT in
each time period Tij is equal to:
θi j(ti j,T i j) = ∑
3
k=1
z1, j,k
n1, j
exp(−λkT i j)
∑
3
k=1
z1, j,k
n1, j
exp(−λkT i j)
(1− exp(−λkti j))
0
BB@
1
CCA (8)
Studies based in antenatal clinics
Two studies181,182 were set in antenatal clinics. One clinic181 recruited pregnant women between 8 and
23 weeks of gestation, and the other clinic182 between 36 and 40 weeks of gestation. These studies, in
principle, could be considered as having the same recruitment process as a screening study. However,
it would also be plausible to consider at least a proportion of those recruited to have been infected at
the same time that they conceived, on average, say, 16 weeks or 38 weeks prior to the initial sample.
We therefore explored including the antenatal studies under the extreme assumptions that (1) they are
left-truncated screening studies, and (2) infection was acquired at the point of conception.
Sensitivity and specificity of diagnostic tests for Chlamydia trachomatis used
in the studies
Poor test sensitivity may overestimate the clearance rate, as patients who have not cleared infection may
be thought to have done so. Most of the studies use NAATs, which we assumed to be 100% sensitive and
100% specific. Sensitivity is defined as the probability of detecting a CT infection, given that it is present.
For example, if sensitivity of culture is ψ then studies of clearance rate that test for CT using culture
estimate θij(tij)/ψ, rather than θi(ti). Geisler et al.73 used both NAAT and culture tests, and reported the
sensitivity of culture given a previous culture positive result for that infection as 78 out of 86 (90%),
and we use this as an estimate of ψ.
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Note that we distinguish between test sensitivity in the initial testing to determine infection status, and
sensitivity in subsequent tests to establish whether or not the infection has cleared. A failure to detect
infection initially will mean that the individual is not recruited into the study, and we assume that this has
no bearing on the estimates of clearance rates. Although we can estimate the sensitivity of culture in
women who are initially culture positive, it is difficult to estimate sensitivity of NAAT in women who are
initially NAAT positive, and we make the simplifying assumption that this is 100%. An alternative, but
equivalent, assumption would be that if the bacterial load is so low that it cannot be detected by NAAT,
then it does not constitute a clinically relevant infection.
Prior distributions
For the RE model, we place a flat normal prior on the log mean clearance rate and a Uniform(0,5) prior on
the log SD, and the effect of this prior is assessed through sensitivity analysis. Because the shortest follow-up
period is 1 week, the Table 4 data do not allow us to adequately identify λ1, the rate of clearance of passive
infection, in the three-class model. To improve the identifiability, we set λ1= 120 per year, implying that
passive infection lasts, on average, only 3 days. We confirmed subsequently that the precise value chosen
has negligible impact on the other parameters. We assigned priors of the following form to the clearance
rates: log(λ2)∼Uniform(A,B), and log(λ3)∼Uniform(C,λ2). We chose the values A= –1, B= 4.8 and C= –2.62,
corresponding to durations between 3 days and 2.7 years for the duration of a fast-clearing infection and
between 1/λ2 and 13.7 years for slow clearing. As a sensitivity analysis for the three-class model, we varied
the values of A, B and C, and also considered placing Uniform priors on clearance rate, and on duration
(1/clearance rate), as alternatives. We also estimated a two-rate model, in which p3= 0, λ3= 0, and
log(λ3)∼ Exponential(0.001). A prior distribution for the sensitivity of diagnostic tests of ψ∼ Beta(78,8) was
based on the results from Geisler et al.73 The mixing proportions p1, p2, p3 were given Beta(1,1) and
Dirichlet(1,1,1) priors in the two- and three-rate mixture models, respectively.
Estimation of Chlamydia trachomatis infection duration from each model
The target parameter is the average duration of asymptomatic infection. For the one-class FE model, this is
simply 1/λ1. For the RE model, at least two estimates can be generated, depending on how the model
is interpreted (see Discussion, below). One would focus on the RE mean, which would generate an
estimate of duration. In this case we monitor a node 1/exp(µ) and report its summary statistics. Another
interpretation might be that the rate obtained in any future situation is effectively another sample from the
RE distribution whose parameters have been estimated from the data. The estimate produced by this
‘predictive’ interpretation is readily found in the MCMC framework, by monitoring the nodes αnew∼N(µ,σ2)
and 1/exp(αnew), and reporting summary statistics for the distribution of the latter.
In the two-class mixture model, a proportion p1 of CT+ patients do not have a true infection, so the
estimate of CT duration is 1/λ2. Under the three-class mixture model, the estimate of CT duration is a
weighted average of the durations of the fast- and slow-clearing infections:
p2
λ2(p2 + p3)
+
p3
λ3(p2 + p3)
(9)
The WinBUGS code for the two-class model is presented in Appendix 2.
Results
Model fit statistics
There were a total of 28 data points from 11 studies informing CT duration, constituting the independent
observations for the evidence synthesis. The models that include the antenatal data assuming it represents
prevalent infection fit better than when these data are assumed to represent infection that is incident at
the time of conception (results not shown). The model fit statistics (Table 5) show, however, that when the
antenatal data (assumed to be prevalent cases) is included none of the models fits well.
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The residual deviance D is expected to approximate the number of data points (28), but the best-fitting
model, the RE model, has a D of 36. The FE and the latent class models fit even worse. If the antenatal
studies are excluded, the two- and three-class models now fit the data well. The RE model is an acceptable
fit, but the DIC, a measure that sums D and the number of effective parameters pD, strongly favours the
mixture models, as they have fewer effective parameters as well as having a better fit. Further results
are reported for only the reduced data set, excluding the antenatal studies, to which we return in
the discussion.
Parameter estimates
The rate estimates from each model are shown in Table 6. The rate estimate generated by the one-class
FE model (1.1 per year) is lower than the RE model (1.7 per year) because the former is more strongly
influenced by the largest studies, which happen to be the screening studies with their longer follow-up and
TABLE 6 Posterior summaries – mean (2.5th, 50th, 97.5th) percentiles – of parameter estimates.168 Reproduced
from: Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia
trachomatis infection. Stat Med 2013;32:1547–60
Parameter Symbol One-class FE Two-class Three-class RE
Clearance rate Class 1 λ1 1.09
(0.93, 1.09, 1.26)
120a 120a –
Class 2 λ2 – 0.74
(0.61, 0.74, 0.89)
9.5
(0.69, 1.77, 74.7)
–
Class 3 λ3 – – 0.64
(0.25, 0.66, 0.84)
–
Proportion Class 1 p1 1 0.23
(0.16, 0.23, 0.31)
0.19
(0.03, 0.20, 0.29)
–
Class 2 p2 – 0.77
(0.69, 0.77, 0.84)
0.31
(0.01, 0.26, 0.76)
–
Class 3 p3 – – 0.49
(0.02, 0.56, 0.79)
–
Mean clearance rate exp(µ) – – – 1.70
(0.57, 1.51, 3.89)
Predictive clearance rate exp(αnew) – – – 18.5
(0.08, 1.50, 28.9)
Between-study SD σ – – – 1.33
(0.74, 1.24, 2.46)
a Note that λ1 was fixed at 120 (see text).
One-class FE, RE, two-class and three-class models. Rates are per year.
TABLE 5 Model fit statistics: one-class FE, RE, two-class and three-class models.168 Reproduced from: Mixture-of-
exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection.
Stat Med 2013;32:1547–60
Model fit
statistics
With antenatal studies, 28 data points Without antenatal studies, 25 data points
One-class, FE Two-class Three-class RE One-class, FE Two-class Three-class RE
D-bar 268 128 76 36 170 25 25 31
pD 1.6 7.5 6.8 10.7 1.4 6.8 6.9 9.8
DIC 270 136 82 47 171 32 32 40
D-bar residual deviance; DIC, Deviance Information Criterion; pD effective number of parameter.
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slower clearance, whereas the latter allows greater influence of the more numerous high-clearance-rate
studies. A prediction for a new study has an expected rate of 18.5. This is due to the skew in the posterior
distribution (median 1.5). The degree of between-studies heterogeneity according to the RE model, as
indicated by the between-studies SD, is extraordinary. The posterior mean of the between studies SD is 1.33
on the log scale, indicating that a study on the 95th percentile of clearance rate would have a clearance rate
almost 200 times higher than the fifth percentile. The mean clearance rates estimated from the exponential
mixture models were 0.74 per year for the two-class model, and 9.5 and 0.64 per year for fast and slow
clearers, respectively, in the three-class model. They identify 19–23% of infections as ‘passive’, clearing
exceptionally rapidly. Note that the three-class mixture model is barely identified by the data, with the
proportions in each class and the class-specific clearance rates having extremely wide CrIs. This is largely a
result of the sparseness of data at long follow-up times.
The estimates of the target parameter, mean duration of CT (Table 7), indicate broad agreement between
the two- and three-class models (1.36 years, 1.24 years, respectively), and considerably lower estimates
from the one-class FE and RE models. The posterior medians of the mean duration in the RE model,
whether based on the mean or on the predictive distribution, are barely half those from the mixture
models. The RE distribution is so skewed, however, and its variance so large, that the mean of the
predictive distribution is 23 years.
The ‘observed’ durations in each observation from Table 4 are compared with those predicted by the
two-class model taking into account study design and duration of follow-up, and with duration plotted
on a log scale (Figure 7). Note that for the longer-duration screening studies the predicted duration
stabilises to a single value, which is, in fact, the expected duration of true CT infection. This is because in
a screening study the chances of recruiting a woman with passive infection are very low indeed. This is
also evident from equation 6. It is interesting that the results from the longer-duration screening studies
systematically deviate from the two-rate model in showing that observed duration increases with length of
follow-up. This is evidence that favours a three-rate model but, because the data are so sparse, the global
statistical fit does not support the three-rate against the two-rate model.
Sensitivity analysis
Sensitivity to priors was also explored. When the RE variance prior was changed from Uniform(0,5) to
Uniform(0,3), this changed the posterior expectation of the RE mean by less than 1%. Similarly, the
posterior between-studies SD was changed by only 1%. This suggests the prior is having only a small
effect on the between-study variance and we conclude that the Table 4 data are adequate to estimate the
RE model.
TABLE 7 Posterior summaries – mean (2.5th, 50th, 97.5th) percentiles – of the mean duration of CT infection in
years.168 Reproduced from: Mixture-of-exponentials models to explain heterogeneity in studies of the duration of
Chlamydia trachomatis infection. Stat Med 2013;32:1547–60
Model
Expression for mean CT duration,
under each model
Mean (2.5th, 50th, 97.5th)
percentiles
One-class FE 1/λ1 0.92 (0.79, 0.92, 1.07)
Two-class 1/λ2 1.36 (1.13, 1.35, 1.63)
Three-class p2
λ2(p2 + p3)
+
p3
λ3(p2 + p3)
1.24 (0.85, 1.25, 1.59)
RE (mean) 1/exp(µ) 0.75 (0.26, 0.66, 1.76)
RE (predictive) 1/exp(αnew) 23.2 (0.03, 0.67, 13.24)
pk, proportion of infections that are type k; αnew; log clearance rate in a new study under the RE model; λk, clearance rate in
infections of type k; µ, population mean log clearance rate in a RE model.
One-class FE, RE, two-class and three-class models.
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Joyner79
Morre180
Sorensen185
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FIGURE 7 Forest plot of the ‘observed’ log duration (black) and predicted (green) based on the two-rate model,
mean and 95% CrI, for each study observation (in the same order as Table 4).68 Adapted from: Mixture-of-exponentials
models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection. Stat Med
2013;32:1547–60. Results of the RE meta-analysis are presented at the base.
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We examined a two-class model in which λ1 was not restricted to a fixed value: it did not fit better and
has the same residual deviance as the model restricted to λ1= 120. It converged to a very high rate of
clearance of passive infection, with p1 estimated at 0.23 (0.16,0.32), very close to the estimate from the
restricted model. This finding supports our use of the value of 120 to improve model stability. All
reasonable priors for λ2 gave essentially identical answers. Sensitivity analysis of the three-class models
showed that the rate and probability parameters were sensitive to priors, which might be expected from
the fact that the model is only barely identifiable. The estimated duration of CT, the target parameter,
was, however, relatively insensitive, with values ranging from 1.17 to 1.24 years.
Discussion
We have compared standard fixed- and random-effect models with mixtures of exponentials models,167
in which the proportions are latent variables estimated from the data. The latter are considerably more
complex to fit because of the impact of the patient recruitment processes in the different study designs.
This had two aspects: first, once one abandons models in which there is a single constant clearance rate, it
is necessary to take into account the left truncation in the screening studies.188 Second, although the latent
class model proposes that the proportions of incident infections belonging to each class is a fixed property
of chlamydia infections, each different study in effect constitutes a different sample in which the
proportions in each class differ from their expectations owing to both sampling variation and selective
attrition in previous periods.
The choice between the alternative models must be considered both from the viewpoint of model fit and
in terms of scientific interpretation. In this application, we found that the latent mixture models both
provided a better fit and used fewer parameters, but this was true only when the two antenatal
studies181,182 were excluded. With the antenatal studies181,182 included, none of the models fitted particularly
well, although the RE model gave by far the best fit. These studies have unusually high clearance rates,
considering they are not studies of incident infection, and this is at variance with what would be expected
biologically.28,189 However, the higher clearance rate in Sheffield et al.181 may have been because of
problems with the ligase chain reaction (LCR) NAAT test, which was withdrawn in 2001 owing to
problems including non-repeating positives.190 The other antenatal study, Alexander et al.,182 recruited
patients while pregnant, who may be less likely to resolve infection than non-pregnant women, and
retested them 6 weeks post partum when their cell-mediated immune response was likely to have
returned to normal. Clearance rates would thus be expected to be higher than for non-pregnant women.
This is, however, post-hoc reasoning.
The two-class model not only fits the data very well with a very small number of parameters, but it also
represents a biologically driven model of transmission and infection (see Chapter 2). Interestingly, the
concept of ‘passive infection’ was also proposed by the investigators of one of the duration studies.79
The further distinction between Fast and Slow clearers is attractive, as it could reflect potential differences
in the human protective immune response to CT,74,191 but there is no previous suggestion that there is a
relation between clearance rates and immune response to CT. Although there is little prior support for
the three-class model, it is important to note that the target parameter, mean duration of CT, is not
particularly sensitive to choice of two- or three-class mixture model, from which we conclude that results
are relatively insensitive to model assumptions.
The analysis provided by the two- and three-class models is dependent on our conception of the studies as
clinic-based or screening studies, and on our assumption that clinic studies recruit women with incident
infection, while screening studies recruit women with prevalent infection. This is a somewhat simplistic
view of the clinic studies, where women may be attending at varying intervals from the time of
transmission, but it is required to make the analysis tractable.
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None of the models examined allowed for re-infection. However, the model including fast and slow
clearers provided no improvement in residual deviance, and the bias introduced by not accounting for CT
re-infection in duration studies is far lower than the bias introduced by not accounting for clearance in
studies of incidence. This conclusion is supported by a recent analysis by Althaus et al.,166 who fit a model
to data extracted from Kaplan–Meier curve in the Molano et al.169 study. They showed that a single-rate
model provided a good fit, and found that allowing for re-infection had almost no impact on estimates
of duration.
Setting aside their generally poor fit, the RE models are not scientifically plausible because they imply an
extraordinary degree of between-study variation in clearance rates, a 300-fold difference between 2.5th
and 97.5th percentile. This seems to defy any biological interpretation.
Among the further models that could be advanced would be a meta-regression against length of
follow-up, or a subgroup analysis by study design, perhaps with RE within groups. We have not fitted
such models on the grounds that they cannot be used to provide an estimate of the true duration of CT
infection for modelling purposes. This is because they assume that the duration of CT infection is not a
biological property of CT, but depends on the duration and/or the design of the studies carried out to
estimate it. Even if these models could be shown to fit the data, they would, at best, be no more than
descriptively adequate: they lack explanatory power as well as public health utility.
Another model that could be suggested would have a two-rate latent class model, similar to the one we
have proposed, but with random between-studies variation in the clearance rates in each class. This model
has a DIC of 33: one point higher than the two- and three-rate models. The model is certainly a possible
view of the data, but random variation between studies again creates problems of interpretation when
applied to a public health context, with an estimate based on the RE mean (1.50 years, 95% CI 0.75
to 2.68 years) differing from an estimate based on the predictive distribution (27 years, 95% CI 0.29 to
6.7 years, median 1.4 years).
Latent class models are not the only models possible. A wide range of failure time distributions, such as
Weibull or Gamma, in which the clearance rates can decline over time, could also have been fitted to
these data, although biological interpretations of such models would perhaps be less compelling. In this
connection it is worth noting that Weibull distributions with shape parameter less than 1 can always be
generated by mixtures of exponentials.167
Asymptomatic infection: summary of findings and assumptions
Assumptions
1. Studies of duration have been either based in STI clinics, or they have been studies following individuals
whose infection was detected by screening. We have assumed that these two designs recruit incident
and prevalent infections respectively.
Summary of findings
1. The data are not compatible with a single-class (FE) model, and the degree of variability implied by the
RE model is not scientifically plausible.
2. The exponential mixture models, whether two- or three-class, fit the data best, and accord with our
understanding on the biological mechanisms of transmission and infection. The data does not
distinguish between two- and three-class models.
3. The expected duration of asymptomatic infection in women, based on this data alone, is 1.36 years
(95% CI 1.13 to 1.63 years), based on the two-class model.
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Chapter 5 Synthesis of data on incidence,
prevalence and duration
Objectives
To:
1. determine whether the estimated duration of asymptomatic CT infection in women, developed in the
previous chapter, is consistent with the available evidence on incidence and prevalence of CT in the UK
2. produce a coherent set of estimates of incidence and prevalence by age group, and duration, and the
proportion of infections that are asymptomatic.
Introduction
This chapter sets out to produce a set of age group-specific estimates of CT incidence and prevalence in
the general population of women in England. First, we re-analyse the data from the LaMontagne et al.192
incidence study accounting for CT clearance, informing clearance rate from the Chapter 4 synthesis of the
duration of asymptomatic infection. Second, we use information on setting-specific prevalence106 of CT in
the UK – which included estimates in the general population as well as in GP, FP and STD settings – to
‘recalibrate’ the estimated incidence rates from LaMontagne et al.192 to the general population setting.
Third, we exploit the well-known epidemiological relationship: prevalence= incidence × duration to
generate an independent set of incidence estimates based on prevalence and duration data. This provides
a degree of independent validation for the estimates obtained directly from the incidence study. Finally,
having established there is consistency between the alternative estimates, we produce a coherent set of
estimates of age-specific incidence and prevalence, and duration, in women in the general population that
both conform to the appropriate epidemiological relationships and are based on all the available data.
The work in this chapter has been published.193
Methods
Evidence sources
Duration of asymptomatic infection in women, and proportion symptomatic
For the duration of asymptomatic CT infections, ΔA, we use the estimate of 1.36 (95% CI 1.11 to 1.62) years
based on the two-rate model described in Chapter 4. The proportion of CT infections, φ, in which symptoms
develop can be estimated from studies where asymptomatic women within a few days of exposure are
followed without treatment to determine if symptoms develop. The one study194 of this type reported that
26 out of a total 115 women developed symptoms, estimating φ at 23% (95% Crl 16% to 31%).
Duration of symptomatic infection in women
We define the duration of symptomatic infection, ΔS, as the time between the point at which the patient
becomes infected, and the point at which the infection is diagnosed, or the patient is empirically treated
and the infection is cleared. This could be derived from information on the incubation period of CT
and studies of time taken to seek health care in women who are subsequently diagnosed with CT.
A recent literature search142 found no data on incubation period, and although there were studies of time
to seek health care in women with genital symptoms, specific information on those diagnosed with CT
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was not found. Based on a clinical understanding of incubation time, and the time taken to seek and
obtain treatment, we placed an informative prior on the time from infection to diagnosis, assuming it is
uniformly distributed between 4 and 8 weeks, and, that, once diagnosed, a woman would not participate
in a prevalence survey. We assess sensitivity to this by fitting a model where the duration of symptomatic
infection varies uniformly from 3 to 12 weeks. The distributions used for each duration parameter are
summarised in Table 8.
Chlamydia trachomatis incidence data
Only one published report on incidence in England was identified: LaMontagne et al.192 Women aged
16–24 years were screened for chlamydia in GP, FP and STD clinic settings in two areas in England, and
were followed prospectively at 6-month intervals for 6–18 months to assess CT infection and re-infection.
However, this study is restricted to GP and clinic patients and does not address incidence in the English
general population. A LCR test was used, for which we assumed 100% sensitivity and specificity. Table 9
gives the proportions of 6-month-long observations in which CT-negative (CT–) women were CT+ at
follow-up. These are divided into ‘infections’ and ‘re-infections’, the latter being infections observed in
women who were CT+ on recruitment or were infected for the second time during the follow-up period.
The data are reported for age groups (a= 1, 16–17 years; a= 2, 18–20 years; a= 3, 21–24 years).
TABLE 8 Data on duration (years) of CT Infection, and proportion symptomatic. From Price et al.193
Parameter Mean (95% CrI) Source
Duration of asymptomatic infection 1.36 (1.11 to 1.62) see Chapter 4
Duration of symptomatic infection 0.115 (0.079 to 0.151) See text
Duration of symptomatic infection (sensitivity analysis) 0.144 (0.062 to 0.227)
Proportion of incident infections in which symptoms develop 0.231 (0.159 to 0.311) Geisler 200873
TABLE 9 Infection and reinfection rates per 100 women-years
Setting Age (years)
Infection Re-infection
r Rate na r Rate na
GP 16–17 4 11.2 73 5 86.2 14
18–20 3 3.1 195 7 22.8 65
21–24 4 4.3 188 10 26.9 79
FP 16–17 9 9.5 194 13 29.4 95
18–20 5 3.7 273 12 19.9 127
21–24 7 7.1 201 5 16.6 63
STD 16–17 5 10.1 102 6 32.3 40
18–20 16 14.1 235 15 22.8 139
21–24 9 7.5 245 5 12.8 39.1
a Note that n is estimated as the total number of 6-month follow-up periods (events were assumed to happen half way
between observations when the rates were estimated in the LaMontagne study192). This has been calculated from the
reported rates and numbers of events.
Numerators r and denominators n.
Adapted from tables 2 and 4, LaMontagne et al.192
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Given that observations are interval censored in this study, and the fact that CT infections can clear
spontaneously, it is possible for women to have both acquired and cleared the infection during the periods
between observations, leading to underestimation of incidence. This was not accounted for in the
original paper.
Chlamydia trachomatis prevalence by age and setting
Chlamydia trachomatis prevalence information was derived from a recent synthesis of UK data.106 CT
prevalence varies by age and setting. Table 10 shows estimates of CT prevalence by age in the general
population from a logistic regression of UK prevalence studies106 identified by a systematic review in 2004.
Other prevalence data have been collected subsequently19,81 but have not been incorporated, as it was
considered preferable to use results from a single comprehensive study.
Table 11 shows prevalence ORs for the different settings: FP, STD clinics, and general population settings,
relative to the GP, from the same study. These are used to inform setting-specific relative risks (RRs).
The interpretation of ORs as RRs is an approximation that is justified by the rarity of the infection.149
Statistical models
Model for the overall duration of CT infection in women
The mean duration of infection, Δ, can be expressed as a weighted average of the length of asymptomatic
(untreated) infection ΔA and symptomatic (treated) infection ΔS:
Δ=Δsφ+ΔA.(1−φ) (10)
with φ being the proportion of incident infections in which symptoms develop.
TABLE 10 Estimated prevalence of CT in females in the general population
Age (years) Prevalence (95% CI)
18–19 0.048 (0.032 to 0.076)
20–24 0.032 (0.021 to 0.049)
25–29 0.015 (0.010 to 0.025)
30–44 0.008 (0.005 to 0.013)
Adapted from table 4, Adams et al.106
TABLE 11 Adjusted ORs for the effect of setting on chlamydia prevalence in females in the UK
Setting OR (95% CI)
General population vs. GP 0.6 (0.37 to 0.95)
FP vs. GP 1.27 (1.00 to 1.62)
STD vs. GP 2.39 (0.72 to 3.33)
Adapted from table 3, Adams et al.106
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Regression estimates of infection and re-infection rates by age and setting
We model the infection rates as a function of a baseline infection rate λ1,1,1 multiplied by the between-setting
HRs ρs and the between-age group HRs γa. The age- and setting-specific re-infection rates λa,s,2 equal the
respective infection rate multiplied by a setting-specific re-infection HR ηs (equation 11). Other regression
models are considered in Appendix 3:
λa,s,1 = γaρsλ1,1,1 and λa,s,2 = ηsλa,s,1 (11)
The infection rates λa,s,i in equation 11 are informed by the data in Table 9, which shows the number of
initially uninfected women in each age within each setting who were found to be infected after a 6-month
follow-up period. However, the mathematical relationship between the infection rates in each group and
the proportions infected κ(t)a,s,i at the end of a period of time length t is complex. The formula shown in the
DAG (Figure 8) allows for the fact that in the LaMontagne et al. data192 it is possible for a woman to clear
infection spontaneously or through treatment, and then re-acquire infection within the 6-month follow-up.
It is necessary, therefore, to take account of the clearance rates of symptomatic and asymptomatic infection,
and the proportion of incident infections that become symptomatic (see Appendix 4).
Estimation of force of infection
The infection and re-infection rates can be used to estimate the mean force of infection (FOI) ~λFOIa,s in the
CT– women in each setting and age group using equation 12:
~λ
FOI
a,s = (1 pa,s).λa,s,1 + pa,s.λa,s,2 (12)
where the weights pa,s are given by the prevalence of CT in each setting observed in the LaMontagne
study192 (see Appendix 4). However, as the LaMontagne study192 samples from only GP, STD and FP
settings, it is necessary to turn to a third source of evidence, CT prevalence, to map these estimates of FOI
to estimates for the general population.
The CT prevalence data inform the absolute prevalence in 18- to 19-years-olds π1,pop (the youngest age
group in the study), and the relative risks RRa of infection in the generic age group a relative to age
18–19 years so that:
πa,pop = π1,pop.RRa (13)
In order to use these data to map our estimates of FOI to the general population, we make the
assumption that the between-setting and between-age group RRs in the prevalence data directly inform
the HRs (γa and ρs) in the incidence model described above. For a fixed duration, prevalence ratios must be
equal to incidence rate ratios, so the assumption is that ratios of incidence are equivalent to ratios of FOI,
and of infection. We consider this assumption further in Appendix 3.
A first estimate of Chlamydia trachomatis incidence in England (method A)
We use the OR between the general population setting and the GP setting, which informs the parameter
ρpop to map the FOI in the GP setting to provide an estimate of the FOI in women in the general
population ~λFOIa,pop:
~λ
FOI
a,pop = ρpop~λ
FOI
a,GP (14)
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Estimates of FOI are of interest in themselves. However, we can easily calculate the annual population
incidence rate ~λINC1a,pop: (years
–1) for the age groups 16–17, 18–20 and 21–24 years as a function of FOI
(years–1) and duration using equation 15:
~λ
INC1
a,pop =
~λ
FOI
a,pop
1−~λ
FOI
a,popΔ
(15)
A second estimate of Chlamydia trachomatis incidence in England
(method B)
A second estimate of the annual population incidence can be obtained using data on duration and data
on prevalence using the relationship incidence= prevalence/duration so that:
~λ
INC2
a,pop =
πa,pop
Δ
(16)
Where duration is estimated as previously described and prevalence πa,pop is informed directly by the data in
Table 10 so ~λINC2a,pop is estimated for the age groups 18–19, 20–24, 25–29 and 30–44 years.
Full synthesis model
The method A and method B analyses can be combined in a single joint synthesis using the relationship:
πa,pop = ~λ
INC
a,pop.Δ (17)
Where ~λINCa,pop is informed as described in method A, and the parameters πa,pop and Δ are informed as
described in method B. This is shown in the DAG in Figure 8. This single joint analysis provides estimates
of population incidence for the age groups 16–17, 18–20, 21–24, 25–29 and 30–44 years. The only age
groups for which incidence is estimated in both methods A and B are 18–20 and 21–24 years. However,
estimates for the other age groups are also expected to change. The full synthesis model provides estimates
for all parameters based on the entire data ensemble. So, for example, when our knowledge of the
regression parameters described in method A are updated by the data described in method B, estimates of
the annual population incidence rate in 16- to 17-year-olds may change.
Note that the DAG in Figure 8 also describes methods A and B above. We remove the constraint that
prevalence= incidence × duration shown on the DAG under the heavy black bar replacing it with equation 17
above, and place uninformative priors on πa,pop. This single unconstrained model then produces estimates from
both methods A and B in parallel.
Model critique
We compare the goodness of fit of the combined synthesis model and the model with separate incidence
estimates: this provides a global assessment of the statistical assumptions. A graphical comparison of the
separate incidence estimates is also presented. We assess the validity of some more specific statistical
assumptions in Appendices 3 and 4. Unless otherwise stated vague priors are employed throughout,
so that results are dominated by the data. The WinBUGS code is available along with the data sets in
Appendix 5. It has been annotated to help readers to understand the model.
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Results
Table 12 shows the posterior estimates of the annual population incidence from method A (column 2),
method B (column 3) and the full synthesis model (column 4). Estimates from method A are available for the
16–17, 18–19, and 20–24 years age groups, method B provides estimates for age groups 18–19, 20–24,
25–29 and 30–44 years, and estimates for all age groups are available from the full synthesis model.
Estimates from the full synthesis model are around a factor of 1.5 lower than those obtained from method A
but only marginally higher than those obtained from method B. This is because the uncertainty in the
incidence information from the LaMontagne data192 is much greater than in the combined duration and
prevalence information. This effect is shown pictorially in Figure 9, which compares the estimates of incidence
in the age groups 18–19 years and 20–24 years, and also shows the combined estimate incorporating all data
sources. Results from the full synthesis model for all five age groups are also given in Figure 10.
Table 13 shows the estimates of the basic parameters in the model estimated when the constraint that
prevalence= incidence × duration is excluded (column 2) and included (column 3) in the model,
representing, respectively, methods A and B being performed simultaneously in parallel, and the full
synthesis model. It shows that for most parameters: duration, proportion symptomatic, re-infection-to-
infection rate ratios, age- and setting-specific risk ratios, and prevalence parameters, the synthesis has not
contributed much additional information over and above the ‘direct’ data already available. However,
the general population to GP RR is lowered by a factor of about 1.35 compared with method A, and the
95% CrIs are about half of the width.
Our separate models of incidence in women aged 16–24 years included nine parameters and had a
residual deviance of 18.4 for a data set with 21 data points (see Tables 9–11) representing a good fit
(Table 14). When these data are combined with the prevalence information, residual deviance increases
only marginally (19.5), indicating a lack of conflict between the different sources of information on
incidence. Prevalence and duration data also fitted equally well. Results (not shown) with a wider uniform
prior distribution on the duration of symptomatic infection, 3–12 weeks rather than 4–8 weeks, were
almost identical (< 1% multiplicative change). We therefore recommend using results from the full
synthesis model that uses all of the data, giving an estimated incidence rate in 16- to 24-year-old females,
the population targeted by the NCSP, of 0.05 per year (95% CrI 0.035 to 0.071) and in 16- to 44-year-olds
0.021 per year (95% CrI 0.015 to 0.028).
TABLE 12 Population CT incidence rate per year in women by age estimated using each method. From Price et al.193
Parameter (years)
Method A (adjusted
incidence data)
(95% CrI)
Method B (prevalence
and duration data)
(95% CrI)
Full synthesis model
(95% CrI)
~λINC16–17,pop incidence, 16–17 0.122 (0.057 to 0.235) – 0.082 (0.047 to 0.134)
~λINC18–19,pop incidence, 18–19 0.070 (0.036 to 0.126) 0.046 (0.028 to 0.072) 0.048 (0.032 to 0.068)
~λINC20–24,pop incidence, 20–24 0.060 (0.032 to 0.106) 0.031 (0.019 to 0.048) 0.039 (0.027 to 0.054)
~λINC25–29,pop incidence, 25–29 – 0.015 (0.009 to 0.023) 0.015 (0.0087 to 0.024)
~λINC30–44,pop incidence, 30–44 – 0.0078 (0.0045 to 0.013) 0.0080 (0.0045 to 0.013)
Incidence, 16–24 0.050 (0.035 to 0.071)
Incidence, 16–44 0.021 (0.015 to 0.028)
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FIGURE 10 Posterior distribution of incidence, by age range, based on all available information.
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FIGURE 9 Posterior distributions of incidence parameters, comparing results based on incidence data, with results
based on information in prevalence and duration studies; (a) age group 18–19 years, (b) age group 20–24 years.193
Reproduced from Price M, Ades A, De Angelis D, Welton NJ, Macleod J, Turner K, et al. Incidence of Chlamydia
trachomatis infection in England: two methods of estimation. Epidemiol Infect 2014;142:562–67. This work is under
the Commons Attribution-NonCommercial license 3.0: http://creativecommons.org/licenses/by-nc/3.0/.
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TABLE 14 Model fit statistics for each data set from the separate models fitted using methods A and B in parallel
and the full synthesis model. From Price et al.193
Source Number of data points
Number of parameters Mean residual deviance
Separate models Full model Separate models Full model
Incidence 21 9 9 18.4 19.5
Prevalence 4 4 2 4.0 4.1
Duration 2 2 2 2.0 2.2
Total 27 15 13 24.3 25.7
TABLE 13 Incidence, prevalence, duration estimates obtained from the separate models, and from the full
synthesis model. From Price et al.193
Parameter
Separate models:a
mean (95% CrI)
Full synthesis model:
mean (95% CrI)
CT duration and clearance rate
λA clearance rate, asymptomatic 0.74 (0.62 to 0.90) 0.77 (0.64 to 0.95)
ΔA duration of asymptomatic infection 1.36 (1.13 to 1.63) 1.31 (1.06 to 1.56)
Δ mean duration (years) 1.07 (0.86 to 1.29) 1.03 (0.82 to 1.25)
Φ proportion symptomatic 0.23 (0.16 to 0.31) 0.23 (0.16 to 0.32)
CT incidence: regression parameters
ηGP re-infection: infection ratio, GP 7.31 (4.07 to 11.9) 7.08 (3.97 to 11.6)
ηFP re-infection: infection ratio, FP 3.52 (2.09 to 5.52) 3.66 (2.16 to 5.77)
ηSTD re-infection: infection ratio, STD 2.01 (1.17 to 3.17) 2.08 (1.21 to 3.28)
ρFP HR, GP (reference group) 1 1
ρpop HR, general population 0.62 (0.37 to 0.96) 0.46 (0.33 to 0.63)
ρFP HR, FP 1.28 (1.02 to 1.59) 1.30 (1.03 to 1.61)
ρSTD HR, STD 2.38 (1.78 to 3.11) 2.45 (1.83 to 3.20)
CT prevalence, %
π16–17,pop general population, 16–17 years – 8.38 (4.94 to 13.5)
π18–19,pop general population, 18–19 years 4.91 (3.13 to7.28) 4.85 (3.47 to 6.59)
π20–24,pop general population, 20–24 years 3.27 (2.10 to 4.83) 3.96 (2.89 to 5.30)
π25–29,pop general population, 25–29 years 1.54 (0.95 to 2.35) 1.54 (0.95 to 2.37)
π30–44,pop general population, 30–44 years 0.82 (0.50 to 1.28) 0.83 (0.50 to 1.29)
General population, 16–24 years 5.15 (3.76 to 6.93)
General population, 16–44 years 2.11 (1.63 to 2.71)
a Methods A and B.
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Discussion
Although CT prevalence in the general UK population has been studied,106 incidence estimates have been
produced only in clinic patients.192 We used data on ratios between clinic settings and the general population
in prevalence studies to ‘recalibrate’ the incidence data to a lower value that was appropriate to a general
population setting. The possibility of clearance of infection and re-infection during the follow-up period was
also taken into account: the effect of this is to raise incidence estimates above the levels that are directly
observed. The estimate based on the recalibrated incidence study was found to be compatible with an
estimate based on combining prevalence and duration information.
A certain degree of simplification is involved. The incidence data were collected in 2003–4, 2–3 years later
than the NATSAL (National Survey of Sexual Attitudes and Lifestyles) study,195 which contributes all of the
general population prevalence information to the estimates in the Adams study,106 and in a period before
intensive screening was taking place. We have assumed that incidence is unlikely to have changed greatly
between these dates, and that our estimates are therefore relevant to the years 2001–5.
As with any evidence synthesis method, conclusions are limited by the quality of the original data and the
assumptions made in interpreting them. The CT prevalence information in NATSAL195 was based on
self-testing in a structured population sample and is vulnerable to response biases, although these have
been extensively analysed elsewhere.196 The incidence data were collected in two English areas, which
were metropolitan and urban, respectively. The extent to which these data can be assumed to be
nationally representative is not known. The final estimates are more influenced by the prevalence data
than the incidence data, and this is dominated by the NATSAL195 data collected in 2000. Finally, the
estimates of duration of asymptomatic CT duration, 1.36 (95% CrI 1.11 to 1.62) years, are based
on the Chapter 4 synthesis of studies with different designs and subject to the assumptions made in
that chapter.168
Additional validation of our estimates and of our overall approach is available by multiplying our estimated
infection rate by the number of women aged 16–24 years in England, based on population census
projections for 2002.197 This predicts a total of 137,100 (95% CrI 95,520 to 192,500) infections. This can
be compared with the 31,510 and 34,660 women aged 16–24 years who were treated for CT in STD
clinics in 2002 and 2003, respectively.198 The ratios of numbers treated to predicted total infections in
women aged 16–24 years are 24% (95% CrI 16% to 33%) for 2002 and 26% (95% CrI 18% to 36%)
for 2003. This accords closely with the proportion of infections in which symptoms develop estimated from
the model, and the Geisler et al.73 findings. Therefore, had we partitioned women as treated or untreated
when estimating the mean duration as is often done in dynamic models and used recursive equations to
estimate the proportion treated from routine data, we would have obtained almost identical results.
Although the estimates of CT incidence and prevalence in England may be of limited interest elsewhere,
the study does have wider implications. First, the fact that incidence, prevalence and duration evidence is
internally consistent provides a degree of independent validation of our estimates of all three parameters.
Second, it indicates that estimates of CT prevalence or CT incidence in other countries can each be
generated from the other, using our estimates of duration. Alternatively, where information is available on
both incidence and prevalence, a similar exercise could be carried out to provide a further validation of our
results and the models on which they are based.
The study raises the question: what is the best way to obtain accurate population-based estimates of
CT incidence? Further direct study of infection and re-infection rates among opportunistically recruited
women appears to be worthwhile. However, as well as taking account of clearance and re-infection during
follow-up, it will probably always be necessary to ‘recalibrate’ setting-specific estimates to the general
population. Studies of either prevalence or incidence based on structured general population surveys are,
therefore, essential.
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Our analysis of incidence, prevalence and duration has relied on an essentially static epidemiological
model. The alternative would be to assess the consistency of a somewhat wider evidence base within a
dynamic modelling context. For example, a dynamic model could be estimated from the same sources
of data (incidence, prevalence, duration of symptomatic and asymptomatic infection, proportion
symptomatic), but also incorporating information on contact rates and transmission rates per contact
(see Chapter 12).
Summary of assumptions and findings
Key assumptions
1. The LaMontagne study192 of incidence in FP, STI and GP groups is nationally representative.
2. The incidence and prevalence estimates are based on several data sources, but are relevant to the
years 2000–5.
Summary of findings
1. The available data on incidence in the UK agree with predictions based on duration (see Chapter 4) and
UK prevalence.
2. The mean duration of CT infection in women (including symptomatic and asymptomatic infections) is
1.03 years (95% CrI 0.82 to 1.25 years). The proportion of incident infections that are symptomatic
is 0.23 (95% CrI 0.16 to 0.32).
3. CT incidence in the general population aged 16–24 years is 5.04 per 100 person-years (95% CrI 3.52
to 7.09) and in women aged 16–44 years it is 2.07 per 100 person-years (95% CrI 1.50 to 2.81).
4. CT prevalence in the general population aged 16–24 years is 5.15% (95% CrI 3.76% to 6.93%), and
in women aged 16–44 years it is 2.11% (95% CrI 1.63% to 2.71%).
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Chapter 6 Risk of pelvic inflammatory disease
following Chlamydia trachomatis: analysis of
prospective studies
Objectives
To:
1. develop and apply appropriate models for trials of screening and other prospective studies that follow-up
women with CT to observe whether they develop PID
2. estimate the risk of PID following a CT infection
3. estimate the proportion of CT-related PID infection in women with CT that can be prevented by CT
screening and treatment at annual intervals.
Introduction
A range of observational studies have followed untreated CT infected (CT+) women prospectively and
observed the number of women developing PID.73,165,184,199,200 In some studies,73,184,199,200 the infection,
presumably mostly symptomatic, has been diagnosed in a clinic, and in one study165 it was identified by
screening asymptomatic cases. There have also been controlled trials randomising large numbers of
women to screening and treatment or to no screening.12,13,19 However, as we note earlier, there is a
remarkable lack of consensus on the risk of PID attributable to an episode of CT, despite a major
authoritative review.98
Previous reviews20,61,98,144 of prospective data on progression to PID have been qualitative. In this chapter
we synthesise data from these studies to provide quantitative estimates of the difference in the rates at
which PID develops in women with and without CT. From these estimates we derive first the probability
that an episode of CT causes an episode of PID, and then the proportion of episodes of PID caused by CT
in women with CT, that could be prevented by screening at 1-yearly intervals. By this we mean annual
screening not associated with recent risk of infection.
First, we re-appraise the prospective studies, including non-randomised and uncontrolled studies. We
then present a three-state continuous time Markov model, which allows not only for different rates of
development of PID in CT-infected (CT+) and uninfected (CT–) women but also spontaneous clearance of
CT, a competing risk. It also allows for CT infection in women who are initially uninfected (CT–), and for
re-infection with CT in women who are initially CT+ but who spontaneously clear infection or are tested
and treated. We then re-analyse each of the controlled studies, both randomised and not, under the
assumptions of the model. Finally, we synthesise them altogether to obtain estimates of the proportion
of incident CT that results in PID, and the proportion of CT-caused PID in women with CT that can be
prevented by annual screening. The work in this chapter has been published previously.201
The definition of PID that was used in the prospective studies is, of course, a key issue in their
interpretation. Our assumption is (see Chapter 2) that, in prospective studies, the 89% of PID that is not
asymptomatic103 will be picked up.
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
53
Methods
Evidence identification
We sought prospective studies of women with CT including observational studies with or without a control
group, and RCTs of screening interventions. We identified studies from recent review papers,20,61,98,144
reference searches of published economic and population transmission models,1,2,8,29,140,141,170–174 and as part
of a wider review of the literature on the natural history of CT. Included among these was a recent
systematic review instituted at an Expert Advisory Meeting of the Centers for Disease Control and
Prevention.98 We exclude the study by Bachmann et al.202 because the follow-up time was not reported;
the study by Stamm et al.203 because the patients were co-infected with gonorrhoea; and the study by
Westergaard et al.204 because the patients were women who had just undergone an abortion, and this is a
very unrepresentative population. The study by Morre et al.180 is excluded because of uncertainty about the
adequacy of outcome assessment.40 We identified eight studies12,13,19,73,165,184,199,200 (Table 15) that followed
up women with CT to assess the proportion who developed PID in the absence of, or prior to, treatment.
Note that four of the studies73,165,184,200 shown in Table 15 are excluded from the modelling because of a
lack of a control group.
Information sources and their interpretation
Some studies were set in STD clinics, and others were based on infected women recruited by population
screening. Five were observational, one of which, a clinic-based study, included a control group. The
remainder were RCTs, all based on screened populations. In the POPI trial,19 both arms were screened; one
was treated immediately, whereas in the other arm treatment was deferred until the end of the study.
Table 15 shows the proportion of women with PID in each arm at the end of each study. Most
investigators have focused attention on these proportions, and in controlled studies, on RRs. However, it is
necessary to account for the mean follow-up time t0 for each observation o. The last column of Table 15
shows crude study-specific estimates of the rates of progression to PID, based on a constant hazard within
each study and arm.
The crude estimates of the progression rate in CT+ women vary by factors of 30-fold: studies based in STI
clinics having shorter follow-up periods and higher apparent progression rates, whereas those based on
screened populations tend to have longer follow-up periods and lower progression rates. There are three
possible contributory explanations for this. First, CT infections spontaneously resolve without treatment, so
even if progression rates were constant over time, with CT clearance as a ‘competing risk’, the numbers
acquiring PID must slowly decrease over time towards a background level seen in a representative control
group. The effect of this will tend to be greater in studies with a longer follow-up. However, the mean
duration of untreated CT has been estimated to be over 1 year74,142,166 (see Chapter 4) so this would
explain only a small part of the apparent differences. A second possible explanation is that women visiting
STI clinics are more likely to have symptoms than those identified through screening, and the higher CT
load associated with symptoms205–207 may confer a greater risk of developing PID. A third possible
explanation is if the risk of developing PID is greater in the period immediately after CT infection,98,208
even if the infection is asymptomatic.
There is a fundamental difference between STI clinic studies and screening studies. Women are most likely
to attend clinics because of the onset of symptoms, or because of concern following recent possible
exposure to infection. They are therefore more likely to be recently infected. This is supported by evidence
that symptoms mostly occur soon after infection (6) (see Chapter 4). Screening studies, by contrast, recruit
participants with asymptomatic, prevalent CT infection, who have already ‘survived’ an unknown period of
time without developing PID. Further, if the risk of PID is higher immediately following infection, the
screening studies must underestimate the overall progression rate. For example, if asymptomatic infection
lasted exactly 12 months, and if 20% of incident cases develop PID (at which point they are treated for
CT), always exactly 3 months after infection, the annual progression rate that would be observed in
patients recruited from a prevalent population would be only 5.9% [i.e. 3/(0.8 × 12+ 0.2 × 3) × 0.2],
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TABLE 15 Information from prospective studies that followed women with chlamydia to PID. From Price et al.201
First
author
Study
design
Study
population Arm
Data:
ro/no
Crude
proportion
developing
PID (95% CrI):
po= ro/no
Follow-up
period: to
Crude annual
PID rate
(95% CrI):
(–log(1 –po))/to
Hook200 Uncontrolled Clinic CT+ 3/93 0.032
(0.012 to 0.091)
2 weeks 0.82
(0.30 to 2.40)
Geisler73 Uncontrolled Clinic CT+ 2/115 0.017
(0.005 to 0.061)
2 weeks 0.44
(0.14 to 1.59)
Paavonen184 Uncontrolled Clinic CT+ 3/15 0.200
(0.078 to 0.481)
1 month 2.79
(1.01 to 8.21)
Rahm165 Uncontrolled Screened CT+ 4/102 0.048
(0.016 to 0.097)
3 months 0.18
(0.07 to 0.46)
Rees199 Controlled Clinic CT+ 8/67 0.119
(0.063 to 0.222)
7–90 days 1.02
(0.52 to 2.01)
CT– 3/62 0.048
(0.018 to 0.135)
0.40
(0.15 to 1.16)
Oakshott19 RCT Screened Untreated
CT+
7/74 0.093
(0.047 to 0.183)
1 year 0.099
(0.049 to 0.205)
Delayed
screen CT–
16/1112 0.014
(0.009 to 0.023)
0.014
(0.009 to 0.024)
Treated
CT+
1/63 0.016
(0.004 to 0.087)
0.016
(0.004 to 0.089)
Screened
CT–
14/1128 0.011
(0.007 to 0.019)
0.012
(0.007 to 0.021)
Scholes13 RCT Screened Unscreened 33/1598 0.021
(0.015 to 0.029)
1 year 0.021
(0.015 to 0.029)
Screened 7/645 0.011
(0.005 to 0.022)
0.011
(0.005 to 0.022)
Chlamydia
prevalence
44/645 0.068
(0.051 to 0.091)
Ostergaard12 RCT Screened Unscreened 20/487 0.041
(0.027 to 0.063)
1 year 0.042
(0.027 to 0.065)
Screened 9/443 0.020
(0.011 to 0.038)
0.021
(0.011 to 0.039)
Chlamydia
prevalence
43/867 0.050
(0.037 to 0.066)
ro, no, to are the numerator, denominator and time interval in observation o.
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a gross underestimate. In such a scenario, only screening and treatment occurring during the first
3 months of a 12-month infection would prevent PID due to these infections. As a result, a single screen
every year would prevent only 29.4% (5.9/20%= 29.4%) of the PID cases caused by CT.
A model for progression to pelvic inflammatory disease in the controlled
prospective studies
In our model for prospective studies (Figure 11), women who are CT+ and CT– at the start of the study
begin in states 1 and 2, respectively. Women in state 1 may clear infection and progress to the CT– state,
state 2, at rate λC, or they may develop PID (state 3) at a study-specific rate θCT+s for study s. Women in
state 2 may become infected with CT, which occurs at rate λls or may develop PID at rate θ
CT−
s if they
acquire, or already had, a non-CT infection that carries a PID risk. We assume that the prevalence and
incidence rates for other STIs are the same in each arm. The difference δ between θCT+s and θ
CT−
s represents
the rate of acquiring PID in women with a current CT infection that can be causally attributed to CT.
The Figure 11 model is represented by the Markov transition rate matrix (G) shown in equation 18:
G =
ðλC + θCT+s ) λC θCT+s
λls −(λ
l
s + θ
CT−
s ) θ
CT−
s
0 0 1
2
64
3
75 (18)
Only comparative studies can contribute information on δ but we cannot derive estimates of δ from
comparative studies without information on λC and λls. We assume that the CT clearance rate for
asymptomatic infection, λC, is constant across studies, at 0.74 (95% CrI 0.61 to 0.89) per year, based on
the Chapter 4 evidence synthesis of studies on CT duration. Similar estimates have been reported
elsewhere.166 Note that the information on incidence and prevalence can back-propagate through the
evidence network and impact on the posterior distribution of the duration of asymptomatic infection,
although the latter was not materially changed.
For CT incidence λls we assume an infection rate of 5% per year in women who are CT– at the outset, and
a re-infection rate of 15% per year in women who are CT+ and tested and treated. Given a CT average
duration of 1–1.5 years, a 5% incidence reflects a CT prevalence of 5–7.5%, which accords with the
baseline CT prevalence in the three trials. Re-infection rates are higher by approximately a factor of 3.192
We assume that all women in the Scholes13 and Ostergaard12 (95% CT–) studies are at risk of infection,
whereas all women in the Rahm165 (50% CT+) and POPI19 (100% CT+) studies are assumed to be at risk
of re-infection. Detailed sensitivity analyses (see Appendix 6) show that conclusions are relatively insensitive
to the values assumed.
Some of the screening studies record the proportion of women who were tested and treated for CT during
follow-up, thus shortening their time at risk of CT-related PID. This was 43% for the POPI trial,19 32% for
Ostergaard et al.12 and 8.1% for Rees.199 The Scholes et al. paper13 implies that some women were tested
but does not report how many: we have assumed a proportion of 32%, following Ostergaard et al.,12
but the impact of a lower rate is explored in sensitivity analyses (see Appendix 6).
State 1:
CT+
State 2:
CT–
State 3: PID
λC
λIs
θ CT–s
θ δCT+s θ= +CT–s
FIGURE 11 Multi-state transition model for disease progression in prospective studies. From Price et al.201
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We consider two models. In the first, the causal rate of PID due to CT (δ) is constant throughout the
duration of infection. In the second, the causal rate in the period immediately following CT infection (δ1) is
different from the causal rate during the remainder of the infection (δ2). We fit models with the rate δ1
lasting for periods of 30 days, 60 days and 90 days post infection.
Estimation
Details of the estimation methods are given in Appendix 7. In brief, each study arm provided data with a
binomial likelihood, which estimates a probability parameter, say pi→ js,t , representing the study-specific
transition probability that a person in state i occupies state j, t years later. These probabilities are entries in
the transition probability matrix Pt. If the transition rates are constant over the period t then the transition
probabilities, on which we have data (see Table 15), are functionally related to the transition rates in
equation 18 by Kolmogorov’s Forward Equations (equation 19):209
dPt
dt
= Pt .G (19)
Estimation is carried out using a Bayesian approach, where the posterior distribution is sampled through
Markov chain Monte Carlo (MCMC) simulation. The rate parameters in equation 18 are given vague priors,
the values of which are updated by the data. Numerical solutions to the Forward Equations are found in
each MCMC cycle, using the WinBUGS44 add-on WBDiff,161 which uses the Runge–Kutta method.210,211
Only the CT+ groups from the POPI trial19 were included in the analysis because the treatment effect
estimate is thereby based on a randomised comparison. The proportion with CT in the early treated arm
are considered, in effect, as being CT– at the start of the observation period. Those in the deferred
treatment group are, of course CT+. However, in the Scholes13 and Ostergaard12 trials, although the
women in the screened arm are again taken to be CT– at the start of follow-up, those in the unscreened
arm are a mixture of (untreated) CT+ and CT–. The study-specific CT prevalences in the screened arms are
estimators of these mixing proportions.
Further details on how the observed data informs the rate parameters in the matrix G (equation 18) are
given in Appendix 7. The joint posterior distribution of the rate parameters is used to obtain posterior
distributions for the two parameters of interest: the proportion of CT infections that result in PID and the
proportion of CT-caused PID preventable by annual screening.
Probability that incident Chlamydia trachomatis will cause an episode of
pelvic inflammatory disease
Although the comparative studies provide an estimate of the difference δ in progression rates between
CT+ and CT– women, the target parameter of interest is the proportion of incident CT infections that
cause PID. We assume that a proportion, φ, of incident CT cases are symptomatic and treated, clearing at
rate λT, and with no increased risk of PID. The remaining 1 – φ infections are asymptomatic. To simplify the
equations and maintain generality we ignore non-CT-related PID as a competing risk at this stage. Even if
the rate of non-CT PID were twice that observed in the screened arm of POPI,19 this would change the
value of our target parameter by a multiplicative factor of only about 2.5%. The probability that either
type of infection will cause PID is the ratio of the rate of leaving state 1 for state 3 to the rate of leaving
state 1, a standard result from competing risks analysis.212 The proportion of incident cases of CT leading
to an episode of PID in a homogeneous model is therefore:
κ = (1−φ).
δ
δ + λC
+ φ.
δ
δ + λΤ
(20)
Calculation of κ requires estimates of φ and λT. For the former, we use the estimate from Geisler et al:73
0.24 (95% CrI 0.17 to 0.32). For the latter we assume that treated infection lasts 4–8 weeks.
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In the two-stage piecewise homogeneous model, with the initial rate lasting for B days, the probability of
developing PID in the first B days and the probability of developing PID subsequently conditional on having
neither developed PID nor cleared infection in the first B days, are summed (equation 21):
κ = (1−φ). 1− exp −(λC + δ1).
B
365
 
.
δ1
δ1 + λC
 
+ exp −(λC + δ1).
B
365
 
.
δ2
δ2 + λC
  
+ φ. 1− exp −(λT + δ1).
B
365
 
.
δ1
δ1 + λT
 
+ exp −(λT + δ1).
B
365
 
.
δ2
δ2 + λT
   (21)
Estimation of the proportion of pelvic inflammatory disease episodes
prevented by screening
Even with 100% coverage, an annual screening programme for CT would not prevent all cases of PID.
We estimate the proportion of episodes of CT-related PID that could be prevented in women who become
infected with CT. The expressions for this quantity are derived and presented in Appendix 7. This applies to
the benefits to CT+ women who are screened and treated, and is not designed to measure the full effect
of screening as it does not take into account reduction in PID due to reduced CT incidence.
Plan of analysis
The data analysis is carried out in several steps in order to show the influence of the different types of data
on the estimates of interest. First, we examine each of the comparative studies separately. We then
synthesise information from all three RCTs, and then from the four comparative studies. Studies are
combined on the basis that the progression rates in CT– women vary between studies in an arbitrary way,
but the difference δ between the progression rates from CT– and CT+ has the same fixed effect across
studies. WinBUGS code is provided in Appendix 8.
Results
Table 16 shows the study-specific estimates from the homogeneous Markov model of the difference δ,
which we interpret as the causal rate of PID in CT+ women, and the proportion of incident CT infections
that result in PID. Although the POPI trial19 data delivered the lowest estimates of both parameters, the
CrIs for the estimates from the other studies were considerably wider and approximately compatible with
the POPI19 results. The estimates from the Scholes study13 were relatively insensitive to changes in
assumptions on the proportion tested during the follow-up period (see Appendix 6).
TABLE 16 Posterior means and 95% CrIs for the causal rate of PID in CT+ women, and the probability that an
incident CT case causes PID.201 Reproduced from Price M, Ades A, De Angelis D, et al. Risk of Pelvic Inflammatory
Disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.
Am J Epidemiol 2013;178:484–92
Study Causal PID rate in CT+, δ Pr(CT causes PID)
POPI 0.15 (0.02 to 0.31) 0.12 (0.02 to 0.24)
Scholes 0.26 (0.03 to 0.55) 0.20 (0.03 to 0.34)
Ostergaard 1.03 (0.13 to 2.49) 0.42 (0.11 to 0.64)
Rees 0.73 (0.06 to 1.71) 0.36 (0.06 to 0.58)
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Table 17 presents the results of combining the information from the different studies under each of the
homogeneous and piecewise homogeneous models. In all of the models the mean residual deviance was
close to the number of data points, indicating a good fit. Also, it was apparent that the estimates under the
one-rate model were broadly similar for data (1) from the POPI trial19 only, or (2) pooled from all trials, or
(3) including the observational study as well. The causal rate of PID ranged from 0.15 to 0.19 per year, and
the probability of CT causing PID from 0.12 to 0.16. The proportion of CT-caused PID preventable by
annual screening remained at 61–63%. The degree of overlap between these estimates, and the shape of
the posterior distributions can be seen in Figure 12.
The data did not distinguish between the one- and two-rate models in terms of goodness of fit. The rate
in the initial period is estimated to be approximately 50% higher than the rate during the remainder of
infection, which is slightly lower than for the one-rate model. Both rates are insensitive to the assumed
time period of the higher rate between 30 and 90 days (see Table 17). Credible intervals are, however,
very wide, and a Bayesian p-value, testing the null hypothesis of equal rates in the 60-day model, was only
0.67. The assumption of two rates had no real effect on the causal probability of PID from an episode of
CT. The estimated proportion of PIDs that can be prevented by screening reduced marginally to between
54% and 58% for B= 90 days and 30 days, respectively, although CrIs were wide (Figure 13).
Sensitivity analyses (see Appendix 6) showed that although results from some of the individual studies can
be sensitive to changes in assumed infection and re-infection rates, none of the results for the pooled
analyses using the single rate model was changed by more than a multiplicative factor of 4%. Results from
the two-rate model were more sensitive, with κ varying between 0.15 and 0.20 when B= 60 days.
TABLE 17 Synthesis models. Residual mean deviance, numbers of data points and marginal posterior means with
95% CrIs for key parameters. From Price et al.201
Method
Mean
residual
deviance
Number
of data
points Causal rate of PID
Probability CT
causes clinical PID
Proportion
prevented by
screening
One-rate models
POPI data only 2.0 2 δ 0.145 (0.021 to 0.31) 0.125 (0.021 to 0.24) 0.625 (0.56 to 0.69)
Trials only 8.5 8 δ 0.178 (0.049 to 0.33) 0.148 (0.048 to 0.25) 0.615 (0.55 to 0.68)
All controlled
studies
10.6 10 δ 0.189 (0.057 to 0.34) 0.156 (0.056 to 0.25) 0.612 (0.55 to 0.67)
Two-rate models
All controlled
studies, 30 days
10.3 10 δ1 0.280 (0.016 to 0.65) 0.161 (0.068 to 0.26) 0.576 (0.42 to 0.68)
δ2 0.187 (0.055 to 0.35)
All controlled
studies, 60 days
10.3 10 δ1 0.288 (0.018 to 0.65) 0.163 (0.073 to 0.26) 0.552 (0.32 to 0.72)
δ2 0.182 (0.046 to 0.35)
All controlled
studies, 90 days
10.3 10 δ1 0.281 (0.017 to 0.63) 0.165 (0.075 to 0.26) 0.543 (0.26 to 0.76)
δ2 0.179 (0.038 to 0.36)
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Discussion
Early literature on the progression from CT to PID cited high rates based on uncontrolled studies in high
risk populations.184,203 Over time, these estimates were increasingly questioned.5,39,213 Quantitative estimates
of the causal relation between CT and PID have been made from a wide range of study types,40 including
linkage studies of treated women,36,107,214–217 arguments from retrospective data1,36,107,214–217 and the use of
CT serology.88,101,218 More recently, it has been accepted that linkage studies cannot be used to generate
reliable estimates.20,98
The approach presented here has some novel aspects. The Markov model characterises the causal rate as
the difference in progression rates in CT– and CT+ individuals. It takes account of the ‘competing’ role of
CT clearance and of the fact that persons testing CT+ upon screening have already ‘survived’ a period
without developing PID. Finally, we have allowed for the impact of CT treatment of women in the
untreated arms of trials, and probable re-infection rates among those who were treated.
The continuous time Markov formulation avoids the limitations of traditional RR estimates12,13,19 of the
effect of CT screening. As the follow-up period is extended, the risk ratio estimate will be diluted by CT
clearance and PID caused by infections (both CT and non-CT) acquired after the screening and treatment,
while in time the risk difference should converge to a stable estimate. Crude risk difference estimates19,219
should also be interpreted with caution. The POPI trial19 data suggest that screening can prevent 83% of
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FIGURE 13 Marginal posterior distributions of the proportion of CT-related PID episodes, in women with CT,
prevented by annual screening. From Price et al.201
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PID occurring in the following year in a prevalent CT+ population (11). Based on the Markov model, these
data tell us that the proportion of incident CT-caused PID that can be prevented by annual screening is
lower, between 55% and 65%.
The study has also shown for the first time that similar estimates can be derived, though indirectly and with
less precision, from trials of screening versus no screening. The Scholes trial in particular has been criticised18
because testing and treatment rates outside the protocol are unlikely to be the same in the two arms.
We have used the information available, and sensitivity analyses, to mitigate this. Even with this defect, the
trials are clearly superior sources of evidence on the causal effects of CT to the often-cited observational
studies, in which the difference in CT status at the outset is likely to correlate with risk factors that favour
development of PID: higher partner change, greater risk of exposure to other agents that cause PID, and
greater prior exposure to CT.
The study relates to ‘annual screening’ at a random point in time. In practice, the benefit of screening
for the individual infected women may be greater if it occurs soon after partner change, as recommended
in some countries, or less if partner testing and treatment are not pursued effectively.
The main weakness of this analysis lies in the reliance of almost all prospective studies on clinical PID as the
outcome and between-study variation in case definition.40 There is a clear risk that prospective studies may
underdiagnose PID, as case–control studies of TFI suggest that up to 80% of women with TFI report no
history of PID.34,99,220 However, Wolner-Hanssen103 found that only 11% of women with TFI reported never
having had clinical symptoms. In prospective studies in which participants are questioned about symptoms
of PID, few cases are likely to be missed. The risk of overdiagnosis of PID depends on the definitions used.
The definition used in the POPI trial19 corresponded very closely with ‘probable/definite’ PID as defined in
Chapter 2. To the extent that the POPI trial19 has a dominating influence on the pooled estimate, it is
reasonable to assume that the estimate of progression risk applies to ‘probable/definite’ PID.
However, as noted in Chapter 2, although it is believed that a high proportion, 66% of PID is
undiagnosed, only a small proportion, 11%, is asymptomatic.103 In the POPI trial19 women were alerted to
the risks of PID as part of the consenting process, as follows: ‘. . . This is why if you could have been at risk
of infection, or have any symptoms which could be due to a sexually transmitted infection, it is vital that
you have a check up at a genitourinary clinic even if you are participating in the study’.221 Women would
also have been aware that they would be followed up at the end of the study. Our assumption therefore is
that in the POPI trial,19 and probably in all prospective studies following women at risk of STIs and PID, only
the small proportion of PID – the ‘silent’ proportion – will be missed.
The progression risk from CT to PID was estimated to be 14.8%. This estimate is based on the trial data
alone. A previously published rate from this study,201 which was a little higher (16%), was based on the
trial together with the single non-randomised study with a control group. However, in discussing the
progression rate from CT to PID, we should bear in mind not one single estimate but three estimates, each
reflecting a different level of ascertainment of PID. The 14.8% estimate most likely represents the 87%
of PID that is symptomatic, a 17.1% estimate would be more appropriate for all PID, diagnosed and
undiagnosed, whereas an estimate of approximately 6% would correspond to the level of ascertainment
that is represented in routine statistics.
The systematic difference in observed PID rates in studies with shorter and longer follow-up periods has led
to the suggestion that the progression rate is not constant over time.98 The potential impact of this has
been explored in the mathematical modelling literature, using Markov or similar models208,222 to predict the
proportion of PID prevented. However, with one exception,222 these studies have generated estimates of
the proportion prevented from scenario analyses based on estimates of progression rates that were derived
from models that do not allow for the competing risk of clearance or the left truncation inherent in
screening studies. The key contribution of this paper is to actually estimate all of these parameters
consistently within the Markov model framework. We found that the proportion of CT-related PID that
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could be prevented by annual screening may be as low as 55%, which might represent only 20–25% of
all PID in younger women62 (see later chapters). Estimates based on two-rate models were relatively
insensitive to the duration of a period of heightened PID risk following CT infection, but were derived from
a single, non-randomised study. The sparse data available do not distinguish homogeneous and piecewise
homogeneous models statistically, and the credible intervals on the parameters are wide. However, both
one- and two-rate models are considered plausible a priori.98
Summary of assumptions and findings
Assumptions
1. Studies based on screening asymptomatic individuals recruit prevalent infection, whereas clinical-based
studies recruit recently incident cases.
2. The definitions of PID used in the POPI study19 correspond closely with the definition of probable/
definite PID used in Chapter 2.
Summary of findings
1. The data do not distinguish between a model that assumes a constant hazard of PID following CT
infection, and a model in which the rate is higher over the initial 1–3 months.
2. The results of the POPI trial19 are consistent with the results of other trials and controlled prospective
studies although there is a high degree of uncertainty.
3. The CT-related risk of PID following CT infection is 14.8% (95% CrI 4.8% to 24.8%), based on the trial
evidence on PID that would be ascertained in a prospective study.
4. The total CT-related risk of PID following CT, including undiagnosed PID, is 17.1% (95% CrI 5.6%
to 28.9%).
5. 61% (95% CrI 55% to 67%) of CT-related PID could be prevented by screening at annual intervals.
The estimate is slightly lower if CT-to-PID progression rates are higher in the first 1–3 months.
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Chapter 7 Chlamydia and pelvic inflammatory
disease: Population Excess Fraction based on
prospective, retrospective and routine data
Objectives
To:
1. generate and compare estimates of the incidence of PID
2. generate and compare plausible estimates of the proportion of PID attributable to CT (the PEF)
3. produce coherent estimates of: CT incidence, PID incidence, the CT-to-PID progression rate, and
the PEF.
Introduction
The previous chapter produced estimates of the risk of clinical PID (as defined in Chapter 2) caused by an
episode of CT, based on prospective, and, particularly, randomised, data. We now consider the relation
between CT and PID from a broader perspective: not only the risk of PID following CT, but also how much
PID is attributable to CT. Viewed in isolation, the two questions are technically independent of each other.
However, suppose we had independent estimates of (1) CT incidence; (2) PID incidence; (3) the CT-to-PID
progression risk; and (4) the proportion of PID attributable to CT, the PEF. It would then be possible to
generate a prediction for each of these quantities from the other three. Therefore, estimates of the two
quantities are not independent if we examine the available data sources more broadly.
In fact, the relation between untreated CT and PID has been studied in a wide variety of ways, drawing on
prospective, retrospective and routine data. Following a MPES approach, we want to know whether the
different methods give consistent answers.
Given that previous chapters have dealt with CT incidence and the CT-to-PID progression risk, in order to
provide a complete account of CT and PID, we must answer two remaining questions: first, what is the
incidence of all-cause PID; and second, how much PID is caused by CT. We begin by describing evidence
sources and statistical methodology for each topic. Two sources of evidence of PID incidence are
considered: a direct estimate from the control arm of the POPI trial19 and an estimate derived from routine
data. We then consider five separate methods of estimating the PEF in turn. For each estimate we first
review the evidence sources available, describing the relationships between the different elements. We
then set out the statistical models used to obtain estimates from the data. In the results we assess the
consistency of evidence on PID incidence, and compare the various estimates of PEF. In discussion we
review some of the key assumptions made and provide a rationale for our choice of PEF estimate to take
forward to later chapters. We also present a coherent set of estimates of CT incidence, prevalence and
duration, CT-to-PID progression rate, PID incidence and the PEF.
We note here that there is a wider literature on the relation between CT and PID which we have not
reviewed here, although it is, on the face of it, highly relevant. In particular, we have not included
estimates of the CT-to-PID progression risk based on register studies36,215 because women with CT in these
studies are treated, and are therefore not able to inform the CT-to-PID progression risk in untreated
infection. Further, although these studies have been used for this purpose in the past,2,15 the CDC Task
Force98 also concluded that such studies could not help determine the relationship between CT and PID.
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
63
A second set of estimates not reviewed here are those of van Valkengoed et al.,39 who used a complex
procedure to estimate the prospective risk of PID, EP and TFI, following CT, from retrospective and routine
data sources. These risk estimates are extraordinarily low, and a methodological critique is given in
Appendix 9.
Methods: review of evidence sources and statistical estimation
Estimates of the incidence of all-cause pelvic inflammatory disease
This section describes two independent sources of PID incidence estimates, and a third estimate based on
pooling them.
Estimates based on the control arm of the Prevention of Pelvic Infection trial
A comparatively direct estimate of λALL PIDa can be derived from the control arm of the POPI trial,
19 if we
assume that the trial sample is approximately representative of the general female population of the same
age, approximately age 16–24 years. In the unscreened arm, 23 (rPOPI) cases of clinical PID were reported in
a sample of 1186 (nPOPI) women, aged 16–27 years, followed up for a period of 1 year. Following
comments on the definition and ascertainment of PID in Chapters 2 and 6, we assume that all
symptomatic PID meeting the ‘probable/definite’ criteria will be ascertained, including those normally
undiagnosed. The POPI estimates are therefore ‘grossed up’ to account for the underascertainment of
asymptomatic (silent) PID in prospective studies. The POPI19 control arm estimates λALL PIDa . ψ
Sym, where ψSym
is the proportion of PID that is symptomatic.
rPOPIeBin(pPOPI,nPOPI)
pPOPI = 1−exp(−λPOPI)
λPOPI = λAll PID.ψ Sym
rSymeBin(ψ Sym,nSym)
(22)
The probability that incident PID is symptomatic ψSym is informed by the 32 out of 36 cases who reported
symptoms in the Wolner-Hanssen study.103
Incidence of all-cause pelvic inflammatory disease based on routine data
A second, more indirect, estimate of incidence can be derived from PID data routinely collected in England.
These data represent only diagnosed ‘probable/definite’ PID, and so must be grossed up by an estimate of
the proportion of PID that is diagnosed in a general population context (see below).
There are three sources of data on PID in England: HES,117 GPRD90 and KC-60 (the routine returns from STI
clinics198) (Table 18). The three sources pick up cases from different care pathways. HES117 reports the
number of cases of PID diagnosed in hospital (codes N70-N74). GPRD90 reports all diagnosis made in an
TABLE 18 Number of incident cases of PID in England, 2002
Age (years) HES (A) GPRDa (B) GUM clinicsb (C) MinC+Max (B,A) Max A+B+C Female population
16–19 1233 5083 3212 8295 9528 1,199,600
20–24 3101 8842 4399 13,241 16,342 1,519,100
25–34 9756 14,932 3919 18,851 28,607 3,502,100
35–44 10,526 9609 1388 11,914 21,523 3,795,600
Max, maximum; Min, minimum.
a Definite and probable PID as defined in French et al.90
b Data by age not available for 2002 so we assume that the age distribution for these data were the same as in 2009.
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approximately 8% sample of patients registered with general practices across the country. These data do
not include PID as a separate diagnosis, so we take our estimate from a recent paper that used the
recorded clinical descriptions of symptoms to estimate population incidence of definite and probable, and
of possible, PID diagnosed in this setting.90 Finally, PID diagnosed in STI clinics is reported as ‘complicated
chlamydia’. Data shown in Table 18 is for 2002, the final year before the introduction of the National
Chlamydia Screening Programme.
To use these data to derive age group-specific estimates of the annual incidence of diagnosed PID, we
need to make assumptions about the degree of overlap between the three sources. Consultation with
experts suggests that referrals of PID cases to and from departments of GUM (STI clinics) were rare prior to
2008. Referrals from GP practices to hospital are likely to have been more common for severe cases.
A primary care guideline for STI management published in 2006223 recommended referral to a GUM clinic
for mild/moderate cases of PID, and immediate commencement of treatment was advised if an urgent
appointment was not available. Prior to 2008, access to GUM services within 48 hours was poor.105 It was
recommended that severe cases should be referred to gynaecology for admission to hospital. We therefore
assume that the total of the STI, GPRD and HES data, within each age group, represents an upper bound
for the number of PID cases diagnosed in England each year. A minimum was formed by adding the
number of GUM cases to either the GPRD or the HES cases, whichever was largest.
Routine data on diagnosed PID, given information on age-specific population sizes Na, provides information
on λDiagPIDa . An estimate of total (all cause) rate of PID can then be constructed by using information on the
proportion diagnosed, ψDiag:
λΑLLPIDa =
λDiagPIDa
ψDiag
(23)
Binomially distributed data based on Table 18 are used to inform minimum and maximum limits for the
annual probability of (diagnosed) PID, and these are used to define the upper and lower limits for λDiagPIDa .
The WinBUGS ‘cut function’ was used to ensure that this uniform distribution was not updated (see
Chapter 3).
rmina eBinomial(pmina , Na), rmaxa eBinomial(pmaxa , Na)
paeUniform(pmina , pmaxa )
λDiagPIDa = −log(1−pa)
λALLPIDa = λ
DiagPID
a =ψ
Diag
rDiageBin(ψDiag, nDiag)
(24)
where Na is the number of women in each age group in England in 2002 from Census data.
The degree of underdiagnosis was based on a single study of 36 infertile women, only 11 of whom
(30.6%) reported that they had been diagnosed with PID.103 This study reported data with a
binomial likelihood.
Synthesis of pelvic inflammatory disease incidence estimates
The two estimates of PID incidence were compared. A DAG (Figure 14) shows how the two estimates
were combined. The WinBUGS code and data sets are set out in Appendix 10.
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Population Excess Fraction: how much PID is caused by chlamydia?
In this section we examine estimates of the PEF based on microbiological studies, estimates based on
retrospective case–control studies, and estimates derived from the ratio of CT-related PID incidence and
all-cause PID incidence, and finally estimates based on randomised trials. DAGs for each of the estimates
are shown in Figure 15.
Uncontrolled studies of the microbial aetiology of PID
Microbiological analysis of samples from the genital tract of women with PID provides direct information
on potentially causative organisms. Based on 19 microbiological studies conducted between 1977 and
1992, in a number of countries, Paavonen et al.82 reported that CT was involved in 30% of PID cases.
It has been argued20 that this must be an underestimate of the current role of CT, as gonorrhoea was a
common cause of PID during the period when many of these studies were undertaken, and it is generally
agreed that gonorrhoea is a far less common aetiology at present, particularly in Europe.
Simms and Stephenson62 provide a summary of studies in which patients with laparoscopically proven PID,
in other words salpingitis (see Chapter 2), recruited in various clinical settings, were examined for evidence
of current CT infection. The proportion with evidence of current CT in upper genital tract samples varied
from 12% to 65%, reflecting considerable variation over time and between countries. The largest UK
study,224 conducted between 1989 and 1993, reported 39%. In another UK study,37 conducted from 2000
to 2002, 42 of 140 (30%) salpingitis cases had evidence of exposure to CT.37
It is tempting to consider these studies as producing a direct estimate of the proportion of PID that is
attributable to CT.1 But this may be misleading for several reasons, the most obvious of which is that a
control group is required consisting of women without PID. The proportion of control samples in which we
would expect to find evidence of CT is, of course, quite small. The general population prevalence of CT is
in the order of only 3% (see Chapter 5).
A more serious weakness is that the results obtained depend markedly on the sites from which samples
are taken. In particular, the presence of CT in the upper genital tract, which is more likely to be causally
related to PID, may not be well predicted by its presence in the lower genital tract.225,226 These issues were
clarified by a recent study in Erfurt, Germany,225 looking at 363 women with laparoscopically confirmed
PID. CT was found in the genital tract of 103 (28.4%), and in 55 (15.2%) it could be isolated from the
cervix. In 23 (6.3%), CT was isolated from both the cervix and the fallopian tubes, whereas in 47 (12.9%)
CT was isolated in the fallopian tubes only.
=
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FIGURE 14 Directed acyclic graph showing combination of two sources of evidence on PID incidence.
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a incidence of all-cause PID; θ
CT→PID
a CT-to-PID
progression risk. PEF-4: Ptrt probability of PID in POPI19 treatment arm; pCtrl probability of PID in POPI19 deferred
treatment (control) arm; pCtrl adjusted p
Ctrl; pIT probability independent testing in CT+ controls.
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If we take infection in the fallopian tubes as the causal factor in subsequent reproductive damage, this
implies that studies based on cervical isolates may be underestimating the role of CT in PID-related
reproductive damage by a factor of 103/(103–47)= 1.84. The Erfurt study225 found CT in the fallopian
tubes of just under 20% of cases of laparoscopically confirmed PID. Few studies of PID routinely sample
both the cervix and fallopian tubes for CT, so direct comparisons are difficult. However, high titre antibody
can be used as a surrogate for upper genital tract infection.85 Taylor-Robinson et al.88 also observed that
infection at the cervix probably underestimates the role of CT in PID-related reproductive damage by a
similar factor 16/(16–6), or 1.6. This was based on the observation that of the 22 women diagnosed with
acute salpingitis on laparoscopy: 10 had CT detected at the cervix and an additional six had high-titre
serum CT IgG antibody.
These considerations help to quantify the likely degree of underestimation of the OR, and hence the PEF,
from case–control studies based on lower genital tract samples, and this can be used to adjust estimates
from those studies.
Population Excess Fraction based on case–control studies
We noted in Chapter 3 that the presence of positive confounding in estimates of the RR of the disease
(PID) given the exposure (CT), if based on observational data, would tend to result in overestimation of the
PEF. This can be mitigated to some extent by choosing study designs in which the risk of confounding is
minimised. For example, it is preferable to use a marker of current CT infection rather than a marker of
previous CT infection. We have therefore used data only from case–control studies that use current
infection as a marker of exposure. (We set aside, here, the further difficulties with the serological markers
used in the published literature, namely their poor sensitivity and specificity: this is discussed at greater
length in Chapter 11.)
Identification of case–control studies on CT prevalence in women with PID
and control subjects
We searched for studies using current CT infection as a marker of CT exposure. Strictly speaking, in a
synthesis focusing on prevalence and sequelae of CT in the UK, only contemporary UK data should be
used. We have, nevertheless, used data from Europe on the basis that the epidemiology of STIs is generally
similar in Western European countries. Studies from North America have been excluded because
gonorrhoea has tended to have a more important role in the aetiology of PID in North America than the
UK.227–229 We also excluded studies published before the 1990s. Our literature identification process
(see Chapter 3) identified three studies,31,37,230 shown in Table 19.
TABLE 19 Odds ratios from retrospective studies
Study Group Dataa Crude CT prevalence Crude OR
Paavonen31 Cases 13/30 0.43 (0.28 to 0.63) 6.9 (0.77 to 61.4)
Controlsb 1/10 0.10 (0.03 to 0.44)
Mascellino230 Cases 22/110 0.20 (0.14 to 0.29) 7.0 (3.1 to 15.8)
Controls 9/261 0.03 (0.02 to 0.06)
Simms37 Cases 17/140 0.12 (0.08 to 0.19) 18.7 (2.45 to 142)
Controlsb,c 1/136 0.01 (0.00 to 0.04)
a Binomial numerators and denominators.
b Illustrative, as there are insufficient numbers to assume asymptotic normality.
c GP control Group used.
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Estimates of the Population Excess Fraction from case–control studies,
PEF-1 and PEF-2
A pooled OR was estimated from these studies (see below), and used to derive an estimate of the PEF,
using equation 1. Although the same OR is assumed to apply to women of all ages, the formula will
generate age-specific estimates of PEF, because age-specific estimates of CT prevalence from Chapter 5 are
entered, as follows:
PEF (1)a = γ
(1)
a =
πa.(RR−1)
πa.(RR−1) + 1
(25)
The six data points are used to estimate four parameters: three study-specific ‘baselines’, the log odds in
the control groups µs, with s indexing study, and one ‘FE’ log OR β. Using a standard logistic regression
model, with 0 for controls, 1 for PID cases:
logit(λs,0) = µs
logit(λs,1) = µs + β
(26)
The OR can be recovered via: OR= exp(β), and used as a RR in (see equation 25) (see Chapter 3) to
generate a set of estimates, PEF-1.
A second set of estimates (PEF-2) were generated by adjusting the OR from the retrospective studies for
under-ascertainment of CT in the PID cases, using the 1.84 estimate from the Erfurt study.225 The
uncertainty in the adjustment is taken into account by setting: ORAdj=OR/ψErf, where ψErf∼ Beta(56,47).
Estimates of Population Excess Fraction based on CT-related and all-cause PID
incidence, PEF-3
Adams et al.1 obtained estimates of all-cause PID incidence in 16- to 44-year-olds from a GP-based
study.231 Based on a retrospective study,37 they reckoned that a maximum of 30% of PID could be
attributed to CT, and used this to identify a range of estimates of CT-related PID incidence. They then
multiplied a number of CT-to-PID progression rates into estimates of CT incidence, to identify progression
rates that were consistent with their results on CT-related PID. We mention this study,231 not to review the
findings in detail but simply to draw attention to the general method, which we use below in an inverted
form to estimate the PEF, although with different data inputs.
Here, the age-specific PEF is taken to be the ratio of the incidence of CT-related PID to the incidence of
all-cause PID, where the incidence of CT-related PID is the product of CT incidence (see Chapter 5) and the
CT-to-PID progression rate (see Chapter 6):
PEF (3)a = γ
(3)
a =
λCTa θ
CT→PID
λALLPIDa
(27)
To implement this, we pool two independent sources for estimating all-cause PID incidence (see below),
and estimates of CT incidence and CT-to-PID progression rate from Chapter 6.
For these last two parameters, we use a multivariate normal approximation to the posterior distribution
estimated in the incidence, prevalence, duration synthesis (see Chapter 5), and this is entered as data in
the calculations. Specifically, incidence and duration were normal on the log scale, the proportion
symptomatic was normal on the natural scale, and prevalence was normal on a logit scale. Similarly,
a normal likelihood for CT-to-PID progression risk is derived from the posterior analysis in Chapter 6.
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Estimates of Population Excess Fraction based on screening trials, PEF-4 and PEF-5
The Scholes trial13 compared PID risk 1 year later in women randomised to screening and treatment and
women randomised to no screening. The observed RR was 0.44 (95% CI 0.20 to 0.88). This represents a
RRR of 0.56, implying that 56% of PID is due to CT in the study population, and this can be interpreted as
an estimate of the PEF (see Chapter 3). One of the early criticisms of the trial18 was that this was an
unrealistically optimistic result because it conflicted with the microbiological studies cited above, apparently
showing that 30% of PID was CT related. Gottlieb et al.,226 in an important review, also draw attention to
this apparent discrepancy, but points out that a similar RR was observed in the Ostergaard trial.12
An approximate PEF can be derived from the RR of PID in the POPI trial, using equation 3.12 There were 23 PIDs
in the untreated group of 1186, and 15 in the treated group of 1191. An estimate of the PEF is therefore:
pCtrleBeta(23,1163), pTrteBeta(15,1176)
PEF (4) = γ(4)a =
pCtrl−pTrt
pCtrl
(28)
However, this estimate is likely to be biased because 29 out of 67 (43%) untreated controls, who were
initially CT+ undertook to be tested independently. We can assume, therefore, that the excess risk of PID
in the untreated controls, pCtrl – pTrt has been underestimated by a factor of 1 – pIT, where pIT is the
probability that a CT+ control is independently tested and treated. Accordingly, we can form an
adjusted estimate:
pITe Beta(29,38)
pCtrl =
pCtrl−pTrt
1−pIT
 
+ pTrT
PEF (5) = γ(5)a =
pCtrl −pTrt
pCtrl
(29)
This should be regarded as a ‘maximum’ correction, as it assumes that all the independent testing took
place at the outset.
Results
Consistency of evidence on pelvic inflammatory disease incidence
Table 20 provides a series of age-specific estimates for the incidence of (all cause) PID, from the
different data sources. The ‘direct’ estimate from the POPI trial,19 2.0% per year – when adjusted for
under-ascertainment due to asymptomatic presentation – represents a 2.4% per year incidence. This is
consistent with the estimate derived from routine data, 3.0% per year for that age range, following
adjustment for the underdiagnosis inherent in routine PID statistics. Figure 16 shows the posterior
distributions of PID incidence from the two sources, and the pooled estimate, and establishes the
consistency of the estimates. The consistency of registry data with the POPI study19 can be studied only
for the 16- to 24-year-old age group.
Note that when combining the direct and indirect evidence sources, the incidence information
back-propagates to ‘update’ the estimate of the proportions of PID that is undiagnosed. This was 31%
in the original study but is estimated to be 36% following synthesis with the POPI19 data.
The final pooled PID incidence estimates are 2.5% per year (95% CrI 1.8% to 3.4%) in women aged
16–24 years, and 1.6% (95% CrI 1.1% to 2.2%) in women aged 25–44 years. Taking into account the
age structure of the female population, we can estimate that 62.9% (95% CrI 57.8% to 67.4%) of PID
episodes occur in women over 24 years.
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Estimates of the Population Excess Fraction
The synthesis of the three retrospective studies31,37,230 of CT in women with PID and control subjects
(see Table 19) produces a posterior mean OR of 9.2 (95% CrI 4.4 to 18.1). The model fitted well (residual
deviance of 5, compared with six data points). The OR adjusted by the under-ascertainment factor from
the Erfurt study225 is 17.1 (95% CrI 7.9 to 34).
The several estimates of the PEF are shown in Table 21. The adjustment for under-detection of CT
infection in the case–control studies, based on the Erfurt study,225 almost doubles the overall PEF (women
aged 16–44 years) from 14.5% to 24.6%. The dramatic fall in PEF with age is no more than a reflection of
our assumption that the OR is not related to age, whereas the incidence and prevalence of PID varies, as is
evident from the routine data (see Table 18).
TABLE 21 Alternative estimates of the PEF, the percentage of PID caused by CT
Age
(years)
Retrospective
(OR= 9.2):
case–control studies,
see Chapter 6
Adjusted
retrospective
OR= 17.1, based
on Erfurt study225
CT-related PID
divided by all-cause
PID incidence
POPI trial19
alone, from
reported RR
POPI trial,19
adjusted for
treatment
during
follow-up in
the control
group1 2 3 4
16–19 33.8 (16.9 to 54.8) 49.5 (29.4 to 70.3) 53.5 (15.6 to 100) – –
20–24 23.7 (11.1 to 41.4) 37.4 (20.4 to 58.0) 24.3 (7.2 to 47.6) – –
25–34 8.5 (3.4 to 17.2) 15.2 (6.7 to 28.8) 10.3 (2.9 to 21.2) – –
35–44 6.2 (2.3 to 13.5) 11.5 (4.6 to 23.3) 11.5 (3.0 to 25.7) – –
16–24 28.6 (14.0 to 47.9) 43.5 (25.0 to 23.3) 35.3 (10.5 to 68.5) 35.7 (0 to 67.2) 49.4 (0 to 78.9)
25–44 7.3 (2.9 to 15.1) 13.3 (5.8 to 25.8) 10.6 (3.0 to 21.9) – –
16–44 14.5 (6.4 to 27.1) 24.6 (12.3 to 42.0) 19.7 (5.9 to 38.1) – –
Column 1: Estimates based on three case–control studies; column 2, same, but OR adjusted by data from the Erfurt study225
(see text); column 3, ratio of CT-related PID incidence, estimated as the product of CT incidence (see Chapter 5) and
CT-to-PID progression risk (see Chapter 6) to all-cause PID incidence (synthesis model, see Table 20); column 4, median PEF
derived directly from RR reported in the POPI trial;19 and column 5, median PEF from POPI trial19 adjusted for independent
testing in the deferred treatment group.
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FIGURE 16 Evidence consistency plot for the incidence of all-cause PID in England in women aged 16–24 years.
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The PEF-3 estimates (column 3) based on the ratio of CT-related PID to all-cause PID also show a marked
falling off with age. It is reassuring that the adjusted estimates based on case–control studies are close to
estimates derived in a very different way from the progression rate, CT incidence and all-cause PID incidence.
The direct estimate of the PEF based on the POPI trial,19 PEF-4, is 35.7%, but if this is corrected for
independent testing in the deferred treatment (control) arm, this becomes 49.4%. The CrIs on both
estimates are wide, and span zero because the difference in the crude PID rates between the two trial
arms itself is too uncertain to rule out no difference with 95% confidence.
Discussion
The chapter establishes that routine data on PID incidence collected from GP, hospital and STI clinic
sources, taking account of the likely overlap between these sources and the extent of undiagnosed PID,
is consistent with an estimate of PID derived from the POPI19 trial.
Second, setting aside the actual estimates obtained, we have established for the first time a coherent
framework in which CT incidence and prevalence, PID incidence, CT-to-PID progression rate, and the PEF
can all be considered together. The coherent set of estimates obtained, for the first time in any country or
region, reflect what we feel is the totality of evidence on all these parameters, subject, of course, to our
interpretation of the evidence sources.
Although one might wish for greater precision in each one of the data inputs that have been examined
here, we would suggest that the analysis lends a degree of robustness to our interpretation of all of the
data sources, but particularly to our quantitative information on the causal connection between incident
CT and PID. This estimate of the causal connection between CT and PID is pivotal, as the further
downstream sequelae of CT, namely EP and infertility, are viewed as arising from CT-related PID, and not
from CT in the absence of PID.
The general consistency between the various estimates of PEF, based on fundamentally different sources, is
reassuring, although the CrIs are wide. The two direct estimates based on the POPI trial,19 PEF-4 and PEF-5,
probably represent lower and upper limits, and they are close to estimates from previous trials. Interestingly,
of the 26 PID patients in the POPI trial19 who were tested, 16 (61.5%) were CT+ at the time the PID was
diagnosed. Of the 16 who were CT– at the start of the trial, 10 (62.5%) were CT+ at diagnosis. These
further observations from the POPI trial19 suggest that that the corrected estimate may be closer to the truth.
Although the failure to find inconsistency raises the credibility of the analyses, confidence in the estimates
has to be tempered by their relatively low precision, which makes inconsistency difficult to demonstrate.
Moreover, each of the analyses are subject to a number of caveats.
Limitations of the analysis
Overlap between sources of routine data on incident pelvic
inflammatory disease
One important limitation is the poor information currently available on the degree of overlap between the
three routine data sources contributing information on incident PID (see Table 18). Our assumption was
that the true number of incident cases was from a uniform distribution bounded by a ‘minimum’ (GUM
plus the largest of GPRD and HES) and a ‘maximum’ in which there was no overlap. Although this seems a
reasonable way to use the data available, the ‘gap’ between the minimum and maximum estimates was
30–37% of the lower estimate, depending on age. A recent paper on PID management based on GPRD
noted that only 56% of the 3669 cases examined were managed entirely within the practice. If the
age-specific GPRD figures are divided by 0.56, the number obtained lies between the minimum and
maximum, which provides some support for the procedure we have followed.97
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Obtaining a more precise estimate of the number of incident cases, by collecting data on referrals between
GPRD, hospital and GUM clinics, could improve the accuracy of estimates considerably. This would be a
useful avenue for further research (see Chapter 12).
Proportion of pelvic inflammatory disease patients diagnosed
and ascertained
Our estimate of the proportion of PID episodes diagnosed is based on a single study looking at infertile
women with evidence of past PID.103 This study103 has informed two key parameters which have been used
to ‘gross up’ each of two estimates of PID incidence. First, we grossed up the estimate seen in the POPI
trial,19 to account for the proportion of ‘silent’ PID that would not be observed even in a prospective study.
Second, we use it to gross up evidence from routine data, to account for both silent PID and for
symptomatic PID that does not lead to medical treatment or which is not diagnosed. This single, small
study,103 carried out in another country 30 years ago, is being asked to carry quite a considerable weight
and this must be recognised as a limitation of our analyses.
Retrospective data and confounding
As noted earlier in this chapter and elsewhere, the use of equation 25 to estimate the PEF from
retrospective data is inherently likely to overestimate it as a result of positive confounding with other
exposures, both other STIs that are known to be causal agents for PID, and non-STI infections that can
be transmitted as a result of sexual intercourse. It is therefore possible that the PEF-1 estimate, and
particularly the PEF-2 estimate, which is adjusted for probable under-ascertainment of CT infection in
women with PID, represent overestimates. On the other hand, this adjustment may not fully account for
under-ascertainment if a proportion of women with CT-related PID may clear their infection before the
diagnosis of PID is made.88,226 In addition, estimates of PEF are time- and place-dependent: the extent to
which we can generalise from these results to the UK situation is very hard to assess. Therefore, although
the PEF-1 and PEF-2 estimates based on retrospective data are of interest, we conclude that they are
biased to an extent that is had to quantify, and they play no further role in this report.
Impact of age on the relationship between Chlamydia trachomatis and
pelvic inflammatory disease
The PEF estimates show a clearly declining trend with age. In the retrospective estimates, this follows as a
consequence of assuming a constant OR and applying this to a prevalence that declines steeply with age.
In the case of PEF-3, the decline with age is partly due to the decline in CT incidence with age (exactly
mirroring the decline in prevalence with age), the age profile of PID in the routine data, and the
assumption that the proportion of PID that is undiagnosed is constant over age.
Although the decrease in PEF with age is to some extent a result of our assumption that neither the
probability that PID is diagnosed nor the risk of PID following CT are age-dependent, the degree of
variation with age, a factor of 4–6 between age 16–19 years and age 35–44 years, is so extreme that we
would have to propose quite extreme trends in one or both of those quantities to reverse it. The proposal
that PEF decreases with age is, apparently, not one that has been made before, but it is consistent with
the observation that estimates based on the trial evidence tend to be higher because the trials are heavily
weighted towards younger women.
Age dependency in PEF, if confirmed (see Chapter 2 for discussion of alternative explanations), would have
significant impact on the public health importance of CT, as the majority of EP and TFI occurs in older
women. Although it is certainly possible that CT infections in younger women have a key role in
reproductive health problems that emerge many years later, these results focus attention on the distinctly
different age profiles of CT and PID. There are insufficient data in either the prospective or retrospective
studies to address this question more fully. Further work to examine these issues directly is proposed in our
research recommendations.
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Post-hoc element in choice of estimates
We record here that, when the work in this chapter was first carried out, we included only the unadjusted
(PEF-1), and we pooled that information with the evidence sources contributing to estimate PEF-3. At that
time we believed that the estimates based on retrospective studies must be upper bounds, and we did not
examine the trial-based estimates. After we had completed the work on TFI (see Chapters 10 and 11), we
became aware that the PEF-1 estimates were too low to be consistent with the results of those chapters.
We then reconsidered the relationship between CT and PID, and re-examined the trial-based estimates of
PEF, particularly in the light of the comments in Gottlieb et al.226 At the same time, results from the recent
Erfurt study225 made it clear that the retrospective estimates were not necessarily upper bounds. There is,
therefore, a post-hoc element to the reasoning in this chapter. The ‘hypothesis-generating’ aspect to our
findings on PEF are reflected in the research recommendations. Nevertheless, that fact that two estimates
of PID incidence are consistent with each other, and with an account of the PEF that is consistent with
other independent sources of data, to some extent mitigates the post-hoc process in our investigation.
Coherent estimates of CT and PID incidence, CT-to-PID risk, and
Population Excess Fraction
There is an option to strengthen our estimate of the PEF by pooling PEF-3 with either the adjusted
retrospective evidence PEF-2, or the evidence directly derived from the POPI trial,19 PEF-4 or PEF-5, or both.
We have chosen not to do this, on the basis that the PEF-2 estimate is vulnerable to many biases, and
relates to a different time and place, as discussed above. The estimate of PEF from the POPI trial19 is not
statistically independent of the estimate of the CT-to-PID risk estimate, and is also subject to uncertainties
described above. However, we regard the similarity of these independently derived estimates as an
important validation.
In taking forward the PEF-3 estimate γCT←PIDa , which is calculated from the CT incidence estimates in Chapter 5,
the CT-to-PID progression risk in Chapter 6, and all-cause PID incidence in this chapter, we have generated a
fully coherent set of estimates for CT incidence, prevalence, duration and the proportion of infection that is
symptomatic; PID incidence, the proportion of PID that is symptomatic and the proportion that is diagnosed,
the CT-to-PID progression risk, and the PEF. The summary posterior means and CrIs can be found in Tables 13
(full synthesis model), 17 (trials only), 20 (synthesis model) and 21 (column 3).
These estimates are carried forward to the analyses in the subsequent chapters.
Summary of assumptions and findings
Summary of assumptions
1. The probability that PID is diagnosed is independent of age.
2. The risk of PID due to CT is independent of age.
3. The probability of diagnosis is the same in CT- and non-CT-related PID.
4. In prospective studies, including the screening trials, all PID – except for asymptomatic PID –
is diagnosed.
5. In routinely collected data on PID, a lower proportion of all PID is diagnosed than in prospective studies.
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Summary of findings
1. Two estimates of PID incidence in the UK were consistent: one derived from the control arm of the
POPI trial,19 and the other from routine statistics combined with evidence on the proportion of PID that
is diagnosed.
2. A pooled estimate of PID incidence in age 16- to 24-year-olds is 2.5% per year (95% CrI 1.8 to 3.4),
and 1.8% per year (95% CrI 1.3% to 2.5%) in 16- to 44-year-olds.
3. 36% (95% CrI 26% to 48%) of PID that causes reproductive damage is diagnosed; 12.6% (95% CrI
4 to 25) is asymptomatic.
4. Estimates of the PEF were compared: (1) an estimate based on retrospective studies adjusted for
under-ascertainment; (2) an estimate based on CT incidence, CT-to-PID progression rate, and PID
incidence; and (3) estimates based on the POPI19 trial. There was no evidence of inconsistency although
Crls were wide.
5. We estimate that 62.9% of PID episodes (95% CrI 57.8% to 67.4%) occur in women aged over
24 years.
6. The PEF declines sharply with age.
7. Our estimate of PEF, derived from CT and PID incidence data and the CT-to-PID progression risk is
19.7% (95% CrI 5.9% to 38.1%) in women aged 16–44 years, and 35.3% (95% CrI 10.5% to
68.5%) in women aged 16–24 years.
The analyses thus far in the report establish a set of coherent estimates for the UK of CT incidence, CT
prevalence, CT duration, probability that an incident CT infection is symptomatic, PID incidence, proportion
of PID that is diagnosed, proportion of PID that is symptomatic, the CT-to-PID progression, and the PEF of
PID due to CT.
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Chapter 8 Cumulative incidence of pelvic
inflammatory disease: results from a Markov model
Objectives
1. To estimate the proportion of women, by age, who have ever experienced (1) an episode of PID;
(2) an episode of salpingitis; (3) an episode of non-CT-related PID; and (4) an episode of
non-CT-related salpingitis.
2. To estimate the proportion of women, by age at index salpingitis who experience zero, one, or two or
more subsequent episodes of PID.
Introduction
The critical evidence on the relation between PID and both EP and TFI derives from the Lund study,
represented by a series of classic papers published between 1980 and 1992,33,110,124,232 although new
analyses of these data continue to appear. Named after a county in Sweden, the Lund study was based on
the relatively long-term follow-up of large numbers of women hospitalised with a diagnosis of PID that
was confirmed as salpingitis on laparoscopy. Control subjects with the same initial diagnosis but no
evidence of salpingitis on laparoscopy were also followed up, with subsequent episodes of PID, EPs and TFI
as the recorded outcomes. The findings are described in detail in Chapters 9 and 10, respectively.
The Lund study established three clear principles:
The risks of EP and TFI:
l were raised above the background rate only in women with salpingitis; there was no evidence of
heightened risk following PID that was not confirmed as salpingitis on laparoscopy
l increased with the severity of the salpingitis
l increased with the number of subsequent episodes of PID.
In Chapters 9 and 10 we derive predictions of the numbers of EP and TFI cases that would occur in the
UK, based on the risks observed in the Lund study. To do this we need to estimate the proportion of
women who have been exposed to salpingitis, and the proportion of these who have experienced zero,
one, two or more subsequent episodes of PID. In this chapter we provide such estimates, based on the PID
incidence estimates from Chapter 7, the evidence on repeat infections in CT from Chapter 5, and the data
reported in the Lund study33 on the proportion of women with PID who had experienced one, two, three
or more episodes of PID subsequent to their index salpingitis.
It needs to be recognised that to achieve this analysis a number of assumptions have to be made, which
cannot be properly supported by empirical evidence, which are even somewhat arbitrary, and which, at
best, must be considered as no more than ‘reasonable’. In the discussion section of this chapter we will
nonetheless ‘reality check’ our results on the cumulative incidence of PID and salpingitis, and the
prevalence of one, two or more previous PIDs, by comparing our predictions to other sources of evidence
on PID incidence and cumulative incidence.
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Methods
Model for repeat pelvic inflammatory disease episodes
Estimates of age-specific incidence of CT-related PID, all-cause PID, and therefore non-CT-related PID are
available from earlier chapters. What we need, however, is a way to estimate what proportion of these PID
episodes are occurring in women who have already experienced a previous episode. In a homogeneous
population, PID incidence would be the same in women who had previously had PID and those who had
not. However, in the Lund study33 it was observed that the majority of women who experience a second
PID did so within 2 years. We therefore assume that women acquire PID at a rate λPIDa,1 in age group a,
and that this rate increases to λPIDa,2 for the 2 years following a PID. To determine the ratio of λ
PID
a,2 to λ
PID
a,1
we use information from the LaMontagne study192 of CT infection and re-infection rates for up to a
18-month period. This was described in Chapter 5. Specifically, we use the ratio on the GP group, which
was 7.08 (3.97 to 11.6) from Table 13, and assume that this same ratio applies to PID incidence so
that: λPIDa,2 = η
GP.λPIDa,1.
The GP group was chosen, rather than the FP or STI groups, as it was the most likely to reflect re-infection
rates in the general population. Using data on recurrent CT makes the further strong assumption that the
pattern of infection and re-infection in CT is the same as the pattern of PID and repeat PID, for PID from
any cause. Apart from the observation by Westrom33 that repeat PIDs usually occurred within 2 years of
follow-up, this assumption, and its many implications, do not have strong a priori validity. Our results are,
however, consistent with the Lund study33 observations on the incidence of repeat PID, and with other
data, as we show below.
We have posterior estimates of ηGP from Chapter 4 and λALL PIDa from Chapter 7, and our task is to calculate
λPIDa,1 and λ
PID
a,2. The parameter λ
ALL PID
a denotes the incidence of all PID, whether first, second, or subsequent,
and from any cause. There are several ways to parameterise the problem but the simplest is as follows:
λPIDa,1 = ρ:λ
ALL PID
a
λPIDa,2 = λ
PID
a,1.η
GP (30)
The equations, together with estimates of λALL PIDa and η
GP, uniquely determine ρ, which is a calibration
constant ensuring that when we sum first PIDs and subsequent PIDs we end up with the correct total PID
incidence. It is interpreted as the ratio of PID incidence in women who have not had a PID in the last
2 years to the incidence of PID in all women. ρ is calculated through a trial and error process. The model
was run from ages 16–44 years for different values of ρ until a value was found where the estimated
incidence of any PID agreed with our estimates of PID incidence from Chapter 7 (see Table 20).
Proportion of clinical pelvic inflammatory disease confirmed on laparoscopy
The Lund study33 analysis relates to hospital-diagnosed PID that has been laparoscopically confirmed. In the
Lund study33 itself, the ‘control subjects’ were women admitted with PID in whom there were no findings
of inflammation on laparoscopy. Interestingly, the proportion of all those referred with clinical PID who
were confirmed by laparoscopy fell systematically from 80% in those recruited 1960–4 and 1965–9, to
78% in 1970–4, to 70% in 1975–9, and to 60% in 1980–4.110 A 2003 paper by Simms et al.233 reviews
seven studies reporting between 31% and 79% confirmation rates, with the lowest figure coming from
the most recent study published in 2003. A continuing decrease in the proportion of clinical PID that is
confirmed on laparoscopy is probably to be expected in view of the fact that it is now recognised that
acute PID is difficult to diagnose because of the wide variation in the symptoms and signs. Many women
with PID have subtle or mild symptoms.63,234 Because of the difficulty of diagnosis and the potential for
damage to the reproductive health of women (even by apparently mild or subclinical PID), health-care
providers are now advised to maintain a low threshold for the diagnosis of PID.63,234
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If this is the case, then the most relevant evidence comes from a recently published UK study on a cohort
of women with abdominal pain.235 A total of 112 women were graded as ‘almost certain’, ‘probable’ or
‘possible’ PID, or were ‘very unlikely’ to have PID on the basis of their symptoms; 42.9% (12/28) of those
with grades as having at least probable PID were confirmed on laparoscopy, and 87% of these had high
titres of specific IgG antibody to CT. If a grading of ‘possible PID’ is included, 19 out of 56 (33.9%) were
confirmed. The definition of ‘probable’ here accords with the definitions used in our analyses of routine
UK data from HES and GPRD (see Chapter 6). Therefore, the rate at which women with ‘probable/definite
PID’ acquire salpingitis λsalpa,1 , λ
salp
a,2 can be estimated by applying the ϕ
salpjPID to the clinical PID incidence rates
estimated above. We assign an informative prior to ϕsalpjPID based on the data, Beta(12,16):
λsalpa,1 = ρ:λ
ALL PID
a ϕ
salpjPID
λsalpa,2 = λ
PID
a,1.η
GP
(31)
Markov model
Figure 17 shows a Markov model of PID development. It is assumed that women start in state 1 at age
15 years and progress through the model until age 44 years. It is a discrete time model with 1-year cycles,
programmed in WBDEV and WinBUGS161,236 (see Appendix 11). Expressions for the transition probabilities
are shown in Table 22, with the parameters defined as in equations 30 and 31. Note that the model
shows progression to first salpingitis and subsequent PID episodes. Exactly the same structure is used to
assess numbers of PID episodes, or number of salpingitis as described later in the section.
To generate estimates of the proportion of women who have ever had one, two or three or more PIDs,
we assume that further PIDs occur within a 2-year time period. The logic of the model is that individuals
start in state 1 (no previous salpingitis), and progress to state 2 (salpingitis 0–1 years) at the constant
incidence rate λSalpa,1 . The probability of a transition to state 2 with a 1-year period is therefore 1−e−λ
Salp
a,1 .
State 1
Never
salpingitis
p11
p12 p23 p34 p45
p35
p44
p56
p58
p78p67
p77
p68
State 2
Salpingitis 
0 – 1 years ago
State 3
Salpingitis 
1 – 2 years ago
State 6
Salpingitis and
PID 1 – 2 years
ago
State 7
Salpingitis and
one PID
 ≥ 2 years ago
State 8
Salpingitis and
≥ 2 PIDs
State 4
Salpingitis
 ≥ 2 years ago
State 5
Salpingitis and
one PID 
1 – 2 years ago
FIGURE 17 Markov model of salpingitis and subsequent PID incidence. Individuals start in state 1 (no previous
salpingitis) and progress to state 2 (salpingitis in the last 0–1 year). Once in state 2, women can (a) fail to have a second
PID and enter state 3 (salpingitis 1-2 years ago) or (b) have a second PID episode within a 2-year period and enter state
5 (salpingitis and 1 PID 0–1 year ago). From state 3 it is also possible to progress to state 5 at the faster ‘recurrence’
rate or to progress to state 4 (salpingitis 2+ years ago) by failing to experience a further PID episode within 2 years.
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Once in state 2, women can (1) fail to have a subsequent PID episode and enter state 3 (salpingitis 1–2 years
ago), or (2) have a subsequent PID episode and enter state 5 (salpingitis and 1 PID 0–1 years ago) at a
rate 1−e−λPIDa,2 . From state 3 it is also possible to progress to state 5 at the faster ‘recurrence’ rate, or to
progress to state 4 (salpingitis 2+ years ago) by failing to experience a PID episode. The subsequent
transitions follow the same logic.
Given values of λPIDa,1, λ
PID
a,2 and λ
Salp
a,1 , the model is run for a cohort of women aged 16–44 years on a 1-year
cycle, generating proportions of the female population φk,a in each state k, at each age a. From these state
probabilities the proportions of the population who have experienced no salpingitis, or salpingitis with
zero, one or two or more subsequent PID episodes can readily be found (see below).
We also validate our results against results from the Lund data set.33 The study reports data on the
distribution of numbers of PID episodes in women who have had salpingitis, for a mean follow-up period
of approximately 8 years, for women aged < 25 years, and for women aged ≥ 25 years. The Markov
model was run separately for women starting at each of the 22 ages, 16–37 years, in each case starting in
state 2. An 8-year time-horizon was used in order to compare results with those observed in the Lund
study.33 The average predicted number of women with a single subsequent PID and women with two or
more subsequent PIDs were obtained by averaging across the age ranges 16–24 years and 25–37 years,
respectively. Results were obtained for all PID and diagnosed PID only, and these are shown alongside the
observed results in the Lund study33 (Table 23).
Model inputs
Besides ϕsalp|PID and ρ (see above), the key parameters are:
1. the proportion of all PID that is due to CT, the PEF, for each age group, γCT←PIDa
2. the incidence of all-cause PID, by age group, λALL PIDa
3. the CT re-infection to infection ratio rate for the GP setting, ηGP
4. the proportion of PID that is diagnosed in the general population, ψDiag.
These parameters are all correlated, as they are estimated simultaneously from a common combined data
set in Chapter 7. After suitable transformations (log transformations for λPIDa and η
GP; a logit transformation
for γCT←PIDa ; ψ
Diag on the natural scale) the joint uncertainty in these parameters is described by a multivariate
normal distribution.
TABLE 22 Parameters of the 1-year cycle transition matrix of the Markov model
Destination states
1 2 3 4 5 6 7 8
From state
1 e−λ
Salp
a,1 1−e−λSalpa,1 0 0 0 0 0 0
2 0 0 e−λ
PID
a,2 0 1−e−λSalpa,2 0 0 0
3 0 0 0 e−λ
PID
a,2 1−e−λPIDa,2 0 0 0
4 0 0 0 e−λ
PID
a,1 1−e−λPIDa,1 0 0 0
5 0 0 0 0 0 e−λ
PID
a,2 0 1−e−λPIDa,2
6 0 0 0 0 0 0 e−λ
PID
a,1 1−e−λPIDa,1
7 0 0 0 0 0 0 e−λ
PID
a,1 1−e−λPIDa,1
8 0 0 0 0 0 0 0 1
The cell probabilities correspond to the pj’,a in equation 33.
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Model outputs
Our primary output from the chapter is πS+PIDm,a , the proportion of women age a who have had an episode of
salpingitis and zero, one, or two subsequent episodes of PID (indexed by m = 0,1,2 respectively). At age
15 years, all women are assumed to have never had PID so that φ1,15 = 1, φ2,15⋯φ8,15 = 0 . If φk,a is the
proportion of women at age a in state k, then:
1− ∑
m = 0,1,2
πS+PIDm,a = φ1,a
πS+PID0,a = φ2,a + φ3,a + φ4,a
πS+PID1,a = φ5,a + φ6,a + φ7,a
πS+PID2,a = φ8,a
(32)
where:
φ j,a = ∑
8
j’=1
φ j’,a−1⋅P j’, j,a (33)
P j’, j,a is the transition probability from state j’ to state j where a indexes from ages 16 to 44. The model
was run first for all-cause PID, and then separately for diagnosed all-cause PID. Although the true
progression through the model is the same, only a proportion ψDiag of PIDs are observed. The probability of
diagnosis for each PID is assumed to be independent of the number of previous PIDs, and it is assumed
that no women have more than three PIDs, so the results will be a slight underestimate. As such, the
proportion of women observed to have had zero, one, two or three or more PIDs, respectively, πobsPIDn,a , is:
πobsPID0,a = 1−(π
obsPID
1,a + π
obsPID
2,a + π
obsPID
3,a )
πobsPID1,a = π
PID
1,a⋅ψ
Sym + 2⋅πPID2,a⋅ψ
Sym⋅(1−ψ Sym) + 3⋅πPID3,a⋅ψ
Sym⋅(1−ψ Sym)2
πobsPID2,a = π
PID
2,a⋅(ψ
Sym)2 + 3⋅πPID3,a⋅(ψ
Sym)3⋅(1−ψ Sym)
πobsPID3,a = π
PID
3,a⋅(ψ
Sym)3
(34)
Incidence of all-cause PID and incidence of all-cause salpingitis
Exactly the same model that estimates the proportion of women who have had one, two or three or more
episodes of PID can be applied to one, two, or three or more episodes of salpingitis, by substituting all
instances of the parameter λALL PIDa with the parameter λ
Salp
a as calculated in equation 31 and vice versa.
TABLE 23 Distributions of numbers of PIDs from our model after 8 years, posterior mean % in each category
(95% CrIs), compared with the findings from the Lund study33 (see text)
Age
Model
Lund study33All PID Diagnosed PID
16–24 years
1 PID 66.3 (51.3 to 78.0) 85.4 (78.3 to 90.2) 77.7 (75.1 to 80.3)
2 PID 23.6 (18.3 to 27.2) 12.8 (9.1 to 17.8) 16.0 (13.8 to 18.4)
3+ PID 10.1 (3.75 to 21.5) 1.8 (0.7 to 3.9) 6.2 (4.8 to 7.8)
25–44 years
1 PID 75.2 (62.3 to 84.7) 90.0 (84.4 to 93.5) 87.0 (82.6 to 90.9)
2 PID 19.3 (13.5 to 25.0) 9.3 (6.2 to 13.6) 11.0 (7.5 to 15.1)
3+ PID 5.5 (1.8 to 12.7) 0.9 (0.3 to 2.0) 2.0 (0.6 to 4.0)
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Incidence of non-CT-related PID and salpingitis
Using our PEFs from the previous chapter, we calculate the incidence rate of non-CT related-PID and non
CT-related salpingitis for age a as:
λnonCT PIDa = λ
ALL PID
a (1− γ
CT←PID
a )
λnonCT,Salpa = λ
Salp
a (1− γ
CT←PID
a )
(35)
Exactly the same model as above can then be used to calculate the numbers of women who would ever
have had 0, one, two or three or more PIDs, and ever had one, two or three or more diagnosed PIDs,
by age, if there were no CT-related PIDs. We make the fundamental assumption that the proportion of
salpingitis caused by CT is the same as the proportion of clinical PID caused by CT.
Results
The calibration parameter ρ, the ratio of PID incidence in women who have not had a PID in the last
2 years, and the incidence of all-cause PID, was varied in order to find the value at which model
predictions best fitted the age-specific all-cause PID incidence derived from Chapter 7. The best fitting
value was 0.85 (Table 24).
Table 23 shows the correspondence between the results from the Markov model run for an 8-year period
and the Lund data.33 Note that the comparisons between observed and predicted distributions relate
most directly to the proportions of PIDs that are second or third (or more) PIDs. The proportion of women
who have ever had PID is not relevant to the comparison because only women who have a PID were
recruited into the Lund study.33 Note that there is no reason to expect the credible intervals to agree.
The first column shows the proportions of women in the study whom the model predicts would develop
one or two or more PIDs, of whatever cause and whether diagnosed or not, during the follow-up period.
Column 2 shows how many PIDs would be expected to be observed (diagnosed) in these women. The
Lund study33 results (column 3) lie between the results in the first two columns, which is exactly what is to
be expected, as it seems reasonable that subsequent PIDs in women who have had a previous, relatively
recent, hospital diagnosed PID are more likely than average to be diagnosed, on the basis that (1) these
women will be more likely to recognise the symptoms and (2) such PIDs may be more severe than average.
On the other hand, the Lund study33 is not technically a cohort study: unlike the prospective studies
analysed in Chapter 6 we would not necessarily expect all, or even most, symptomatic PID to be diagnosed.
Table 25a gives the predicted numbers of women who have had zero, one, two or three or more previous
PID episodes, whether diagnosed or not, by age. This is shown for both all-cause PID, and for non-CT-related
PID. An exactly analogous set of predictions is shown for salpingitis (see Table 25b). These tables show, for
TABLE 24 Calibration of the Markov model
Age (years) From cumulative incidence model Estimated PID incidence
16–44 1.9 (1.2 to 2.8) 1.8 (1.3 to 2.5)
16–19 2.0 (1.4 to 2.9) 2.1 (1.5 to 2.9)
20–24 3.0 (2.0 to 4.6) 2.8 (2.0 to 3.8)
25–34 2.0 (1.2 to 3.2) 1.9 (1.3 to 2.8)
35–44 1.2 (0.72 to 2.0) 1.3 (0.78 to1.9)
Estimated all-cause PID incidence rate per 100 person-years from Chapter 7 and predictions of the Markov model with the
rescaling factor ρ set to 0.85.
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example, that 33.6% of women aged 35–44 years have experienced at least one episode of PID, and 16.1%
have experienced at least one episode of salpingitis, again all cause and whether diagnosed or not.
The figures that are taken forward to later chapters (Table 26) are the proportions of the population that
have experienced at least one episode of salpingitis, followed by zero, one or two or more episodes of PID,
these being the risk categories used throughout the Lund study.33 Here we see that, although 16.1% have
experienced at least one episode of salpingitis, 10.7% have experienced one salpingitis episode and no
further PID episodes, 3.7% one salpingitis and one further PID episode, and 1.7% one salpingitis episode
and two or more further PID episodes.
Figures 18–21 give essentially the same results in 1-year bands from age 16 to 44 years for: PID,
undiagnosed PID, salpingitis, and salpingitis followed by zero, one, two or three or more episodes of PID.
TABLE 25a Predicted age-specific distributions of numbers of episodes: all-cause clinical PID and non-CT-related
clinical PID, based on the Markov model
Age (years)
PID episodes
0 1 2 3+
All PID
16–19 95.7 (94.2 to 96.9) 3.89 (2.90 to 5.09) 0.43 (0.19 to 0.81) 0.03 (0.01 to 0.10)
20–24 86.7 (82.5 to 90.2) 10.3 (7.94 to 12.9) 2.38 (1.25 to 3.91) 0.64 (0.16 to 1.69)
25–34 75.3 (67.9 to 81.6) 17.2 (13.7 to 21.0) 5.30 (3.10 to 7.95) 2.16 (0.64 to 5.25)
35–44 66.4 (56.9 to 74.6) 22.2 (18.2 to 26.3) 7.76 (4.78 to 11.15) 7.76 (4.78 to 11.2)
Non-CT related
16–19 97.9 (95.7 to 100) 1.98 (0.00 to 3.87) 0.13 (0.00 to 0.43) 0.01 (0.00 to 0.03)
20–24 91.6 (86.0 to 97.0) 7.05 (2.79 to 10.9) 1.17 (0.22 to 2.68) 0.22 (0.01 to 0.82)
25–34 82.1 (72.4 to 89.3) 14.2 (9.03 to 19.0) 3.15 (1.38 to 6.43) 1.11 (0.18 to 3.31)
35–44 72.4 (61.3 to 82.4) 19.7 (14.2 to 24.8) 5.73 (2.59 to 9.36) 2.15 (0.45 to 5.85)
TABLE 25b Predicted age-specific distributions of numbers of episodes: all-cause salpingitis and non-CT-related
salpingitis, based on the Markov model
Age (years)
Salpingitis episodes
0 1 2 3+
All salpingitis
16–19 98.1 (97.0 to 99.0) 1.85 (1.02 to 2.88) 0.04 (0.01 to 0.14) 0.00 (0.00 to 0.00)
20–24 94.1 (90.7 to 96.8) 5.56 (3.18 to 8.35) 0.34 (0.07 to 0.93) 0.02 (0.00 to 0.10)
25–34 88.6 (82.3 to 93.6) 10.4 (6.11 to 15.0) 0.99 (0.23 to 2.44) 0.10 (0.01 to 0.40)
35–44 83.9 (75.3 to 91.0) 14.2 (8.55 to 20.1) 1.71 (0.45 to 3.96) 0.20 (0.02 to 0.78)
Non-CT related
16–19 99.1 (97.9 to 100) 0.90 (0.00 to 2.01) 0.01 (0.00 to 0.01) 0.00 (0.00 to 0.00)
20–24 96.3 (93.0 to 98.8) 3.56 (1.16 to 6.50) 0.15 (0.01 to 0.52) 0.01 (0.00 to 0.04)
25–34 91.4 (85.3 to 96.0) 7.92 (3.85 to 12.84) 0.60 (0.10 to 1.69) 0.05 (0.00 to 0.22)
35–44 87.1 (78.6 to 93.5) 11.7 (6.22 to 18.0) 1.15 (0.24 to 3.00) 0.11 (0.00 to 0.48)
Posterior mean% in each category (95% CrIs).
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TABLE 26 Predicted age-specific distributions of numbers of women with a salpingitis and zero, one or two-plus
subsequent PID episodes: all-cause, and non-CT related, based on the Markov model
Age (years) 0 salpingitis
1 salpingitis, 0 further
PID episodes
1 salpingitis, 1 further
PID episode
1 salpingitis,
2+ further PID
episodes
All cause
16–19 98.1 (97.0 to 99.0) 1.69 (0.93 to 2.64) 0.19 (0.07 to 0.38) 0.01 (0.00 to 0.04)
20–24 94.1 (90.7 to 96.8) 4.59 (2.59 to 6.99) 1.06 (0.46 to 1.96) 0.28 (0.06 to 0.79)
25–34 88.6 (82.3 to 93.6) 8.03 (4.63 to 12.0) 2.44 (1.15 to 4.21) 0.98 (0.25 to 2.55)
35–44 83.9 (75.3 to 91.0) 10.7 (6.32 to 15.7) 3.66 (1.80 to 6.14) 1.69 (0.48 to 4.18)
Non-CT related
16–19 99.1 (97.9 to 100) 0.86 (0.00 to 1.87) 0.06 (0.00 to 0.20) 0.00 (0.00 to 0.01)
20–24 96.3 (93.0 to 98.8) 3.11 (1.07 to 5.58) 0.51 (0.09 to 1.28) 0.10 (0.00 to 0.37)
25–34 91.4 (85.3 to 96.0) 6.48 (3.24 to 10.4) 1.59 (0.52 to 3.26) 0.50 (0.07 to 1.57)
35–44 87.1 (78.6 to 93.5) 9.31 (5.07 to 14.3) 2.66 (1.01 to 5.08) 0.98 (0.18 to 2.85)
Posterior mean% in each category (95% CrIs).
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FIGURE 18 Cumulative exposure to PID: proportion experiencing one two and three-plus episodes. (a) All cause;
and (b) if no CT.
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FIGURE 19 Cumulative exposure to diagnosed PID: proportion experiencing one two and three-plus episodes.
(a) All cause; and (b) if no CT.
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FIGURE 20 Cumulative exposure to salpingitis: proportion experiencing one two and three-plus episodes.
(a) All cause; and (b) if no CT.
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Discussion
This chapter proposes, as far as we are aware for the first time, a methodology for estimating the
proportion of incident PID episodes, and salpingitis episodes, that are first, second or third PIDs, by age.
We have applied it to both all-cause PID and salpingitis and non-CT-related PID and salpingitis. The
method is based on assumptions about the CT re-infection to infection rate ratio, and the length of time
after which the re-infection rate applies. With these two assumptions, the results are compared with data
on the distribution of second and third episodes in women with an index episode.
In the Lund study that was used for this purpose, 22.1% of women aged 16–24 years with an index
salpingitis were observed to have a further PID episode within 8 years, and 6.2% had more than one
further episode (see Table 23). In women aged 25–44 years, 11% had a further PID episode, and 2%
more than one episode. A short-coming of our methodology is that the Lund study follows women whose
index PID was sufficiently severe to be not only diagnosed, but also treated in hospital. As a result, our
estimate of the proportion of PIDs that are diagnosed in the general population from Chapter 7 will
probably be lower than the proportion in the Lund data, so any comparison must be informal. All we can
say is that the Lund results must lie somewhere between our estimates for the numbers of subsequent
PIDs and the numbers of subsequent PIDs that are likely to be diagnosed in the general population, which
are quite different.
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FIGURE 21 Cumulative exposure to salpingitis and subsequent PID episodes: proportion experiencing one episode
of salpingitis followed by zero, one and two-plus episodes of PID. (a) All cause; and (b) with no CT.
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The Lund data on the distribution of repeat PIDs is consistent with data on repeat CT infections in other
data linkage studies. For example, in the Uppsala study,36 of the 3415 CT infections registered in a cohort
with a median 15 years’ follow-up, 76.9% were first infections. In the nearly 30,000 women in the
Norwegian cohort,215 with an average 8 years’ follow-up, 62% CT infections were first infections, 25%
second and 13% third or more. Nevertheless, there is no strong empirical basis for choosing the
re-infection rate in the GP group from the LaMontagne study,192 nor for choosing a 2-year period during
which the higher re-infection rate applies: both assumptions are somewhat arbitrary. Clearly, other
assumptions could be made, which would generate different estimates of the relative proportions of
subsequent PIDs that are first, or second-plus episodes. However, the total numbers of PIDs – whether
first, second or third – must remain the same as our estimates in Chapter 7; similarly, the distribution of
the number of subsequent PIDs is required to be consistent with the Lund data. It is therefore to be
expected that, given these constraints, similar results will be obtained with different inputs.
An interesting aspect of the modelling approach we have taken is that it correctly captures the age profile
of PID, which peaks in the 20- to 24-year-old age band, not in the < 20-year-old age band in which CT
incidence peaks. As we will see when considering the epidemiology of EP (see Chapter 9) and TFI (see
Chapter 10), the different age profiles of CT and each of its sequelae provide important insights into the
aetiology of these conditions, which have perhaps not been adequately addressed in previous work.
We use data from the UK study by Taylor-Robinson235 to estimate the proportion of PID cases that are
salpingitis. Although the study was published fairly recently, the data were collected in the 1990s and
patients were diagnosed in hospital, so it is unclear how applicable it is to all PID in 2002. Over time,
clinical guidance has changed to treat women with possible or probable PID instead of only treating
women with probable PID, so this is likely to be an overestimate for the proportion in all PIDs in 2002.
Although we included only PID cases from the GPRD database that are definite and probable, it is unclear
whether the Taylor-Robinson study235 provides an overestimate for clinical PID cases diagnosed in GUM
clinics. We also assume the same proportion of salpingitis in undiagnosed PID cases, and there is no real
evidence to say whether this is reasonable. On the one hand, undiagnosed women are likely to have
less severe symptoms and symptoms are likely to correlate to severity of inflammation and presence of
salpingitis. However, laparoscopy identifies the presence of salpingitis at a single point in time. Some of
the women in the Taylor-Robison study235 may have developed inflammation that would be visible on
laparoscopy at a later date had they not been treated, as would be the case if they were undiagnosed.
There are some quite severe limitations to our interpretation of the present findings, however. One relates
to the fact that our estimates of PID incidence and the age-related population attributable fractions, are
based on 2002 data. We are therefore implicitly assuming that age-specific PID incidence is constant
over time, although evidence from most countries suggests that it has been declining steadily since the
1970s.237 Although the numbers of PIDs reported through the HES has remained fairly constant since
2002, the numbers coming through KC-60 returns have increased, and those reported in GPRD have
nearly halved.90
Given the lack of empirical basis for some of the assumptions made in our analysis of cumulative PID,
it is important to compare our quantitative findings with as broad a range of other studies as possible.
Our estimates of cumulative incidence of PID seem high, and our estimates of cumulative incidence of
diagnosed PID are considerably higher than NATSAL,195 which reported that 2.2% (1.8% to 2.6%) of
female respondents said they have ever been treated for PID compared with our estimate of about 10% in
31-year-olds (see Figure 18). However, NATSAL is also highly inconsistent with other UK data sources. The
POPI trial19 observed all-cause PID incidence to be 2% in a single year. Furthermore, HES data alone reports
a total of approximately 15,000 PIDs in women by the age of 35 years: given that an annual birth cohort
would comprise some 300,000 females, unless over half of these episodes occurred in the same women
this equates to more than the amount reported by NATSAL.
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Recruitment and participation biases in surveys such as NATSAL may selectively under-sample or those who
would be considered at increased risk (and some groups at reduced risk). On top of this, there may be a
tendency among responders to under-report health problems linked to STD, and it may be that not
everyone diagnosed with PID is told this diagnosis and remembers it. The discrepancy between NATSAL
and our results is, nevertheless, large and requires further investigation.
Our projections can also be compared with the 2002 US National Survey of Family Growth in which 5.1%
of women aged 16–44 years reported having been treated for PID.238 This figure is sharply down on the
1995 Survey, which reported 8% had been treated for PID, with 11% in the 1988 and 14% in the
1982.238 Our average estimate for this age range is around 10% (see Figure 19a).
The Scandinavian linkage studies provide another opportunity to ‘reality check’ the predictions. In the
Uppsala study, the cumulative incidence of PID was reported as 3.9% by 35 years36 compared with our
estimate of 13.4% for all (diagnosed) PID (see Figure 19a). The Uppsala figures, however, cover only
hospital-diagnosed PID. It is not known what proportion of PID was diagnosed and treated outside the
hospital setting. However, we can obtain a comparable estimate from our model by substituting our
age-specific estimates of the proportion of PID cases diagnosed in hospital (see estimation of
κ1,a in Chapter 9) for ψsym in equation 34. This gives an estimate of 4.6% for the proportion of women
aged 35 years who have ever been diagnosed with PID in hospital, which is close to the Uppsala figure.
Summary of assumptions and findings
Summary of assumptions
1. The distribution of zero, one and two or more subsequent PID episodes in women with salpingitis in
the UK approximates that found in the Lund study.
2. The probability that PID is diagnosed does not depend on the number of previous episodes, nor on
whether previous episodes would have confirmed as salpingitis on laparoscopy.
3. It is assumed that the re-infection rate for CT applies equally to all other causes of PID and salpingitis.
Summary of findings
1. 33.6% of women age 35–44 years have experienced at least one episode of PID (diagnosed or not).
2. 16.1% of women age 35–44 years have experienced at least one episode of salpingitis (diagnosed
or not).
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Chapter 9 Pelvic inflammatory disease and
ectopic pregnancy
Objectives
To:
1. use routinely collected data to estimate the proportion of pregnancies that are ectopic in the UK,
by age
2. apply the information on group-specific risks of EP reported in the Lund study (severity of salpingitis,
number of diagnosed PID episodes) to estimates of the distribution of these risk factors in the UK,
to predict the proportion of salpingitis-related pregnancies that are ectopic in the UK
3. compare predicted and observed proportions of pregnancies that are ectopic
4. estimate the proportion of EP attributable to salpingitis
5. estimate the proportion of EP attributable to CT.
Introduction
This chapter looks at the evidence relating PID, and particularly salpingitis, and EP. As we have seen, the
most important findings, from the Lund studies,33,110,124,232 are that the risks of subsequent EP and TFI
depend on salpingitis severity at laparoscopy, and that they increase with number of episodes of PID.
However, these observations relate exclusively to women with PID diagnosed and treated in hospital, and
were made some 30 years ago in Sweden. We therefore need to address the huge evidence gap regarding
the role of PID that is diagnosed and treated outside the hospital setting and the role of undiagnosed PID.
Evidence presented in Chapters 2 and 7 suggested that these make up the majority of PID episodes.103
We also need to obtain contemporary estimates that are relevant to the UK.
In previous chapters we have been able to set out a mathematical model a priori, based for example on
the well-understood relationship between incidence, prevalence and duration (see Chapters 4 and 5) or
based on relatively familiar Markov processes (see Chapter 6). We have then been able to assess whether
the different evidence sources were consistent under a mathematical model that was not only prespecified
but whose form and structure could not be influenced by the evidence available. In this chapter and the
next we are unable to follow such a rigorous approach because the natural history of PID and the
mechanisms that lead from PID to EP and TFI are far less well understood.
We can, however, retain the essential element of our approach, which is the critical examination of a wide
range of different types of evidence bearing on the relationship between a small set of outcomes within a
coherent mathematical model, in this case CT, PID, salpingitis and EP. However, rather than assessing the
consistency of the evidence sources under a prespecified model, we instead try to answer the question:
‘under what models can these data sources be considered consistent?’ The exercise therefore takes on
more of a ‘hypothesis generation’ role. However, as shown in Chapter 2, there is a single common
pathway between PID and EP, and PID and TFI. Therefore, we would expect any structural assumptions we
make for EP to also hold for TFI. This will provide an opportunity to assess consistency and the
compatibility of findings on EP risk and TFI risk in the concluding Chapter 12.
We have referred previously to the strong ‘dose–response’ relationship reported in prospective studies
following women with hospital diagnosed PID. The Lund studies,33,110,124,232 in particular, followed women
for approximately 8 years after hospitalisation for PID. The proportion of women whose first subsequent
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pregnancy was an EP increased systematically with severity of salpingitis as determined by laparoscopy, and
also with the number of diagnosed subsequent PID episodes.124 A similar pattern of findings was reported
for TFI.33
A record linkage study in the USA following high-risk women with a diagnosed CT infection over an
average 6-year period, again reported a similar increase in risk of EP, but this time in relation to the
number of previous CT infections rather than the number of diagnosed PID episodes.107 These studies
constitute overwhelming evidence of the causal role of PID in reproductive damage, and point to the
significance of cumulative exposure to risk factors, as described in Chapter 2. In addition, the similarity
of the ‘dose–response’ effect attaching to CT and PID suggests that the risk of EP and TFI may be
approximately the same whatever the cause of the PID, although the agreement could be coincidental if
the aetiology changes with age in a way that approximately cancels out any differences.
Review and interpretation of evidence sources
In this section we describe what data sources are potentially available and we develop a rationale that
explains which ones we have selected for use. At the same time, we develop a framework that embraces
the different types of study: prospective studies of EP risk in women with diagnosed PID, routine data on
the incidence of EP in England, and retrospective studies of the PEF of EP that is caused by PID.
Prospective evidence: ectopic pregnancy following pelvic
inflammatory disease
We identified studies from a recent systematic review of the sequelae of CT,98 from the knowledge of
collaborators, and as part of a wider search of the literature on CT. We exclude a study by Buchan et al.239
because it does not report data on number of pregnancies (see below). Table 27 summarises the results of
the six prospective studies33,228,240–243 following women forward from PID to a next pregnancy. These studies
have very different follow-up times. However, we can control for this approximately by estimating the
proportion of pregnancies that are ectopic, φEPjpreg. Study-specific crude estimates are presented in column 7.
Apart from the small study by Heinonen et al.,240 in which EP rates are unaccountably low, estimates from
studies following women with laparoscopically confirmed salpingitis are reasonably homogeneous, at
≈7–10%. The study by Ness et al.228 estimates a much lower proportion (≈1%). It follows women with mild
to moderate PID, not laparoscopically confirmed salpingitis, and the most serious 3% of cases are excluded.
The results from the prospective studies are otherwise broadly similar.
Our quantitative analysis of the prospective risk of EP following salpingitis is based solely on the Lund
study,124 for four reasons: it is by far the largest study; it is the only study to include a control group;
uniquely it presents EP risk by age, severity of salpingitis in women with PID, and numbers of episodes of
PIDs; and also it delivers a related set of estimates of the risk of TFI following hospital diagnosed PID with
salpingitis. This last feature is especially significant, as it provides an opportunity to check the consistency
between observed and predicted EP and TFI frequency in the UK on the same basis.
Application of the Lund results to the epidemiology of pelvic inflammatory
disease in the UK
As described in Chapter 8, we assume that the proportion of diagnosed ‘probable/definite’ PID that would
be accompanied by salpingitis if examined on laparoscopy is 0.429 (95% CrI 0.27 to 0.63). We further
assume that this proportion is the same regardless of PID severity, clinical presentation, place of diagnosis
or whether it is diagnosed or not. Note that this implies the existence of undiagnosed but symptomatic
salpingitis, and asymptomatic or ‘silent’ salpingitis, as discussed by Wolner-Hanssen.103 We assume that
only PID that would be confirmed under laparoscopy (salpingitis) can cause EP or TFI. This is supported by
observations in the control group in the Lund study33 (women with hospital-diagnosed PID but no visual
evidence of laparoscopy) that 0 out of 601 women developed TFI. The EP rate in this group was slightly
higher than the general population but there is considerable uncertainty (only six cases).
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Outline of prospective analysis
The prospective analysis of EP proceeds in the following four steps:
1. A logistic regression model is fitted to the data available from the Lund study (Table 28),124 to estimate
the risks that the pregnancy will be ectopic ηm,s,a in women whose index salpingitis of severity s at age a
was followed by m= 0,1,2+ subsequent episodes of PID. The non-salpingitis control group informs an
age-specific baseline θEPjpregControl,a, the probability that a pregnancy is ectopic in age group a in women with
no previous salpingitis.
2. Because the Lund analysis relates only to hospital-diagnosed PID, we explore a range of five scenarios
that relate the EP risks θEPjSalp,pregm,d,a following d= hospital diagnosed PID (HD), PID diagnosed outside of
hospital (nHD), or undiagnosed PID (UD), to the EP risks at different severities s adjusted by the
proportion of PID estimated to be salpingitis. These five models can be thought of as ‘mappings’
between the ηm,s,a and the θ
EPjSalp,preg
m,d,a parameters.
3. The proportion of PID at age a in the categories HD, nHD, and UD, κd,a, is derived from the UK routine
data on PID and information on the proportion of PID that is diagnosed, ψDiag. This is multiplied into the
proportion of population prevalence of salpingitis in age band a, followed by m= 0, 1, 2+ subsequent
PID episodes πS+PIDm,a from Chapter 8, to form π
S+PID
m,d,a, which has the same interpretation but breaks the
population into nine groups by age, diagnosis setting, and number of subsequent PIDs.
4. Estimates of the population proportion of conceptions that are ectopic because of salpingitis are formed
by weighting the estimates θEPjSalp,pregm,d,a , generated by the five ‘mapping’ models (see below), by the
population proportions πS+PIDm,d,a.
The full prospective synthesis is shown in the form of a DAG in Figure 22.
TABLE 28 Proportion of pregnancies that are ectopic by number of PIDs, severity and age group: comparison of
observed marginal risks with those predicted from the logistic regression model
Risk factor
Original data, Westrom:124
no. with EP/total pregnancies
Crude estimates as
published (95% CI)
Marginal estimates based on
regression model (95% CrI)
Control group 6/439 0.014 (0.005 to 0.026) 0.014 (0.005 to 0.026)
No. of PIDs
One 61/912 0.067 (0.052 to 0.084) 0.067 (0.058 to 0.077)
Two 24/148 0.162 (0.108 to 0.225) 0.163 (0.107 to 0.228)
Three 15/39 0.384 (0.240 to 0.54) 0.382 (0.242 to 0.536)
Age (years)a
16–24 39/713 0.055 (0.039 to 0.073) 0.054 (0.042 to 0.067)
25–44 22/199 0.111 (0.071 to 0.158) 0.113 (0.077 to 0.153)
Severityb
Mild 7/309 0.023 (0.009 to 0.042) 0.021 (0.008 to 0.039)
Moderate 19/420 0.045 (0.028 to 0.067) 0.045 (0.029 to 0.064)
Severe 35/185 0.191 (0.138 to 0.251) 0.195 (0.150 to 0.242)
a Women with one PID only, read from figure 2 in Westrom et al.124
b Taken from table 2 in Westrom et al.124 first pregnancy only.
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Five models relating the Lund estimates in hospital-diagnosed pelvic
inflammatory disease to other diagnostic settings
We fit a series of five models with different assumptions about the relation between the risk of ectopic
pregnancy reported in the Lund study124 and the risk in the UK in three groups: (1) hospital diagnosed
salpingitis; (2) salpingitis not diagnosed in hospital; and (3) undiagnosed salpingitis. In all five models, we
assume that women with hospital diagnosed PID have the same average risk as women (of the same age) in
the Lund study. The following five models can be ranked in order from the highest predicted progression
rate. To assist distinguishing between the models we use the abbreviations ‘Av’ for the average progression
rate observed in the Lund study, and ‘Mi’ for the rate in the ‘mild’ salpingitis.
Model 1 (Av, Av, Av): Lund average for all salpingitis following PID. Here, salpingitis in those with PID
diagnosed outside hospital and salpingitis in undiagnosed PID are assumed to have the same risk of EP as
hospital diagnosed PID in the Lund study.
Model 2 (Av, Av, Mi): Lund average for salpingitis following diagnosed PID, Lund ‘mild’ for undiagnosed PID.
Salpingitis in all diagnosed PIDs, whether diagnosed in hospital or not, carries the same EP risk as the Lund study;
salpingitis in undiagnosed PID has the same level of EP risk as the ‘mild’ salpingitis group in the Lund study.
Model 3 (Av, Mi, Mi): Lund average for salpingitis following hospital diagnosed PID, Lund ‘mild’ for
salpingitis in GP diagnosed and undiagnosed salpingitis. In this model, salpingitis associated with
hospital-diagnosed PID progresses to EP at the average rate observed in the Lund study; salpingitis
associated with non-hospital diagnosed and undiagnosed PID progress at the Lund study ‘mild’ rate.
Model 4 (Av, Mi, Mi/2): Lund average for salpingitis following hospital diagnosed PID, Lund ‘mild’ for
non-hospital-diagnosed. Salpingitis in undiagnosed PID progresses at a rate that is half-way between the
‘mild’ rate and zero.
Model 5 (Av, Mi, 0): Lund average for salpingitis following hospital diagnosed PID, Lund ‘mild’ for
non-hospital-diagnosed, no risk following salpingitis in those whose PID is undiagnosed.
This choice of models was based on a presumption that the risk of EP will be lower in PID that is diagnosed
outside of hospital, and the same or lower again in undiagnosed PID. This is based on the assumption that
the risk of poor reproductive outcomes will be lower in women with less severe clinical symptoms, who will
be less likely to be diagnosed. This assumption is not necessarily correct. It is also perfectly possible that the
milder the clinical manifestation of PID, the later the diagnosis, and the more damage that follows.
In addition to severity of salpingitis, the numbers of subsequent PID episodes also impact on EP risk. Below
we describe how we derive predictions for the EP risk attaching to each of the 18 (3 × 3 × 2) number of
subsequent PID episodes, severity and age strata from the information that has been published.
Distribution of pelvic inflammatory disease diagnostic status in the
English population
In order to apply the prospective risks informed by the Lund studies to predict EP outcomes in England, it is
necessary to have estimates of the risk factor distributions, by age. Estimates of the proportion of women
in age band a who have had an episode of salpingitis that has been followed by m= 0,1,2+ episodes of
PID, πS+PIDm,a , where obtained in Chapter 8. However, we need to consider the proportions κd,a of women in
age band a who were hospital diagnosed (d=HD), diagnosed elsewhere (d= nHD) or undiagnosed
(d=UD). To do this, we make several fundamental simplifying assumptions, in the absence of clear
information to the contrary, and in order to make the analytic task tractable. First, that the probability a
PID is diagnosed in hospital is independent of the number of previous PIDs a woman has had; second that
the increase in odds of EP given one or two or more as compared to zero, subsequent PID episodes
conditional on having an initial PID that is confirmed as salpingitis is independent of whether or where the
initial PID was diagnosed, and clinical severity of the initial salpingitis.
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Routine ectopic pregnancy data
The premise behind the use of routine data on EP is that it should be possible to compare the observed
risk of EP in pregnant woman of age a, based on routine HES data for 2002 (Table 29), taking account
that not all EP is caused by salpingitis, to what would be predicted from the Lund study.
In order to avoid having to explicitly model the complex processes underlying conception including the
competing risk of TFI, we have taken as our outcome the proportion of conceptions that are EPs. This is
estimated by dividing the number of EPs in HES (see Table 29), by the number of conceptions in England
and Wales (Table 30), to obtain the proportion of conceptions that are ectopic (Table 31).
TABLE 29 Hospital episode statistics EP numbers reported, by age and year117
Age (years)
Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
15 8 10 6 18 9 10 11 20 14 16
16–19 305 321 291 356 361 362 416 411 386 381
20–24 1156 1098 1154 1284 1342 1381 1397 1511 1546 1530
25–34 4471 4317 4340 4283 4461 4520 4674 4864 4768 4895
35–44 1750 1862 1840 1957 2038 2048 2141 2223 2221 2213
TABLE 30 Numbers of conceptions, by age and year118
Age
(years)
Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
13–15 8100 7900 7900 8000 7600 7900 7800 8200 7600 7200
15–17 41,300 41,000 42,000 42,200 42,200 42,300 41,800 43,000 41,400 38,300
15–19 97,700 96,000 97,100 98,600 101,300 102,300 103,100 106,300 103,300 97,900
20–24 159,000 161,600 167,800 175,300 181,300 185,500 191,200 198,700 198,500 199,500
25–29 209,300 199,300 199,400 199,800 205,100 211,300 222,200 234,800 237,800 242,200
30–34 195,300 196,700 204,300 209,000 209,600 209,200 212,400 211,500 207,100 213,300
35–39 88,700 92,200 98,900 103,100 106,800 110,000 115,400 118,000 115,600 116,500
40+ 17,000 17,800 19,600 20,900 22,800 23,600 25,500 26,500 26,500 26,800
TABLE 31 Percentage of conceptions that are ectopic, by age and year
Age (years)
Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
16–19 0.34 0.36 0.33 0.39 0.39 0.38 0.44 0.42 0.40 0.42
20–24 0.73 0.68 0.69 0.73 0.74 0.74 0.73 0.76 0.78 0.77
25–34 1.11 1.09 1.08 1.05 1.08 1.07 1.08 1.09 1.07 1.07
35–44 1.66 1.69 1.55 1.58 1.57 1.53 1.52 1.54 1.56 1.54
Note
We assume that all conceptions in females aged 13–15 years occur at age 15 years, and all conceptions in females aged
40+ years occur between the ages of 40 and 44.
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This conditions out all of the complexities of conception rates, such as their dependency on fecundity and
time taken to conceive, and it links directly to the Lund study, in which outcomes are also reported as the
proportion of conceptions that are EPs.
Retrospective case–control studies of ectopic pregnancy and pelvic
inflammatory disease/salpingitis
We searched for case–control studies comparing history of salpingitis in cases with EP and pregnant
controls with no EP. A meta-analysis of studies on risk factors for EP147 identifies previous gonorrhoea,
serological evidence of previous CT, PID, smoking, number of previous sexual partners, and previous EP
and tubal surgery as risk factors for EP. Another risk factor that was not included in this study, but which
has received considerable attention, is previous use of an IUD.244,245 There was, however, considerable
heterogeneity between studies, with different risk factors being reported in different studies. Therefore, as
in our search for case–control studies looking at PID, we limited attention to studies conducted in Europe
during the 1990s or later in order to exclude studies for which the spectrum of causative agents for EP,
such as smoking, were likely to have been different. We also only consider studies in which PID history was
assessed through laparoscopy because of the poor specificity of clinically diagnosed PID as a proxy for
salpingitis. Papers were identified through the knowledge of collaborators and our wider review of the
literature, from modelling studies and economic evaluations, and citation and reference searches of a
systematic review,147 and any studies that were identified as relevant.246,247 Retrospective studies were not
considered in the recent series of systematic reviews by the CDC. We identified two studies,246,247 both
carried out in France.
The study by Bouyer et al.246 is the largest and most recent. It provides estimates of both the crude OR for
probable PID (fever, abdominal pain, vaginal discharge) and for laparoscopically confirmed PID (salpingitis).
Estimates were based on a logistic regression model that adjusts for a number of possible confounders.
The unadjusted OR (5.42, 95% CI 2.60 to 11.28) is likely to be an overestimate, in view of the likely
positive correlation between risk factors, the adjusted estimate (3.39, 95% CI 1.44 to 7.96) is likely to be
too low as a result of ‘over-controlling’. For example, history of infertility is included as a covariate. But, it
seems unlikely that a history of infertility causes EP; instead, both of these outcomes will share some of
the same risk factors, including PID. We therefore assume that the crude OR represents an upper bound,
whereas the adjusted OR from the regression model is a lower bound for the OR for PID. The above
figures are for ‘confirmed PID’ (see below), which constituted 90% of all PID reported in the study. The
fact that the ORs for confirmed are higher than for probable PID suggests that the more stringent criteria
are better predictors of subsequent EP and therefore a better reflection of the causal process.
The Coste study247 reports crude ORs of 5.8 (95% CI 2.4 to 14.3) for laparoscopically confirmed PID, and 3.2
(95% CI 1.3 to 7.8) for probable PID. This study247 also reports an adjusted estimate based on a regression
controlling only for age, hospital, current smoking, previous use of IUD, and current contraception method.
This adjusted OR (4.7, 95% CI 1.7 to 13.6) seems less likely to be ‘over-controlled’, and is between the
higher and lower estimates from the Bouyer et al. study.246 Rather than attempt a formal synthesis of these
estimates we use the higher and lower limits from Bouyer et al.246 in the analyses reported below.
It should be noted that the definition of ‘confirmed’ PID in both studies is not entirely clear. It appears that
confirmation could be either by laparoscopy or positive CT serology. The circumstances under which
laparoscopy was routinely carried out in cases of suspected PID is not specified, nor is it known what
proportion of ‘confirmed PID’ was confirmed by serology alone or what cut-offs and tests were used.
As EP is a rare disease, we may use the adjusted OR from these studies to estimate the proportion of EP
attributable to salpingitis, based on the standard formula (see Chapter 3). Values for the prevalence of
exposure to salpingitis are derived from Chapter 8.
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Statistical methods
Risk of ectopic pregnancy in pregnant women as a function of age, PID
severity and number of PID episodes, based on Lund data
We fit the following logistic regression model to the data in Table 28 on EP outcomes in patients with an
index salpingitis:
logit(ηm,s,a) = β0 + β1,mM + β2,sS + β3,aA (36)
where ηm,s,a is the risk factor specific risk of EP, β0 is the (baseline) log odds that a pregnancy will be ectopic
following a mild salpingitis episode at age < 29 years and not followed by any further PID episodes.
Similarly, β1,m is the log odds ratio (LOR) of EP for a woman with m subsequent PID episodes compared
with none, β2,s is the LOR for a woman whose index salpingitis was moderate, or severe compared with
mild, and β3,a is the log OR for age group a compared with age group 1. The dummy variables M,S, and A
denote M= one or two further episodes, S moderate or severe, A= age ≥ 29 years.
Note that the risks of EP due to salpingitis are considered to be additional to a baseline risk ηEPjpregControl
experienced by the general population, which we estimate from the non-salpingitis PID controls in
Table 28.
The parameters of equation 37 model can be identified from the published data124 that are available
(see Table 28) but we are unable to identify interaction terms. Although this does not necessarily oblige us
to assume there are no interactions, in the absence of any evidence, this is the assumption that is made.
Finally, we note that, in the Lund study,124 the results are reported by the age groups of < 25 years and
≥ 25 years. This refers to age-at-diagnosis, at study entry, and our analysis requires knowledge of the age
when EP occurs. The study has almost a 9-year follow-up, so we assume that EP happens on average just
over halfway through and that the ≤ 24 age group represents women who have EP by the age of 29 years.
We assume that the numerators, the number of EPs, in the Lund data (see Table 28), by number of PIDs
r1,m, by severity r2,s, and by age r3,a, have binomial likelihoods:
r1,me Binomial (p1,m,n1,m)
r2,s e Binomial (p2,s,n2,s)
r3,a e Binomial (p3,a,n3,a)
where:
p1,m =
∑
2
a=1
∑
3
s=1
ηm,s,a⋅n3,a
∑
3
s=1
n2,s
0
BB@
1
CCA
∑
2
a=1
n3,a
, p2,s =
∑
2
a=1
η1,s,a⋅n3,a
∑
2
a=1
n3,a
, p3,a =
∑
3
s=1
η1,s,a⋅n2,s
∑
3
s=1
n2,s
(37)
The assumption of independence of the likelihoods is not quite correct, as the same data are being used in
different breakdowns, and this will have the effect of exaggerating somewhat the precision of our
estimated risk coefficients.
The parameters β0, β1,m, β2,s and β3,a are given flat normal priors.
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Distribution of number of salpingitis episodes and number of subsequent
PID episodes and severity in the English population
We embed the WBDEV code described in Chapter 8 directly into the program to estimate πS+PIDm,a from
parameters relating to PID incidence from previous chapters. These are λPIDa,1 , the incidence of a first PID of
any cause, diagnosed or not; ηGP the ratio of CT re-infection to infection rates in the GP group; ψDiag the
proportion of PID that is diagnosed; and ϕsalpjPID the probability of salpingitis given PID. These are given a
multivariate normal prior, as described in Chapter 8. In parallel, we use the PEF(CT←PID) to estimate the
equivalent distribution πNoCT,S+PIDm,a in a world with no CT.
To estimate κHD,a, the age-specific proportion who have experienced m subsequent PID episodes following
a hospital-diagnosed PID confirmed as salpingitis, we consider the ratio of HES PID episodes by age to the
total number of PIDs diagnosed using the same model, as in Chapter 7, for the same age groups; this is
multiplied by our estimate of the proportion of PID episodes that are diagnosed, ψDiag, from Chapter 7.
The proportion diagnosed but not hospital referred κnHD,a can be calculated from this and the proportion
diagnosed, which leads directly to an estimate of the proportion undiagnosed κUD,a. The calculations are
shown below.
Routine data on PID diagnoses in different settings in the general population have binomial likelihoods:
rHESPIDa ∼ Binomial(pHESPIDa , Na)
rGPRDa ∼ Binomial(pGPRDa , Na)
rkc−60:08a ∼ Binomial(p
kc−60:08
a , Na)
(38)
where Na is the total number of women in age group a in the general population in 2002 estimated from
census data. KC-60 returns for PID diagnosed in GUM clinics are not available by age before 2008. Data
for 2008 are available from Genitourinary Medicine Clinic Activity Dataset (GUMCAD)248 for approximately
70% of cases. We assume that these cases are a representative sample and that the age distribution
within this setting was the same in 2002. The number of cases for each age from GUMCAD are then
rescaled to the total number of KC-60 cases in 2002 so:
pkc−60:02a =
13421:pkc−60:08a
12117
(39)
Using the same model as in Chapter 7:
pmina = p
kc−60
a +max(p
HESPID
a ,p
GPRD
a )
pmaxa = p
kc−60
a + p
HESPID
a + p
GPRD
a
Xa ∼ Uniform(pmina ,p
max
a )
(40)
The parameters pHESPIDa , p
GPRD
a , p
kc60
a are given Beta(1,1) priors and:
κHD,a = ψDiag
pHES PIDa
Xa
κnHD,a = 1− κHD,a− κUD,a
κUD,a = 1−ψDiag
(41)
Finally, we form the full breakdown of population weights, πS+PIDm,d,a, as follows:
πS+PIDm,d,a = π
S+PID
m,a κd,a (42)
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Prospective estimate of the probability that a pregnancy was ectopic
due to salpingitis
An estimate of the proportion of pregnancies that are ectopic as a result of salpingitis in the UK in 2002
from prospective evidence from the Lund study,124 and estimates of the distribution of numbers and
severity of PID, can be generated as follows. First, the proportion of pregnancies that are ectopic because
of PID with salpingitis – in women who have had an episode of PID that would confirm as salpingitis on
laparoscopy – is constructed by subtracting the proportion of EP pregnancies in women from the same
population, the control group with no index salpingitis, from a weighted average of the risks in women
with mild, moderate and severe PID:
θEPjSalp,pregm,HD,a =
∑
3
s=1
ηm,s,a⋅n
Lund
s
∑
3
s=1
nLunds
 θEPjpregControl,a (43)
The weights nLunds are the number of women with salpingitis of severity level.
Then the population proportion of pregnancies that are ectopic due to salpingitis, as a function of age,
severity of salpingitis, and number of subsequent PID episodes, is constructed as a weighted average using
the estimated proportions πS+PIDm,d,a of women in the UK exposed to d=Hospital Diagnosed (HD), Not
Hospital Diagnosed (nHD), and Undiagnosed PID (UD), and the prevalence of zero, one and two-plus PID
episodes subsequent to the index salpingitis:
θPOP,EPjSalp,prega = ∑
d=HD,nHD,UD
∑
m=0,1,2+
πS+PIDm,d,a θ
EPjSalp,preg
m,d,a (44)
The five different models of how the EP rates in the Lund hospital-diagnosed PID might apply to GP
diagnosed and undiagnosed PID can then be set out in the following way, where ‘Av’ refers to the
average rate reported in the Lund study124 and ‘Mi’ to the rate in Mild PID:
Model 1 (Av, Av, Av): Lund average for all salpingitis
θEPjSalp,pregm,nHD,a = θ
EPjSalp,preg
m,UD,a =
∑
3
s =1
ηm,s,a⋅n
Lund
s
∑
3
s=1
nLunds
− θEPjpregControl,a (45)
Model 2 (Av, Av, Mi): Lund average for salpingitis following all diagnosed PID, Lund ‘mild’ for
Undiagnosed PID
θEPjSalp,pregm,nHD,a =
∑
3
s=1
ηm,s,a⋅n
Lund
s
∑
3
s=1
nLunds
− θEPjpregControl,a
θEPjSalp,pregm,UD,a = ηm,1,a− θ
EPjpreg
Control,a
(46)
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Model 3 (Av, Mi, Mi): Lund average for salpingitis following HD PID, Lund ‘mild’ for salpingitis following
nHD diagnosed and UD PID.
θEPjSalp,pregm,nHD,a = θ
EPjSalp,preg
m,UD,a = ηm,1,a− θ
EPjpreg
Control,a (47)
Model 4 (Av, Mi, Mi/2): Lund average for salpingitis following HD PID, Lund ‘mild’ for nHD. Salpingitis
following UD PID progresses at a rate that is half-way between the ‘mild’ rate and zero.
θEPjSalp,pregm,nHD,a = ηm,1,a− θ
EPjpreg
Control,a
θEPjSalp,pregm,UD,a ∼Uniform (0,Am,a)
Am,a = ηm,1,a− θ
EPjpreg
Control,a
(48)
Model 5 (Av, Mi, 0): Lund average for salpingitis following HD PID, Lund ‘mild’ for nHD, no risk with
salpingitis following UD PID.
θEPjSalp,pregm,nHD,a = ηm,1,a−θ
EPjpreg
Control,a
θEPjSalp,pregm,UD,a = 0
(49)
The risk in the control arm ηEPjpregControl is not reported by age. While keeping the average risk the same as in the
controls in the Lund study,124 we assume that the age distribution of EP in the control group is the same as
in the general population in England in 2002.
θEPjpregControl,a = η
EPjpreg
Control
ϕEPjprega
∑
4
a=1
ϕEPjprega
(50)
Model for routine ectopic pregnancy data
Data on numbers of conceptions, and hospital episodes of EP for 2002 by age, have a binomial likelihood
with the denominator taken from census population estimates for that year.
rHES,EPa ∼ Binomial(pHES,EPa , Na)
rCONCa ∼ Binomial(p
CONC
a , Na)
(51)
The parameters pHESPIDa and p
GPRD
a are given effectively uninformative Beta(1,1) priors. Finally, the proportion
of pregnancies that were ectopic in the English population in 2002 ϕEPjprega equals:
ϕEPjprega =
pHES,EPa
pCONCa
(52)
We use the routine data on EP in two ways. The first involves informally comparing the all-cause
probability that a pregnancy is ectopic to the predicted proportions due to PID from our model. Second,
we combine it with retrospective data to estimate the proportion of EPs caused by PID.
A DAG for the prospective analysis is shown in Figure 22, and WinBUGS code is shown in Appendix 12.
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Model for retrospective data
Lower and upper bounds for the odds of past PID in women with EP compared with women who gave
birth (controls) are given informative log-normal priors based on Bouyer et al.246 respectively:
OR^l = 3:39, (95%CI : 1:44−7:96)= > log(ORl)∼ Normal(1:22,0:19)
OR^u = 5:42, (95%CI : 2:60−11:28)= > logðORu)∼ Normal(1:69,0:14)
(53)
The age-specific prevalence of a history of salpingitis is:
πS+PID,a = ∑
m= 0,1,2þ
πS+PIDm,a (54)
which is calculated using the method described in Chapter 8 and uses the same MCMC samples as those
used in the prospective analysis described above. An analogous estimate can be formed for the prevalence
of a history of non-CT-related salpingitis:
πNoCT,S+PID,a = ∑
m= 0,1,2þ
πNoCT,S+PIDm,a (55)
Estimates of the PEF(Salpingitis←EP) and PEF(Non-CT-related Salpingitis←EP) can then be found using
equation 1:
γSalp←EPa =
πS+PID,a (OR−1)
πS+PID,a (OR−1) + 1
γNoCT.Salp←EPa =
πNoCT.S+PID,a (OR−1)
πNoCT.S+PID,a (OR−1) + 1
(56)
Finally, we can form an estimate for the PEF(CT-related Salpingitis←EP). Bearing in mind that an EP can be
caused by CT only through a CT-related salpingitis:
γCT←EPa = γ
Salp←EP
a −γ
NoCT.Salp←EP
a (57)
Lower and upper bounds for all these PEFs based on retrospective data are then calculated by substituting
the lower and upper estimates of the OR into the formula. Note, however, this final calculation generates
an underestimate, because it assumes the distribution of PIDs in women with a salpingitis would be the
same in a world where CT does not exist. However, we might expect the shape of the whole distribution
to change such that a higher proportion of women who have ever had salpingitis would have fewer
subsequent PID episodes. Because of the multiplicative dose–response relationship observed in the Lund
study124 we would expect to observe a lower OR in this population. This would likely be true of the removal
of any risk factor. As such the true PEF could perhaps be up to 50% higher than our estimate.
Figure 23 shows a DAG for the retrospective analyses, and WinBUGS code is given in Appendix 12.
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Results
Risk of ectopic pregnancy in based on prospective data from the Lund study
Table 32 shows the full conditional estimates ηm,s,a from the model by number of subsequent PID episodes,
age group and severity. It also shows the average for hospital diagnosed salpingitis (i.e. averaged over
severity with numbers of mild, moderate and severe salpingitis observed in the Lund study.124 The
assumption of no interaction yields a set of cell-specific estimates (where cell is defined as a combination
of age, severity, and number of episodes) with an extraordinary range of risk, ranging over 40-fold in the
16- to 24-year-old group from 0.017 for a single ‘mild’ PID, to 0.698 in a women with three or more
subsequent PID episodes following a ‘severe’ index salpingitis.
The adequacy of these estimates can be judged only from the close agreement of the marginal estimates
of the probability that a pregnancy is ectopic by number of subsequent PID episodes, age group and
severity, from our model (see Table 28, column 3) compared with the crude estimates from the Lund
study124 (see Table 28, column 2). The residual deviance was 7.2 for a model with seven parameters and
nine data points. The very good fit of the model is to be expected, given the number of parameters
and the number of observations.
Table 33 shows the proportions πS+PIDm,d,a and π
NoCT S+PID
m,d,a of the female population at each level of clinical
severity of the index episode of salpingitis and the subsequent PID episodes, for the 16–24 and 25–44 age
bands, for all salpingitis and non-CT-related salpingitis, respectively.
Population Excess Fraction: the contribution of salpingitis and Chlamydia
trachomatis to ectopic pregnancy
The upper and lower bounds on the PEF of EP due to salpingitis, PEF (Salpingitis←EP) are given in Table 34,
by age, based on the PEF formula (see equation 1). Also shown for completeness are the cumulative PID
prevalence figures used in the calculation and the ORs. Averaging over the age range 16–44 years, between
21% and 33% of EP is due to salpingitis, these being the lower and upper estimates, with CrIs spanning
11% to 46%. We can take the mean, 27%, as a best estimate. In the absence of CT, the equivalent overall
estimates would be 22%, with CrIs spanning 7% to 43%. The proportion of EP attributable to CT is found
by subtraction: 4.9% (95% CrI 1.2% to 12.1%).
TABLE 32 Probability a pregnancy is ectopic by age, severity of salpingitis, and number of subsequent PID episodes
Risk factor Controlb
No further PID
episodes (95% CrI)
One further PID
episode (95% CrI)
Two or more further
PID episodes (95% CrI)
Age 16–24 yearsa 0.010
Mild – 0.017 (0.007 to 0.033) 0.052 (0.019 to 0.103) 0.183 (0.066 to 0.351)
Moderate – 0.035 (0.021 to 0.053) 0.101 (0.052 to 0.169) 0.316 (0.154 to 0.514)
Severe – 0.162 (0.117 to 0.211) 0.371 (0.236 to 0.522) 0.698 (0.492 to 0.857)
Overall 0.054 (0.042 to 0.067) 0.139 (0.087 to 0.200) 0.350 (0.209 to 0.505)
Age 25–44 years 0.026
Mild – 0.040 (0.015 to 0.076) 0.113 (0.041 to 0.224) 0.335 (0.133 to 0.582)
Moderate – 0.078 (0.043 to 0.123) 0.207 (0.105 to 0.341) 0.509 (0.280 to 0.733)
Severe – 0.310 (0.203 to 0.434) 0.572 (0.384 to 0.750) 0.836 (0.664 to 0.943)
Overall 0.112 (0.076 to 0.153) 0.250 (0.153 to 0.361) 0.517 (0.329 to 0.705)
a Assume lower age group applies to 16- to 29-year-olds for the time of the EP.
b Assumes the same age ratio in the control group as the general population. There is no severity distribution in women
without salpingitis (controls).
Cell-specific estimates, ηm,s,a derived from the logistic regression model of the marginal data in Table 28.
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TABLE 33a Proportion of the entire population in each risk group by age at index salpingitis, diagnosis category,
and number of subsequent episodes of PID, expressed as per cent (95% CrI)
Age (years)
No. of subsequent PIDs
Total0 1 2+
16–24
Undiagnosed 3.26 (1.68 to 5.37) 0.87 (0.34 to 1.71) 0.31 (0.01 to 0.89) 4.44 (2.16 to 6.24)
Non-hospital diagnosed 1.21 (0.70 to 1.77) 0.30 (0.16 to 0.47) 0.09 (0.03 to 0.23) 1.61 (0.96 to 2.31)
Hospital diagnosed 0.58 (0.33 to 0.88) 0.16 (0.08 to 0.25) 0.06 (0.02 to 0.14) 0.80 (0.47 to 1.19)
Total 5.05 (2.89 to 7.61) 1.33 (0.61 to 2.36) 0.47 (0.12 to 1.24) 6.85 (3.78 to 10.7)
25–44
Undiagnosed 6.34 (3.39 to 5.37) 2.12 (0.89 to 3.99) 0.97 (0.22 to 2.65) 9.42 (4.67 to 16.1)
Non-hospital diagnosed 1.45 (0.70 to 2.38) 0.47 (0.22 to 0.78) 0.20 (0.06 to 0.46) 2.11 (1.05 to 3.40)
Hospital diagnosed 2.04 (1.11 to 3.25) 0.67 (0.36 to 1.08) 0.29 (0.10 to 0.65) 3.00 (1.70 to 4.67)
Total 9.83 (5.77 to 14.4) 3.26 (1.59 to 5.50) 1.46 (0.41 to 3.66) 14.5 (8.16 to 22.3)
16–44
Undiagnosed 5.02 (2.64 to 8.02) 1.58 (0.65 to 2.98) 0.68 (0.16 to 1.86) 7.27 (3.58 to 12.4)
Non-hospital diagnosed 1.34 (0.74 to 2.07) 0.39 (0.20 to 0.63) 0.16 (0.05 to 0.36) 1.89 (1.06 to 2.86)
Hospital diagnosed 1.41 (0.79 to 2.19) 0.45 (0.24 to 0.71) 0.19 (0.06 to 0.43) 2.05 (1.19 to 3.11)
Total 7.77 (4.52 to 11.5) 2.42 (1.17.4.13) 1.03 (0.28 to 2.59) 11.2 (8.14 to 17.3)
Table gives estimates of πS+PIDm,d,a .
TABLE 33b Proportion of the entire population in each risk group by age at index not-CT-related salpingitis,
diagnosis category, and number of subsequent episodes of PID, expressed as per cent (95% CrI)
Age (years)
No. of subsequent PIDs
Total0 1 2+
16–24
Undiagnosed 2.42 (0.94 to 4.44) 0.52 (0.13 to 1.22) 0.15 (0.02 to 0.51) 3.08 (1.10 to 6.02)
Non-hospital diagnosed 0.86 (0.40 to 1.38) 0.17 (0.06 to 0.33) 0.04 (0.01 to 0.13) 1.08 (0.48 to 1.76)
Hospital diagnosed 0.44 (0.22 to 0.71) 0.10 (0.04 to 0.18) 0.03 (0.00 to 0.08) 0.57 (0.27 to 0.92)
Total 3.73 (1.63 to 6.30) 0.78 (0.23 to 1.70) 0.22 (0.03 to 0.71) 4.73 (1.93 to 8.44)
25–44
Undiagnosed 5.41 (2.57 to 9.13) 1.51 (0.47 to 3.22) 0.55 (0.08 to 1.74) 7.47 (3.20 to 13.66)
Non-hospital diagnosed 1.22 (0.57 to 2.03) 0.32 (0.12 to 0.60) 0.11 (0.02 to 0.30) 1.65 (0.75 to 2.78)
Hospital diagnosed 1.74 (0.93 to 2.79) 0.47 (0.20 to 0.84) 0.16 (0.03 to 0.43) 2.37 (1.24 to 3.84)
Total 8.36 (4.47 to 12.98) 2.30 (0.85 to 4.47) 0.82 (0.14 to 2.42) 11.48 (5.64 to 19.11)
16–44
Undiagnosed 4.12 (1.88 to 7.10) 1.08 (0.33 to 2.35) 0.37 (0.05 to 1.21) 5.58 (2.31 to 10.36)
Non-hospital diagnosed 1.06 (0.53 to 1.71) 0.26 (0.10 to 0.47) 0.08 (0.02 to 0.22) 1.40 (0.68 to 2.29)
Hospital diagnosed 1.18 (0.63 to 1.87) 0.31 (0.13 to 0.55) 0.11 (0.02 to 0.28) 1.59 (0.84 to 2.55)
Total 6.37 (3.28 to 10.08) 1.65 (0.58 to 3.27) 0.56 (0.10 to 1.68) 8.57 (4.07 to 14.49)
Table gives estimates of πNoCT,S+PIDm,d,a .
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Comparison of prospective and retrospective estimates of the proportion of
pregnancies that are ectopic as a result of salpingitis
The overall proportion of pregnancies that are ectopic, shown in the last column of Table 35, represents an
absolute upper bound on the proportion of pregnancies that can be ectopic and due to salpingitis. Taken
over the 16- to 44-year age range, 1.13% of conceptions are ectopic. Predictions of the proportion of
pregnancies that are ectopic as a result of salpingitis based on the estimate PEF from retrospective data are
given in columns 6 and 7: between 0.24% and 0.36%.
The predictions from the five prospective model range from a minimum 0.38 (Model 5: Av, Mi, 0) to a
maximum 1.54 (Model 1: Av, Av, Av). This means that, given that the PEF is in the range of 21–33%, the
Lund study estimates are consistent with the EP rates for England only under Model 5, that is only if we
assume there is no EP risk from undiagnosed salpingitis and the risk following salpingitis diagnosed outside
the hospital setting is at the rate seen in ‘mild’ salpingitis in the Lund study (Figure 24).
Note that the steep age gradient seen in the observed HES data is closely mirrored by the age gradient in
the predictions from the prospective models. This provides a degree of support for the model of
cumulative CT and PID incidence developed in Chapter 8 and our view that EP risk is determined by
cumulative exposure to risk factors.
TABLE 34 Retrospective evidence on EP
Age (years) OR (95% CI)
Cumulative
salpingitis
(95% CI)
Cumulative
salpingitis,
no CT
PEFSal←EP
(95% CI)
PEFNoCTSalp←EP
(95% CI)
PEFCT←EP
(95% CI)
16–24
Lower bound 3.39
(1.44 to 7.96)
4.15
(2.27 to 6.51)
2.48
(0.66 to 4.83)
9.11
(4.13 to 16.1)
5.65
(1.37 to 12.0)
3.46
(0.92 to 7.95)
Upper bound 5.42
(2.60 to 11.3)
4.15
(2.27 to 6.51)
2.48
(0.66 to 4.83)
15.44
(8.33 to 24.4)
9.80
(2.69 to 18.8)
5.65
(1.61 to 12.4)
25–44
Lower bound 3.39
(1.44 to 7.96)
13.9
(7.75 to 21.3)
10.84
(5.28 to 18.1)
24.7
(12.8 to 38.8)
20.4
(9.36 to 34.5)
4.28
(1.23 to 9.20)
Upper bound 5.42
(2.60 to 11.3)
13.9
(7.75 to 21.3)
10.84
(5.28 to 18.1)
37.4
(23.6 to 51.4)
31.8
(17.7 to 47.0)
5.63
(1.62 to 11.9)
16–44
Lower bound 3.39
(1.44 to 7.96)
11.22
(6.27 to 17.3)
8.57
(4.07 to 14.49)
21.1
(10.58 to 34.0)
16.9
(7.41 to 29.6)
4.13
(1.17 to 8.98)
Upper bound 5.42
(2.60 to 11.3)
11.22
(6.27 to 17.3)
8.57
(4.07 to 14.49)
32.7
(20.02 to 46.2)
27.04
(14.2 to 41.4)
5.70
(1.66 to 12.1)
ORs at upper and lower limits, cumulative prevalence and PEFs (as percentages), by age.
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Discussion
Summary of present findings and relation to previous work
The overall proportion of pregnancies that are EP in women aged 16–44 years, based on HES data, is
around 1.13%. Based on retrospective studies on the prevalence of a history of salpingitis in EP versus
non-EP control subjects, we have suggested that the proportion of EP attributable to PID is between 21%
and 33%, so that the proportion of pregnancies that are PID-related EP should be between 0.24% and
0.36%. However, these results are only compatible with progression rates from the Lund study if we
assume that there is no EP risk following salpingitis associated with undiagnosed PID, and a level of risk
only at the ‘mild’ level for all salpingitis associated with PID that is diagnosed outside of hospital. Further
discussion of these results is deferred to the summary (see Chapter 12), where they can be considered
alongside results from other chapters, and particular alongside similar analyses of the role
of PID/salpingitis in TFI.
Comparison of our results with other studies is problematic because of the different methodologies used,
the different assumptions being made about CT and PID, and different ways of taking into account that
there must be a pregnancy for there to be an EP. Roberts et al.,2 for example, assumed that the risk that a
future pregnancy would be an EP was 0.008 per day of CT duration, but this was based on a calibration
against the Uppsala data, where women with CT were treated, and on CT duration of 200 days,
compared with our estimate which is approximately double that.
A slightly different calculation based on similar assumptions was proposed by Low et al.15 But in both cases
the EP rate was assumed to be independent of the PID rate, which runs counter to what is known about
their relationship. Adams et al.106 assumed the risk of EP following PID (conditional on conception) was
7.6%, based on the Lund study,124 equating to a risk of 0.76% per incident CT infection, given a 10%
progression rate from CT to PID. Van Valkengoed et al.,39 based on a form of argument critiqued in
Appendix 9, proposed that the risk of EP following CT was 10 times less, at 0.07%. Comparison of
these results with predictions from this report are reserved till Chapter 12, at which point we will have
established a credible estimate for the proportion of conceptions that are EP due to PID.
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FIGURE 24 Predicted proportions of conceptions that are ectopic due to salpingitis based on five prospective
models of the Lund data, and retrospective estimates.
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Limitations
There are a wide range of limitations, many of which have already been implicit in the description of our
methodology. Undoubtedly, the main difficulty has been the complete lack prospective data on the
sequelae of undiagnosed PID, let alone salpingitis following undiagnosed PID, and our reliance on
progression rates observed in the Lund study,124 which was carried out between 30 and 50 years ago, at a
time when the microbiological spectrum of PID was more weighted towards gonorrhoea and treatment for
PID was quite different. There have been other studies following PID cases forward (see Table 27), but
these have lacked controls, have been very considerably smaller and have not generally produced
different results.
The derivation of predictions from our prospective model also involved a wide range of assumptions
that are based on no or very limited evidence. At a technical level our analysis of the separate risk
factor-specific risks is not quite correct, as we have taken the age, severity and number of PID episodes as
independent data samples. Methods have been developed for deriving estimates from marginal data,249,250
but these require full conditional data from at least one study. However, Table 28 shows that our
estimates accord well with the evidence available; the precision is overstated as a result of our assumptions
about the data, but probably not by very much. Our assumption that there are no interactions between
the risk factors cannot be verified with these data.
Also difficult to verify are our assumptions that the severity distribution of any salpingitis remains the same
following first, second and third episodes of PID, and that the proportion of clinical PID episodes that are
salpingitis is the same in undiagnosed and non-hospital-referred PID as hospital PID.
Our estimates of the PEFs relating to salpingitis and non-CT-related salpingitis must be considered only
approximate because the distribution of salpingitis exposure would be different in the absence of CT.
However, the use of these retrospective studies is a much greater cause for concern due to the general
difficulties with case–control designs (recall bias, confounding), and the uncertain applicability of these
results from France to the UK in the present day.
The interpretation of the results in Table 35 comparing retrospective and prospective results will be
discussed further in Chapters 10 and 12, where they will be considered alongside similar analyses of TFI.
Summary of assumptions and findings
Summary of assumptions
1. The proportion of all PID, whether diagnosed or not and whether CT related or not, in which salpingitis
would be found on laparoscopy, is the same.
2. The severity distribution of salpingitis observed in the Lund study holds for all salpingitis, and whether
CT-related or not.
3. The proportion of EP that is due to salpingitis, estimated in a French study in 2001, approximates the
proportion in the UK.
Summary of findings
1. Of UK pregnancies, 1.13% are ectopic.
2. An estimated 27% (95% CrI 11% to 46%) of EP in women aged 16–44 years is due to salpingitis.
3. An estimated 4.9% (95% CrI 1.2% to 12.1%) of EP in women aged 16–44 years is due to CT.
4. These results are compatible with the Lund study124 if it is assumed that there is no EP risk following
salpingitis in women with undiagnosed PID, and that in women with salpingitis associated with PID
diagnosed outside of hospital, the EP risk is at or below the rate for ‘mild’ salpingitis.
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Chapter 10 Pelvic inflammatory disease and tubal
factor infertility
Objectives
To:
1. estimate the proportion of women in the UK with TFI at the end of their reproductive lives
2. apply the information on group-specific risks of TFI reported in the Lund study (number of PID episodes,
severity of PID) to estimates of the distribution of these risk factors in the UK to predict the proportion
of proportion of women who have TFI
3. compare the predictions based on the Lund study with estimates of the proportion of women with
TFI derived from UK fertility surveys
4. estimate the proportion of TFI attributable to CT.
Introduction
This chapter examines the relationship between PID, and particularly salpingitis, and TFI. The structure of the
chapter and the methods used mirror Chapter 9 on EP. We can carry over a substantial part of the analysis
from the previous chapter, including the estimates of the UK distribution of risk factors (numbers of previous
episode of salpingitis, by severity and age: see Table 33). As with EP, we use the Lund study33 on risk of TFI
in women with salpingitis who were hospitalised for PID, to define the risk of TFI in the specific subgroups.
We then apply the five prediction models that map the Lund study risks in women with hospitalised PID to
what might be expected in other diagnosed salpingitis and in undiagnosed salpingitis.
These predictions are then compared with estimates of the prevalence of TFI in the UK, based on fertility
surveys. As noted in Chapter 2, in order to achieve a definition of TFI prevalence that allows us to compare
predictions from the Lund study33 to prevalence in the UK, we adopt the strategy of considering infertility,
including both primary and secondary, as an unresolved failure to conceive at the end of a woman’s
reproductive life, defined here as age 44 years.
The particular point of interest is whether the prediction model that agrees best with prospective evidence
on EP is also the best fit for TFI. This will be examined in Chapter 12.
Outline of evidence sources and approach to synthesis
Prospective evidence: following pelvic inflammatory disease forward to
tubal factor infertility
A number of prospective studies228,240–242,251–254 have followed up women with PID to infertility-related
outcomes. However, there are major differences in the way that exposures and outcomes have been
defined. Studies have recruited women with mild/moderate PID, with severe PID, with all except the most
severe PID, or with any PID which is sometimes subclassified to ‘mild’, ‘moderate’ or ‘severe’. PID was
clinical or with laparoscopically confirmed salpingitis, whereas the outcome was either laparoscopically
confirmed TFI, unilateral or bilateral tubal occlusion, both, pregnancy rates, or all-cause infertility defined as
either 1 or 2 years of trying for a baby, and this could have been primary or all infertility. Finally, a number
of studies are based on the same sample. Because of these difficulties, we do not consider these
studies further.
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Instead, as with EP, rather than attempting to synthesise these disparate studies, we have relied on the
Lund study33 because of its size, length of follow-up, relatively specific exposures and outcomes, and
because it uses a similar set of definitions in the follow-up to EP.124 Table 36 shows the number of women
diagnosed with TFI during follow-up by age group at index salpingitis (< 25 years, ≥ 25 years), its severity
and number of subsequent PID episodes during follow-up.
Prevalence of infertility and tubal factor infertility in the UK
The types of evidence sources used to estimate the prevalence of infertility and TFI in the UK were
reviewed in Chapter 2, and definitions of these terms were given. We identified papers on the prevalence
of infertility in the UK and on the prevalence of TFI (Table 37), relying on the recent review and synthesis
paper by Kavanagh256 and on references found in our wider review of the literature.
TABLE 36 Prospective data on the risk of TFI following PID from the Lund study33 by number of PIDs, age
and severity
Number of PIDs
Aged < 25 years at index Aged > 25 years at index
r n Crude risk, % (95% CrI) r n Crude risk, % (95% CrI)
One 59 771 7.7 (6.0 to 9.7) 20 220 9.1 (6.0 to 13.7)
Mild 2 241 0.8 (0.3 to 3.0) 0 71 0.0 (0.0 to 5.1)
Moderate 23 361 6.4 (4.3 to 9.4) 5 89 5.6 (2.5 to 12.6)
Severe 34 369 9.2 (6.7 to 12.6) 15 60 25.0 (16.0 to 37.8)
Two 29 158 18.4 (13.2 to 25.3) 7 27 25.9 (13.7 to 46.2)
Three plus 23 61 37.7 (27.0 to 51.0) 3 4 75.0 (39.7 to 99.4)
Total 111 990 11.2 (9.4 to 13.3) 30 251 12.0 (8.5 to16.7)
r, numerators; n, denominators.
TABLE 37 Data used to estimate the prevalence of TFI in women aged 44 years
Publication Age (years) r n p= r/n(%) (95% CrI)
Primary infertility
Templeton126 46–50 27 766 3.5 (2.4 to 5.1)
Gunnell128 41–50 31 1609 1.9 (1.4 to 2.7)
Bhattacharya127 41–50 79 2347 3.4 (2.7 to 4.2)
Oakley129 40–55 159 6584 2.4 (2.1 to 2.8)
Oakley, adjusted129 40–55 153.8 6128 2.5 (2.2 to 2.9)
Not involuntarily childless
Templeton126 and Bhattacharya127 41–50 2910 3113 93.5 (92.6 to 94.3)
Secondary infertility
Templeton126 46–50 17 766 2.2 (1.4 to 3.5)
Gunnell128 41–50 41 1609 2.5 (1.9 to 3.4)
Bhattacharya127 41–50 5 2347 0.2 (0.1 to 0.5)
Proportion TFI
Maheshwari255 > 35 442 1782 24.8 (22.9 to 26.9)
n, denominator; p= study-specific estimate; r, numerator.
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The approach we adopt takes the following steps:
1. The data on primary infertility in women aged 41–50 years from four surveys126–129 is pooled. The data
from one of the surveys129 has to be adjusted to take account of the proportion of women who were
voluntarily childless, which was estimated from data in two surveys.126,127
2. A second synthesis was carried out for the prevalence of secondary infertility, using data from three
surveys,126–128 and this estimate was adjusted for the possibility that these women would have become
pregnant subsequently (see Appendix 13).
3. The primary infertility and adjusted secondary infertility estimates were added together to form an
estimate of the prevalence of infertility.
4. This was multiplied by an estimate of the proportion of infertility due to TFI. Because data from the
HFEA are unlikely to be representative, we have used an estimate of the proportion of infertility due to
TFI of approximately 25%, based on women aged > 35 years old from a clinic-based study conducted
in Aberdeen between 1993 and 2006.255 This is the only UK survey of infertility reporting this statistic.
Approximately 13% of tubal damage can be caused by endometriosis257 but this is classified as
endometriosis rather than TFI in that study.
As noted in Chapter 2, we assume that virtually all TFI has an infective aetiology and is caused by
salpingitis, and that PID that does not confirm as salpingitis on laparoscopy does not carry a risk of TFI.35
Statistical methods
Model for the prospective data of the risk of tubal factor infertility
following pelvic inflammatory disease
The Lund study33 provides data on the risk of TFI first by age and severity of index salpingitis, and second by
age and number of subsequent PID episodes, zero, one and two-plus, averaging over severity (see Table 36).
Each of the 10 data points describing progression to TFI has a binomial likelihood,
r1,s,a ∼ Binomial(η1,s,a,n1,s,a)
r ′m,a ∼ Binomial(p′m,a,n′m,a) : m = 2,3
(58)
where a indexes over age group (< 25 or > 25 years at recruitment), m over number of subsequent PID
episodes during follow-up (zero, one, two-plus) and s over severity of the index salpingitis episode (s= 1,
mild; 2, moderate; 3, severe). r1,s,a is the number of women with one salpingitis episode of severity s at age
a developing TFI in a sample size n1,s,a of women in these groups who were follow-up and tried to
conceive. r′m,a is the number of women with one or two subsequent PID episodes by age group
(aggregated over severity) in a sample size of n′m,a with probability parameter p′m,a where:
p′m,a =
∑
3
s=1
ηm,s,a⋅n1,s,a
∑
3
s=1
n1,s,a
: m = 2,3 (59)
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As with EP, we fit a model to the marginal data to estimate the risk factor-specific risk of TFI, ηm,s,a:
logit(ηm,s,a) = β0 + β1,mM + β2,sS + β3,aA (60)
β0 is the log odds of TFI in a woman aged < 30 years at the time of her mild index salpingitis, with no
further PID episodes, β1,m is the LOR of TFI for a woman with m subsequent PID episodes compared with
none, β2,s is the LOR for a woman whose index salpingitis was moderate or severe compared with mild and
β3,a is the LOR in women aged 30 years or over relative to those aged under 30 years. The covariates M, S
and A have the same interpretations as in Chapter 9. The parameters β0, β1,m, β2,s and β3,a are given flat
normal priors. As with our model in Chapter 9, the reported data do not provide the sufficient statistics to
identify interaction terms. Although this does not necessarily mean there are no interactions, we assume
there are none, as in the analysis of EP. We assume that results for 16- to 24-year-old women are
applicable for women aged 16–29 years because of the mean 9-year follow-up.
In the Lund study,33 TFI was not found in any of 601 control women with PID which was not confirmed as
salpingitis on laparoscopy.
Model for the distribution and diagnostic setting of pelvic inflammatory
disease in the general population.
Estimates of the proportion of women in age band a who had experienced an episode of salpingitis at age
a, diagnosed in setting d, and followed by m subsequent PID episodes, πS+PIDm,d,a and π
NoCT,S+PID
m,d,a were
introduced in Chapter 9 (see Table 33).
Prospective estimate of the prevalence of tubal factor infertility caused by
CT-related PID
To estimate the prevalence of TFI due to salpingitis in the UK θPOP,TFIjsalpa , we use the same approach as in
Chapter 9 for EP. We adopt the same five ‘models’ to ‘map’ the ηm,s,a severity-specific estimates of TFI risk
into θTFIjsalpm,d,a diagnostic-setting specific estimates of risk. Then, the population estimates θ
POP,TFIjsalp
a are found
by taking a weighted average of the θTFIjsalpm,d,a using the π
S+PID
m,d,a as weights.
As the Lund study33 was set in the Hospital Diagnosed setting, we can estimate θTFIjsalpm,HD,a directly from the
ηm,s,a. Note that, because there were no TFI cases among the non-salpingitis controls, we interpret the
parameters θTFIjsalpm,d,a as causal estimates:
θTFIjsalpm,HD,a =
∑
3
s=1
ηm,s,a⋅n
Lund
s
∑
3
s=1
nLunds
(61)
Then, the risk of TFI due to salpingitis as a function of age group, severity and number of subsequent PID
episodes is constructed as a weighted average using the proportion of women at each severity level and
the cumulative prevalence of salpingitis and zero, one or two-plus subsequent PID episodes, πS+PIDm,d,a. An
analogous estimate can be formulated for salpingitis that is not CT related:
θPop,TFIjsalpa = ∑
d =HD,nHD,UD
∑
m= 0,1,2+
πS+PIDm,d,a⋅θ
TFIjsalp
m,d,a (62)
θPopnoCT,TFIjsalpa = ∑
d =HD,nHD,UD
∑
m= 0,1,2+
πnoCT,S+PIDm,d,a ⋅θ
TFIjsalp
m,d,a (63)
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The five different models of how the TFI risks in the Lund hospital-diagnosed PID might apply to
non-hospital-diagnosed PID, and undiagnosed PID can then be set out in the same way as in Chapter 9,
where, as before, ‘Av’ refers to the average risk reported in the Lund study33 and ‘Mi’, to the risk in mild
salpingitis, with HD, nHD and UD referring to hospital diagnosed, non-hospital diagnosed and
undiagnosed PID:
Model 1 (Av, Av, Av): Lund average risk of TFI due to salpingitis following all PID. All salpingitis, whether
associated with HD, nHD, or UD PID, carries the same risk of TFI as those with hospital diagnosed PID in
the Lund study:
θTFIjsalpm,nHD,a = θ
TFIjsalp
m,UD,a =
∑
3
s=1
ηm,s,a⋅nLunds
∑
3
s=1
nLunds
(64)
Model 2 (Av, Av, Mi): Lund average for salpingitis following diagnosed PID, Lund ‘mild’ following
undiagnosed PID. Salpingitis associated with both HD and nHD PID carries the same TFI risk as in the Lund
study; salpingitis associated with UD PID has the same TFI risk as the ‘mild’ salpingitis group in the
Lund study.
θTFIjsalpm,nHD,a =
∑
3
s=1
ηm,s,a⋅n
Lund
s
∑
3
s=1
nLunds
θTFIjsalpm,UD,a = ηm,1,a
(65)
Model 3 (Av, Mi, Mi): Lund average for salpingitis following hospital diagnosed, Lund ‘mild’ following
non-hospital diagnosed and undiagnosed salpingitis. In this model HD salpingitis progresses to TFI at the
average rate observed in the Lund study; nHD and UD at the Lund ‘mild’ rate.
θTFIjsalpm,nHD,a = θ
TFIjsalp
m,UD,a = ηm,1,a (66)
Model 4 (Av, Mi, Mi/2): Lund average for salpingitis following HD PID, Lund ‘mild’ following nHD PID.
Salpingitis following UD PID progresses at a rate that is half-way between the ‘mild’ rate and zero.
θTFIjsalpm,nHD,a = ηm,1,a
θTFIjsalpm,UD,a ∼ Uniform(0,ηm,1,a)
(67)
Model 5 (Av, Mi, 0): Lund average for salpingitis following HD PID, Lund ‘mild’ for following nHD PID,
no risk following UD PID:
θTFIjsalpm,nHD,a = ηm,1,a
θTFIjsalpm,UD,a = 0
(68)
The WinBUGS code for the prospective analyses of TFI is set out in Appendix 15.
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Model for the prevalence of tubal factor infertility based on UK
fertility surveys
All the data, which have binomial likelihoods, are set out in Table 37. The data on primary infertility in
women aged 41–50 years is pooled on the assumption that the proportions are from a common beta
distribution, whose parameters are estimated from the binomial data, and are given vague exponential
prior distributions. The target parameter is the mean of this distribution. The data from one of the
surveys129 is adjusted to take account of the proportion of women who were voluntarily childless. This
fraction was estimated from data in two surveys.126,127 The effective sample size of the Oakley survey
was imputed based on a simulation taking account of the uncertainty in both fractions.
The synthesis of secondary infertility, based on three surveys, is also based on a common beta distribution,
and adjusted for over-reporting, which was assumed to be between 0% and 12% (see Appendix 13).
Total infertility was multiplied by an estimate of the proportion of infertility due to TFI,255 based on a vague
Beta prior and binomial likelihood. WinBUGs code for the synthesis is provided in Appendix 14.
The proportion of tubal factor infertility episodes caused by
chlamydia trachomatis
Under our assumption that all TFI is caused by salpingitis, we can estimate the proportion of TFI due to CT,
the PEF, by age group, as a function of the prevalence of TFI due to salpingitis, and the predicted
prevalence of TFI due to salpingitis if there is no CT. These are based on the estimates of πS+PIDm,d,a and
πnonCT S+PIDm,d,a from Chapter 8, through equations 61 and 62, respectively:
γCT←TFIa =
θPOP,TFIjsalpa −θ
POPnoCT,TFIjsalp
a
θPOP,TFIjsalpa
(69)
The same estimate will be derived from each of the five prospective models. A DAG of the prospective
analysis can be found in Figure 25.
PELVIC INFLAMMATORY DISEASE AND TUBAL FACTOR INFERTILITY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
C
h
ap
te
r 
8 
an
al
ys
es
 o
f 
PI
D
 a
n
d
re
p
ea
t 
PI
D
 in
ci
d
en
ce
R
o
u
ti
n
e 
PI
D
 d
at
a,
W
o
ln
er
-H
an
se
n
 (
19
95
)
Pr
o
p
o
rt
io
n
 o
f 
PI
D
 in
ea
ch
 d
ia
g
n
o
si
s 
se
tt
in
g
Pr
o
p
o
rt
io
n
 w
it
h
 s
al
p
in
g
it
is
an
d
 0
,1
,2
+
 s
u
b
se
q
u
en
t
PI
D
 e
p
is
o
d
es
, w
it
h
 a
n
d
 w
it
h
o
u
t 
C
T
d
, a
κ
0β
η
1,
 m
m
, s
, a
β
2,
 s
β
+
) =
lo
g
 it
(
 +
3,
 a
β
 +
1,
 2
…
5
η
θ
η
m
, s
, a
m
, d
, a
TF
I|S
al
p
C
o
n
tr
o
l
=
,
(
)
M
o
d
el
θ a
Po
p
TF
I  |S
al
p
π
Σ
m
, d
, a
S  
+
 P
ID
θ m
, d
, a
TF
I  |S
al
p
=
π
Pr
o
p
o
rt
io
n
 w
it
h
 s
al
p
in
g
it
is
 a
n
d
 0
,1
,2
+
 
su
b
se
q
u
en
t 
PI
D
 e
p
is
o
d
es
 b
y 
d
ia
g
n
o
si
s 
se
tt
in
g
, w
it
h
 a
n
d
 w
it
h
o
u
t 
C
T
Po
p
u
la
ti
o
n
 r
is
k 
o
f 
TF
I d
u
e 
to
 s
al
p
in
g
it
is
,
 w
it
h
 a
n
d
 w
it
h
o
u
t 
C
T
Pr
(T
FI
|S
al
p
) 
w
it
h
 m
 s
u
b
se
q
u
en
t
PI
D
 e
p
is
o
d
es
, i
n
d
ex
 s
al
p
 s
Pr
(T
FI
 w
it
h
 m
 s
u
b
se
q
u
en
t
PI
D
 e
p
is
o
d
es
, d
ia
g
n
o
si
s 
ca
te
g
o
ry
 d
, M
o
d
el
s 
1–
5
m
, d
, a
S 
+
 P
ID
β
Lu
n
d
 d
at
a 
o
n
 T
FI
 r
is
k 
in
 h
o
sp
it
al
-d
ia
g
n
o
se
d
sa
lp
in
g
it
is
 c
as
es
 w
it
h
 m
 s
u
b
se
q
u
en
t 
PI
D
ep
is
o
d
es
, a
n
d
 in
 n
o
n
-s
al
p
in
g
it
is
 c
o
n
tr
o
ls
m
, d
θ a
Po
p
TF
I  |N
o
C
T,
Sa
lp
π
Σ
m
, d
, a
N
o
C
T.
S  
+
 P
ID
θ m
, d
, a
TF
I  |S
al
p
=
m
, d
an
d
m
,a
S 
+
 P
ID
π
m
,a
N
o
C
T 
. S
 +
 P
ID
π
an
d
m
,d
,a
N
o
C
T  
. S
 +
 P
ID
π
θ
=
PE
F 
(C
T 
   
TF
I)
γ
a
C
T 
   
TF
I
Po
p
,T
FI
|S
al
p θ a
Po
p
,T
FI
|S
al
p
θ a
Po
p
n
o
C
T,
TF
I|S
al
p
–
FI
G
U
R
E
25
D
ir
ec
te
d
ac
yc
lic
g
ra
p
h
o
f
th
e
p
ro
sp
ec
ti
ve
an
al
ys
is
o
f
TF
I.
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
117
Results
Population prevalence of tubal factor infertility based on infertility surveys
The posterior summaries from our synthesis of the British fertility surveys are shown in Table 38. The
prevalence of infertility in women at the end of their reproductive lives, notionally age 44 years for the
purposes of this project, including both primary and secondary infertility, is 4.4% (95% CrI 3.2% to 6.2%)
and the prevalence of TFI is 1.1% (95% CrI 0.8% to 1.6%).
Risk of tubal factor infertility following salpingitis, by age, severity and
number of exposures
Our modelled cell-specific risks ηm,s,a of TFI, based on the marginal risk table in the Lund study,33 are set out
in Table 39. The risk of TFI in women aged 16–29 years is only slightly less than in women aged 30–44 years,
but there is a 20-fold increase in risk as one goes from mild to severe disease, and a more than threefold
increase from no subsequent PID episodes, to one and then two or more episodes, suggesting a positive
multiplicative relationship between number of salpingitis episodes and risk of TFI.
TABLE 38 Estimates of primary, secondary infertility and proportion TFI: posterior means and 95% CIs
Parameter Mean (%) 95% CI
Primary infertility 2.82 2.25 to 3.50
Secondary infertility 1.63 0.66 to 3.44
Secondary infertility, adjusted 1.54 0.63 to 3.26
All infertility 4.36 3.23 to 6.19
Prevalence of TFI 1.08 0.79 to 1.55
TABLE 39 Risk of TFI due to PID, by age, severity of index salpingitis and number (95% CrI) of subsequent
PID episodes
Risk factor No salpingitis
PID episode(s)
No further One further Two further
16–24
Mild – 0.01 (0.00 to 0.02) 0.02 (0.00 to 0.06) 0.07 (0.01 to 0.18)
Moderate – 0.06 (0.04 to 0.08) 0.17 (0.11 to 0.25) 0.44 (0.28 to 0.63)
Severe – 0.21 (0.15 to 0.27) 0.46 (0.34 to 0.60) 0.76 (0.61 to 0.88)
Overall 0
25–44
Mild – 0.01 (0.00 to 0.02) 0.02 (0.00 to 0.07) 0.08 (0.01 to 0.23)
Moderate – 0.07 (0.04 to 0.11) 0.21 (0.11 to 0.33) 0.49 (0.29 to 0.71)
Severe – 0.24 (0.16 to 0.33) 0.51 (0.35 to 0.67) 0.79 (0.63 to 0.91)
Overall 0
Cell-specific estimates of ηm,s,a derived from the logistic regression model of the marginal data in Table 36 (mean 8.9-year
follow-up).
Assumes lower age group applies to 16- to 29-year-olds for the time of the TFI.
There is no severity distribution in controls.
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Comparison of tubal factor infertility prevalence predicted from the Lund
study with tubal factor infertility in British surveys
The 1.08% (95% CrI 0.79% to 1.54%) prevalence of TFI in 44-year-old women, based on the above
synthesis of the British fertility surveys can now be compared with the range of projected TFI prevalence
obtained when the Lund study progression rates from salpingitis to TFI33 are applied to the distribution of
age, severity of index salpingitis, and number of subsequent PID episodes (Table 40 and Figure 26). The
estimates for age 44 years appear to fall between the Model 1 (Av, Av, Av) projection of 1.74% (95% CrI
0.9,2.9) (all salpingitis progresses at the average rate observed in the Lund study), and the Model 2
(Av, Av, Mi) projection of 0.70% (95% CrI 0.4% to 1.2%) (all diagnosed salpingitis progresses at the
average rate, undiagnosed at the ‘mild’ rate). The estimates are not compatible with the Model 3 (Av, Mi,
Mi) projection of 0.5% (95% CrI 0.2% to 0.9%), even taking into account the uncertainty in the estimates
and the projections.
TABLE 40 Prevalence (95% CrI) of TFI as predicted from the distribution of salpingitis severity and exposure, and
Lund study progression rates33 (prospective models 1–5), compared with prevalence of TFI in England, based on
fertility surveys
Age (years)
Prospective model
All TFI in
England1 (Av, Av, Av) 2 (Av, Av, Mi) 3 (Av, Mi, Mi) 4 (Av, Mi, Mi/2) 5 (Av, Mi, 0)
16–19 0.14
(0.07 to 0.23)
0.06
(0.03 to 0.09)
0.02
(0.01 to 0.04)
0.01
(0.01 to 0.03)
0.01
(0.01 to 0.02)
–
20–24 0.44
(0.23 to 0.73)
0.18
(0.10 to 0.28)
0.06
(0.03 to 0.14)
0.05
(0.02 to 0.11)
0.04
(0.02 to 0.07)
–
25–34 1.00
(0.52 to 1.64)
0.40
(0.22 to 0.63)
0.21
(0.10 to 0.38)
0.19
(0.09 to 0.32)
0.16
(0.09 to 0.26)
–
35–44 1.57
(0.78 to 2.67)
0.63
(0.33 to 1.04)
0.45
(0.21 to 0.81)
0.41
(0.20 to 0.70)
0.37
(0.18 to 0.65)
–
44 1.74
(0.88 to 2.94)
0.70
(0.36 to 1.16)
0.50
(0.23 to 0.89)
0.46
(0.22 to 0.80)
0.41
(0.17 to 0.53)
1.08
(0.79 to 1.54)
16–44 1.03
(0.53 to 1.71)
0.41
(0.22 to 0.66)
0.26
(0.13 to 0.45)
0.23
(0.12 to 0.39)
0.21
(0.11 to 0.34)
–
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0% 1% 2% 3% 4% 5%
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Percentage of women with TFI at age 44 years
Model 1
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Model 3
Model 4
Model 5
TFI in England
FIGURE 26 Predicted prevalence of TFI in 44-year-olds, based on five prospective models of the Lund data.33
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Estimates of the population excess fraction (Chlamydia trachomatis←tubal
factor infertility) based on the prospective analysis
Table 41 compares the predicted population prevalence of TFI under Models 1 and 2, as presented in
Table 40, with alternative predictions under a scenario in which CT-related salpingitis did not exist.
A prediction for TFI prevalence caused by CT-related salpingitis is formed by subtraction, leading to an
estimate of the PEF(CT←TFI) of 28.7% (95% CrI 8.9% to 56.3%). Note that this estimate of the PEF does
not depend on the model for TFI risk that is adopted.
TABLE 41 Estimates of the percentage (95% CrI) of the female population with TFI caused by all salpingitis,
with TFI caused by non-CT-related salpingitis, and CT-related salpingitis, and estimates of the PEF(CT←TFI)
Age (years)
Prevalence of TFI due to:
PEF(CT←TFI),
(A–B)/A (as %)Salpingitis A
Non-CT-related
salpingitis B
CT-related
salpingitis A–B
Model 1 (Av, Av, Av)
16–19 0.14 (0.07 to 0.23) 0.07 (0.00 to 0.16) 0.07 (0.02 to 0.16) 52.7 (16.1 to 100)
20–24 0.44 (0.23 to 0.73) 0.28 (0.08 to 0.54) 0.17 (0.05 to 0.36) 38.1 (11.9 to 74.5)
25–34 1.00 (0.52 to 1.64) 0.75 (0.33 to 1.33) 0.25 (0.08 to 0.54) 25.8 (8.1 to 50.5)
35–44 1.57 (0.78 to 2.67) 1.26 (0.57 to 2.28) 0.31 (0.08 to 0.67) 20.0 (5.9 to 40.0)
44 1.74 (0.88 to 2.94) 1.41 (0.61 to 2.54) 0.33 (0.10 to 0.71) 19.2 (6.0 to 38.0)
16–44 1.03 (0.53 to 1.71) 0.79 (0.35 to 1.42) 0.24 (0.07 to 0.51) 28.7 (8.9 to 56.3)
Model 2 (Av, Av, Mi)
16–19 0.06 (0.03 to 0.09) 0.03 (0.00 to 0.06) 0.03 (0.01 to 0.07) 52.7 (16.1 to 100)
20–24 0.18 (0.10 to 0.28) 0.11 (0.04 to 0.20) 0.07 (0.02 to 0.15) 38.1 (11.9 to 74.5)
25–34 0.40 (0.22 to 0.63) 0.30 (0.14 to 0.50) 0.10 (0.03 to 0.22) 25.8 (8.1 to 50.5)
35–44 0.63 (0.33 to 1.04) 0.50 (0.24 to 0.87) 0.12 (0.03 to 0.28) 20.0 (5.9 to 40.0)
44 0.70 (0.36 to 1.16) 0.56 (0.27 to 0.97) 0.13 (0.04 to 0.30) 19.2 (6.0 to 38.0)
16–44 0.41 (0.22 to 0.66) 0.31 (0.15 to 0.54) 0.10 (0.03 to 0.21) 28.7 (8.9 to 56.3)
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Discussion
In this section we comment on the relation between our results in this chapter on risks of TFI following
salpingitis, in the light of previous work on this topic. We then turn to consider the relationship between
the results in this chapter and those from Chapter 9, where the observed UK EP rates were compared with
the same five models of prospective risk derived from the Lund study.
Comparison with previous work on Chlamydia trachomatis, pelvic
inflammatory disease and tubal factor infertility
We have already provided some comments on the relation between CT, PID and TFI in the HPA and ClaSS
economic models, and on the approach taken by van Valkengoed et al.39 (see Appendix 9). There appear
to have been few attempts to reconcile information on incidence and prevalence of CT, PID and TFI in a
quantitative way since then, until the important recent work by Kavanagh et al.256 This attempts to
estimate the risk of TFI associated with CT infection. This study does not use PID or salpingitis as an
intermediate variable, but, instead, considers only previous CT. For women aged 40–44 years (estimates
are also provided for younger age groups) they estimated a prevalence of TFI of 0.75%, that 43% of
women in this age group in the general population have ever had chlamydia, and that, based on
serological surveys of women with TFI, 72% have ever had chlamydia. From this the authors estimate the
probability of TFI in women ever infected with chlamydia to be 1.3%, and estimate a PEF for CT of 62.9%.
Although there are similarities with our estimates, there are several difficulties with Kavanagh el al.’s
approach, many of which are highlighted in their paper: first, the estimated prevalence of TFI at age
40–44 years (0.75%) may be too low, as only primary infertility was considered. Our estimate was 1.1%,
which includes both primary and secondary infertility. Second, the estimate of cumulative incidence of CT,
which is taken to be 42.9% by age 44 years, based on testing and prevalence data, must be an
overestimate because it sums over incidence rates rather than summing over conditional incidence
proportions applied to women who have never been infected.
Their estimates of the prevalence of TFI in women with a history of CT are derived by substituting the
above parameters into the Bayes’ theorem. However, as the authors point out (also see Appendix 9), this is
not a causal estimate. Even if CT never caused TFI, and CT exposure was not confounded with other STIs,
we would still expect this estimate to equal the background prevalence of TFI. As a result of the above
issues, Kavanagh et al.’s estimates of the proportion of TFI attributable to CT must be considered to be an
upper bound, and, on this basis, are not incompatible with our estimated PEF(CT←TFI) of 28.7%.
This estimate, it should be emphasised, although derived from the prospective models based on the Lund
study, is entirely independent of the model selected, and is chiefly influenced by the estimates of the CT
incidence (see Chapter 5), PID incidence and the PEF(CT←PID) (see Chapter 7), and the Markov model for
repeat infection (see Chapter 8).
Changes in pelvic inflammatory disease management since the Lund study
There are a number of reasons for questioning whether the rates of progression of laparoscopically
defined PID to EP reported in the Lund study would apply to the UK now.
Antibiotic treatments for PID have certainly changed since the Lund study, with an increasing use of broad-
spectrum antibiotics capable of treating the range of micro-organisms that are now implicated in PID.258
Although these treatments are highly effective in achieving microbiological cure and elimination
of PID symptoms, little is known about their effect on reproductive outcomes.
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One treatment variable that is known to have a major impact is time to treatment. In the Lund study
(1960–84), in which it was reported that 18% were treated within 72 hours, treatment in less than
72 hours from the onset of symptoms was associated with a 2.8-fold reduction in risk of infertility (95% CI
1.3 to 6.1).107 During the PEACH study (1996–1999),259 there were still only 23% treated within 3 days. It
is generally believed that in the UK, where access to health care is universal, there was a distinct shift in
the mid to late 1990s towards presumptive treatment and treatment of milder cases.260
If we assume, optimistically, that 50% of diagnosed PID is treated within 3 days, and that the risk
reduction is by 2.8, then we would predict that progression rates among diagnosed PID cases, which
would confirm on laparoscopy, should be approximately 76.7% of the rates reported in the Lund study.
Applying this reduced risk to the prevalence of TFI predicted by the five models in Table 40, and bearing in
mind that the reduction in progression rates would apply to only the minority diagnosed salpingitis, it is
evident that changes in treatment efficacy and management do not materially affect our conclusions, other
than to shift the balance more in favour of Model 1 (Av, Av, Av).
Relation between predictions for ectopic pregnancy and tubal
factor infertility
The main finding from this chapter is that the model of the Lund study that could predict the UK EP rates
adjusted down to reflect the proportion of EP caused by salpingitis, namely Model 5 (Av, Mi, 0), cannot
predict the UK TFI rates, which are compatible with Models 1 (Av, Av, Av) or 2 (Av, Av, Mi) and vice versa.
Specifically, the models that were compatible with the EP data would under-predict the TFI results by a
factor of 2–2.5, whereas the models compatible with the TFI data would over-predict the EP results by
a factor of 1.5–3, if we accept the retrospective estimates of the proportion of EP due to salpingitis. This
issue is taken up in Chapter 12.
Assumptions and limitations
The evidence on infertility is based on studies undertaken over a 20-year period. However, following our
comments on the aetiology of TFI, we expect that TFI prevalence will respond relatively slowly to changes
in CT and PID incidence. We therefore assume that our analyses of this data are approximately relevant to
the target period for this report, 2002.
We also need to acknowledge assumptions inherent in our interpretation of the Lund study results on
progression from PID to TFI.33 The limited follow-up of the Lund cohort means that, although the study has
a relatively long follow-up time (mean 8 years), there is still the possibility that some cases of TFI will not
have been identified at the end of the observation period, leading to a potential underestimation of the
risk of TFI. However, because the denominator is women who have ever been pregnant this should not
cause bias. Also, the same women may have gone on to experience further PID episodes leading to TFI at
a later date.
A second issue to bear in mind is the small amount of data available on the risk of TFI in those with a
single ‘mild’ salpingitis. Only 2 out of 241 women aged < 25 years at the index PID with a single mild
salpingitis developed TFI, and 0/71 women aged ≥ 25 years developed TFI (see Table 36). Although this is
fairly strong evidence of low risk, this is the largest risk group, and projections for a number of the five
models are therefore very sensitive to this particular parameter. If there had been just one observed case of
TFI, rather than none, in those aged > 25 years, this would have had a substantial impact on our estimates
of θpopTFIjsalpa in that group.
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Summary of assumptions and findings
Summary of assumptions
1. The proportion of PID in which salpingitis would be found on laparoscopy is the same, whether
diagnosed or not, and whether CT related or not.
2. The distribution of severity of salpingitis observed in the Lund study holds for all salpingitis, whether
diagnosed or not, and whether CT related or not.
Summary of findings
1. The proportion of women in the UK who are infertile at the end of their reproductive lives (age 44 years)
is estimated to be 4.4% (95% CrI 3.2% to 6.2%).
2. The proportion with TFI is 1.1% (95% CrI 0.8% to 1.6%).
3. These results are compatible with the Lund study if it is assumed that the TFI risk following salpingitis in
women with diagnosed PID is at the average level observed in the Lund study,33 and among those with
undiagnosed PID the rate is between the ‘mild’ and average rates.
4. The estimated proportion of TFI attributable to CT is 29% (95% CrI 9% to 53%).
5. The prospective model of the Lund data that provides the best fit between observed and predicted
TFI prevalence, does not agree with the best-fitting model for EP.
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Chapter 11 Tubal factor infertility: previous
exposure to Chlamydia trachomatis infection
Objectives
To estimate the proportion of TFI attributable to CT using retrospective serological case–control studies.
Introduction
There have been a large number of retrospective studies comparing the prevalence of serum antibodies to
CT in women with TFI and controls.143,261,262 The motivation was to assess the diagnostic potential of
serological tests, or to study the causal role of CT in TFI. In some cases the purpose was to estimate the
proportion of TFI that could be causally attributable to CT,263 using the formula for PEF (equation 1)
presented in Chapter 3.
Besides the issue of positive confounding with other STIs (see Chapter 3), the use of this formula in
serological studies comparing TFI with controls faces two further obstacles. First, as indicators of previous
CT infection, CT antibody tests are relatively insensitive. Their specificity is also poor, with earlier assays
showing cross-reactivity with antigens to Chlamydia pneumoniae.262,264 Even so, given estimates of
sensitivity and specificity,55 estimates of true prevalence can be recovered from observed CT prevalence in
cases and controls. Unfortunately, reliable estimates of sensitivity and specificity are not generally available.
Sensitivity can be assessed in individuals identified as infected following bacterial culture or NAATs. But a
true-negative population in which specificity can be estimated is less easy to identify: patients who are
culture negative and/or NAAT negative cannot be regarded as ‘never infected’, as they may have
experienced a CT infection which subsequently cleared.169 ‘Discrepancy analysis’, as proposed by Morre
et al.,265 is recognised to overestimate test accuracy.266,267 A better strategy to assess specificity is to take
samples from children, who would not normally be expected to have been exposed to CT. It is necessary
to choose children who old enough to have cleared maternal antibody.268,269
A further complication is that antibody levels, and hence test sensitivity, may not be the same in women
with TFI whose TFI was caused by CT and women who were previously infected but do not have TFI. There
are consistent reports of higher antibody titres in women with TFI270,271 compared with controls, including
control subjects who have been previously exposed to CT. It is believed that these high titres reflect an
inflammatory response to CT, which may, in turn, cause tubal occlusion.272 The same findings have been
reported in women with salpingitis and women with EP.88,273
The standard formula that allows estimation of the PEF from case–control studies is, therefore, not to be
relied on. For example, one study263 using a micro-immunofluorescence (MIF) assay reported antibody
prevalence in TFI cases was 72%, compared with 22%, an OR of 9.2, and an aetiological fraction of 64%.
This would imply that 64% of all TFI could be attributed to CT. The high reported prevalence in TFI cases is
sometimes attributed to false positives, but sensitivity must always be higher than observed prevalence.
For example, if we make an optimistic assumption that sensitivity is 85% and specificity 95%, the
corrected prevalences would be 90% and 21.5%, an OR of 33.4 and an aetiological fraction of 87.3%.
However, lower levels of sensitivity yield ORs and aetiological fractions that are even more extreme.
The study can be explained if it is assumed that CT antibody titre, and hence sensitivity, is higher in the
subgroup whose TFI was caused by CT. This hypothesis, suggested above, forms the basis for the
approach we have taken.
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In this chapter we propose a new way to estimate the population aetiological fraction of TFI due to CT.
The method is applied to a comparative study of antibody prevalence in TFI cases and controls, which used
three peptide-based assays and two MIF assays.274 Our re-analysis of this data set addresses the problems
attaching to equation 1: we adjust for the bias caused by imperfect sensitivity and specificity of the assays;
we take account of the especially high antibody levels in women with TFI caused by CT; and for the
confounding influence of other STIs.
We begin by setting out our approach to literature identification, and explaining the reason why have
focused attention on the Land et al. study.274 We then show how test sensitivity and specificity can be
characterised, and how properties of the tests may depend on the stage that the patient has reached in
the natural history of CT infection. We then outline how the Land et al. data274 on the prevalence of
anti-CT antibody in women with TFI and control subjects, in several tests, can be re-analysed to estimate of
the proportion of TFI that might be due to CT. Some additional analyses and technical details are given in
Appendix 16. The work in this chapter has been published previously.275
Methods
Evidence identification
We identified studies from review papers,143,261,276 from co-authors’ knowledge of the literature, and as part
of a wider review of the literature on the natural history of CT.
Although there have been many studies of CT antibody prevalence in TFI cases and controls, the statistical
modelling methods used in this paper require that the assays are used at more than one cut-off in order
to estimate the large number of parameters in the model. Only one study, by Land et al.,274 met this
requirement, using five different assays at between two and five different cut-offs. The study population,
whose age was not reported, were recruited in an infertility clinic.
Having identified this study, our method further required information on the sensitivity and specificity of
the assays used. These were the Biomérieux and Labsystems MIF assays and three peptide-based assays: the
Medac pELISA, the Savyon ELISA, and the Labsystems ELISA (ELISA, enzyme-linked immunosorbent assay).
Three studies265,268,269 were identified which provided evidence of sensitivity and specificity in these assays.
We provide analyses of test resolution based on each of these sources (see Appendix 16). However, the
estimates used in the analyses were those from Wills et al.,269 for reasons explained below (see Discussion).
Analysis of serological assay performance
We characterise test performance as follows. The resolution (R) of each test T is a fixed property of the
test, reflecting its intrinsic ability to distinguish between true positives and true negatives: high resolution
implies greater discrimination. As the threshold titre at which a sample is declared ‘positive’ is moved from
low titres to high titres, sensitivity is raised and specificity lowered. This traces out the receiver operator
characteristic (ROC) curve,277 which defines the sensitivity that is achieved for a given false-positive rate.
Resolution for test T is defined as:
RT = logit(sensivityT )− logit(1− specif icityT ) (70)
We use data on the sensitivity and specificity of a pgp-3 assay studies by Wills et al.,269 and three
peptide-based assays: the Medac pELISA, Savyon SeroCT ELISA and Labsystems ELISA. The mean RT for
these four assays was 4.1, with a SD of 0.8. The analyses on which this estimate is based are shown in
Appendix 16, along with analyses of the performance of tests described by Morre et al.265 and Narvanen
et al.268 To give an example of the relationship between resolution, sensitivity and specificity: if RT= 4.1,
and if we set sensitivity to 65%, then, from equation 70, specificity is 97%; with a sensitivity of 75%,
we obtain specificity 95.3%.
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Test sensitivity in individuals with an inflammatory reaction to
Chlamydia trachomatis
Using a whole cell immunofluorescence (WIF) assay,278 Akande et al.270 reported that in women with
antibody titres of > 64, and therefore likely to be previously exposed to CT, 84% (301/357) of those with
tubal damage had titres of ≥ 256 compared with only 43% (83/193) of those with no signs of tubal
damage (figures read from the published histogram). If the logit probability of a positive test result
increases with log titre, then these results correspond to an increase in logit (sensitivity), and hence in test
resolution of 1.96 (95% CrI 1.56 to 2.37). Similar results are found if a cut-off of 1 : 512 or 1 : 1024 is
used. This provides an estimate of the difference in sensitivity, and hence test resolution, between
those previously exposed to CT, with and without a CT-related inflammatory process: ΔSe= logit
(SeMax) – logit(SePrevious)= 1.96.
Thus, based on results from Akande et al.,270 we estimate that test sensitivity, and hence resolution, is 1.96
(95% CI 1.56 to 2.37) higher in this group than in women with previous CT but no inflammatory reaction.
For example if resolution RT= 4.1 in women who were previously infected with CT, but who have not
experienced an inflammatory reaction, it would be 4.1+ 1.96= 6.06 in women with TFI caused by CT.
This illustrates how the interpretation of sensitivity and specificity depend on the population being tested.
For example, if we take 97% as a benchmark specificity, then the sensitivity in the group whose TFI was
caused by CT would be 93%, but only 75% in CT-exposed women without an inflammatory reaction.
Analysis of a retrospective study of antibody prevalence in women with
tubal factor infertility and control subjects
In a test T, given information on its sensitivity in a control group, SeT,Previous, and a false-positive rate (FpT),
the true prevalence in the control group, π0, can be deduced from the observed prevalence pT,Controls,
via the equation:55
pT,Controls = π0⋅SeT.Previous + (1−π0)⋅FpT (71)
Here, the observed prevalence is conceived as a weighted average of true positives and false-positives,
with π0 as the weight.
The same reasoning can be applied to the prevalence in the TFI group. Their observed prevalence pT,TFI has
three components. First, a proportion π1 has been previously exposed to CT without it causing TFI. This
group has a sensitivity SeT,Previous. Second, there is a further proportion π2 of TFI cases whose TFI was caused
by CT. The sensitivity in this group is SeT,TFI. Third, the remaining 1 – π1 – π2 patients are true negatives,
and so the prevalence of antibody in this group is the false-positive rate, FpT:
PT,TFI = π1⋅SeT,Previous + π2⋅SeT,TFI + (1−π1−π2)⋅FpT (72)
We should expect that the prevalence of past CT infection in women with TFI not caused by CT is higher
than in an otherwise comparable control group of fertile women. This is because most TFI is caused by
STIs.257 Therefore, women whose TFI is caused by other infections are more likely to have been exposed to
CT. To capture this belief, we impose the constraint π1/(1 – π2)≥ π0 and rely on sensitivity analyses to assess
its impact on results.
The Land et al. study274 reports CT antibody prevalence in 51 laparoscopically verified TFI cases and 264
controls, on five different antibody tests, and at between two and five different cut-offs. The above model
is fitted to this data set as described below.
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In our base-case model, the difference ΔSe in sensitivity between SeT,Previous and SeT,TFI is assumed to be the
same for every assay. Alternative models are explored in the sensitivity analyses. We fit the model with
RT, ΔSe and π0 ranging over a wide ‘grid’ of fixed values, in a total 7 × 3 × 9 × 5= 945 combinations,
as follows:
l Test resolution RT associated with each test T, is assumed to come from a normal distribution with
means fixed at 0.5, 1.5, 2.5, 3.5, 4.5, 5.5 and 6.5, and SDs fixed at 0.5, 0.8 or 1.1. As reported above,
the mean and SD in the Wills et al. study269 (above) were 4.1 and 0.8, respectively. To give an idea of
what this range in RT would mean: with sensitivity 60%, RT= 0.5 implies 52.4% specificity, whereas
RT= 6.5 implies 99.8% specificity.
l We fixed ΔSe values at 0, 1, 2, 3, 4, 5, 6, 7 and 8. Based on Akande et al.,270 ΔSe= 1.96. Values above
3 or 4 imply sensitivity in the region of 100% at typically accepted levels of specificity.
l The prevalence of previous CT exposure, π0, i.e. the cumulative incidence, in the control group, was set
to 25%, 30%, 35%, 40% and 45%.
The parameter estimates and goodness of fit for each model were recorded.
Statistical estimation
Appendix 16 details the prior distributions, and describes methods for taking account of the uncertainty
regarding the true status of serological samples. Appendix 17 gives the WinBUGS code and data sets used
to compute the reported results.
Results
Goodness of fit of the data in the Land et al. study,274 based on residual deviance, is plotted against mean
resolution, with different values of Δse in Figure 27. In this graph, π0 has been held fixed at 0.25, and SD
at 0.8. Based on the size of the data set, a model that fits well would be expected to have a residual
deviance of 34. Residual deviance of > 40 suggests a conflict between data and model. If we adopt a
residual deviance of 40 as a maximum, the evidence in the Land et al. data suggests that values of RT of
> 3.5 and values of Δse of < 2 are implausible, although Δse= 2 is the best fitting. The poor fit obtained
when Δse= 0 or 1 provides strong support for our interpretation of Akande et al.’s results.270
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FIGURE 27 Mean residual deviance of models fitted to the Land data plotted against mean resolution of the
serological assays, showing the impact of assumptions on ΔSe, the difference in test resolution between those
exposed only to CT and those suffering an inflammatory reaction. From Price MJ, Ades AE, Welton NJ, Macleod J,
Turner K, Simms I, et al. How much tubal factor infertility is caused by chlamydia? Estimation based on serological
evidence adjusted for sensitivity and specificity. Sex Transm Dis 2012;39:608–13.275
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The estimated mean PEF (π2) is plotted against baseline prevalence of past infection in the control arm (π0)
(Figure 28). This is restricted to models with SD= 0.8 and mean residual deviance of less than 40. Also
excluded are models with a mean resolution below 2, which is unrealistically low, given Wills et al.’s
findings269 (see Appendix 16). A reasonable maximum Δse was set at 3, and this restriction was also applied.
To take account of the uncertainty in choice of model, we have applied an averaging procedure to the
Figure 28 models. This uses the smoothed residual deviance to calculate a weighted parameter estimate.279
This generates a central estimate of π2, the aetiological fraction, of 0.45, with CrI (0.28 to 0.62). Finally,
the observed prevalence in TFI cases and controls reported in the Land study is compared with the
predictions from the best-fitting model: (resolution= 2.5, Δse= 2, and π0= 25%, with residual deviance
of 34), in which the aetiological fraction was estimated to be 50% (95% CrI 37% to 60%) (Figure 29).
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factor infertility is caused by chlamydia? Estimation based on serological evidence adjusted for sensitivity and
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Sensitivity analyses
Altering the SD over the range 0.5 or 1.1 does not have a material impact on results (not shown).
Increasing π0 to 45% increased the residual deviance by around 15% at all points on Figure 27, but did
not change the overall pattern of results.
The model identified as best fitting in Figure 27 shows a systematic lack of fit. Fitted values for the control
group in this model are very close to the data, as can be seen from their proximity on the horizontal axis
(see Figure 29). For the TFI cases, the model underpredicts some of the data where the detection rates are
highest (particularly the MIF tests), but overpredicts the data where the detection rates are low (particularly
the Labsystems ELISA and the Savyon ELISA). A similar pattern is found for all sets of parameter values.
These results point to an apparent anomaly in the Land data: some tests detect more positives in the
control group than others yet identify fewer positives in the case group. One explanation is that assays
differ in which CT serovars they are sensitive to. Thus, the detection threshold can be lowered, raising the
false-positive rate without detecting any more cases. The low correlation sometimes observed between
titres on different tests may be a reflection of this.280 As a second sensitivity analysis, we performed a
post-hoc analysis in which all parameters were held at the same values, but the Labsystems and Savyon
ELISAs were able to detect only a proportion of CT cases detected by other tests. This model fitted well
(residual deviance of 25) and removed the systematic lack of fit (Figure 30). The Labsystems detected an
estimated 60% (95% CrI 42% to 82%) and the Savyon 69% (95% CrI 51% to 88%) of CT cases. The
attributable fraction was 58% (95% CrI 47% to 67%), somewhat higher than the model in the main text,
but suggesting that results are not overly sensitive to this aspect of the model assumptions.
A third sensitivity analysis explored the assumption that ΔSe was the same in all tests. Alternative models
were explored in which the mean RT is set to 2.5 or 3.5, with a between-test SD of 0.8, as in the main
analyses, but ΔSe was allowed to vary between tests with mean values set at 2 or 3 and with between-test
SD set at 1 or 1.5. The eight models all fitted well (residual deviance between 27 and 36). Estimates of the
aetiological fraction ranged from 44% (95% CrI 31% to 54%) to 51% (95% CrI 38% to 62%).
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Welton NJ, Macleod J, Turner K, Simms I, et al. How much tubal factor infertility is caused by chlamydia?
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A fourth sensitivity analysis was run to assess the impact of dropping the constraint π1/(1 – π2)≥ π0, which
builds into the models the assumption that women with TFI whose TFI is not caused by CT are likely to
have a higher probability of prior exposure to CT than control subjects. Twelve models were evaluated
(RT= 2.5, 3.5; ΔSe= 2,3; π0= 0.25, 0.35, 0.45). The aetiological fraction was between 0 and 6.3 percentage
points higher. In the four models that conformed to our criterion for goodness of fit, i.e. mean residual
deviance of < 40, the increase was between 0 and 4.3 percentage points.
Discussion
In this chapter we have derived estimates of the performance of contemporary serological assays for CT in
different populations, based on literature. This literature suggests that CT antibody levels, and with it test
sensitivity, depend on the population tested. Specifically, antibody levels – and thus sensitivity – are higher
in women with TFI caused by CT than in women whose TFI was caused by another organism, or in women
with a previous CT infection and no TFI. The model of serology induced from this evidences was used to
obtain estimates of the PEF, the proportion of TFI that is caused by CT from a published case–control study
comparing antibody prevalence in TFI cases compared with non-TFI controls.
We estimated that 45% (95% CrI 28% to 62%) of TFI cases were caused by CT. Although the CrIs are
wide, consistent results were obtained from a range of models. It was also possible to demonstrate a fair
degree of insensitivity to reasonable variation in modelling assumptions.
Our approach contrasts with the standard method of estimating PEF from ORs. Rather than control for
the positive confounding between TFI and CT that is not causally related, which would be difficult to
implement in this data set, we model the PEF directly based on assumptions about the titre distributions in
cases and controls. If we apply the standard formula to the Land data as it stands, we obtain PEF of
between 28% (95% CrI 13% to 44%) and 60% (95% CrI 37% to 78%).
The study gives us some fresh insights into the interpretation of sensitivity and specificity as typically
reported, and suggests that contemporary CT antibody assays may be less sensitive than has been
reported. The test resolution of 4.1 derived from the Wills et al. study269 would imply 71% sensitivity at
96% specificity. However, judging from our results from the Land data set, it appears that resolution is,
at best, only 3.5. This would imply, at best, 58% sensitivity at 96% specificity. Although disappointingly
low, in a population where most antibody positive women are likely to have already cleared their CT
infection, this is probably a reasonable estimate. Sensitivity is normally defined in currently infected
individuals, and antibody levels are known to decline with time since infection.281 Previous experience with
a pgp3 Indirect ELISA assay, suggested that sensitivity was 89% (95% CrI 75% to 98%) within 6 months
of infection, but no more than 64% (95% CrI 51% to 77%) 2 years after the last known infection. This is
equivalent to a 1.5-point drop in test resolution after infection has cleared.
Two further studies265,268 of test performance in peptide-based assays are re-analysed in Appendix 16.
In one study,265 a discrepancy analysis was used to examine the same three peptide-based assays and a
MIF test. We estimated an average test resolution of 5.9, possibly due to the well-recognised tendency of
discrepancy analysis to exaggerate sensitivity at a given specificity.266,267 An even higher estimate of
resolution, 6.29 (95% CI 4.84 to 8.19), was obtained from a second study of an EIA peptide assay,268
which was sponsored by its manufacturers. In this study true positives were identified using CT culture.
As this is much less sensitive than the NAAT tests used by Wills et al.269 we can expect that the
manufacturer study preferentially selected patients with more severe infections, and therefore higher
antibody levels.
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
131
We observed above that raised antibody levels have often been reported in women suffering from
complications of CT. Our analysis of the Land data decisively rejects the hypothesis that sensitivity in
women with CT-related TFI is the same as in women previous CT infection and no complications.
The analysis further suggested a 2-point difference in resolution between these groups, which is exactly
consistent with the findings from the Akande et al. study.270
We must conclude that most published estimates of CT antibody test performance lack face validity, as it
depends wholly on the criteria and method for patient selection. Among the critical factors are: current
infection versus previous infection; NAAT versus culture to identify true positives; methodology to identify
true negatives; and inclusion versus exclusion of women with an inflammatory response to CT. This tells us
that, although the development of assays with superior performance must be welcome, methods for
characterising test performance should perhaps be given even higher priority.
Limitations of the analysis
The study has relied on a series of assumptions about parameter values. Although we have done as much
as possible to justify these values and base them on published literature, further systematic study is
needed. The final estimate of the PEF emerging from our study (45%, 95% CrI 28% to 62%) has wide
credible limits, reflecting, in part, the uncertainty about parameter values and modelling assumptions.
Even so, we suspect that other assumptions and other models could be found to fit these data, so the
uncertainty in the estimate may yet be understated.
A second set of limitations relate to the extent to which the results generalise to the UK situation. As
noted in earlier chapters, estimates of PEF are specific to time and place, and it is not known how close
the spectrum of infections leading to salpingitis in the Netherlands and the UK might be. Given the decline
in the CT PEF estimates in PID (see Chapter 8), in projecting the results to the UK we must certainly take
into account the age of the women recruited into the Land study. The authors do not report an age range,
but as the study was based in an infertility clinic, we can infer that, on average, women would be older
than typical pregnant women, and the majority would be aged > 24 years.
A further concern about generalisability relates to the specific selection procedures in the Land study. The
authors reported that MIF titres were assessed at the first visit and were used to assess TFI risk. Those with
titres of > 64 had laparoscopy to establish TFI status, whereas others received laparoscopy only after a
positive result on hysterosalpingography. This may have induced a reduced probability of recruiting TFI
cases with low titres. Similarly, the laparoscopic criteria for a diagnosis of TFI was selected on the basis that
it had been shown previously to ‘reflect chlamydia-related tubal disease most accurately’. The authors
noted that selection and verification biases were difficult to avoid and that likelihood ratios would be
overestimated by the procedures followed. It is not clear how the extent of the upwards bias in PEF
estimates can be assessed.
Looking to the future, the study suggests that a greater role for direct modelling of the distributions of
titres in TFI or EP cases compared with carefully chosen controls. This could be invaluable both in
aetiological studies of CT and its sequelae, and in surveillance of CT for purposes of prevention and
control. Serology could help assess the impact of public health interventions, including the NCSP, to
reduce the population burden of genital CT.264 The possibility that serology could improve our estimates of
the burden of CT, and contribute to understanding its natural history,38,98 will be taken up later in the
research recommendations.
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Summary of assumptions and findings
Summary of assumptions and limitations
1. TFI caused by CT is associated with higher serum antibody levels than previous CT infection not leading
to TFI.
2. Sensitivity of CT antibody tests depends on the stage of CT natural history.
3. It is not known how closely the proportion of TFI attributable to CT (PEF) in the Netherlands
approximates the PEF in the UK.
Summary of findings
1. High CT titres are associated with TFI.
2. CT titres can be used to estimate the proportion of TFI attributable to CT.
3. The estimated PEF from the Land study is 45% (95% CrI 28% to 62%).
This estimate relates primarily to women aged > 24 years, and, in view of the age gradients reported in
Chapters 7 and 10, would be likely to be an underestimate of the PEF for the female population aged
16–24 years.
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Chapter 12 Summary and conclusions
Objectives
To:
1. identify and, if necessary, reconcile inconsistencies in the results presented in previous chapters
2. summarise the additional risks of poor reproductive outcomes following from CT infection in
individual women
3. summarise the public health significance of the research
4. identify remaining areas of uncertainty and make research recommendations to address them.
Introduction
In this final chapter we review the results of previous chapters, and ask whether or not, when everything is
put together, this programme of work has generated a consistent picture of the clinical epidemiology of
CT and its sequelae in the UK, as it was in 2002. We then consider what further assumptions are needed
to reconcile inconsistencies that remain.
Having proposed what we regard as the most plausible overall model, consistent with all sources of
evidence, we then set out the implications for individual women and for public health. We include some
brief comments summarising the contribution of this report to the study of the clinical and population
epidemiology of chlamydia, and the role of the MPES methodology. We conclude by proposing research
recommendations, based on our judgement of the key areas of uncertainty and the research designs that
have the best chance of decreasing the uncertainty in policy-sensitive parameters.
Summary of findings from previous chapters
Chlamydia trachomatis and pelvic inflammatory disease
Chapters 4–7 provided a comprehensive account of the CT incidence, prevalence and duration, the
proportion of CT that is symptomatic, the incidence of diagnosed ‘probable/definite’ PID and total PID
(diagnosed and undiagnosed), the CT-to-PID progression risk, and the proportion of PID attributable to CT.
Summary
The main results were as follows (see chapter summaries for more detailed quantitative results):
1. The extreme heterogeneity of results in studies of CT duration could be effectively explained by
(1) distinguishing screening studies of prevalent infection from clinic studies of incident infection
and (2) assuming that a proportion of infections are ‘passive’, which accords with existing biological
understanding of infection (see Chapter 2).
2. The estimate of duration is consistent with independent sources of evidence on age-specific CT
incidence in the UK, age-specific CT prevalence in the UK, and the proportion of infections that
are asymptomatic.
3. We derived an estimate of the CT-to-PID progression risk from CT screening trials. This was based on a
Markov model that allowed for CT clearance as a ‘competing risk’. Trials of different designs gave consistent
results, with a pooled estimate of the CT-to-clinical PID risk of 14.8% (95% CrI 4.8% to 24.8%).
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4. We interpret this progression risk as representative of a level of ascertainment of PID that can be
expected to be seen in prospective studies of women at risk of PID. The risk of progression to all PID,
including symptomatic and asymptomatic, is 17.1% (95% CrI 5.6% to 29%).
5. Two independent sources of evidence on the incidence of clinical PID were derived: one from the
control arm of the POPI trial19 taking into account the degree of ascertainment expected in prospective
studies, the other from routine GPRD, HES and KC-60 data, taking account of overlap, and of
independent data on the proportion diagnosed. The two sources were in agreement, and a pooled
incidence of PID is 2.5% per year in women aged 16–24 years, and 1.8% per year in women age
16–44 years.
6. If age-specific CT incidence, age-specific PID incidence and CT-to-clinical PID progression risk are put
together, assuming progression risk is independent of age, we predict that the proportion of clinical PID
attributable to CT is 35% in the 16–24 years age group, and 20% overall (age 16–44 years).
7. These predictions of the PEF are in agreement with (a) estimates based on retrospective studies of CT
infection in PID cases and controls, corrected for under-ascertainment of infection in cases, and
(b) estimates based directly on the POPI trial corrected for independent testing in the control group.
However, there is considerable uncertainty in all these estimates.
In our analysis of the PEF there was an element of post-hoc reasoning: this arose from conflicts between
our initial estimates and results of later chapters (see Chapter 7 discussion).
Clinical pelvic inflammatory disease, salpingitis, ectopic pregnancy and tubal
factor infertility
Chapter 8 developed estimates of the proportion of women who have experienced PID, salpingitis and
subsequent episodes of PID in the UK. In Chapters 9 and 10, the risks of EP and TFI in women with
salpingitis that were observed in the Lund study were then applied to these risk factor distributions to
predict the risk of EP per pregnancy and the prevalence of TFI in the UK. Chapter 11 reports an estimate
of the PEF (CT←TFI) based on analyses of serological data. More detailed results appear in the
chapter summaries.
Summary
1. The proportion of ‘probable/definite’ PID in which salpingitis can be confirmed on laparoscopy is
estimated to be 43%.
2. An estimated 16.1% of 35- to 44-year-old women have experienced at least one episode
of salpingitis.
3. Based on HES data, the rate of ectopic pregnancies as a proportion of pregnancies rises with age and
averages 1.1% in women aged 16–44 years.
4. Based on UK fertility surveys, 1.1% of women aged 44 years have TFI (including both primary and
secondary infertility).
5. Of EPs, 27% are due to salpingitis, based on French case–control studies.
6. Of EPs, 4.9% are due to CT.
7. Given our core assumptions, the observed EP incidence in the UK is compatible with the Lund study if
it is assumed that salpingitis in those whose PID is not diagnosed in hospital has the same risk of EP as
was observed in those with ‘mild’ salpingitis, and that undiagnosed salpingitis carried no risk of EP.
8. Given our core assumptions, the observed TFI prevalence in the UK is compatible with the Lund study
if it is assumed that the risk of TFI following salpingitis is the same as, or slightly less than, the
average risk observed in the Lund study, in which the salpingitis is associated with diagnosed or
undiagnosed PID.
9. Based on our analysis of the proportion of salpingitis due to CT and the relation between salpingitis
and TFI, 29% of TFI is due to CT.
10. In an analysis of retrospective serological data collected from women attending an infertility clinic in
the Netherlands, 45% (95% CrI 28% to 62%) of TFI was due to CT.
SUMMARY AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
Conflicts in the overall evidence and their resolution
Two clear points of conflict emerge in the evidence presented in the report:
1. The models that correctly predict the risk of TFI following salpingitis seriously over-predict the risk of EP
following salpingitis.
2. The two estimates of the proportion of TFI due to CT are inconsistent, one based on our prospective
analysis of salpingitis and TFI, the other on retrospective serological data.
Ectopic pregnancy and tubal factor infertility
It is important to note that, to the extent that we are correct in assuming that salpingitis-related
reproductive damage represents a single common pathway to EP and TFI, the conflict between prediction
for EP incidence per pregnancy and TFI prevalence is largely independent of the way we have analysed the
Lund data on EP and TFI, and also of our analyses of the incidence of PID, the cumulative incidence of PID,
the relation between clinical PID and salpingitis, and the role of undiagnosed PID. Whatever the precise
truth about these factors, they should be operating the same way in EP as in TFI.
One major difference between EP and TFI in this context is that salpingitis is not the only cause of EP,
but it is virtually the only cause of TFI.35 As a result, the Lund study findings for EP are more vulnerable to
confounding, whereas those on TFI are not. One well-recognised confounding factor is smoking, which is
likely to have been more prevalent in women with more exposure to STIs. A second possible confounder
is IUD use. The role of the earlier IUDs in the aetiology of EP is not entirely clear. Chavkin282 reviews
mechanisms that could generate a positive confounding effect. First, it is likely that IUDs are highly
effective in preventing uterine implantation, but much less effective at preventing tubal implantation, so
that women with IUD are selectively more likely to experience an EP. However, this does not explain why
no increased risk of EP was observed in the Lund study in women with IUDs but without salpingitis.110
A second possibility is that the older-generation non-medical IUDs were associated with some form of
non-bacterial salpingitis that raises the risk of EP in the absence of any infective mechanism. This seems to
be ruled out by the observation that women with no visible infection on laparoscopy did not have elevated
risks of EP or TFI.283
A third proposal was that the presence of an IUD could have raised the risk of PID-associated EP. On this
model, IUD is not so much a confounder as a risk-modifier. Based on changes in salpingitis exposure and
changes in IUD exposure, the Lund investigators themselves attributed a high proportion of the observed
doubling in EP rates during the course of their study to an increase in IUD use.110 It is likely, indeed, that
the Lund study could even have underestimated the role of IUDs, because the pain and discomfort
associated with PID and IUDs can be similar, and many IUDs could have been removed prior to entry to
the study.
It is unlikely that further study will resolve this issue, because the IUDs used during that period have been
replaced by medicated IUDs, which are much less likely to cause problems.77,114 We can, therefore, only
offer the suggestion that the EP progression rates in the Lund study may be greatly overestimated through
the presence of confounders, such as smoking, or effect modifiers, such IUD use. As there seems to be no
way of estimating the extent of this bias independently, in coming to final conclusions we will effectively
discount the prospective Lund data on EP risk entirely, and accept salpingitis-related EP rates based on the
PEF from the retrospective French studies applied to the observed HES data, which give between 0.24%
and 0.37% of all conceptions as salpingitis-related EPs.
We note again that this estimate is based on a post-hoc re-interpretation of the evidence, after
examination of other results, and therefore requires independent confirmation.
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Causal role of Chlamydia trachomatis in tubal factor infertility
The applicability of the PEF from the serological data from the Netherlands to the UK must be considered
doubtful. This is not so much because of the uncertain relevance to the UK of evidence from the
Netherlands, but, more seriously, because the study authors explicitly warn of the high risk of verification
and selection biases in the study, which would artificially raise the PEF (see discussion in Chapter 11).
We therefore proceed with the lower estimates based on the Chapter 10 analyses – 29% in women aged
16–44 years – but note once again a post-hoc element to this decision.
Final set of coherent estimates
A set of coherent estimates for the parameters covered in Chapters 5–7 was provided in those chapters.
The retrospective estimates on EP (see Chapter 9) and the prospective estimates on TFI (see Chapter 10)
are also technically coherent with estimates from earlier chapters, as they are based on estimates of
salpingitis prevalence from Chapter 8, which are based on forward simulation from the estimates in
Chapters 5–7, and there is no feedback of the evidence on EP and TFI back on to these earlier parameters.
Future investigators citing or using the marginal results directly from the tables included throughout the
report are accessing a fully coherent set of estimates. However, these summaries are insufficient to
characterise the full joint distribution of the parameters, as they do not express the correlations between
parameters. Investigators using our results in ways that take uncertainty into account should therefore
obtain the joint parameter distributions by running the WinBUGs code in the appendices.
Significance for patient, clinicians and public health
Summary outcomes and contribution of Chlamydia trachomatis in
the population
Table 42 gives an impression of the numbers of PID, EP and TFI outcomes that occur in England each year,
and the numbers attributable to CT, based on our estimates of PEF in previous chapters. Based on our
estimate that the incidence of CT in women aged 16–44 is 2.1 per 100 person-years (see Chapter 7), we
can use the information in Table 42 on the numbers of sequelae attributable to CT, to calculate the risk of
sequelae following CT infection. Every 1000 CT infections on average give rise to approximately 171 PID
episodes, 73 salpingitis episodes, 2.0 EPs, and 5.1 women with TFI by age 44.
Public health implications
We have estimated in Chapter 7 that that only 12.6% of PID is asymptomatic, although a much higher
proportion is undiagnosed in practice. These findings require confirmation from large contemporary
studies, but, if accepted, they have the important public health implication that, in women who are aware
of the risk of PID and aware of the symptoms, few PID episodes will be missed. This suggests that much
could be gained from improved public understanding of signs and symptoms that should lead women to
seek early medical attention to avoid the risk of reproductive damage.
Our findings do not suggest any changes to current guidelines on diagnosis and management of PID,
which advise early treatment with broad-spectrum antibiotics. However, there is a degree of ambiguity and
inconsistency in current UK guidance, which focuses on younger women and possibly overemphasises the
role of STIs (see Chapter 2). It is relevant, here, that our analyses of PID incidence in Chapter 7 suggest that
about 63% of PID occurs in women aged > 25 years.
Although the trial evidence demonstrates that treating prevalent asymptomatic CT infection is effective in
preventing clinical PID, we estimated that, at best, a woman aged 16–24 years undergoing screening at
annual intervals would on average prevent only 61% of CT-related PID. Given our analysis of the
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proportion of PID that can be attributed to CT, it appears that annual screening would directly prevent no
more than 22% (95% CrI 7% to 43%) of all-cause PID in this age range.
Although our estimates of the risks of PID and salpingitis are high compared with previous estimates, this
assessment of the benefits of annual testing to individual women is relatively pessimistic. Taken together,
the findings suggest that greater benefit to individual women could be achieved by increased attention to
incident infection, in other words a greater focus on women at an increased risk of recent exposure, as is
the intention of current policy that advises screening after partner change, and re-screening 3 months after
a diagnosis (acknowledging a high risk of re-infection). This could also suggest testing women following
unprotected sex with a high-risk partner. Such strategies should have a higher yield, in terms of the
number of infections detected per test carried out, and should also increase the chance that treatment
would prevent the development of PID. This also fits well with an integrated public health approach to all
STIs (chlamydia, gonorrhoea, human immunodeficiency virus (HIV), syphilis, genital herpes, genital warts
and trichomonas) in the general population, with an emphasis both on prevention and on the early
detection of infection and treatment, and effective management strategies to reduce onwards
transmission, for example through rapid partner notification.284
The study has also clarified both the incidence of PID and the risks PID poses to reproductive health. These
may be greater than has been appreciated. We have estimated a relatively high incidence of PID in women
aged 16–44 years, 1.8% per year, of which 66% undiagnosed. But we have also shown that it is difficult
to explain the UK prevalence of TFI, unless it is assumed that the risk of salpingitis is the similar in
diagnosed and undiagnosed PID and that salpingitis, whether diagnosed or not, carries a similar risk of
TFI – at, or close to – the level of risk reported in the Lund study.
It has been suggested, based on a systematic review of prospective studies, that there is no evidence for a
causal link between CT and TFI.145 Our estimate is that 29% of TFI is due to CT. Although the CrIs on this
estimate are wide (95% CrI 9% to 56%), it derives from our estimates of the proportion of PID due to CT.
In addition, although it is difficult to obtain reliable quantitative estimates of the PEF from serological and
microbiological studies, an extensive body of literature, some of which is cited in Chapter 2, as well as our
analyses in Chapter 11, confirms that CT is strongly implicated in TFI.
Effective commissioning of interventions and services is key to improving outcomes. Most sexual health
services will be commissioned by local authorities, but Clinical Commissioning Groups (CCGs) and the NHS
Commissioning Board (NHS CB) will also have a role.
Priorities for future research
It is possible to envisage more randomised studies of screening, perhaps involving different populations,
infection ascertainment, treatment or partner-tracing methods. However, there is little realistic foreseeable
prospect of interpretable comparative studies following CT infection to longer-term outcomes. The
obligation to treat CT infection makes non-randomised designs, including linked register studies, virtually
uninterpretable. In addition, the extended follow-up required to assess reproductive outcomes inevitably
leads to dilution of the effects, as a proportion of women in both comparison groups will seek testing and
treatment independently, acquire subsequent CT infections, and experience episodes of PID.
In view of the difficulties associated with prospective studies, we outline, below, a series of relatively easy
to conduct field studies based on routine health service activity. Further dynamic modelling using a MPES
approach is also required to assess the cost-effectiveness of the NCSP as currently configured, extensions
to it, and other chlamydia preventive measures.
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Serological case–control studies and the age profiles of Chlamydia trachomatis,
pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility
Serological case–control studies were popular over 20 years ago, when they were used to throw light on
the aetiology of these conditions; there was also an interest in using CT serology in treatment decisions.
On a few occasions they have been used to estimate a PEF.
These studies fell out of favour because of the poor sensitivity and specificity of the assays, and also
because these properties were difficult to characterise. However, better performing assays are now
available, and there is better information on their performance characteristics. More recent assays have
high specificity,269 and the relation between the measured ‘sensitivity’ and the time since the infection is
better understood.281
A number of investigators have reported that exceptionally high CT antibody titres can be found in a
proportion of women with PID, EP or TFI,88,270,271,273,285 with many studies reporting a clearly bimodal
distribution of positive titres. These high titres have been attributed to an upper genital tract inflammatory
response.61,113 Using finite mixture models,286 it would be possible to draw conclusions about the
proportion of PID, EP and TFI cases that can be associated with these high CT titres. Given suitable control
samples, and assuming that the high titres are indicative of causation, this form of analysis could provide
direct estimates of PEF for CT.
Such studies could also be used to explore other assumptions made in this report. First, they could confirm
or disconfirm whether the age profile of the PEFs accord with the predictions in this report. Variation with
age in the proportion of PID, salpingitis, EP and TFI that is due to CT, is of considerable scientific interest
and public health importance. Second, information could be collected on sexual and reproductive history,
referral pathways, and, particularly, on previous clinical PID and previously unreported related symptoms.
This could improve our quantification of all-cause PID through routine data, and the level of completeness
of ascertainment that is achieved in trials. The study on which our estimates are based had only 36 TFI
cases.103 Possible risk factors for salpingitis, such as IUD use, could also be re-examined. Finally,
microbiological evidence,287 as well as our own analyses of the proportion of PID attributable to CT,
suggests that the majority of PID is not due to CT. Possibly, these non-CT causes of PID become
progressively more important with age. If this can be confirmed in microbiological studies, this would add
further to our understanding of the aetiology of salpingitis (see Chapter 2).
A relatively simple and inexpensive series of case–control studies could, therefore, provide a great deal of
information about the incidence of undiagnosed PID, the role of CT in diagnosed and undiagnosed PID,
the role of CT in EP and TFI, and how that role depends on age. If this is successful, a set of sentinel clinics
could be established for each of these surveys, providing a stable platform for ongoing surveillance of
trends in PEF of CT, to be considered alongside surveillance of trends in overall EP and TFI rates.
Dynamic modelling
This report has focused on the risks of CT in downstream PID, salpingitis, EP and TFI. It has also touched
on the role of screening in prevention of PID. The focus has therefore been on the reproductive risks to the
individual women exposed to CT infection and the benefits of screening. The other objective of screening
is to lower CT prevalence, and therefore incidence, to reduce the number of CT infections and
downstream complications in the wider population.
Further dynamic modelling is now required, incorporating the new information on natural history that has
been reported in this study, in order to fully assess the potential role for screening, as implemented in the
NSCP, or in other ways. There is a wide consensus that the cost-effectiveness of screening is strongly
determined by the risk of downstream illness and reproductive damage,1,2 and this is relevant to both the
individual and the population motivations for screening. The new information contained in this report is
therefore critical to new modelling exercises in the UK.
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At the same time, it is evident that the methodology of dynamic modelling needs itself to be developed
further using MPES. This will enable more evidence to be incorporated into the models, and will allow the
consistency of the evidence sources to be evaluated.
A distinction is often made between ‘mathematical’ models, which make predictions about long-term
changes in incidence and prevalence, based on estimates previously derived from ‘statistical’ models of
data,288 suggesting a two-stage approach. However, in a multi-parameter evidence synthesis, the same
mathematical models are estimated from the available data in a single step, but in a way that allows
proper statistical inference and uncertainty propagation. In MPES there is no artificial distinction between
evidence sources that are seen as model ‘outputs’ and those that are considered model ‘inputs’ in the
standard mathematical modelling literature, or between data used for model ‘calibration’ and data used to
estimate ‘predictions’. These distinctions inevitably lead to failure to incorporate all the evidence.
Fundamentally, the MPES framework ensures that the (mathematical) model that generates the predictions
is exactly the same model that generates the evidence. Once a certain level of complexity is reached, this
cannot be achieved by a two-stage approach (see Chapter 6).
Although there are technical difficulties in applying the MPES methodology in infectious disease dynamic
modelling, there are already case studies that establish its feasibility.289,290 However, combination of
infectious disease transmission dynamics with sexual network dynamics raises computational challenges,
and the development of other methods of Bayesian computation besides, or in addition to, MCMC has
become an active area of research.291
Contribution of this report
Many of the estimates in this report are similar to estimates that have appeared previously in the literature.
Others, such as the estimates of the proportion of the population exposed to salpingitis, the consequent
risks of EP and TFI, and the proportion of these outcomes that can be attributed to CT, have been based
on new methods and new types of evidence, or have not been attempted at all. Of greater significance
than the individual estimates, however, is the fact that, taken together, they form a coherent and internally
consistent set of estimates which are at the same time consistent with an extensive and multifaceted body
of evidence, including routinely collected statistics on PID, EP and TFI.
The parameters estimates are, in many cases, imprecise, but they have been estimated with as much
precision as the evidence allows. Unlike previous estimates, the evidence base for each parameter has
been explicitly delineated and, wherever possible, cross-validated against other sources of evidence. In the
course of the project, inconsistencies between sources of evidence have been revealed, making it
inevitable that evidence must be re-interpreted in order for inconsistencies to be reconciled. Where we
have resorted to post-hoc reasoning of this sort, this has been made clear. Readers can judge for
themselves whether or not they find the arguments convincing, and whether they can find alternative,
perhaps more plausible, sets of assumptions and interpretations under which coherent sets of estimates
can be obtained.
A key part of the research programme has been the use of MPES, which allows users to combine
information provided in different epidemiological studies which inform different functions of the same
underlying set of parameters. This permits us to include more kinds of evidence in each set of estimates,
and to check consistency of different kinds of evidence, and to propagate uncertainty in evidence correctly
through the model.
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Even so, although the use of MPES methods in the report has required some sophisticated modelling,
much of the intellectual content of the report has gone into understanding the relationships between the
target parameters and what the studies are actually estimating, and to understanding the biases to which
the key study designs are vulnerable. The major contribution of the report may, in fact, not be in the
estimates, nor even in their coherence, but in the consistent set of interpretations we have proposed for all
of the various study designs discussed in the report. These are expressed in the DAGs appearing in each
chapter, which make explicit the relationship between what each study estimates and the parameters
of interest.
No doubt, future investigators will be able to improve on these characterisations, perhaps based on a
better understanding of the same evidence, or perhaps on new evidence. However, we have shown, for
the first time, that the clinical and population epidemiology of CT can be effectively studied by developing
a formal and explicit analysis of the data-generating mechanisms in the many study designs
contributing information.
Summary of findings
1. Two areas of conflict in the work from earlier chapters were identified, and both were resolved by
post-hoc re-interpretations of evidence sources and potential biases.
i. A final estimate of the risk of EP following salpingitis is based on the UK reported rates, multiplied
into an estimate of the proportion of EP due to salpingitis, from case–control studies.
ii. A final estimate of the proportion of TFI attributable to CT, 29%, is derived from our
prospective analysis.
2. The public health messages were:
i. In women aged 16–24 years, annual screening can directly prevent at best 61% of CT-related PID,
and 22% of all-cause PID.
ii. Current guidance for diagnosis and management of PID should not be changed.
iii. Guidance is required on when women should seek early medical attention to avoid the risk of
reproductive damage.
iv. CT carries a significant risk of reproductive damage, particularly TFI. Every 1000 CT infections in
women aged 16–44 years, on average, gives rise to approximately 171 episodes of PID and 73 of
salpingitis, 2.0 EPs and 5.1 women with TFI at age 44.
3. Research recommendations:
i. Serological case–control studies are needed to estimate the proportions of PID, EP and TFI that are
caused by CT.
ii. The same studies could provide information on the relation between age and PEF, on the proportion
of PID that is diagnosed, and on the microbiological basis of salpingitis. They would also allow better
quantification of the overlap between routine data sources on PID, leading to better estimates of
PID incidence.
iii. Further dynamic modelling should be undertaken, using the estimates of the sequelae of CT
infection from this report, to assess whether or not CT screening is cost-effective. This should use a
MPES approach to uncertainty propagation and inference, which may require development of new
methods of Bayesian computation.
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Appendix 1 Mean duration of follow-up in
the Chlamydia trachomatis duration studies
(see Chapter 4)
This appendix gives details of how mean duration of follow-up was estimated for the studies in Table 4when it was not specified in the original publication.
l Johannisson et al.183 report a group of patients followed up after 5–8 weeks and we assume a mean
follow-up of (5+ 8)/2= 6.5 weeks.
l For the study by Joyner et al.,79 the centres of the reported ranges are used except for the last
observation were we use the geometric mean= 100 days.
l Geisler et al.73 report a median follow-up of 13 days, with a range of 4–59 days. The distribution is
skewed but is approximately symmetrical on the log scale. If µ and σ are, respectively, the mean and SD
of the natural log of the follow-up time then the mean follow-up is exp(µ+ σ2/2). We estimate σ as
being one-quarter of the range and µ is the natural log of the reported median follow-up.
l Sorensen et al.185 report a median of 11 months and a range of 2–24 months. This distribution is nearly
symmetrical. The mean is estimated as [11+ (24+ 2)/2]/2= 12 months.
l McCormack et al.186 reported a follow-up of 16–17 months, so we assume a mean follow-up of
16.5 months.
l Sheffield et al.181 report that patients were examined 16–23 weeks into pregnancy and a second time
at 24–29 weeks into pregnancy. In total, 52 out of 140 were followed up for < 5 weeks. The minimum
follow-up is therefore 24 – 23= 1 week and the maximum follow-up is 29 – 16= 13 weeks. We assume
that the first group were followed for 3 weeks, and the second group for 9 weeks.
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Appendix 2 WinBUGS code and data for the
two-rate model (see Chapter 4)
WinBUGS code and Data for the 2-rate model
model {
# likelihood
for (i in 1:studnum) {
for (j in 1:studobs[i]) {
r[i,j] ~ dbin(theta[i,j],n[i,j])
}
}
# model
for (i in 1:studnum-2) {
for (j in 1:studobs[i]) {
theta[i,j] <- ((z[i,j] / n[i,j]) * (1 - exp(-lambda.C[1] * t[i,j])) 
+ (1 - (z[i,j] / n[i,j])) * (1 - exp(-lambda.C[2]
* t[i,j])))
/ (psi / (1 - ((1-psi) * equals(seind[i,j],0))))
}
}
# Left-truncated studies with repeat observations
for (i in 8:9) {
for (j in 1:studobs[i]) {
temp[i,j,1] <- ((z[i,1] / n[i,1]) * exp(-lambda.C[1] * T[i,j]) / 
((z[j,1] / n[i,1]) * exp(-lambda.C[1] * T[i,j]) + 
(1 - (z[i,1] / n[i,1])) * exp(-lambda.C[2] * 
T[i,j]))) *
(1 - exp(-lambda.C[1] * t[i,j]))
temp[i,j,2] <- ((1 - (z[i,j] / n[i,1])) * exp(-lambda.C[2] * 
T[i,j]) / 
(0.00001+(z[i,1] / n[i,1]) * exp(-lambda.C[1] * 
T[i,j]) + 
(1 - (z[i,1] / n[i,1])) * exp(-lambda.C[2] * 
T[i,j]))) *
(1 - exp(-lambda.C[2] * t[i,j]))
theta[i,j] <- (temp[i,j,1] + temp[i,j,2]) /
(psi / (1 - ((1-psi) * equals(seind[i,j],0))))
}
}
# priors
p1 ~ dbeta(1,1)
lambda.C[1] <- 120
lambda.C[2] ~ dexp(0.001)
psi ~ dbeta(78,8) #sensitivity of culture given initial positive
# culture
# Class proportions
# t=0 studies
for (i in 1:4) {
for (j in 1:studobs[i]) {
z[i,j] ~ dbin(p1,n[i,j]) # start at t=0
}
}
# Left-truncated studys
for (i in 5:studnum) {
for (j in 1:studobs[i]) {
z[i,j] ~ dbin(w1,n[i,j]) 
}
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}# deviance
for (i in 1:studnum) {
for (j in 1:studobs[i]) {
dev[i,j] <- 2 * (r[i,j] * log(r[i,j] / (theta[i,j] * n[i,j])) +
(n[i,j] - r[i,j]) * log((n[i,j] - r[i,j]) /
(n[i,j] - (n[i,j] * theta[i,j]))))
}
dev.stud[i] <- sum(dev[i,1:studobs[i]])
}
sumdev <- sum(dev.stud[])
# left truncation
w1 <- (p1 / lambda.C[1]) / (p1 / lambda.C[1] + (1 - p1) / 
lambda.C[2])
# summary statistics
dur <- 1 / lambda.C[2]
# Predicted values for Forest plot
for (i in 1:studnum) {
for (j in 1:studobs[i]) {
stud.lambda.Cexpect[i,j] <- -log(1 - theta[i,j]) / t[i,j]
stud.dur.expect[i,j] <- 1 / stud.lambda.Cexpect[i,j]
}
}
}
# Data
list(
# duration
# study order
# 1 Johhanisson
# 2 Joyner
# 3 Geisler
# 4 Paavonen
# 5 Rahm
# 6 Sorensen
# 7 McCormack
# 8 Morre
# 9 Mollano
r = structure(.Data=c(
10,7,6,6,NA,
2,7,1,0,3,
23,NA,NA,NA,NA,
3,NA,NA,NA,NA,
17,0,0,NA,NA,
8,NA,NA,NA,NA,
3,NA,NA,NA,NA,
2,2,4,0,2,
44,23,7,2,NA
),.Dim=c(9,5)),
n = structure(.Data=c(
23,14,14,8,NA,
12,28,4,8,6,
129,NA,NA,NA,NA,
15,NA,NA,NA,NA,
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93,1,1,NA,NA,
13,NA,NA,NA,NA,
7,NA,NA,NA,NA,
20,5,15,1,13,
82,37,14,6,NA
),.Dim=c(9,5)),
t=structure(.Data=c(
0.038,0.058,0.077,0.125,NA,
0.012,0.03,0.049,0.088,0.274,
0.045,NA,NA,NA,NA,
0.083,NA,NA,NA,NA,
0.25,0.5,0.75,NA,NA,
1,NA,NA,NA,NA,
1.375,NA,NA,NA,NA,
0.083,0.5,0.417,0.917,0.5,
1,1,1,1,NA
),.Dim=c(9,5)),
seind = structure(.Data=c(
1,1,1,1,NA,
0,0,0,0,0,
0,NA,NA,NA,NA,
1,NA,NA,NA,NA,
1,1,1,NA,NA,
0,NA,NA,NA,NA,
1,NA,NA,NA,NA,
0,0,0,0,0,
0,0,0,0,NA
),.Dim=c(9,5)),
T=structure(.Data=c(
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
NA,NA,NA,NA,NA,
0,0,0.083,0.083,0.5,
0,1,2,3,NA
),.Dim=c(9,5)),
studnum = 9,
studobs = c(4,5,1,1,3,1,1,5,4),
)
# Initial values - 1
list(
psi = 0.9,
lambda.C = c(NA,0.7),
p1 = 0.2,
)
# Initial values - 2
list(
psi = 0.6,
lambda.C = c(NA,0.1),
p1 = 0.5
)
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Appendix 3 Assessment of statistical modelling
assumptions in Chapter 5
Appendix 5.1: Regression analysis of the LaMontagne data
We fit the following nine regression models to the 18 data points from the LaMontagne study192 shown in
Table 9:
l Model 1 log(λa,s,i)= α+ γa+ ρs+ ηi+ γρas+ γηai+ ρηsi+ γρηasi
l Model 2 log(λa,s,i)= α+ γa+ ρs+ ηi+ γρas+ γηai+ ρηsi
l Model 3 log(λa,s,i)= α+ γa+ ρs+ ηi+ γηai+ ρηsi
l Model 4 log(λa,s,i)= α+ γa+ ρs+ ηi+ γρas+ ρηsi
l Model 5 log(λa,s,i)= α+ γa+ ρs+ ηi+ γρas+ γηai
l Model 6 log(λa,s,i)= α+ γa+ ρs+ ηi+ γρas
l Model 7 log(λa,s,i)= α+ γa+ ρs+ ηi+ γηai
l Model 8 log(λa,s,i)= α+ γa+ ρs+ ηi+ ρηsi
l Model 9 log(λa,s,i)= α+ γa+ ρs+ ηi,
where γ1, ρ1, η1, γρa1, γρ1s, γηai, γη1i, ρηs1, ρηl1, γρηas1, γρηa1i, γρη1si= 0; γρas represents an interaction between
age and setting, γηai between age and reinfection, ρηsi between setting and reinfection, and γρηasi is a
three-way interaction between age, setting and re-infection.
The estimates of λa,s,i along with estimates of duration are used to estimate κ(t)a,s,i, which is the parameter
in the likelihood function for the LaMontagne data192 (see Figure 8, DAG). Model fit statistics together with
the nominal numbers of parameters for each model are shown in Table 43. Results are based on two
chains, run for 40,000 samples after a 10,000 burn-in. The results show that Model 8, which includes only
the main effects and an interaction between setting and infection/re-infection status has the lowest DIC
(see Chapter 3). A plot of the deviance residuals for Model 8 revealed no evidence of a systematic bad fit.
Model 8 is identical to the one described in the main text, although it has been re-parameterised slightly
to simplify the notation. It is only marginally better in terms of DIC than a model that also includes an
interaction between age and setting (Model 4) or a model that assumes no interactions (Model 9).
TABLE 43 Model fit statistics for each of the regression models fitted to infection and re-infection data, Chapter 5
Model Residual deviance Nominal no. of parameters DIC pD
1 18.6 18 103.2 17.9
2 15.8 14 96.2 13.2
3 19.0 10 95.8 10.1
4 14.5 12 93.1 11.9
5 22.6 12 101.1 11.9
6 21.1 10 97.7 10.0
7 24.1 8 98.9 8.0
8 17.3 8 91.9 8.0
9 22.3 6 95.0 6.0
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Appendix 5.2: assumed relationship between setting-specific
odds ratios from Adams and hazard ratios in the model for the
LaMontagne data
We assume that the between-setting ORs are equivalent to between-setting RRs because of the rare
disease assumption, and that these inform the between-setting HRs in the LaMontagne study.192 This is not
strictly correct, as they should inform the between-setting incidence ratios.
We assess the sensitivity of the results to this assumption. Table 44 shows the between-setting infection
ratios (column 1), FOI ratios (column 2) and incidence ratios (column 3) estimated from the LaMontagne
data192 alone. The corresponding results from Adams et al.106 (introduced in Table 11) are repeated in
column 4. The infection ratios from LaMontagne et al.192 are almost identical to the ORs from Adams
et al.106 However, this is not a reason to conclude that our model is better than the ‘correct’ model, where
they inform incidence ratios. There is some discrepancy between the infection ratios compared with the
incidence or FOI ratios. The FOI and incidence ratios are almost identical.
Because of the lack of data for the general population in LaMontagne et al.,192 it is very difficult to
correctly parameterise the model so that the ORs inform the incidence ratios. It is, however, possible,
although considerably more mathematically complicated than the model described in Chapter 5, to apply
the ORs to FOI ratios. We performed this analysis for the full synthesis model and found that incidence
changed by less than a multiplicative factor of 5% in all age groups (mean < 3%). From this, and the fact
that the incidence and FO ratios agree so closely, we conclude that there is only very negligible bias from
not parameterising the model so that ORs inform incidence ratios.
TABLE 44 Between-setting ratios of infection, FOI and incidence rates, Chapter 5
Ratio
LaMontagne (2007)192 Adams (2004)106
Infection ratios
(95% CrI)
FOI ratios
(95% CrI)
Incidence ratios
(95% CrI)
OR (95% CI)
(repeated from Table 11)
FP to GP 1.27 (0.59 to 2.48) 1.10 (0.65 to 1.74) 1.11 (0.61 to 1.88) 1.27 (1.00 to 1.62)
STD to GP 2.31 (1.11 to 4.45) 1.60 (0.95 to 2.53) 1.74 (0.94 to 2.97) 2.39 (0.72 to 3.33)
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Appendix 4 Details of the statistical methods in
Chapter 5
A full list of basic and functional parameters along with brief descriptions is provided in Table 45, whichshould be viewed alongside the DAG (see Figure 8).
TABLE 45 Master list of parameters for Chapter 5
Basic parameters Priors Interpretation
Incidence
λ1,1,1 Log-normal CT infection rate in women aged 16–17 years
in the GP setting
γa Log-normal HR across age groups
ρs Log-normal HR across settings
ηs Log-normal Setting specific re-infection to infection HRs
pa,s Beta Baseline prevalence of LaMontagne
192
sampling frame
Duration
Δs Normal Mean duration of symptomatic CT infection
ΔA Uniform Mean duration of asymptomatic CT infection
ϕ Binomial Proportion of CT episodes in which symptoms
will develop
Prevalence
πa.pop Note: Prevalence is a basic parameter
in method B but a functional
parameter in the full synthesis model
πa.pop= π1.pop.γa Population prevalence of CT by age group
Functional parameters Function Interpretation
Incidence
λa,s,1 γa.ρ.λ111 Infection rate for women in age group a and
setting s
λa,s,2 ηs.λa,s,1 Re-infection rate for women in age group a
and setting s
~λFOIa,GP (1−pa,s).λa,s,1 + pa,s.λa,s,2 FOI for women in age group a in the GP
setting
~λFOIa,pop ρpop~λ
FO
a,GP FOI for women in age group a in the general
population
~λINC1a,pop λ
FO
a,pop
1−λFOa,popΔ
Incidence rate of CT for women in age group
a in the general population estimated using
method A
~λINC2a,pop
πa,pop
Δ
Incidence rate of CT for women in age group
a in the general population estimated using
method B
κ(t)a,s,i See Figure 8 Proportion of CT– women in age group a,
setting s and re-infection status i, expected to
be CT+ after 6 months
continued
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Most of the functional relationships have been spelled out in the methods section as equations 11–17, or
in the DAG. Some expressions require further explanation.
The expression:
κ(t) = 1−
λC + λe−(λ+λ
C )t
λ + λC
(73)
relates the proportion of infected individuals κ(t), who were initially uninfected, observed after time t, to an
incidence rate λ and a clearance rate λC. This can be derived from the Kolmogorov’s forward equations.209
In the DAG, the more complex relationship for proportion infected at time t represents a weighted average
of two clearance rates: one being in symptomatic women and the other in asymptomatic women. The
proportion of infections in which symptoms develop is the weight, and the clearance rates in each group
are the reciprocals of the mean duration of symptomatic and asymptomatic infections.
Strictly speaking, Figure 8 sets out the relationships as they would be if the incidence and prevalence data
were available on the exact same age groups. As the age groupings in the studies were slightly different,
we used Census information on the English female population sizes from 2002 for each year of age
16–44 years to re-weight the parameters. Readers can see what was done from the WinBUGS code
provided in Appendix 5, which is annotated to make these adjustments clear.
Prior distributions
Vague normal priors were placed on the log incidence rate in the LaMontagne study192 in age group 1 and
GP setting: ln(λ1,GP,1)∼N(0,1002), and also on the rate ratios ρs for setting s relative to the GP setting, and γa
for age group a relative to the 16- to 17-year-old group, and for the ratios ηs in re-infection rate to
infection rate in setting s: ρa, γs, ηs∼N(0,1002).
Priors for the duration of infection and proportion symptomatic were as follows: proportion symptomatic
φ∼ Beta(1,1); ΔA∼ n(0,1002), ΔS∼Uniform(0.0767,0.1533), i.e. uniform between 4 and 8 weeks.
Information on the proportion of patients at recruitment in the GP setting, pa,GP in the LaMontagne study192
who were in the re-infection group (re-weighted to account for disproportionate inclusion into the study
of initially CT+ women) was introduced via informative Beta priors, derived from table 1 in LaMontagne
et al.192 For example, in women aged 16–19 years, who were tested at GP clinics, 663+ 137= 800 were
CT– and 45+ 48= 93 were CT+. So the correct weights for the infection and re-infection groups are
800/893 and 93/893, respectively. We repeated the same calculation for women aged 20–24 years, and
TABLE 45 Master list of parameters for Chapter 5 (continued )
Basic parameters Priors Interpretation
Duration
Δ Δs.ϕ+ΔA.(1 –ϕ) Mean duration of CT infection
λCA
1

ΔA
Mean clearance rate of asymptomatic CT
infections
λCS
1

ΔS
Mean clearance rate of symptomatic CT
infections
Prevalence
πa.pop Note: Prevalence is a basic parameter
in method B but a functional
parameter in the full synthesis model
~λINC
a,pop.Δ Population prevalence of CT by age group
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we assume that the weights are constant within these two age groups. Although testing and treatment
every 6 months interferes with the natural history, CT+ women are subsequently placed in the re-infection
group so this does not bias the results.
Information on two parameters, ΔS, and the proportion of women in the re-infections group, pa,GP, was
introduced via informative priors rather than through the data likelihood. This prevents these ‘data’ from
contributing directly to the global goodness of fit assessment. The decision to treat these inputs differently
was because the source of evidence on the first was expert clinical knowledge that was quite unrelated to
the other sources of data in the synthesis, whereas the second was local to the LaMontagne study.192 We
were therefore interested less in the ‘goodness of fit’ of this information, and more in the goodness of fit
of the other data, conditional on the priors we assigned to these parameters. In addition, we applied the
‘Cut Function’ to both these parameters (see Chapter 3), so in these cases the posterior for the parameter
is the same as the informative prior.
Data likelihoods
The age-specific prevalence data Da,pop in Table 10 was given a normal likelihood on the logit scale:
logit(Da,pop)∼N(πa,pop,Va,pop), with the variance calculated from the 95% CIs. The setting-specific ORs in
Table 11 were handled in the same way: logit(ORs)∼N(γs,Vs). The data on duration of asymptomatic
infection (see Table 8) was entered as a normal likelihood: DurA∼N(ΔA,VA).
The numbers infected in Table 9 denoted ‘r’ are considered as having a binomial likelihood, with
parameters κ(t)a,s,i, and denominators also shown in the table so that ra,s,i∼ Bin(κa,s,i(0.5),na,s,i). The number of
symptomatic infections, (r= 26), reported by Geisler et al.73 is binomially distributed with parameter φ and
denominator 115.
The WinBUGS code in Appendix 5 consists of the priors and likelihoods as described above, and the
functional relationships described exactly as in Figure 8 and in the text.
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Appendix 5 WinBUGS code and data for the
Chapter 5 analysis
model {
# Duration 
# Duration of asymptomatic infection
dura ~ dnorm(0,0.0001) I(0,)
D ~ dnorm(dura,pr.D) 
dev.D <- pr.D*pow((dura-D),2)  # Duration Deviance
lambdaC <- 1/dura              # clearance rate
# Duration of symptomatic infection
durs ~ dunif(0.0767,0.1533) # symptomatic, 4-8 weeks
#durs ~ dunif(0.0577,0.2308) #symptomatic, 3-12 weeks sensitivity 
# analysis
cut.durs <- cut(durs)        # pevents updating of durs
lambdaS <- 1 / cut.durs # clearance rate
# Probability ct is symptomatic
r.phi ~ dbin(phi,n.phi) phi ~ dbeta(1,1) 
dev.phi <- 2 * (r.phi * log(r.phi / (phi *  n.phi)) +  (n.phi -
r.phi) *
log((n.phi - r.phi) / (n.phi - (n.phi * phi)))) #
# Deviance
# Mean duration of infection
dur <- phi*cut.durs + (1-phi)*dura
# Incidence model
# Likelihood and model
for (i in 1:2) { # loop over rate, 1=infection, 2=reinfection
for (s in 1:3) { # loop over setting - GP=1, fP=2, GUM=3
for (a in 1:3) { # loop over age group:1=16,17;2=18-20, 3=21-24
lambda[i,s,a] <- equals(i,1)*(gamma[a] * rho[s] * lambda111) +
equals(i,2)*(gamma[a] * rho[s] * lambda111 * 
eta[s])
r.inc[i,s,a] ~ dbin(theta.inc[i,s,a],n.inc[i,s,a])
theta.inc[i,s,a] <- phi * (
(1 - (lambdaS + lambda[i,s,a] *
exp(-(lambdaS + lambda[i,s,a]) * 0.5)) /
(lambdaS + lambda[i,s,a]))
) + (1 - phi) * (
(1 - (lambdaC + lambda[i,s,a] *
exp(-(lambdaC + lambda[i,s,a]) * 0.5)) /
(lambdaC + lambda[i,s,a]))
)
dev.inc.rat[i,s,a] <- 2 * (r.inc[i,s,a] * log(r.inc[i,s,a] /
(theta.inc[i,s,a] * n.inc[i,s,a])) + 
(n.inc[i,s,a]-
r.inc[i,s,a]) * log((n.inc[i,s,a] -
r.inc[i,s,a]) /
(n.inc[i,s,a] - (n.inc[i,s,a] *
theta.inc[i,s,a]))))
}
}
}
sumdev.inc.rat <- sum(dev.inc.rat[ , , ]) # Deviance, # LaMontagne
#priors for log incidence parameters
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loglambda111 ~ dnorm(0,.0001)                  #Age 16-17, GP, 
# infection
log(lambda111) <- loglambda111
for (s in 1:3) {
logeta[s] ~ dnorm(0,.0001)     # GP=1, fP=2, GUM=3
log(eta[s]) <- logeta[s]
}
logrho[1] <- 0                  # GPtheta.inc
for (s in 2:4) {
logrho[s] ~ dnorm(0,.0001) # 2=fp, 3=GUM, 4=pop, rel to GP
}
for (s in 1:4) {
log(rho[s]) <- logrho[s]
}
loggamma[1] <- 0            #1 = 16-17
for (a in 2:5) {
loggamma[a] ~ dnorm(0,.01) #2=18-19, 3=20-24,4=25-29,5=30-44 rel to 
# 16-17
}
for (a in 1:5) {
log(gamma[a]) <- loggamma[a]
}
# setting specific Odds ratios from Adams
for (s in 1:3) {                            #s+1= 2=FP, 3=GUM, 4=pop, 
# rel to GP
r.OR[s] ~ dnorm(logrho[s+1],pr.OR[s]) 
dev.OR[s] <- pr.OR[s] * pow((r.OR[s]-logrho[s+1]),2)  # OR 
# deviance
}
sumdev.OR <- sum(dev.OR[])
# overall age-specific incidence in population, 1=16-17, 2=18-19,
# 3=20-24,
#                                               4=25-29, 5=30-44
for (a in 1:3) {
p[a] ~ dbeta(aprior[a],bprior[a])
cut.p[a] <- cut(p[a]) # prevents updating p[a]
lamda.F[a] <- rho[4]*((1-cut.p[a])*lambda[1,1,a] + 
cut.p[a]*lambda[2,1,a])
lamda.pop[a] <- lamda.F[a] / (1 - lamda.F[a] * dur)
}
for (a in 4:5) { 
lamda.pop[a] <- lamda.pop[1] * gamma[a]
}
# Age-specific Prevalence from Adams, 1=18-19, 2=20-24, 3=25-29,
# 4=30-44
for (a in 1:4) {
Lprev[a]~dnorm(lprev[a+1],pr.Lprev[a])
dev.prev[a] <- pr.Lprev[a] * pow((Lprev[a]-lprev[a+1]),2)
}
for (a in 1:5) {
lprev[a] <- logit(prev[a])
}
for (a in 1:3) {
prev[a] <- min(.999,(dur * lamda.pop2[a])) 
}
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prev[4] <- prev[3] * gamma[4]/gamma[3]
prev[5] <- prev[3] * gamma[5]/gamma[3]
sumdev.prev <- sum(dev.prev[])
sumdev <- dev.D + sumdev.inc.rat + sumdev.OR + sumdev.prev + dev.phi
# incidence in difference age bands, using population weights N[]
for (a in 16:17) {inc[a] <- lamda.pop[1]}
for (a in 18:20) {inc[a] <- lamda.pop[2]}
for (a in 21:24) {inc[a] <- lamda.pop[3]}
for (a in 25:29) {inc[a] <- lamda.pop[4]}
for (a in 30:44) {inc[a] <- lamda.pop[5]}
lamda.pop2[1] <- lamda.pop[1]  # age 16,17
lamda.pop2[2] <- lamda.pop[2]  # age 18,19.
lamda.pop2[3] <- inprod(inc[20:24],N[20:24])/sum(N[20:24])  # age 20-
# 24
inc1624 <- inprod(inc[16:24],N[16:24])
inc2544 <- inprod(inc[25:44],N[25:44])
inc1644 <- inprod(inc[16:44],N[16:44])
lamda.pop2[4] <- inc1624 / sum(N[16:24]) # age 16-24
lamda.pop2[5] <- inc2544 / sum(N[25:44]) # age 25-44
lamda.pop2[6] <- inc1644 / sum(N[16:44]) # age 16-44
# other population summaries
prop.treat.1624.2002 <- 31510 / inc1624
prop.treat.1624.2003 <- 34660 / inc1624
prop.asymp.clin.1624.2003 <- 1 - (phi / prop.treat.1624.2003)
# prevalence in reconstructed age groups
for (a in 1:6) {
prev.pop2[a] <- dur * lamda.pop2[a] 
}
} # end of program
Data
list(
# duration
D=1.36, pr.D=59.17,    # from Duration paper 2-Class estimate 
# incidence 
r.inc=structure(.Data=c(
4,3,4, 9,5,7, 5,16,9, 
5,7,10, 13,12,5, 6,15,5
),.Dim=c(2,3,3)),
n.inc=structure(.Data=c(
73,195,188, 194,273,201, 102,235,245, 
14,65,79, 95,127,63, 40,139,81
),.Dim=c(2,3,3)),
# priors for infection/reinfection weights, 16-17, 18-20, 21-24
aprior=c(46.5,73.1,106.4), bprior=c(400,634.6,938.4),
# Logit Prevalence 
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Lprev=c(-2.987,-3.41,-4.185,-4.82),
pr.Lprev=c(19.3,20.8,18.4,17.2),
# Setting-specific Log Odds Ratios. Fp,GUM, pop
r.OR= c(0.239,0.871, -.511),
pr.OR= c(67.03,35.21, 17.28),
# symptomatic ct - Geisler
r.phi = 26, n.phi = 115,
# Population sizes from census, age =1...44 - 2002
N=c(NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, 
305500,306300,296400,291400,294800,
310100,313900,305600,294700,295000,
304100,317000,329600,349600,370300,
380900,376900,387800,390900,399400,
401200,402600,398700,391900,381900, 370900,356200,349000,343800)
)
# Initial values - 1
# Duration
list(dura=1,  durs=.115,
# incidence
loglambda111=-2.5,
logeta=c(1,.5,.5),
logrho=c(NA, 1, 1.5,-.5),
loggamma=c(NA,-.2,-.5,-.7,-.8),
# probability symptomatic
phi = 0.5,
# proportion re-infection
p=c(.1, .1, .1)
)
# Initial values - 2
# Duration
list(dura=.2,  durs=.112,
# incidence
loglambda111=-4,
logeta=c(.5,1,1),
logrho=c(NA, 0, 0,0), 
loggamma=c(NA,0,0,0,0),
# probability symptomatic
phi = .1,
# proportion re-infection
p=c(.3, .05, .2)
)
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Appendix 6 Sensitivity analyses in Chapter 6
We performed three sets of sensitivity analysis.
First, the proportion of patients in the Scholes et al. trial13 who were assumed to have been tested during
the trial was lowered from 32% to 15%. This had no measurable effect on results of the final synthesis
(results not shown).
The effect on key model results of changing the infection and reinfection rates for both the one- and
two-rate models is shown in Table 46. The results show clearly that in the full synthesis the assumed
infection/re-infection rates have a minimal impact on the results altering the estimates of κ, the probability
that an incident CT episode causes PID, by at most a multiplicative factor of 4%.
In summary, we found that results from the full synthesis models were insensitive to these
modelling assumptions.
TABLE 46 Effect on key results of altering the assumed infection and reinfection rates, Chapter 6
Infection rate
(Scholes 1996,13
Ostergaard
200012)
Re-infection
rate (POPI
2010,18 Rees
1980199)
Mean
residual
deviance
Causal rate of PID
(95% CrI)
Probability CT
causes clinical
PID (95% CrI)
Proportion
prevented by
screening
(95% CrI)
One-rate model: all controlled studies
0 0 10.8 0.19 (0.06 to 0.36) 0.16 (0.06 to 0.26) 0.61 (0.55 to 0.67)
0 0.05 10.7 0.19 (0.06 to 0.36) 0.16 (0.06 to 0.26) 0.61 (0.55 to 0.67)
0 0.1 10.6 0.19 (0.06 to 0.35) 0.16 (0.06 to 0.26) 0.61 (0.55 to 0.67)
0.05 0.1 10.6 0.19 (0.06 to 0.35) 0.16 (0.06 to 0.26) 0.61 (0.55 to 0.67)
0.05 0.15 10.7 0.19 (0.06 to 0.34) 0.16 (0.06 to 0.25) 0.61 (0.55 to 0.68)
0.05 0.20 10.8 0.19 (0.06 to 0.34) 0.15 (0.06 to 0.25) 0.61 (0.55 to 0.68)
0.1 0.15 10.6 0.18 (0.06 to 0.31) 0.15 (0.05 to 0.24) 0.61 (0.56 to 0.68)
0.1 0.20 10.7 0.18 (0.05 to 0.31) 0.15 (0.05 to 0.24) 0.62 (0.56 to 0.68)
Two-rate models: all controlled studies – 60 days
0 0 10.3 δ1 0.74 (0.07 to 1.72) 0.20 (0.09 to 0.31) 0.40 (0.13 to 0.68)
δ2 0.16 (0.03 to 0.33)
0 0.05 10.4 δ1 0.62 (0.05 to 1.46) 0.19 (0.09 to 0.30) 0.43 (0.16 to 0.69)
δ2 0.17 (0.03 to 0.34)
0 0.1 10.8 δ1 0.48 (0.03 to 1.18) 0.18 (0.08 to 0.28) 0.48 (0.20 to 0.70)
δ2 0.17 (0.04 to 0.34)
continued
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TABLE 46 Effect on key results of altering the assumed infection and reinfection rates, Chapter 6 (continued )
Infection rate
(Scholes 1996,13
Ostergaard
200012)
Re-infection
rate (POPI
2010,18 Rees
1980199)
Mean
residual
deviance
Causal rate of PID
(95% CrI)
Probability CT
causes clinical
PID (95% CrI)
Proportion
prevented by
screening
(95% CrI)
0.05 0.1 10.6 δ1 0.32 (0.02 to 0.68) 0.16 (0.07 to 0.26) 0.54 (0.30 to 0.72)
δ2 0.18 (0.04 to 0.35)
0.05 0.15 10.9 δ1 0.29 (0.02 to 0.64) 0.16 (0.07 to 0.26) 0.55 (0.32 to 0.72)
δ2 0.18 (0.05 to 0.35)
0.05 0.20 11.2 δ1 0.25 (0.01 to 0.60) 0.16 (0.07 to 0.25) 0.57 (0.34 to 0.72)
δ2 0.18 (0.05 to 0.35)
0.1 0.15 11.0 δ1 0.18 (0.01 to 0.38) 0.15 (0.06 to 0.25) 0.61 (0.43 to 0.73)
δ2 0.19 (0.05 to 0.36)
0.1 0.20 11.1 δ1 0.17 (0.01 to 0.37) 0.15 (0.06 to 0.24) 0.61 (0.44 to 0.73)
δ2 0.19 (0.05 to 0.36)
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Appendix 7 Development of functional
relationships (see Chapter 6)
Note that the notation used in the chapter is extended here to facilitate a full mathematical descriptionof the non-homogeneous model. Here we develop the mathematical relationships between the model
parameters and data estimands.
Note: in our analyses the values of λl, u’, u, θCT– and hence any functions of them such as pij(t) are all study
dependent but the s subscript has been dropped for ease of reading.
Expression in a homogeneous model
In a single rate model θCT+ is constant over time and the data from women who are CT+ and the women
who are CT– at baseline in study s inform the transition probabilities p13(t) and p23(t), respectively, where t
is the mean follow-up time of the study. These transition probabilities are obtained by solving equation 19
numerically in each iteration of the MCMC simulation using the Runge–Kutta method in WBDiff.
Expression in a two-step piecewise homogeneous model
We use a 1-day discrete time approximation to the underlying continuous process to simplify the
calculations. It is necessary to extend the notation used in the paper. Let πi,h be the state occupancy
proportion for state i in day h of the study. The proportion in state i= 1 is further subdivided into the
proportion πhii,h, who are subject to developing PID caused by CT at rate δ1, and the proportion π
low
i,h who
develop PID caused by CT at rate δ2 where π1,h = π low1,h + π
hi
1,h.
Finally, phii j and p
low
i j are the daily transition probabilities from state i to state j, for women who are subject
to developing PID caused by CT at rates δ1 and δ2, respectively. phii j and p
low
i j are calculated using equation 19,
and solved using WBDiff, with the appropriate expression for θCT+s substituted into equation 18. The observed
data inform the proportions π3,H calculated for each arm where H is equal to the follow-up period of the study
in days. So π3,H is the proportion of patients in state 3 at the end of the study, which is the parameter in the
binomial likelihood. Equations for the state occupancy proportions on day h of the study can be written
as follows:
π1,h = π low1,h−1⋅plow11 + πhi1,h−1⋅phi11 + π2,h−1⋅phi21
π2,h = π2,h−1⋅phi22 + π low1,h−1⋅plow12 + πhi1,h−1⋅phi12
π3,h = 1−π2,h−π1,h
(74)
where π1,0 = π low1,0 + π
hi
1,0, π2,0 = 1−π1,0, π3,0 = 0.
It just remains to specify equations for πhi1,h and π
low
1,h , which depend on whether the study is clinic or
screening based. To speed up the processing time, the code is written in WBDev.160
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Clinic-based studies
πhi1,h = π1,h
o
h = 1,…, B
πhi1,h = ∑
h
i= (h+1−B)
(π2, i−1⋅phi21)p
hi(h−i)
11
o
h = B + 1,…, H
π low1,h = π1,h−π
hi
2,h
(75)
Recall from the main text that B is the number of days for which patients are subject to the rate δ1 of PID
caused by CT after entering state 1 if they do not leave during this period. So, in clinic-based studies,
all women in state 1 during the first B days are subject to the rate δ1. Equation 19 shows the proportion of
women who are in state 1 and progress at rate δ1 for each day h in the study after B days have elapsed.
Equation 18 sums over all patients who have moved to state 1 in the last B days multiplied by the
probability they have remained there until day h. In the case arm, πhi1,0 = 1 and π
low
1,0 and π2,0 equal 0. In the
control arm, πhi1,0 and π
low
1,0 equal 0, and π2,0 equals 1.
Screening-based studies
In screened populations women who are CT+ have already been infected for a period of time before
recruitment. We assume that a proportion, ϕ, of incident CT cases are symptomatic and treated, clearing
at rate λT, and the remaining infections, 1 – ϕ, are asymptomatic and clear at rate λC. The probability wb
that a recruited patient was recruited exactly b days after infection is:
ωb = φ⋅ exp −λT ⋅
(b−1)
365
 
−exp −λT ⋅
b
365
  
+(1−φ)⋅ exp −λC ⋅
(b−1)
365
 
−exp −λC ⋅
b
365
  
(76)
The proportions in the high and low rate groups are:
πhi1,h = ∑
B
i=h
ωB+1−iπ1,0.p
h
11 + ∑
h
i=1
(π2, i−1.p
hi
21)p
hi(h−i)
11
o
h = 1,…, B (77)
πhi1,h = ∑
h
i= (h+1−B)
(π2, i−1.p
hi
21)p
hi(h−i)
11
o
h = B + 1,…, H
π low1,h = π1,h−π
hi
2,h
(78)
Equation 77 calculates the proportion of women who are in state 1 and subject to the first causal
progression rate δ1 on each day h of the study from 1 to B. The first term is the proportion of women who
began the study as CT+ and were infected within 60 days of day h, multiplied by the probability they have
remained in state 1 until day h. This term is not included in equation 78 because, after B days, all of the
remaining patients move to the δ2 rate. The second term sums over all patients who have moved to state 1
by day h, multiplied by the probability they have remained there until day h. Equation 78 is the same as for
clinic based studies. In the CT+ group, πhi1,0 = ∑
B
b=1
ωb, π low1,0 = 1−πhi1,0 and π2,0 equals 0. In the CT– group,
πhi1,0 and π
low
1,0 equal 0, and π2,0 equals 1.
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Proportion of Chlamydia trachomatis-related pelvic
inflammatory disease that is prevented by screening
We consider an annual screening programme, in which women are screened at exactly 365-day intervals.
We derive an expression for the proportion of episodes of PID prevented by annual screening in women
who become infected with CT. We assume that treatment is administered 14 days after testing (the results
are fairly insensitive to different reasonable assumptions about this time period). Women are screened
within a year of infection, with each day having an equal probability (1/365) of this occurring. The
expression differs between the one- and two-rate models.
One-rate model
The probability that an episode of PID is caused by a CT episode exactly b days after infection is:
κb = φ.ð 1− exp − λT + δ .tu0ub  − 1− exp − λT + δ .tu0u b−1ð Þ  . δλT + δ
+ ð1−φÞ.ð 1− exp − λC + δ .tu0ub  − 1−exp − λC + δ .tu0u b−1ð Þ  . δλC + δ
(79)
Under the assumptions outlined above, the probability κSCN a CT infection causes an episode of PID in a
woman who is screened at random annually is:
kSCN = ∑
14
b=1
κb’ + ∑
379
b=15
κb’ 1−
(b−14)
365
 
(80)
And the proportion of PID episodes that are caused by CT, in women with CT, which are prevented by
annual testing, χ, equals:
χ = 1−
κSCN
κ
(81)
Two-rate model
In a two-rate model the probability that an episode of PID develops exactly b days after infection equals:
κb =
φ.ðexp − λT + δ1 .tu0u b−1ð Þ−exp − λT + δ1 .tu0ub  . δ1λT + δ1 +
1−φð Þ.ðexp − λC + δ1 .tu0u b−1ð Þ−exp − λC + δ1 .tu0ub  . δ1λC + δ1
φ. expð− λT + δ2 .tu1u b−1ð Þ−exp − λT + δ2 .tu1ub  . δ2λT + δ2 +
ð1−φÞ. exp − λC + δ2 .tu1u b−1ð Þ−expð− λC + δ2 .tu1ub  . δ2λC + δ2 g b ≤ Bb > B (82)
Where B= 30, 60, 90 days, the proportion of PID cases prevented by screening is calculated from
equation 80 and 81 as before.
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Appendix 8 WinBUGS code for the two-rate
model (see Chapter 6)
model {
# chlamydia informative priors
r.phi ~ dbin(phi,129)
lambda.c ~ dnorm(0.743,193)
dur.symp ~ dunif(0.077,0.15) # 4 - 8 weeks
lambda.t <- 1 / cut(dur.symp)
# Prospective PID analysis constant progression rate
# Likelihood
for (s in 1:4) {
for (i in 1:2) {
r[s,i] ~ dbin(p[s,i],n[s,i])
}
}
# transistion probability calulations 
for (s in 1:4) {
for (i in 1:2) {
for(j in 1:3) {
theta[s,1,index[i,j]] <- lambda[s,1,i,j]
theta[s,2,index[i,j]] <- lambda[s,2,i,j]
}
}
lambda[s,1,1,1] <- - lambda[s,1,1,2] - lambda[s,1,1,3]
lambda[s,1,1,3] <- theta.CTpos1[s]
lambda[s,1,2,2] <- - lambda[s,1,2,1] - lambda[s,1,2,3]
lambda[s,1,2,3] <- theta.CTneg[s]
lambda[s,2,1,1] <- - lambda[s,2,1,2] - lambda[s,2,1,3]
lambda[s,2,1,3] <- theta.CTpos2[s]
lambda[s,2,2,2] <- - lambda[s,2,2,1] - lambda[s,2,2,3]
lambda[s,2,2,3] <- theta.CTneg[s]
}
# Infection rate
for (s in 1:2) {
lambda[s,1,2,1] <- 0.0
lambda[s,2,2,1] <- 0.0
}
for (s in 3:4) {
lambda[s,1,2,1] <- 0.0
lambda[s,2,2,1] <- 0.0
}
# Clearance + treatment rate
lambda[1,1,1,2] <- lambda.c + 0.64
lambda[1,2,1,2] <- lambda.c + 0.64
lambda[2,1,1,2] <- lambda.c + 0.43
lambda[2,2,1,2] <- lambda.c + 0.43
lambda[3,1,1,2] <- lambda.c + 0.32
lambda[3,2,1,2] <- lambda.c + 0.32
lambda[4,1,1,2] <- lambda.c + 0.32
lambda[4,2,1,2] <- lambda.c + 0.32
# Models for rates
for (s in 1:4) {
theta.CTpos1[s] <- alpha[s] + delta[1]
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theta.CTpos2[s] <- alpha[s] + delta[2]
theta.CTneg[s] <- alpha[s]
}
# Other data
r.sch ~ dbin(pi.sch,n.sch) # Scholes - ct prevalence
r.ost ~ dbin(pi.ost,n.ost) # Ostergaard - ct prevalence
# Priors
delta[1] ~ dexp(0.00001) 
delta[2] ~ dexp(0.00001) 
for (s in 1:4) {
alpha[s] ~ dexp(0.00001)
}
pi.sch ~ dbeta(1,1)
pi.ost ~ dbeta(1,1)
phi ~ dbeta(1,1)
# Calculation of parameters in the likekihood
for (s in 1:4) {
solution1d[s,1,1:dim] <-
three.state(init[1:dim],time,theta[s,1,1:n.par],
origin, tol)
solution1d[s,2,1:dim] <-
three.state(init[1:dim],time,theta[s,2,1:n.par],
origin, tol)
for (i in 1:2) {
for (z in 1:6) {
vectorforwbdev[s,i,z] <- solution1d[s,1,z]
vectorforwbdev[s,i,z+6] <- solution1d[s,2,z]
}
vectorforwbdev[s,i,13] <- round(t[s] * 365)
vectorforwbdev[s,i,14] <- B
vectorforwbdev[s,i,15] <- lambda.c
vectorforwbdev[s,i,16] <- lambda.t
vectorforwbdev[s,i,17] <- phi
vectorforwbdev[s,i,18] <- clinorscreen[s]
vectorforwbdev[s,i,19] <- caseprop[s,i]
p[s,i] <- generatep(vectorforwbdev[s,i,1:19])
}
caseprop[s,2] <- 0
}
caseprop[1,1] <- 1
caseprop[2,1] <- 1
caseprop[3,1] <- pi.sch
caseprop[4,1] <- pi.ost
clinorscreen[1] <- 0 # clinic based study
for (s in 2:4) {
clinorscreen[s] <- 1 # screening studies
}
# Residual Deviance
for (s in 1:4) {
for (i in 1:2) {
dev[s,i] <- 2 * (r[s,i] * log(r[s,i] / (p[s,i] * n[s,i])) +
(n[s,i] - r[s,i]) * log((n[s,i] - r[s,i]) /
(n[s,i] - (n[s,i] * p[s,i]))))
}
}
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dev.sch <- 2 * (r.sch * log(r.sch / (pi.sch * n.sch)) + 
(n.sch - r.sch) * log((n.sch - r.sch) /
(n.sch - (n.sch * pi.sch))))
dev.ost <- 2 * (r.ost * log(r.ost / (pi.ost * n.ost)) + 
(n.ost - r.ost) * log((n.ost - r.ost) /
(n.ost - (n.ost * pi.ost))))
sumdev <- sum(dev[ , ]) + dev.sch + dev.ost
# Results
kappa  <- (1 - phi) * ( 
(1 - (exp( - (lambda.c + delta[1]) * (B / 365)))) *
delta[1] / (lambda.c + delta[1]) +
exp( - (lambda.c + delta[1]) * (B / 365)) *
delta[2] / (lambda.c + delta[2])
) +
phi * (
(1 - (exp( - (lambda.t + delta[1]) * (B / 365)))) *
delta[1] / (lambda.t + delta[1]) +
exp( - (lambda.t + delta[1]) * (B / 365)) *
delta[2] / (lambda.t + delta[2])
)
# proportion of PIDs prevented by annual screening 
# assumes two-week delay between test and treatment
for (i in 1:B) {
temp1[i] <- phi * (
((1 - exp(-(lambda.t + delta[1]) * (i/365))) -
(1 - exp(-(lambda.t + delta[1]) * ((i-1)/365)))) *
(delta[1] / (lambda.t + delta[1])) *
(1 - (max(0,(i-14)) / 365))) +
(1 - phi) * (
((1 - exp(-(lambda.c + delta[1]) * (i/365))) -
(1 - exp(-(lambda.c + delta[1]) * ((i-1)/365)))) *
(delta[1] / (lambda.c + delta[1])) *
(1 - (max(0,(i-14)) / 365)))
}
for (i in B+1:379) {
temp1[i] <- phi * (
((1 - exp(-(lambda.t + delta[2]) * (i/365))) -
(1 - exp(-(lambda.t + delta[2]) * ((i-1)/365)))) *
(delta[2] / (lambda.t + delta[2])) *
(1 - (max(0,(i-14)) / 365))) +
(1 - phi) * (
((1 - exp(-(lambda.c + delta[2]) * (i/365))) -
(1 - exp(-(lambda.c + delta[2]) * ((i-1)/365)))) *
(delta[2] / (lambda.c + delta[2])) *
(1 - (max(0,(i-14)) / 365)))
}
prop.prevent <- 1 - (sum(temp1[ ]) / kappa)
# Bayesian p-value
test <- delta[1] - delta[2]
B.p <- step(test)
}
# Data
list(
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# PID (1 month) prospective
# 1. Rees
# 2. POPI 
# 3. Scholes
# 4. Ostergaard
r=structure(.Data=c(
8,3,
7,1,
33,7,
20,9
),.Dim=c(4,2)),
n=structure(.Data=c(
67,62,
74,63,
1598,645,
487,443
),.Dim=c(4,2)),
t = c(0.125,1,1,1),
B = 60,   # If this were set above 365 WBDEV code would need changing
r.sch = 44,
n.sch = 645,
r.ost = 43,
n.ost = 867,
r.phi=30,
time = 0.00274,
# forward equations
dim=6,origin=0,tol=1.0E-4, init=c(1,0,0, 0,1,0),n.par=6,
index=structure(.Data=c(1,2,3,
4,5,6), .Dim=c(2,3))
)
# Initial values - 1
list(
# Prospective
phi = 0.23, lambda.c = 0.74, delta = c(0.2,0.1),
alpha = c(0.01,0.01,0.01,0.01),
pi.sch = 0.051, pi.ost = 0.07, dur.symp = 0.1
)
# Initial values - 2
list(
# Prospective
phi = 0.7, lambda.c = 2, delta = c(0.1,0.6),
alpha = c(0.15,0.15,0.15,0.15),
pi.sch = 0.2, pi.ost = 0.2, dur.symp = 0.145
)
WBDiff Program to calculate the transition probabilities
MODULE WBDiffThreeState;
IMPORT
WBDiffODEMath,
Math;
TYPE
Equations = POINTER TO RECORD (WBDiffODEMath.Equations) END;
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Factory = POINTER TO RECORD (WBDiffODEMath.Factory) END;
CONST
nEq = 6;
nSt = 4; (* one higher as arrays start at zero*)
VAR
fact-: WBDiffODEMath.Factory;
PROCEDURE (e: Equations) Derivatives (IN theta, C: ARRAY OF REAL; n: INTEGER; t: 
REAL;
OUT dCdt: ARRAY OF REAL);
VAR
index: ARRAY nSt, nSt OF INTEGER;
BEGIN
(* define index of parameters (look-up table) *)
index[1,1] := 0;
index[1,2] := 1;
index[1,3] := 2;
index[2,1] := 3;
index[2,2] := 4;
index[2,3] := 5;
(* define system of nEq Differential Equations *)
dCdt[index[1,1]]:= C[index[1,1]]*theta[index[1,1]] + C[index[1,2]]*theta[index[2,1]];
dCdt[index[1,2]]:= C[index[1,1]]*theta[index[1,2]] + C[index[1,2]]*theta[index[2,2]];
dCdt[index[1,3]]:= C[index[1,1]]*theta[index[1,3]] + C[index[1,2]]*theta[index[2,3]];
dCdt[index[2,1]]:= C[index[2,1]]*theta[index[1,1]] + C[index[2,2]]*theta[index[2,1]];
dCdt[index[2,2]]:= C[index[2,1]]*theta[index[1,2]] + C[index[2,2]]*theta[index[2,2]];
dCdt[index[2,3]]:= C[index[2,1]]*theta[index[1,3]] + C[index[2,2]]*theta[index[2,3]];
END Derivatives;
PROCEDURE (equations: Equations) SecondDerivatives (IN theta, x: ARRAY OF REAL;
numEq: INTEGER; t: REAL; OUT d2xdt2: ARRAY OF REAL);
BEGIN
HALT(126)
END SecondDerivatives;
PROCEDURE (equations: Equations) Jacobian (IN theta, x: ARRAY OF REAL;
numEq: INTEGER; t: REAL; OUT jacob: ARRAY OF ARRAY OF REAL);
BEGIN
HALT(126)
END Jacobian;
PROCEDURE (f: Factory) New (option: INTEGER): WBDiffODEMath.GraphNode;
VAR
equations: Equations;
node: WBDiffODEMath.GraphNode;
BEGIN
NEW(equations);
node := WBDiffODEMath.New(equations, nEq);
RETURN node
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END New;
PROCEDURE Install*;
BEGIN
WBDiffODEMath.Install(fact)
END Install;
PROCEDURE Init;
VAR
f: Factory;
BEGIN
NEW(f); fact := f
END Init;
BEGIN
Init
END WBDiffThreeState.
WBDEV code to calcuate the Binomial likelihood probabilities of PID for the 2-rate 
model
MODULE WBDevgeneratep;
IMPORT
WBDevScalar,
Math;
TYPE
Function = POINTER TO RECORD (WBDevScalar.Node) END;
Factory = POINTER TO RECORD (WBDevScalar.Factory) END;
VAR
fact-: WBDevScalar.Factory;
PROCEDURE (func: Function) DeclareArgTypes (OUT args: ARRAY OF CHAR);
BEGIN
args := "v";
END DeclareArgTypes;
PROCEDURE calculation (func: Function; OUT output: REAL);
VAR
term1, term2, omega, omega_cum,pi_hi, pi_low: ARRAY 366 OF REAL;
pi: ARRAY 4,366+1 OF REAL;
p_hi, p_low: ARRAY 3,4 OF REAL;
H,B,h,i,b: INTEGER;
Hin, Bin, lambdaC, lambdaT, phi, clinicorscreen, caseprop: REAL;
BEGIN
(* Read in the parameter values *)
p_hi[1,1] := func.arguments[0][0].Value();
p_hi[1,2] := func.arguments[0][1].Value();
p_hi[1,3] := func.arguments[0][2].Value();
p_hi[2,1] := func.arguments[0][3].Value();
p_hi[2,2] := func.arguments[0][4].Value();
p_hi[2,3] := func.arguments[0][5].Value();
p_low[1,1] := func.arguments[0][6].Value();
p_low[1,2] := func.arguments[0][7].Value();
p_low[1,3] := func.arguments[0][8].Value();
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
192
p_low[2,1] := func.arguments[0][9].Value();
p_low[2,2] := func.arguments[0][10].Value();
p_low[2,3] := func.arguments[0][11].Value();
Hin := func.arguments[0][12].Value();
Bin := func.arguments[0][13].Value();
lambdaC := func.arguments[0][14].Value();
lambdaT := func.arguments[0][15].Value();
phi := func.arguments[0][16].Value();
clinicorscreen := func.arguments[0][17].Value();
caseprop := func.arguments[0][18].Value();
(* Converts H and B to integer format *)
FOR i:= 1 TO 5000 DO
IF (Hin = i) THEN;
H := i;
END;
END;
FOR i:= 1 TO 5000 DO
IF (Bin = i) THEN;
B := i;
END;
END;
(* Sets B to equal H if follow-up time is shorter than B - Note the program would need 
changing if a  
screening study with a follow-up time shorter than B was included *)
IF (H < B) THEN;
B := H;
END;
(* Calculates the proportion of cases in screening studies infected in the last c = 1 to C days 
*)
IF (clinicorscreen = 1) THEN;
omega_cum[0] := 0;
FOR b := 1 TO B DO
omega[b] := phi * (Math.Exp( - lambdaT * (b - 1) / 365) - Math.Exp( - lambdaT * b / 365)) + 
(1 - phi) * (Math.Exp( - lambdaC * (b - 1) / 365) - Math.Exp( - lambdaC * b / 
365)); omega_cum[b] := omega_cum[b-1] + omega[b];
END;
(* specifies the proportion of women in each state at time zero *)
pi_hi[0] := caseprop * omega_cum[B];   
ELSE
pi_hi[0] := caseprop;
END;
pi[1,0] := caseprop;
pi[2,0]:= 1 - pi[1,0];
pi[3,0] := 0;
pi_low[0] := pi[1,0] - pi_hi[0]; 
(* main analysis *)
FOR h := 1 TO B DO;
pi[1,h] := pi_low[h-1] * p_low[1,1] + pi_hi[h-1] * p_hi[1,1] + pi[2,h-1] * p_hi[2,1];
pi[2,h] := pi[2,h-1] * p_hi[2,2] + pi_low[h-1] * p_low[1,2] + pi_hi[h-1] * p_hi[1,2];
pi[3,h]:= 1 - pi[2,h] - pi[1,h];
IF (clinicorscreen =0) THEN;
pi_hi[h] := pi[1,h];
pi_low[h] := 0
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END;
IF (clinicorscreen =1) THEN;
term1[h] := 0;
FOR i := h TO B DO
term1[h] := term1[h] + omega[B+1-i] * pi[1,0] * Math.Power(p_hi[1,1],h);
END;
term2[1] := 0;
IF (h >= 2) THEN;
FOR i := 1 TO h DO
term2[h] := term2[h-1] + (pi[2,i-1] * p_hi[2,1]) * Math.Power(p_hi[1,1],h-i);
END;
END;
pi_hi[h] := term1[h] + term2[h];
pi_low[h] := pi[1,h] - pi_hi[h];
END;
END;
IF (H > B) THEN;
FOR h := B+1 TO H DO
pi[1,h] := pi_low[h-1] * p_low[1,1] + pi_hi[h-1] * p_hi[1,1] + pi[2,h-1] * p_hi[2,1];
pi[2,h] := pi[2,h-1] * p_hi[2,2] + pi_low[h-1] * p_low[1,2] + pi_hi[h-1] * p_hi[1,2];
pi[3,h]:= 1 - pi[2,h] - pi[1,h];
term1[h] := 0;
FOR i := h+1-B TO h DO
term2[h] := term2[h-1] + (pi[2,i-1] * p_hi[2,1]) * Math.Power(p_hi[1,1],h-i);
END;
pi_hi[h] := term1[h] + term2[h];
pi_low[h] := pi[1,h] - pi_hi[h];
END;
END;
output := pi[3,H];
END calculation;
PROCEDURE (func: Function) Evaluate (OUT value: REAL);
VAR
output: REAL;
BEGIN
calculation(func, output);
value := output;
END Evaluate;
PROCEDURE (f: Factory) New (option: INTEGER): Function;
VAR
func: Function;
BEGIN
NEW(func); func.Initialize; RETURN func;
END New;
PROCEDURE Install*;
BEGIN
WBDevScalar.Install(fact);
END Install;
PROCEDURE Init;
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VAR
f: Factory;
BEGIN
NEW(f); fact := f;
END Init;
BEGIN
Init;
END WBDevgeneratep.
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
195

Appendix 9 Van Valkengoed’s method of
estimating the probability that a case of Chlamydia
trachomatis causes pelvic inflammatory disease
(see Chapter 7)
Van Valkengoed292 pointed out that the incidence of sequelae of CT, including PID, can provide anupper bound on the progression rate. Subsequently,39 she proposed a way of using Bayes’ theorem
to convert information on PID incidence and other items of data into an estimate of the progression
probability, i.e. the probability that an episode of CT causes a case of PID. Here we briefly review
her approach.
The method begins with the observation that, according to register information in Amsterdam, the
incidence of laparoscopically confirmed PID is 34 per 10,000 per year, in women aged 15–40 years. 50%
of them would show evidence of previous CT infection, based on serology, but this estimate would
provide a highly unreliable estimate of the PEF because of the poor sensitivity of serology tests used at the
time and the poor specificity of lifetime exposure to CT as evidence that a PID was caused by CT.
The argument then takes the following form (Table 47):
l The incidence of confirmed PID is 34/10,000/year or 0.0034 per year.
l The prevalence of CT is 3%, 0.03.
l The probability of CT in women with PID is 3.84%. This is based on a series of inferences concerning
the proportions of women previously exposed to CT, and currently exposed to CT, which is
examined below.
l The 3.84% is applied to the 0.0034 incidence of PID, to obtain 0.0001306 in the top left cell in
Table 47.
l Bayes’ theorem is then used:
Pr(PIDjCT ) = Pr(CT jPID).Pr(PID)
Pr(CT )
(83)
l In terms of Table 47, as a proportion of the CT+ column total 0.03, 0.0001306 is 0.0043 – or 0.43%.
This is the final estimate of the probability that a case of incident CT progresses to PID.
TABLE 47 van Valkengoed’s method of estimating the proportion of incident CT that progresses to PID
CT status
PID status
PID+ PID– Total
CT+ 0.0001306 0.00327 0.0034
CT– 0.029864 0.966136 0.9966
Total 0.03 0.97 1
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The 0.43% progression probability is a far lower estimate than had ever been suggested, so low that one
might conclude that CT was not a serious public health issue, in the sense that if we multiplied it by our
CT incidence estimates from Chapter 5, we would predict such a low incidence of PID that screening
would be most unlikely to be cost-effective. However, there are a number of problems with the approach.
The main difficulty with the argument lies in the derivation of 3.84% as Pr(CT|PID), which is highly
inconsistent with evidence from retrospective studies.62
This is based on a further chain of reasoning:
l Serological studies have shown a seroprevalence of 70% in women with current CT infection, and of
26% in currently uninfected women. Assuming perfect sensitivity and specificity, and using serology as
a maker of previous or current infection, it was concluded that the proportion of current infection
among those who have ever been exposed to CT is: 0.70 × 0.03/(0.70 × 0.03+ 0.26 × 0.97)= 0.0769.
l However, only 50% of PID cases were found to have been ever exposed to CT (as measured by
serology), so 0.0769 times 0.5= 0.0384, or 3.84% is the proportion of those with clinical PID who are
expected to be currently infected with CT.
It is immediately clear that this argument assumes that there is no causal role of CT in PID, and indeed no
form of association whatsoever. More precisely, it is assumed that the proportion of current CT among
PID cases ever exposed to CT is exactly the same as the proportion of current CT among the total
population ever exposed to CT. Estimates of the progression rates from CT to both EP and TFI were also
published,39 based on precisely the same flawed technique.
There are several other aspects of the method that are problematic. The incidence of CT should be used,
not its prevalence. Because the duration of CT is in the order of 1 year, however, this does not make much
difference to the calculations. The calculations assume that all PID is diagnosed, and, as stated by van
Valkengoed,292 do not account for the poor sensitivity and specificity of CT antibody tests used at the time.
Finally, setting aside the difficulties with the reasoning that generated the 3.84 estimate for Pr(CT|PID), it is
important to appreciate that, even if this estimate was credible, the use of Bayes’ theorem in this context
cannot in and of itself generate a valid estimate of the probability that a CT infection will cause PID. In
particular, the ‘conditional’ symbol ‘| ’ cannot be interpreted as denoting causation in any way, although if
genuinely causal estimates are plugged in, causal inferences from the results would be legitimate. Bayes’
theorem as applied to 2 × 2 tables is simply a method for calculating a row proportion from a column
proportion, given knowledge of the marginal totals (see Table 15). It implements an equation of the form:
a
X
=
a
Y
Y
X
(84)
Where, for example, a is the top left cell, and X and Y are the proportions of PID and CT, respectively.
Nothing in this procedure implies causality or even association. It tells us nothing about the role of CT in
the aetiology of PID.
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Appendix 10 WinBUGS code for pelvic
inflammatory disease incidence synthesis
(see Chapter 7)
model {
# Routine data
for (ag in 1:4) {
r.routine[ag] ~ dbin(p.routine[ag],N.routine[ag])
p.routine[ag] <- 1 - exp(-lambda.PID.diag[ag])
lambda.PID.diag[ag] ~ dexp(0.0001) 
range.temp[ag] ~ dunif(0,range.max[ag])
range[ag] <- cut(range.temp[ag])
lambda.PID[ag] <- (lambda.PID.diag[ag] + (range[ag] / 
N.routine[ag])) /
(1 - psi[1])
# output for Multivariate Normal #prior
lnlambda.PID[ag] <- log(lambda.PID[ag])
}
N.routine[1] <- sum(N[16:19])
N.routine[2] <- sum(N[20:24])
N.routine[3] <- sum(N[25:34])
N.routine[4] <- sum(N[35:44])
lambda.PID1624 <- (lambda.PID[1] * N.routine[1] + 
lambda.PID[2] * N.routine[2]) / sum(N[16:24])
lambda.PID2544 <- (lambda.PID[3] * N.routine[3] + 
lambda.PID[4] * N.routine[4]) / sum(N[25:44])
lambda.PID1644 <- (lambda.PID[1] * sum(N[16:19]) +
lambda.PID[2] * sum(N[20:24]) +
lambda.PID[3] * sum(N[25:34]) +
lambda.PID[4] * sum(N[35:44])) / 
sum(N[16:44])
RatioofPIDnums <- (lambda.PID2544 * (N.routine[3] + N.routine[4])) /
(lambda.PID1624 * (N.routine[1] + N.routine[2]) +
lambda.PID2544 * (N.routine[3] + N.routine[4]))
# Wolner Hanssen
r.wh.undiagpop ~ dbin(psi[1],n.wh.all)
r.wh.asymp ~ dbin(psi[2],n.wh.undiag)
log(lgpsi[1]) <- psi[1]
log(lgpsi[2]) <- psi[2]
logit(lgtpsi[1]) <- psi[1]
logit(lgtpsi[2]) <- psi[2]
psi[1] ~ dbeta(1,1)
psi[2] ~ dbeta(1,1)
# POPI data
r.POPI ~ dbin(p.POPI,n.POPI)
p.POPI <- 1 - exp(-lambda.POPI)
lambda.POPI <- lambda.PID1624 * (1 - (psi[1] * psi[2]))
# Residual Deviance
for (ag in 1:4) {
dev[ag] <- 2 * (r.routine[ag] * log(r.routine[ag] / (p.routine[ag] *
N.routine[ag])) + (N.routine[ag] - r.routine[ag]) * 
log((N.routine[ag] - r.routine[ag])
/ (N.routine[ag] - (N.routine[ag] * 
p.routine[ag]))))
}
dev[5] <- 2 * (r.wh.undiagpop * log(r.wh.undiagpop / (psi[1] * 
n.wh.all)) + 
(n.wh.all - r.wh.undiagpop) * log((n.wh.all -
r.wh.undiagpop)
/(n.wh.all - (n.wh.all * psi[1]))))
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
199
dev[6] <- 2 * (r.wh.asymp * log(r.wh.asymp / (psi[2] * n.wh.undiag)) 
+
(n.wh.undiag - r.wh.asymp) * log((n.wh.undiag -
r.wh.asymp) /
(n.wh.undiag - (n.wh.undiag * psi[2]))))
dev[7] <- 2 * (r.POPI * log(r.POPI / (p.POPI * n.POPI)) + 
(n.POPI - r.POPI) * log((n.POPI - r.POPI) /
(n.POPI - (n.POPI * p.POPI))))
sumdev <- sum(dev[ ])
}
# Data
list(
# Routine data
r.routine = c(8295,13241,18851,11914),
range.max = c(1233,3101,9756,9609),
# Census data - 2002
N=c(NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, NA,NA,NA,NA,NA,
305500,306300,296400,291400,294800,
310100,313900,305600,294700,295000,
304100,317000,329600,349600,370300,
380900,376900,387800,390900,399400,
401200,402600,398700,391900,381900, 370900,356200,349000,343800),
# Wolner-Hansenn
r.wh.undiagpop = 25, n.wh.all = 36
r.wh.asymp = 4, n.wh.undiag = 25
# POPI
r.POPI = 23,n.POPI = 1186
)
# Initial values 1
list(
# population PID incidence
lambda.PID.diag = c(0.01,0.01,0.01,0.01), range.temp = c(1,1,1,1),
# Proportion of PID cases diagnosed
psi = c(0.4,0.5)
)
# Initial values 2
list(
# population PID incidence
lambda.PID.diag = c(0.1,0.1,0.1,0.1), range.temp = 
c(1000,1000,1000,1000),
# Proportion of PID cases diagnosed
psi = c(0.1,0.1)
)
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Appendix 11 WinBUGS code for cumulative
pelvic inflammatory disease exposure (see Chapter 8)
This Appendix provides the programming code used to estimate the distribution of 
salpingitis and number of subsequent PID episodes in the population. The appendix is 
set out in three sections. (A) provides the WBDev functions written in Component 
Pascal which are called by the WinBUGS code shown in sections B and C. (B) is the 
WinBUGS code that calculates the numbers of PIDs, CT-related and non-CT-related. 
(C) is the WinBUGS code that develops the comparisons with the Lund data. 
(A).  WBDEV code
Note that in appendix A the, philap (the proportion of PID cases that would be diagnosed 
as salpingitis on laparoscopy) parameter can be removed to generate estimates of the 
distribution of clinical PID and diagnosed clinical PID. To generate estimates for 
the distribution of salpingitis it can be included as a multiplier in the exponents 
MODULE WBDevCumulativePIDlap;
IMPORT
WBDevVector,
Math;
TYPE
Function = POINTER TO RECORD (WBDevVector.Node) END;
Factory = POINTER TO RECORD (WBDevVector.Factory) END;
VAR
fact-: WBDevVector.Factory;
PROCEDURE (func: Function) DeclareArgTypes (OUT args: ARRAY OF CHAR);
BEGIN
args := "vv";
END DeclareArgTypes;
PROCEDURE readindata1 (func: Function; OUT lambda_PID: ARRAY OF REAL);
VAR
index,a: INTEGER;
BEGIN
index := 0;
FOR a := 1 TO 4 DO
lambda_PID[a] := func.arguments[0][index].Value();
INC(index);
END;
END readindata1;
PROCEDURE readindata2 (func: Function; OUT psi: REAL);
for all of the transition probabilities.
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BEGIN
psi := func.arguments[0][4].Value();
END readindata2;
PROCEDURE readindata3 (func: Function; OUT eta1: REAL);
BEGIN
eta1 := func.arguments[0][5].Value();
END readindata3;
PROCEDURE readindata4 (func: Function; OUT EF: ARRAY OF REAL);
VAR
index,a: INTEGER;
BEGIN
index := 6;
FOR a := 1 TO 4 DO
EF[a] := func.arguments[0][index].Value();
INC(index);
END;
END readindata4;
PROCEDURE readindata5 (func: Function; OUT philap: REAL);
BEGIN
philap := func.arguments[0][10].Value();
END readindata5;
PROCEDURE readindata6 (func: Function; OUT N: ARRAY OF REAL);
VAR
index,a: INTEGER;
BEGIN
index := 0;
FOR a := 16 TO 44 DO
N[a] := func.arguments[1][index].Value();
INC(index);
END;
END readindata6;
PROCEDURE tranratesall (lambda_PID: ARRAY OF REAL; eta1: REAL; 
OUT lambda_PID2: ARRAY OF ARRAY OF REAL);
VAR
a : INTEGER;
BEGIN
FOR a := 16 TO 19 DO
lambda_PID2[1,a] := lambda_PID[1] * 0.85;
lambda_PID2[2,a] := lambda_PID2[1,a] * eta1;
END;
FOR a := 20 TO 24 DO
lambda_PID2[1,a] := lambda_PID[2] * 0.85;
lambda_PID2[2,a] := lambda_PID2[1,a] * eta1;
END;
FOR a := 25 TO 34 DO
lambda_PID2[1,a] := lambda_PID[3] * 0.85;
lambda_PID2[2,a] := lambda_PID2[1,a] * eta1;
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END;
FOR a := 35 TO 44 DO
lambda_PID2[1,a] := lambda_PID[4] * 0.85;
lambda_PID2[2,a] := lambda_PID2[1,a] * eta1;
END;
END tranratesall;
PROCEDURE tranratesnct (lambda_PID: ARRAY OF REAL; eta1: REAL; EF: ARRAY OF 
REAL;
OUT lambda_PID2nct: ARRAY OF ARRAY OF REAL);
VAR
a : INTEGER;
BEGIN
FOR a := 16 TO 19 DO
lambda_PID2nct[1,a] := (lambda_PID[1]  - lambda_PID[1] * EF[1]) * 0.85; 
lambda_PID2nct[2,a] := lambda_PID2nct[1,a] * eta1;
END;
FOR a := 20 TO 24 DO
lambda_PID2nct[1,a] := (lambda_PID[2]  - lambda_PID[2] * EF[2]) * 0.85;
lambda_PID2nct[2,a] := lambda_PID2nct[1,a] * eta1;
END;
FOR a := 25 TO 34 DO
lambda_PID2nct[1,a] := (lambda_PID[3]  - lambda_PID[3] * EF[3]) * 0.85;
lambda_PID2nct[2,a] := lambda_PID2nct[1,a] * eta1;
END;
FOR a := 35 TO 44 DO
lambda_PID2nct[1,a] := (lambda_PID[4]  - lambda_PID[4] * EF[4]) * 0.85;
lambda_PID2nct[2,a] := lambda_PID2nct[1,a] * eta1;
END;
END tranratesnct;
PROCEDURE tranproball (lambda_PID2: ARRAY OF ARRAY OF REAL; philap: REAL;
OUT p: ARRAY OF ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER;
BEGIN
FOR a := 14 TO 15 DO
p[1,2,a] := 0;
p[1,1,a] := 0;
p[2,2,a] := 0;
p[2,5,a] := 0;
p[2,3,a] := 0;
p[3,3,a] := 0;
p[3,5,a] := 0;
p[3,4,a] := 0;
p[4,5,a] := 0;
p[4,4,a] := 0;
p[5,5,a] := 0;
p[5,8,a] := 0;
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p[5,6,a] := 0;
p[6,6,a] := 0;
p[6,8,a] := 0;
p[6,7,a] := 0;
p[7,8,a] := 0;
p[7,7,a] := 0;
p[8,8,a] := 0;
END;
FOR a := 16 TO 44 DO
p[1,2,a] := 1 - Math.Exp(-lambda_PID2[1,a] * philap);
p[1,1,a] := 1 - p[1,2,a];
p[2,2,a] := 0;
p[2,5,a] := 1 - Math.Exp(-lambda_PID2[2,a]);
p[2,3,a] := 1 - p[2,5,a];
p[3,3,a] := 0;
p[3,5,a] := 1 - Math.Exp(-lambda_PID2[2,a]);
p[3,4,a] := 1 - p[3,5,a];
p[4,5,a] := 1 - Math.Exp(-lambda_PID2[1,a]);
p[4,4,a] := 1 - p[4,5,a];
p[5,5,a] := 0;
p[5,8,a] := 1 - Math.Exp(-lambda_PID2[2,a]);
p[5,6,a] := 1 - p[5,8,a];
p[6,6,a] := 0;
p[6,8,a] := 1 - Math.Exp(-lambda_PID2[2,a]);
p[6,7,a] := 1 - p[6,8,a];
p[7,8,a] := 1 - Math.Exp(-lambda_PID2[1,a]);
p[7,7,a] := 1 - p[7,8,a];
p[8,8,a] := 1;
END;
END tranproball;
PROCEDURE tranprobnct (lambda_PID2nct: ARRAY OF ARRAY OF REAL; philap: REAL;
OUT pnct: ARRAY OF ARRAY OF ARRAY OF REAL);
VAR
a : INTEGER;
BEGIN
FOR a := 16 TO 44 DO
pnct[1,2,a] := 1 - Math.Exp(-lambda_PID2nct[1,a] * philap);
pnct[1,1,a] := 1 - pnct[1,2,a];
pnct[2,2,a] := 0;
pnct[2,5,a] :=  1 - Math.Exp(-lambda_PID2nct[2,a]);
pnct[2,3,a] :=  1 - pnct[2,5,a];
pnct[3,3,a] := 0;
pnct[3,5,a] := 1 - Math.Exp(-lambda_PID2nct[2,a]);
pnct[3,4,a] := 1 - pnct[3,5,a];
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pnct[4,5,a] := 1 - Math.Exp(-lambda_PID2nct[1,a]);
pnct[4,4,a] := 1 - pnct[4,5,a];
pnct[5,5,a] := 0;
pnct[5,8,a] := 1 - Math.Exp(-lambda_PID2nct[2,a]);
pnct[5,6,a] := 1 - pnct[5,8,a];
pnct[6,6,a] := 0;
pnct[6,8,a] := 1 - Math.Exp(-lambda_PID2nct[2,a]);
pnct[6,7,a] := 1 - pnct[6,8,a];
pnct[7,8,a] := 1 - Math.Exp(-lambda_PID2nct[1,a]);
pnct[7,7,a] := 1 - pnct[7,8,a];
pnct[8,8,a] :=1;
END;
END tranprobnct;
PROCEDURE stateoccpropall (p: ARRAY OF ARRAY OF ARRAY OF REAL; 
OUT pi: ARRAY OF ARRAY OF REAL);
VAR
a,s: INTEGER;
BEGIN
FOR a := 13 TO 15 DO
pi[1,a] := 1;
FOR s := 2 TO 8 DO
pi[s,a] := 0;
END;
END;
FOR a := 16 TO 44 DO
pi[1,a] := pi[1,a-1] * p[1,1,a]; 
pi[2,a] := pi[1,a-1] * p[1,2,a]; 
pi[3,a] := pi[2,a-1] * p[2,3,a];
pi[4,a] := pi[3,a-1] * p[3,4,a] + pi[4,a-1] * p[4,4,a];
pi[5,a] := pi[2,a-1] * p[2,5,a] + pi[3,a-1] * p[3,5,a] + pi[4,a-1] * p[4,5,a] + pi[5,a-1] * p[5,5,a];
pi[6,a] := pi[5,a-1] * p[5,6,a]; 
pi[7,a] := pi[6,a-1] * p[6,7,a] + pi[7,a-1] * p[7,7,a];  
pi[8,a] := pi[5,a-1] * p[5,8,a] + pi[6,a-1] * p[6,8,a] + pi[7,a-1] * p[7,8,a] + pi[8,a-1];
END;
END stateoccpropall;
PROCEDURE stateoccpropnct (pnct: ARRAY OF ARRAY OF ARRAY OF REAL; 
OUT pinct: ARRAY OF ARRAY OF REAL);
VAR
a,s: INTEGER;
BEGIN
FOR a := 13 TO 15 DO
pinct[1,a] := 1;
FOR s := 2 TO 8 DO
pinct[s,a] := 0;
END;
END;
FOR a := 16 TO 44 DO
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pinct[1,a] := pinct[1,a-1] * pnct[1,1,a];
pinct[2,a] := pinct[1,a-1] * pnct[1,2,a]; 
pinct[3,a] := pinct[2,a-1] * pnct[2,3,a]; 
pinct[4,a] := pinct[3,a-1] * pnct[3,4,a] + pinct[4,a-1] * pnct[4,4,a];
pinct[5,a] := pinct[2,a-1] * pnct[2,5,a] + pinct[3,a-1] * pnct[3,5,a] + pinct[4,a-1] * pnct[4,5,a] +                  
pinct[5,a-1] * pnct[5,5,a];
pinct[6,a] := pinct[5,a-1] * pnct[5,6,a]; 
pinct[7,a] := pinct[6,a-1] * pnct[6,7,a] + pinct[7,a-1] * pnct[7,7,a];  
pinct[8,a] := pinct[5,a-1] * pnct[5,8,a] + pinct[6,a-1] * pnct[6,8,a] + pinct[7,a-1] * pnct[7,8,a] +                            
pinct[8,a-1];
END;
END stateoccpropnct;
PROCEDURE numberPIDsageall (pi: ARRAY OF ARRAY OF REAL; N: ARRAY OF REAL;
OUT PIDnum: ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDnum[1,a] := (pi[2,a] + pi[3,a] + pi[4,a]);
PIDnum[2,a] := (pi[5,a] + pi[6,a] + pi[7,a]);
PIDnum[3,a] := pi[8,a];
END;
END numberPIDsageall;
PROCEDURE numberPIDsagegpall (PIDnum: ARRAY OF ARRAY OF REAL; N: ARRAY OF 
REAL;
OUT numPIDs: ARRAY OF ARRAY OF REAL);
VAR
n: INTEGER; 
BEGIN
FOR n := 1 TO 3 DO
numPIDs[n,1] := (PIDnum[n,16] * N[16] + PIDnum[n,17] * N[17] + PIDnum[n,18] * N[18] +                                
PIDnum[n,19] * N[19]) / 
(N[16] + N[17] + N[18] + N[19]);
numPIDs[n,2] := (PIDnum[n,20] * N[20] + PIDnum[n,21] * N[21]  + PIDnum[n,22] * N[22]  +                              
PIDnum[n,23] * N[23] + PIDnum[n,24] * N[24]) / 
(N[20] + N[21] + N[22] + N[23] + N[24]);
numPIDs[n,3] := (PIDnum[n,25] * N[25] + PIDnum[n,26] * N[26] + PIDnum[n,27] * N[27]  +  
PIDnum[n,28] * N[28] + PIDnum[n,29] * N[29] + PIDnum[n,30] * N[30] + 
PIDnum[n,31] * N[31] + PIDnum[n,32] * N[32] + PIDnum[n,33] * N[33]+       
PIDnum[n,34] * N[34]) /
(N[25] + N[26] + N[27] + N[28] + N[29] + N[30] + N[31] + N[32] + N[33] + 
N[34]);
numPIDs[n,4] := (PIDnum[n,35] * N[35] + PIDnum[n,36] * N[36] + PIDnum[n,37] * N[37] +          
PIDnum[n,38] * N[38] + PIDnum[n,39] * N[39] +PIDnum[n,40] * N[40] + 
PIDnum[n,41] * N[41] + PIDnum[n,42] * N[42] + PIDnum[n,43] * N[43] + 
PIDnum[n,44] * N[44]) /
(N[35] + N[36] + N[37] + N[38] + N[39] + N[40] + N[41] + N[42] + N[43] + 
N[44]);
END;
END numberPIDsagegpall;
PROCEDURE numberPIDsobsageall (PIDnum: ARRAY OF ARRAY OF REAL; psi: REAL;
OUT PIDnumobs: ARRAY OF ARRAY OF REAL);
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VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDnumobs[1,a] :=  PIDnum[1,a] * psi + 2 * PIDnum[2,a] * psi * (1 - psi) + 
3 * PIDnum[3,a] * psi * (1 - psi) * (1 - psi);
PIDnumobs[2,a] :=  PIDnum[2,a] * psi * psi + 3 * PIDnum[3,a] * psi * psi * (1 - psi);
PIDnumobs[3,a] :=  PIDnum[3,a] * psi * psi * psi
END;
END numberPIDsobsageall;
PROCEDURE numberPIDsagenct (pinct: ARRAY OF ARRAY OF REAL;  N: ARRAY OF 
REAL;
OUT PIDnumnct: ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDnumnct[1,a] := (pinct[2,a] + pinct[3,a] + pinct[4,a]);
PIDnumnct[2,a] := (pinct[5,a] + pinct[6,a] + pinct[7,a]);
PIDnumnct[3,a] := pinct[8,a];
END;
END numberPIDsagenct;
PROCEDURE numberPIDsagegpnct (PIDnumnct: ARRAY OF ARRAY OF REAL; N: 
ARRAY OF                                     
REAL;
OUT numPIDsnct: ARRAY OF ARRAY OF REAL);
VAR
n: INTEGER; 
BEGIN
FOR n := 1 TO 3 DO
numPIDsnct[n,1] := (PIDnumnct[n,16] * N[16] + PIDnumnct[n,17] * N[17] + 
PIDnumnct[n,18] * N[18] + PIDnumnct[n,19] * N[19]) / 
(N[16] + N[17] + N[18] + N[19]);
numPIDsnct[n,2] := (PIDnumnct[n,20] * N[20] + PIDnumnct[n,21] * N[21] + 
PIDnumnct[n,22] * N[22] + PIDnumnct[n,23] * N[23] + 
PIDnumnct[n,24] * N[24]) / 
(N[20] + N[21] + N[22] + N[23] + N[24]);
numPIDsnct[n,3] := (PIDnumnct[n,25] * N[25] + PIDnumnct[n,26] * N[26] + 
PIDnumnct[n,27] * N[27] + PIDnumnct[n,28] * N[28] + 
PIDnumnct[n,29] * N[29] + PIDnumnct[n,30] * N[30] + 
PIDnumnct[n,31] * N[31] + PIDnumnct[n,32] * N[32] + 
PIDnumnct[n,33] * N[33] + PIDnumnct[n,34] * N[34]) /
(N[25] + N[26] + N[27] + N[28] + N[29] + N[30] + N[31] + N[32] + N[33] + 
N[34]);
numPIDsnct[n,4] := (PIDnumnct[n,35] * N[35] + PIDnumnct[n,36] * N[36] + 
PIDnumnct[n,37] * N[37] + PIDnumnct[n,38] * N[38] + 
PIDnumnct[n,39] * N[39] + PIDnumnct[n,40] * N[40] +
PIDnumnct[n,41] * N[41] + PIDnumnct[n,42] * N[32] + 
PIDnumnct[n,43] * N[43] + PIDnumnct[n,44] * N[44]) /
(N[35] + N[36] + N[37] + N[38] + N[39] + N[40] + N[41] + N[42] + N[43] + 
N[44]);
END;
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END numberPIDsagegpnct;
PROCEDURE numberPIDsobsageallnct (PIDnumnct: ARRAY OF ARRAY OF REAL; psi: 
REAL;
OUT PIDnumobsnct: ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDnumobsnct[1,a] :=  PIDnumnct[1,a] * psi + 2 * PIDnumnct[2,a] * psi * (1 - psi) + 
3 * PIDnumnct[3,a] * psi * (1 - psi) * (1 - psi);
PIDnumobsnct[2,a] :=  PIDnumnct[2,a] * psi * psi + 3 * PIDnumnct[3,a] * psi * psi * (1 - psi);
PIDnumobsnct[3,a] :=  PIDnumnct[3,a] * psi * psi * psi
END;
END numberPIDsobsageallnct;
PROCEDURE eventsin8 (pi: ARRAY OF ARRAY OF REAL; p: ARRAY OF ARRAY OF 
ARRAY OF 
REAL; lambda_PID2: ARRAY OF ARRAY OF REAL;  N: ARRAY 
OF REAL;
OUT PIDsin8: ARRAY OF REAL);
VAR
a: INTEGER; 
last2yrs: ARRAY 45 OF REAL;
BEGIN
PIDsin8[14] := 0;
PIDsin8[15] := 0;
FOR a := 16 TO 44 DO
last2yrs[a] := pi[5,a-3] * p[5,8,a-2] + pi[5,a-2] * p[5,8,a-1] + 
pi[6,a-3] * p[6,8,a-2] + pi[6,a-2] * p[6,8,a-1] + 
pi[7,a-3] * p[7,8,a-2] + pi[7,a-2] * p[7,8,a-1];
PIDsin8[a] := last2yrs[a] * ( 1 - Math.Exp(-lambda_PID2[2,a])) + 
(pi[8,a] - last2yrs[a]) * (1 - Math.Exp(-lambda_PID2[1,a])) 
END;
END eventsin8;
PROCEDURE eventsin8nct (pinct: ARRAY OF ARRAY OF REAL; pnct: ARRAY OF ARRAY 
OF 
ARRAY OF REAL; lambda_PID2nct: ARRAY OF ARRAY OF 
REAL;  N: 
ARRAY OF REAL;
OUT PIDsin8nct: ARRAY OF REAL);
VAR
a: INTEGER; 
last2yrs: ARRAY 45 OF REAL;
BEGIN
PIDsin8nct[14] := 0;
PIDsin8nct[15] := 0;
FOR a := 16 TO 44 DO
last2yrs[a] := pinct[5,a-3] * pnct[5,8,a-2] + pinct[5,a-2] * pnct[5,8,a-1] + 
pinct[6,a-3] * pnct[6,8,a-2] + pinct[6,a-2] * pnct[6,8,a-1] + 
pinct[7,a-3] * pnct[7,8,a-2] + pinct[7,a-2] * pnct[7,8,a-1];
PIDsin8nct[a] := last2yrs[a] * ( 1 - Math.Exp(-lambda_PID2nct[2,a])) + 
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(pinct[8,a] - last2yrs[a]) * (1 - Math.Exp(-lambda_PID2nct[1,a])); 
END;
END eventsin8nct;
PROCEDURE predincforpop (pi: ARRAY OF ARRAY OF REAL; p: ARRAY OF ARRAY OF 
ARRAY 
OF REAL; PIDsin8: ARRAY OF REAL;
OUT PIDinc: ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDinc[1,a] := pi[1,a-1] * p[1,2,a]; 
PIDinc[2,a] := pi[2,a-1] * p[2,5,a] + pi[3,a-1] * p[3,5,a] + pi[4,a-1] * p[4,5,a];
PIDinc[3,a] := pi[5,a-1] * p[5,8,a] + pi[6,a-1] * p[6,8,a] + pi[7,a-1] * p[7,8,a]; 
PIDinc[4,a] := PIDsin8[a];
END;
END predincforpop;
PROCEDURE predincforpopnct (pinct: ARRAY OF ARRAY OF REAL; pnct: ARRAY OF 
ARRAY OF                                                                   
ARRAY OF REAL; PIDsin8nct: ARRAY OF REAL;
OUT PIDincnct: ARRAY OF ARRAY OF REAL);
VAR
a: INTEGER; 
BEGIN
FOR a := 16 TO 44 DO
PIDincnct[1,a] := pinct[1,a-1] * pnct[1,2,a]; 
PIDincnct[2,a] := pinct[2,a-1] * pnct[2,5,a] + pinct[3,a-1] * pnct[3,5,a] + 
pinct[4,a-1] * pnct[4,5,a];
PIDincnct[3,a] := pinct[5,a-1] * pnct[5,8,a] + pinct[6,a-1] * pnct[6,8,a] + 
pinct[7,a-1] * pnct[7,8,a]; 
PIDincnct[4,a] := PIDsin8nct[a];
END;
END predincforpopnct;
PROCEDURE predincgpforpop (PIDinc: ARRAY OF ARRAY OF REAL; N: ARRAY OF 
REAL; 
PIDsin8: ARRAY OF REAL;
OUT pred_prop_ag: ARRAY OF REAL);
VAR
a: INTEGER; 
pred_pop: ARRAY 45 OF REAL;
sumN: REAL;
BEGIN
FOR a := 16 TO 44 DO
pred_pop[a] := (PIDinc[1,a] + PIDinc[2,a] + PIDinc[3,a] + PIDinc[4,a]) *  N[a];
END;
pred_prop_ag[1] := (pred_pop[16] + pred_pop[17] + pred_pop[18] + pred_pop[19]) /
(N[16] + N[17] + N[18] + N[19]);
pred_prop_ag[2] := (pred_pop[20] + pred_pop[21] + pred_pop[22] + pred_pop[23] + 
pred_pop[24]) /
(N[20] + N[21] + N[22] + N[23] + N[24]);
pred_prop_ag[3] := (pred_pop[25] + pred_pop[26] + pred_pop[27] + pred_pop[28] + 
pred_pop[29] + 
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pred_pop[30] + pred_pop[31] + pred_pop[32] + pred_pop[33] + 
pred_pop[34]) /
(N[25] + N[26] + N[27] + N[28] + N[29] + N[30] + N[31] + N[32] + N[33] 
+ N[34]);
pred_prop_ag[4] := (pred_pop[35] + pred_pop[36] + pred_pop[37] + pred_pop[38] + 
pred_pop[39] + 
pred_pop[40] + pred_pop[41] + pred_pop[42] + pred_pop[43] + 
pred_pop[44]) /
(N[35] + N[36] + N[37] + N[38] + N[39] + N[40] + N[41] + N[42] + N[43] + 
N[44]);
pred_prop_ag[0] := 0;
sumN := 0;
FOR a := 16 TO 44 DO
pred_prop_ag[0] := pred_prop_ag[0] + pred_pop[a];
sumN := sumN + N[a];
END;
pred_prop_ag[0] := pred_prop_ag[0] / sumN;
END predincgpforpop;
PROCEDURE predincgpforpopnct (PIDincnct: ARRAY OF ARRAY OF REAL; N: ARRAY OF 
REAL;                                                                        
PIDsin8nct: ARRAY OF REAL;
OUT pred_prop_agnct: ARRAY OF REAL);
VAR
a: INTEGER; 
pred_pop: ARRAY 45 OF REAL;
sumN: REAL;
BEGIN
FOR a := 16 TO 44 DO
pred_pop[a] := (PIDincnct[1,a] + PIDincnct[2,a] + PIDincnct[3,a] + PIDincnct[4,a]) *  N[a];
END;
pred_prop_agnct[1] := (pred_pop[16] + pred_pop[17] + pred_pop[18] + pred_pop[19]) /
(N[16] + N[17] + N[18] + N[19]);
pred_prop_agnct[2] := (pred_pop[20] + pred_pop[21] + pred_pop[22] + pred_pop[23] + 
pred_pop[24])  / (N[20] + N[21] + N[22] + N[23] + N[24]);
pred_prop_agnct[3] := (pred_pop[25] + pred_pop[26] + pred_pop[27] + pred_pop[28] + 
pred_pop[29] + pred_pop[30] + pred_pop[31] + pred_pop[32] + 
pred_pop[33] + pred_pop[34]) /
(N[25] + N[26] + N[27] + N[28] + N[29] + N[30] + N[31] + N[32] + N[33] 
+ N[34]);
pred_prop_agnct[4] := (pred_pop[35] + pred_pop[36] + pred_pop[37] + pred_pop[38] + 
pred_pop[39] + pred_pop[40] + pred_pop[41] + pred_pop[42] + 
pred_pop[43] + pred_pop[44]) /
(N[35] + N[36] + N[37] + N[38] + N[39] + N[40] + N[41] + N[42] + N[43] 
+ N[44]);
pred_prop_agnct[0] := 0;
sumN := 0;
FOR a := 16 TO 44 DO
pred_prop_agnct[0] := pred_prop_agnct[0] + pred_pop[a];
sumN := sumN + N[a];
END;
pred_prop_agnct[0] := pred_prop_agnct[0] / sumN;
END predincgpforpopnct;
PROCEDURE (func: Function) Evaluate (OUT values: ARRAY OF REAL);
VAR
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a, n, i: INTEGER;
eta1, psi, philap: REAL;
lambda_PID, EF, pred_prop_ag, pred_prop_agnct: ARRAY 5 OF REAL;
PIDsin8,PIDsin8nct,N: ARRAY 45 OF REAL;
lambda_PID2, lambda_PID2nct: ARRAY 3,45 OF REAL;
p, pnct: ARRAY 9,9,45 OF REAL;
pi, pinct: ARRAY 9,45 OF REAL;
numPIDs, numPIDsnct: ARRAY 4,5 OF REAL;
PIDinc, PIDincnct: ARRAY 5,45 OF REAL;
PIDnum, PIDnumnct, PIDnumobs,PIDnumobsnct: ARRAY 4,45 OF REAL;
BEGIN
readindata1(func, lambda_PID);
readindata2(func, psi);
readindata3(func, eta1);
readindata4(func, EF);
readindata5(func, philap);
readindata6(func, N);
tranratesall(lambda_PID, eta1, lambda_PID2);
tranratesnct(lambda_PID, eta1, EF,   lambda_PID2nct);
tranproball(lambda_PID2, philap, p);
tranprobnct(lambda_PID2nct, philap, pnct);
stateoccpropall(p,  pi );
stateoccpropnct(pnct,  pinct );
numberPIDsageall(pi, N,  PIDnum);
numberPIDsagenct(pinct, N,   PIDnumnct);
numberPIDsagegpall(PIDnum, N,  numPIDs);
numberPIDsagegpnct(PIDnumnct, N,   numPIDsnct);
numberPIDsobsageall(PIDnum, psi,  PIDnumobs);
numberPIDsobsageallnct(PIDnumnct, psi,  PIDnumobsnct);
eventsin8(pi, p, lambda_PID2, N,   PIDsin8);
predincforpop(pi, p, PIDsin8,  PIDinc); 
predincgpforpop(PIDinc, N, PIDsin8,    pred_prop_ag);
eventsin8nct(pinct, pnct, lambda_PID2nct, N,   PIDsin8nct);
predincforpopnct(pinct, pnct, PIDsin8nct,     PIDincnct);
predincgpforpopnct(PIDincnct, N, PIDsin8nct,     pred_prop_agnct);
i := 0;
FOR n := 1TO 3 DO
FOR a := 1 TO 4 DO
values[i] := numPIDs[n,a];
values[i+12] := numPIDsnct[n,a];
INC(i);
END;
END;
FOR i := 24 TO 28 DO
values[i] := pred_prop_ag[i-24];
END;
i := 29;
FOR n := 1 TO 3 DO
FOR a := 16 TO 44 DO
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values[i] := PIDnum[n,a];
values[i+87] := PIDnumnct[n,a];
INC(i);
END;
END;
i := 203;
FOR n := 1 TO 4 DO
FOR a := 16 TO 44 DO
values[i] := PIDinc[n,a];
values[i+116] := PIDincnct[n,a];
INC(i);
END;
END;
i := 435;
FOR n := 1 TO 3 DO
FOR a := 16 TO 44 DO
values[i] := PIDnumobs[n,a];
values[i+87] := PIDnumobsnct[n,a];
INC(i);
END;
END;
END Evaluate;
PROCEDURE (f: Factory) New (option: INTEGER): Function;
VAR
func: Function;
BEGIN
NEW(func); func.Initialize; RETURN func;
END New;
PROCEDURE Install*;
BEGIN
WBDevVector.Install(fact);
END Install;
PROCEDURE Init;
VAR
f: Factory;
BEGIN
NEW(f); fact := f;
END Init;
BEGIN
Init;
END WBDevCumulativePIDlap.
(B).  WinBUGS code to calculate numbers of PIDs and non-CT related 
PIDs 
model {
# PID incidence and ct GP re-infection rate ratio informative priors
Y[1:10] ~ dmnorm(mu[], Omega[ , ]) 
for (ag in 1:4) {
log(lambda.PID[ag]) <- Y[ag]
EF[ag]  <- Y[ag+5] * Y[ag+5]
}
logit(psi) <- Y[5]
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log(eta1) <- Y[10]
# WBDEV call
for (ag in 1:4) {
input1[ag] <- lambda.PID[ag]
input1[ag+6] <- EF[ag]
}
input1[5] <- psi
input1[6] <- eta1
for (i in 1:29) {
input2[i] <- N[i+15]
}
philap ~ dbeta(12,16)
input1[11] <- philap
solution[1:609] <- cumulativePIDlap(input1[1:11],input2[1:29])
for (ag in 1:4) {
Expect.prop[ag] <- 1 - exp(-lambda.PID[ag])
}
total.expect.prop <- (Expect.prop[1] * sum(N[16:19]) +
Expect.prop[2] * sum(N[20:24]) +
Expect.prop[3] * sum(N[25:34]) +
Expect.prop[4] * sum(N[35:44])) / 
sum(N[16:44])
}
# Data
list(
# PID incidence, r-infection raqte, Etological fractions and re-
# infection rate
mu = c(-3.865, -3.595, -3.964, -4.402, -0.5856, 0.7104, 0.4815, 0.3117, 0.3277, 
1.919),
Omega = structure(.Data =c(
573.855, -49.264, -10.817, -3.992, 323.371, 97.687, -112.351, -30.198, -5.401, -2.713,
-49.264, 301.419, -14.194, -3.299, 147.591, -78.069, 176.480, -72.284, -11.551, 2.012,
-10.817, -14.194, 105.908, -20.063, 37.684, -13.275, -46.636, 236.305, -118.245,
0.515,
-3.992, -3.299, -20.063, 57.687, 19.172, -2.664, -8.418, -125.677, 138.728, 0.088,
323.371, 147.591, 37.684, 19.172, 351.620, 1.363, -1.443, -1.164, 1.537, 0.030,
97.687, -78.069, -13.275, -2.664, 1.363, 285.706, -324.389, -85.846, -16.864, -7.957,
-112.351, 176.480, -46.636, -8.418, -1.443, -324.389, 734.182, -295.254, -50.046,
8.090,
-30.198, -72.284, 236.305, -125.677, -1.164, -85.846, -295.254, 1512.713, -758.618,
3.088,
-5.401, -11.551, -118.245, 138.728, 1.537, -16.864, -50.046, -758.618, 839.634, 0.705,
-2.713, 2.012, 0.515, 0.088, 0.030, -7.957, 8.090, 3.088, 0.705, 13.711
),
.Dim = c(10,10)),
# Population sizes from census, age =1...44 - 2002
N=c(NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, 
305500,306300,296400,291400,294800,
310100,313900,305600,294700,295000,
304100,317000,329600,349600,370300,
380900,376900,387800,390900,399400,
401200,402600,398700,391900,381900, 370900,356200,349000,343800)
)
# Initial values 1
list(
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Y = c(-5,-5,-5,-5,-1,-5,-5,-5,-5,-1)
)
# Initial values 2
list(
Y = c(-1,-1,-1,-1,3,-1,-1,-1,-1,3)
)
(C).  WinBUGS code comparisons to Lund data 
# Westrom proportions
model {
r1[1:3] ~ dmulti(p1[1:3],N1)
r2[1:3] ~ dmulti(p2[1:3],N2)
p1[1:3] ~ ddirch(a1[1:3])
p2[1:3] ~ ddirch(a2[1:3])
}
# Data
list(r1 = c(771,158,61),r2 = c(220,27,4), N1 = 990, N2 = 251, 
a1 =c(1,1,1), a2 = c(1,1,1))
# Initial Values
list(p1 = c(0.7,0.2,0.1),p2 = c(0.7,0.2,0.1))
# twelve - comparison of cumulative PID to Westrom
model {
Y[1:10] ~ dmnorm(mu[], Omega[ , ]) 
for (ag in 1:4) {
log(lambda.PID[ag]) <- Y[ag]
}
logit(psi) <- Y[5]
log(eta1) <- Y[10]
# transition rates
for (a in 16:19) {
lambda.PID2[1,a] <- lambda.PID[1] * 0.85
lambda.PID2[2,a] <- lambda.PID2[1,a] * eta1
}
for (a in 20:24) {
lambda.PID2[1,a] <- lambda.PID[2] * 0.85
lambda.PID2[2,a] <- lambda.PID2[1,a] * eta1
}
for (a in 25:34) {
lambda.PID2[1,a] <- lambda.PID[3] * 0.85
lambda.PID2[2,a] <- lambda.PID2[1,a] * eta1
}
for (a in 35:44) {
lambda.PID2[1,a] <- lambda.PID[4] * 0.85
lambda.PID2[2,a] <- lambda.PID2[1,a] * eta1
}
# transition probabilities
# state 1 = 1 PID <1 year
# state 2 = 1 PID 1-2 years
# state 3 = 1 PID 2+ years
# state 4 = 2 PIDs <1 year
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# state 5 = 2 PIDs 1-2 years
# state 6 = 2 PIDs 2+ years
# state 7 = 3 PIDs < 1 year 
# state 8 = 3 PIDs 1-2 years 
# state 9 = 3 PIDs 2+ years 
# state 10 = 4 PIDs < 1 year 
# state 11 = 4 PIDs < 1-2 years 
# state 12 = 4 PIDs < 2+ years 
# state 13 = 5 PIDs assume no more than 5 PIDs
for (a in 16:44) {
p[1,1,a] <- 0
p[1,2,a] <- 1 - p[1,4,a]
p[1,4,a] <- 1 - exp(-lambda.PID2[2,a])
p[2,2,a] <- 0
p[2,3,a] <- 1 - p[2,4,a]
p[2,4,a] <- 1 - exp(-lambda.PID2[2,a])
p[3,3,a] <- 1 - p[3,4,a]
p[3,4,a] <- 1 - exp(-lambda.PID2[1,a])
p[4,4,a] <- 0
p[4,5,a] <- 1 - p[4,7,a]
p[4,7,a] <- 1 - exp(-lambda.PID2[2,a])
p[5,5,a] <- 0
p[5,6,a] <- 1 - p[5,7,a]
p[5,7,a] <- 1 - exp(-lambda.PID2[2,a])
p[6,6,a] <- 1 - p[6,7,a]
p[6,7,a] <- 1 - exp(-lambda.PID2[1,a])
p[7,7,a] <- 0
p[7,8,a] <- 1 - p[7,10,a]
p[7,10,a] <- 1 - exp(-lambda.PID2[2,a])
p[8,8,a] <- 0
p[8,9,a] <- 1 - p[8,10,a]
p[8,10,a] <- 1 - exp(-lambda.PID2[2,a])
p[9,9,a] <- 1 - p[9,10,a]
p[9,10,a] <- 1 - exp(-lambda.PID2[1,a])
p[10,10,a] <- 0
p[10,11,a] <- 1 - p[10,13,a]
p[10,13,a] <- 1 - exp(-lambda.PID2[2,a])
p[11,11,a] <- 0
p[11,12,a] <- 1 - p[11,13,a]
p[11,13,a] <- 1 - exp(-lambda.PID2[2,a])
p[12,12,a] <- 1 - p[9,10,a]
p[12,13,a] <- 1 - exp(-lambda.PID2[1,a])
p[13,13,a] <- 1
}
# State occupancy proportions
for (i in 16:37) {
pi[i,1,i-1] <- 1
DOI: 10.3310/hta20220 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 22
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Price et al. This issue may be freely reproduced for the purposes of private research and study and
extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any
form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
215
pi[i,2,i-1] <- 0
pi[i,3,i-1] <- 0
pi[i,4,i-1] <- 0
pi[i,5,i-1] <- 0
pi[i,6,i-1] <- 0
pi[i,7,i-1] <- 0
pi[i,8,i-1] <- 0
pi[i,9,i-1] <- 0
pi[i,10,i-1] <- 0
pi[i,11,i-1] <- 0
pi[i,12,i-1] <- 0
pi[i,13,i-1] <- 0
}
for (i in 16:37) {
for (a in i:i+7) {
pi[i,1,a] <- pi[i,1,a-1] * p[1,1,a] 
pi[i,2,a] <- pi[i,1,a-1] * p[1,2,a] + pi[i,2,a-1] * p[2,2,a] 
pi[i,3,a] <- pi[i,2,a-1] * p[2,3,a] + pi[i,3,a-1] * p[3,3,a] 
pi[i,4,a] <- pi[i,1,a-1] * p[1,4,a] + pi[i,2,a-1] * p[2,4,a] +
pi[i,3,a-1] * p[3,4,a] + pi[i,4,a-1] * p[4,4,a]
pi[i,5,a] <- pi[i,4,a-1] * p[4,5,a] + pi[i,5,a-1] * p[5,5,a] 
pi[i,6,a] <- pi[i,5,a-1] * p[5,6,a] + pi[i,6,a-1] * p[6,6,a] 
pi[i,7,a] <- pi[i,4,a-1] * p[4,7,a] + pi[i,5,a-1] * p[5,7,a] +
pi[i,6,a-1] * p[6,7,a] + pi[i,7,a-1] * p[7,7,a]
pi[i,8,a] <- pi[i,7,a-1] * p[7,8,a] + pi[i,8,a-1] * p[8,8,a]
pi[i,9,a] <- pi[i,8,a-1] * p[8,9,a] + pi[i,9,a-1] * p[9,9,a]
pi[i,10,a] <- pi[i,7,a-1] * p[7,10,a] + pi[i,8,a-1] * p[8,10,a] +
pi[i,9,a-1] * p[9,10,a] + pi[i,10,a-1] * p[10,10,a]
pi[i,11,a] <- pi[i,10,a-1] * p[10,11,a] + pi[i,11,a-1] * 
p[11,11,a]
pi[i,12,a] <- pi[i,11,a-1] * p[11,12,a] + pi[i,12,a-1] * 
p[12,12,a]
pi[i,13,a] <- pi[i,10,a-1] * p[10,13,a] + pi[i,11,a-1] * 
p[11,13,a] +
pi[i,12,a-1] * p[12,13,a] + pi[i,13,a-1] * 
p[13,13,a]
}
}
# Proportion in each state by age
for (i in 16:37) {
prop[i,1] <- sum(pi[i,1:3,i+7])
prop[i,2] <- sum(pi[i,4:6,i+7])
prop[i,3] <- sum(pi[i,7:9,i+7])
prop[i,4] <- sum(pi[i,10:12,i+7])
prop[i,5] <- pi[i,13,i+7]
propcomp[i,1] <- prop[i,1]
propcomp[i,2] <- prop[i,2]
propcomp[i,3] <- sum(prop[i,3:5])
}
propunder25[1] <- sum(propcomp[16:24,1]) / 9
propunder25[2] <- sum(propcomp[16:24,2]) / 9
propunder25[3] <- sum(propcomp[16:24,3]) / 9
propover25[1] <- sum(propcomp[25:37,1]) / 13
propover25[2] <- sum(propcomp[25:37,2]) / 13
propover25[3] <- sum(propcomp[25:37,3]) / 13
# Proportion expected to be observed in state by age
for (i in 16:37) {
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
prop.obs[i,1] <- prop[i,1] +
prop[i,2] * (1 - psi) +
prop[i,3] * (1 - psi) * (1 - psi) +
prop[i,4] * (1 - psi) * (1 - psi) * (1 - psi) +
prop[i,5] * (1 - psi) * (1 - psi) * (1 - psi) * (1 
- psi)
prop.obs[i,2] <- prop[i,2] * psi + 
2 * prop[i,3] * psi * (1 - psi) +
3 * prop[i,4] * psi * (1 - psi) * (1 - psi) +
4 * prop[i,5] * psi * (1 - psi) * (1 - psi) * (1 -
psi)
prop.obs[i,3] <- prop[i,3] * psi * psi +
3 * prop[i,4] * psi * psi * (1 - psi) +
6 * prop[i,5] * psi * psi * (1 - psi) * (1 - psi)
prop.obs[i,4] <- prop[i,4] * psi * psi * psi +
4 * prop[i,5] * psi * psi * psi * (1 - psi)
prop.obs[i,5] <- prop[i,5] * psi * psi * psi * psi
prop.obscomp[i,1] <- prop.obs[i,1]
prop.obscomp[i,2] <- prop.obs[i,2]
prop.obscomp[i,3] <- sum(prop.obs[i,3:5])
}
prop.obsunder25[1] <- sum(prop.obscomp[16:24,1]) / 9
prop.obsunder25[2] <- sum(prop.obscomp[16:24,2]) / 9
prop.obsunder25[3] <- sum(prop.obscomp[16:24,3]) / 9
prop.obsover25[1] <- sum(prop.obscomp[25:37,1]) / 13
prop.obsover25[2] <- sum(prop.obscomp[25:37,2]) / 13
prop.obsover25[3] <- sum(prop.obscomp[25:37,3]) / 13
}
# Data
list(
# PID incidence, r-infection raqte, Etological fractions and re-
# infection rate
mu = c(-3.865, -3.595, -3.964, -4.402, -0.5856, 0.7104, 0.4815, 0.3117, 0.3277, 
1.919),
Omega = structure(.Data =c(
573.855, -49.264, -10.817, -3.992, 323.371, 97.687, -112.351, -30.198, -5.401, -2.713,
-49.264, 301.419, -14.194, -3.299, 147.591, -78.069, 176.480, -72.284, -11.551, 2.012,
-10.817, -14.194, 105.908, -20.063, 37.684, -13.275, -46.636, 236.305, -118.245,
0.515,
-3.992, -3.299, -20.063, 57.687, 19.172, -2.664, -8.418, -125.677, 138.728, 0.088,
323.371, 147.591, 37.684, 19.172, 351.620, 1.363, -1.443, -1.164, 1.537, 0.030,
97.687, -78.069, -13.275, -2.664, 1.363, 285.706, -324.389, -85.846, -16.864, -7.957,
-112.351, 176.480, -46.636, -8.418, -1.443, -324.389, 734.182, -295.254, -50.046,
8.090,
-30.198, -72.284, 236.305, -125.677, -1.164, -85.846, -295.254, 1512.713, -758.618,
3.088,
-5.401, -11.551, -118.245, 138.728, 1.537, -16.864, -50.046, -758.618, 839.634, 0.705,
-2.713, 2.012, 0.515, 0.088, 0.030, -7.957, 8.090, 3.088, 0.705, 13.711
),
.Dim = c(10,10))
)
# Initial values 1
list(
Y = c(-5,-5,-5,-5,-1,-5,-5,-5,-5,-1)
)
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# Initial values 2
list(
Y = c(-1,-1,-1,-1,3,-1,-1,-1,-1,3)
)
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Appendix 12 WinBUGS code for prediction of
ectopic pregnancy rates in Table 35 (see Chapter 9)
model {
# Population (disecrete time) model - 2 year higher rate
# PID incidence and ct GP re-infection rate ratio informative priors
Y[1:10] ~ dmnorm(mu[], Omega[ , ]) 
for (ag in 1:4) {
log(lambda.PID[ag]) <- Y[ag]
EF[ag] <- Y[ag+5] * Y[ag+5]
}
logit(psi) <- Y[5]
log(eta1) <- Y[10]
# WBDEV call
for (ag in 1:4) {
input1[ag] <- lambda.PID[ag]
input1[ag+6] <- EF[ag]
}
input1[5] <- psi
input1[6] <- eta1
philap ~ dbeta(12,16)
input1[11] <- philap
for (i in 1:29) {
input2[i] <- N[i+15]
}
solution[1:609] <- cumulativePIDlap(input1[1:11],input2[1:29])
# number of previous PIDs [n,a] n = number: 0,1,2,3; a = age-group
for (a in 1:4) { 
numPIDs[1,a] <- 1 - numPIDs[2,a] - numPIDs[3,a] - numPIDs[4,a]
numPIDs[2,a] <- solution[a]
numPIDs[3,a] <- solution[a+4]
numPIDs[4,a] <- solution[a+8]
numPIDsnct[1,a] <- 1 - numPIDsnct[2,a] - numPIDsnct[3,a] -
numPIDsnct[4,a]
numPIDsnct[2,a] <- solution[a+12]
numPIDsnct[3,a] <- solution[a+16]
numPIDsnct[4,a] <- solution[a+20]
numPIDsct[1,a] <- numPIDs[1,a] - numPIDsnct[1,a]
numPIDsct[2,a] <- numPIDs[2,a] - numPIDsnct[2,a]
numPIDsct[3,a] <- numPIDs[3,a] - numPIDsnct[3,a]
numPIDsct[4,a] <- numPIDs[4,a] - numPIDsnct[4,a]
}
# population denominators - 2002
N1619 <- sum(N[16:19])
N2024 <- sum(N[20:24])
N2534 <- sum(N[25:34])
N3544 <- sum(N[35:44])
N1644 <- sum(N[16:44])
N1617 <- sum(N[16:17])
N1820 <- sum(N[18:20])
N2124 <- sum(N[21:24])
N2529 <- sum(N[25:29])
N3044 <- sum(N[30:44])
N1819 <- sum(N[18:19])
N3034 <- sum(N[30:34])
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# Distribution of PID severity - 2002
# hospital
r.HESPID[1] ~ dbin(HESPID[1],N1619) 
r.HESPID[2] ~ dbin(HESPID[2],N2024) 
r.HESPID[3] ~ dbin(HESPID[3],N2534) 
r.HESPID[4] ~ dbin(HESPID[4],N3544) 
# priors
for (a in 1:4) {
HESPID[a] ~ dbeta(1,1)
}
# kc60
r.kc602008[1] ~ dbin(kc602008[1],N1619)
r.kc602008[2] ~ dbin(kc602008[2],N2024)
r.kc602008[3] ~ dbin(kc602008[3],N2534)
r.kc602008[4] ~ dbin(kc602008[4],N3544)
# priors
for (a in 1:4) {
kc602008[a] ~ dbeta(1,1)
}
# data by age not available until 2008
# 13421 / 12117 is the ratio of totals for 2002 and GUMCAD data for 
# 2008
# assumes GUMCAD data representative of all kc60
# assumes age distribution is the same in 2002 as 2008
for (a in 1:4) { 
kc60[a] <- kc602008[a] * 13421 / 12117
}
# GPRD
r.GPRDPID[1] ~ dbin(GPRDPID[1],N1619)
r.GPRDPID[2] ~ dbin(GPRDPID[2],N2024) 
r.GPRDPID[3] ~ dbin(GPRDPID[3],N2534) 
r.GPRDPID[4] ~ dbin(GPRDPID[4],N3544) 
# priors
for (a in 1:4) {
GPRDPID[a] ~ dbeta(1,1)
}
# Distribution
for (a in 1:4) {
pmin[a] <- kc60[a] + max(HESPID[a],GPRDPID[a])
pmax[a] <- kc60[a] + HESPID[a] + GPRDPID[a]
X[a] ~ dunif(pmin[a],pmax[a])
hospdiag[a] <- psi * HESPID[a] / X[a] 
milddiag[a] <- 1 - hospdiag[a] - undiag[a]
undiag[a] <- (1 - psi)
}
# proportion with PIDs by each age, severity, and number 
# all PID
# n = 1
for (s in 1:3) {
for (a in 1:4) {
PIDcat[1,s,a] <- 1 - (PIDcat[2,s,a] + PIDcat[3,s,a] + 
PIDcat[4,s,a])
}
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}# n = 2-4
for (n in 2:4) {
for (a in 1:4) {
PIDcat[n,1,a] <- numPIDs[n,a] * undiag[a]
PIDcat[n,2,a] <- numPIDs[n,a] * milddiag[a]
PIDcat[n,3,a] <- numPIDs[n,a] * hospdiag[a]
}
}
for (n in 2:4) {
for (s in 1:3) {
PIDcat1624_2544[n,s,1] <- (PIDcat[n,s,1] * sum(N[16:19]) +
PIDcat[n,s,2] * sum(N[20:24]) + 
PIDcat[n,s,3] * sum(N[25:29])) /
sum(N[16:29])
PIDcat1624_2544[n,s,2] <- (PIDcat[n,s,3] * sum(N[30:34]) +
PIDcat[n,s,4] * sum(N[35:44])) /
sum(N[30:44])
PIDcat1624_2544[n,s,3] <- (PIDcat[n,s,1] * sum(N[16:19]) +
PIDcat[n,s,2] * sum(N[20:24]) +
PIDcat[n,s,3] * sum(N[25:34]) +
PIDcat[n,s,4] * sum(N[35:44])) /
sum(N[16:44])
}
}
for (a in 1:2) {
for (n in 2:4) {
sumsevPIDcat1624_2544[n,a] <- sum(PIDcat1624_2544[n, ,a])
}
sum2sevPIDcat1624_2544[a] <-sum(sumsevPIDcat1624_2544[2:4,a])
for (s in 1:3) {
sumnumPIDcat1624_2544[s,a] <- sum(PIDcat1624_2544[2:4,s,a])
}
sum2numPIDcat1624_2544[a] <- sum(sumnumPIDcat1624_2544[ ,a])
}
# non-CT related PID
# n = 1
for (s in 1:3) {
for (a in 1:4) {
PIDcatnct[1,s,a] <- 1 - (PIDcatnct[2,s,a] + PIDcatnct[3,s,a] +
PIDcatnct[4,s,a])
}
}
# n = 2-4
for (n in 2:4) {
for (a in 1:4) {
PIDcatnct[n,1,a] <- numPIDsnct[n,a] * undiag[a]
PIDcatnct[n,2,a] <- numPIDsnct[n,a] * milddiag[a]
PIDcatnct[n,3,a] <- numPIDsnct[n,a] * hospdiag[a]
}
}
for (n in 2:4) {
for (s in 1:3) {
PIDcat1624_2544nct[n,s,1] <- (PIDcatnct[n,s,1] * sum(N[16:19]) +
PIDcatnct[n,s,2] * sum(N[20:24]) + 
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PIDcatnct[n,s,3] * sum(N[25:29])) /
sum(N[16:29])
PIDcat1624_2544nct[n,s,2] <- (PIDcatnct[n,s,3] * sum(N[30:34]) +
PIDcatnct[n,s,4] * sum(N[35:44])) /
sum(N[30:44])
PIDcat1624_2544nct[n,s,3] <- (PIDcatnct[n,s,1] * sum(N[16:19]) +
PIDcatnct[n,s,2] * sum(N[20:24]) +
PIDcatnct[n,s,3] * sum(N[25:34]) +
PIDcatnct[n,s,4] * sum(N[35:44])) /
sum(N[16:44])
}
}
for (a in 1:3) {
for (n in 2:4) {
sumsevPIDcat1624_2544nct[n,a] <- sum(PIDcat1624_2544nct[n, ,a])
}
sum2sevPIDcat1624_2544nct[a] <-sum(sumsevPIDcat1624_2544nct[2:4,a])
for (s in 1:3) {
sumnumPIDcat1624_2544nct[s,a] <- sum(PIDcat1624_2544nct[2:4,s,a])
}
sum2numPIDcat1624_2544nct[a] <- sum(sumnumPIDcat1624_2544nct[ ,a])
}
# CT related PID
# n = 1
for (s in 1:3) {
for (a in 1:4) {
PIDcatct[1,s,a] <- 1 - (PIDcatct[2,s,a] + PIDcatct[3,s,a] +
PIDcatct[4,s,a])
}
}
# n = 2-4
for (n in 2:4) {
for (a in 1:4) {
PIDcatct[n,1,a] <- numPIDsct[n,a] * undiag[a]
PIDcatct[n,2,a] <- numPIDsct[n,a] * milddiag[a]
PIDcatct[n,3,a] <- numPIDsct[n,a] * hospdiag[a]
}
}
for (n in 2:4) {
for (s in 1:3) {
PIDcat1624_2544ct[n,s,1] <- (PIDcatct[n,s,1] * sum(N[16:19]) +
PIDcatct[n,s,2] * sum(N[20:24]) + 
PIDcatct[n,s,3] * sum(N[25:29])) /
sum(N[16:29])
PIDcat1624_2544ct[n,s,2] <- (PIDcatct[n,s,3] * sum(N[30:34]) +
PIDcatct[n,s,4] * sum(N[35:44])) /
sum(N[30:44])
PIDcat1624_2544ct[n,s,3] <- (PIDcatct[n,s,1] * sum(N[16:19]) +
PIDcatct[n,s,2] * sum(N[20:24]) +
PIDcatct[n,s,3] * sum(N[25:34]) +
PIDcatct[n,s,4] * sum(N[35:44])) /
sum(N[16:44])
}
}
for (a in 1:3) {
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for (n in 2:4) {
sumsevPIDcat1624_2544ct[n,a] <- sum(PIDcat1624_2544ct[n, ,a])
}
sum2sevPIDcat1624_2544ct[a] <-sum(sumsevPIDcat1624_2544ct[2:4,a])
for (s in 1:3) {
sumnumPIDcat1624_2544ct[s,a] <- sum(PIDcat1624_2544ct[2:4,s,a])
}
sum2numPIDcat1624_2544ct[a] <- sum(sumnumPIDcat1624_2544ct[ ,a])
}
# Probability of EP given PID and conception 
# Likelihood
# Westrom progression to EP by number of episodes
for (n in 1:4) {
r.EPnum[n] ~ dbin(EPnum[n],n.EPnum[n])
}
# Westrom progression to EP by severity in women with 1 PID
for (s in 1:3) {
r.EPsev[s] ~ dbin(EPsev[s],n.EPsev[s])
}
# Westrom progression to EP by age in women with 1 PID
for (a in 1:2) {
r.EPage[a] ~ dbin(EPage[a],n.EPage[a])
}
# functional retionship between model (see below) parameters and 
# likelihood
EPnum[1] <- (control[1] * 713 + control[2] * 199) / 912
for (n in 2:4) {
EPnum[n] <- (((PIDconctoEP[n,1,1] * n.EPsev[1] +
PIDconctoEP[n,2,1] * n.EPsev[2] +
PIDconctoEP[n,3,1] * n.EPsev[3]) /
sum(n.EPsev[1:3])) * n.EPage[1] 
+
((PIDconctoEP[n,1,2] * n.EPsev[1] +
PIDconctoEP[n,2,2] * n.EPsev[2] +
PIDconctoEP[n,3,2] * n.EPsev[3]) /
sum(n.EPsev[1:3])) * n.EPage[2]) / 
sum(n.EPage[1:2])
}
for (s in 1:3) {
EPsev[s] <- (PIDconctoEP[2,s,1] * n.EPage[1] +
PIDconctoEP[2,s,2] * n.EPage[2]) /
sum(n.EPage[1:2])
}
for (a in 1:2) {
EPage[a] <- (PIDconctoEP[2,1,a] * n.EPsev[1] +
PIDconctoEP[2,2,a] * n.EPsev[2] +
PIDconctoEP[2,3,a] * n.EPsev[3]) / 
sum(n.EPsev[1:3])
}
# probability of EP by age - all PID
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# assume EPs occur 5yrs into Westrom (8.9 year foll) for distribution 
# of EP #age 
# Progression probabilities by age, severity, and number
# progress[n,s,a] n: number of PIDs 0,1,2,3+, sev mild,mod,sev, a: 
# age<=29, #30+
# model
for (s in 1:3) {
for (a in 1:2) {
PIDconctoEP[1,s,a] <- EPnum[1] # constant across age!!!
for (n in 2:4) {
logit(PIDconctoEP[n,s,a]) <- beta0 + beta1[n] + beta2[s] + 
beta3[a]
}
}
}
control[1] <- alphatemp * propEP.1624 / (propEP.1624 + propEP.2544)
control[2] <- alphatemp * propEP.2544 / (propEP.1624 + propEP.2544)
logit(alphatemp) <- alpha
# Priors
# alpha control group thing 
alpha ~ dnorm(0,0.0001)
# beta0 = 1 PID, mild, young, 
beta0 ~ dnorm(0,0.0001)
# beta1[n] = effect of 0,1,2or3 PIDs beta1[1] = 0, beta1[2] = 0
beta1[1] <- 0
beta1[2] <- 0
for (n in 3:4) {
beta1[n] ~ dnorm(0,0.0001)
}
# beta2[s] = effect of severity: beta2[1] = 0
beta2[1] <- 0
for (s in 2:3) {
beta2[s] ~ dnorm(0,0.0001)
}
# beta3[a] = effect of age: beta3[1] = 0 
beta3[1] <- 0
beta3[2] ~ dnorm(0,0.0001)
# RESIDUAL DEVIANCE
for (m in 1:4) {
dev1[m] <- 2 * (r.EPnum[m] * log(r.EPnum[m] / (EPnum[m] * 
n.EPnum[m])) +
(n.EPnum[m] - r.EPnum[m]) * log((n.EPnum[m] -
r.EPnum[m]) /
(n.EPnum[m] - (n.EPnum[m] * EPnum[m]))))
}
for (s in 1:3) {
dev2[s] <- 2 * (r.EPsev[s] * log(r.EPsev[s] / (EPsev[s] * 
n.EPsev[s])) +
(n.EPsev[s] - r.EPsev[s]) * log((n.EPsev[s] -
r.EPsev[s]) /
(n.EPsev[s] - (n.EPsev[s] * EPsev[s]))))
}
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for (a in 1:2) {
dev3[a] <- 2 * (r.EPage[a] * log(r.EPage[a] / (EPage[a] * 
n.EPage[a])) +
(n.EPage[a] - r.EPage[a]) * log((n.EPage[a] -
r.EPage[a]) /
(n.EPage[a] - (n.EPage[a] * EPage[a]))))
}
sumdev1 <- sum(dev1[])
sumdev2 <- sum(dev2[])
sumdev3 <- sum(dev3[])
sumdev.tot <- sumdev1 + sumdev2 + sumdev3
# Progression probabilities by age, diagnostic status, and number
# progress[n,s,a] n: number of PIDs 0,1,2,3+,
# 1: undiagnosed (mild), 
# 2: diagnosed outside of Hospital (mild), 
# 3: hospital diagnosed(overall Westrom)
# a: age<=29, 30+
# model 1
#for (n in 2:4) {
# for (a in 1:2) {
#  PIDconctoEP2[n,1,a] <- ((PIDconctoEP[n,1,a] * n.EPsev[1] +
# PIDconctoEP[n,2,a] * n.EPsev[2] +
#                           PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                          sum(n.EPsev[1:3])) - control[a]
#  PIDconctoEP2[n,2,a] <- ((PIDconctoEP[n,1,a] * n.EPsev[1] +
# PIDconctoEP[n,2,a] * n.EPsev[2] +
#                           PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                          sum(n.EPsev[1:3])) - control[a]
#  PIDconctoEP2[n,3,a] <- ((PIDconctoEP[n,1,a] * n.EPsev[1] +
# PIDconctoEP[n,2,a] * n.EPsev[2] +
#                          PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                         sum(n.EPsev[1:3])) - control[a]
#  }
# }
# model 2
#for (n in 2:4) {
# for (a in 1:2) {
#  PIDconctoEP2[n,1,a] <- PIDconctoEP[n,1,a] - control[a]
#  PIDconctoEP2[n,2,a] <- (PIDconctoEP[n,1,a] * n.EPsev[1] +
#                          PIDconctoEP[n,2,a] * n.EPsev[2] +
#                          PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                         sum(n.EPsev[1:3]) - control[a]
#  PIDconctoEP2[n,3,a] <- (PIDconctoEP[n,1,a] * n.EPsev[1] +
#                          PIDconctoEP[n,2,a] * n.EPsev[2] +
#                          PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                         sum(n.EPsev[1:3]) - control[a]
#  }
# }
# model 3
#for (n in 2:4) {
# for (a in 1:2) {
#  PIDconctoEP2[n,1,a] <- PIDconctoEP[n,1,a] - control[a]
#  PIDconctoEP2[n,2,a] <- PIDconctoEP[n,1,a] - control[a]
#  PIDconctoEP2[n,3,a] <- (PIDconctoEP[n,1,a] * n.EPsev[1] +
#                          PIDconctoEP[n,2,a] * n.EPsev[2] +
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#                          PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                         sum(n.EPsev[1:3]) - control[a]
#  }
# }
# model 4
for (n in 2:4) {
for (a in 1:2) {
A[n,a] <- PIDconctoEP[n,1,a] - control[a]
PIDconctoEP2[n,1,a] ~ dunif(0,A[n,a])
PIDconctoEP2[n,2,a] <- PIDconctoEP[n,1,a] - control[a]
PIDconctoEP2[n,3,a] <- (PIDconctoEP[n,1,a] * n.EPsev[1] +
PIDconctoEP[n,2,a] * n.EPsev[2] +
PIDconctoEP[n,3,a] * n.EPsev[3]) / 
sum(n.EPsev[1:3]) - control[a]
}
}
# model 5
#for (n in 2:4) {
# for (a in 1:2) {
#  PIDconctoEP2[n,1,a] <- 0
#  PIDconctoEP2[n,2,a] <- PIDconctoEP[n,1,a] - control[a]
#  PIDconctoEP2[n,3,a] <- (PIDconctoEP[n,1,a] * n.EPsev[1] +
#                          PIDconctoEP[n,2,a] * n.EPsev[2] +
#                          PIDconctoEP[n,3,a] * n.EPsev[3]) / 
#                         sum(n.EPsev[1:3]) - control[a]
#  }
# }
# Risk a pregnancy will be ectopic due to PID by age
# all PID
for (n in 2:4) {
for (s in 1:3) {
EPs[n,s,1] <- PIDcat[n,s,1] * PIDconctoEP2[n,s,1]
EPs[n,s,2] <- PIDcat[n,s,2] * PIDconctoEP2[n,s,1]
EPs[n,s,3] <- PIDcat[n,s,3] * (
(PIDconctoEP2[n,s,1] * N2529 + PIDconctoEP2[n,s,2] * 
N3034)
/ N2534)
EPs[n,s,4] <- PIDcat[n,s,4] * PIDconctoEP2[n,s,2]
}
}
for (a in 1:4) {
EPbyage[a] <- sum(EPs[2:4 , ,a])
}
EPbyage.tot <- (EPbyage[1] * sum(N[16:19]) +
EPbyage[2] * sum(N[20:24]) + 
EPbyage[3] * sum(N[25:34]) + 
EPbyage[4] * sum(N[35:44])) / 
sum(N[16:44])
# non-CT related PID
for (n in 2:4) {
for (s in 1:3) {
EPsnct[n,s,1] <- PIDcatnct[n,s,1] * PIDconctoEP2[n,s,1]
EPsnct[n,s,2] <- PIDcatnct[n,s,2] * PIDconctoEP2[n,s,1]
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EPsnct[n,s,3] <- PIDcatnct[n,s,3] * (
(PIDconctoEP2[n,s,1] * N2529 + PIDconctoEP2[n,s,2] * 
N3034)
/ N2534)
EPsnct[n,s,4] <- PIDcatnct[n,s,4] * PIDconctoEP2[n,s,2]
}
}
for (a in 1:4) {
EPbyagenct[a] <- sum(EPsnct[2:4 , ,a])
}
EPbyagenct.tot <- (EPbyagenct[1] * sum(N[16:19]) +
EPbyagenct[2] * sum(N[20:24]) + 
EPbyagenct[3] * sum(N[25:34]) + 
EPbyagenct[4] * sum(N[35:44])) / 
sum(N[16:44])
for (a in 1:4) {
EPduetoCTbyage[a] <- EPbyage[a] - EPbyagenct[a]
}
EPduetoCTbyage.tot <- (EPduetoCTbyage[1] * sum(N[16:19]) +
EPduetoCTbyage[2] * sum(N[20:24]) + 
EPduetoCTbyage[3] * sum(N[25:34]) + 
EPduetoCTbyage[4] * sum(N[35:44])) / 
sum(N[16:44])
# proportion of PID related EPs due to CT
for (a in 1:4) {
propCTofPIDEPs[a] <- 1 - (EPbyagenct[a] / EPbyage[a])
}
propCTofPIDEPs.tot <- (propCTofPIDEPs[1] * sum(N[16:19]) +
propCTofPIDEPs[2] * sum(N[20:24]) + 
propCTofPIDEPs[3] * sum(N[25:34]) + 
propCTofPIDEPs[4] * sum(N[35:44])) / 
sum(N[16:44])
propCTofPIDEPs.tot2 <- (propCTofPIDEPs[1] * r.HESEP[1] +
propCTofPIDEPs[2] * r.HESEP[2] + 
propCTofPIDEPs[3] * r.HESEP[3] + 
propCTofPIDEPs[4] * r.HESEP[4]) / 
sum(r.HESEP[1:4])
# Population EP rate by age - 2002
# Conception rate by age - 2002
concdata[1] ~ dbin(conc[1],N1619)
concdata[2] ~ dbin(conc[2],N2024)
concdata[3] ~ dbin(conc[3],N2534)
concdata[4] ~ dbin(conc[4],N3544)
# priors
for (a in 1:4) {
conc[a] ~ dbeta(1,1)
}
# EP rate by age - 2002
r.HESEP[1] ~ dbin(HESEP[1],N1619) 
r.HESEP[2] ~ dbin(HESEP[2],N2024) 
r.HESEP[3] ~ dbin(HESEP[3],N2534) 
r.HESEP[4] ~ dbin(HESEP[4],N3544) 
# priors
for (a in 1:4) {
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HESEP[a] ~ dbeta(1,1)
}
# Analysis of retrospective data
# Odds Ratio 
ln.OR.l ~ dnorm(1.22,28.5)
ln.OR.u ~ dnorm(1.69,48.5)
OR.l <- exp(ln.OR.l)
OR.u <- exp(ln.OR.u)
# Population attributable fraction
for (a in 1:4) {
pi.PID[a] <- 1 - numPIDs[1,a]
pi.PIDnct[a] <- 1 - numPIDsnct[1,a]
gamma.l[a] <- (pi.PID[a] * (OR.l - 1)) / (pi.PID[a] * (OR.l -
1) + 1)
gamma.u[a] <- (pi.PID[a] * (OR.u - 1)) / (pi.PID[a] * (OR.u -
1) + 1)
gamma.lnct[a] <- (pi.PIDnct[a] * (OR.l - 1)) / 
(pi.PIDnct[a] * (OR.l - 1) + 1)
gamma.unct[a] <- (pi.PIDnct[a] * (OR.u - 1)) / 
(pi.PIDnct[a] * (OR.u - 1) + 1)
gamma.lct[a] <- gamma.l[a] - gamma.lnct[a]
gamma.uct[a] <- gamma.u[a] - gamma.unct[a]
}
pi.PID1624 <- (pi.PID[1] * sum(N[16:19]) + pi.PID[2] * sum(N[20:24])) 
/
sum(N[16:24])
pi.PID2544 <- (pi.PID[3] * sum(N[25:34]) + pi.PID[4] * sum(N[35:44])) 
/
sum(N[25:44])
pi.PID1644 <- (pi.PID[1] * sum(N[16:19]) + pi.PID[2] * sum(N[20:24]) 
+
pi.PID[3] * sum(N[25:34]) + pi.PID[4] * sum(N[35:44])) 
/
sum(N[16:44])
pi.PID1624nct <- (pi.PIDnct[1] * sum(N[16:19]) +
pi.PIDnct[2] * sum(N[20:24])) / sum(N[16:24])
pi.PID2544nct <- (pi.PIDnct[3] * sum(N[25:34]) +
pi.PIDnct[4] * sum(N[35:44])) / sum(N[25:44])
pi.PID1644nct <- (pi.PIDnct[1] * sum(N[16:19]) + 
pi.PIDnct[2] * sum(N[20:24]) +
pi.PIDnct[3] * sum(N[25:34]) +
pi.PIDnct[4] * sum(N[35:44])) /
sum(N[16:44])
gamma.l.1624 <- (pi.PID1624 * (OR.l - 1)) / (pi.PID1624 * (OR.l - 1)
+ 1)
gamma.u.1624 <- (pi.PID1624 * (OR.u - 1)) / (pi.PID1624 * (OR.u - 1)
+ 1)
gamma.l.2544 <- (pi.PID2544 * (OR.l - 1)) / (pi.PID2544 * (OR.l - 1)
+ 1)
gamma.u.2544 <- (pi.PID2544 * (OR.u - 1)) / (pi.PID2544 * (OR.u - 1)
+ 1)
gamma.l.1644 <- (pi.PID1644 * (OR.l - 1)) / (pi.PID1644 * (OR.l - 1)
+ 1)
gamma.u.1644 <- (pi.PID1644 * (OR.u - 1)) / (pi.PID1644 * (OR.u - 1)
+ 1)
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gamma.l.1624nct <- (pi.PID1624nct * (OR.l - 1)) / 
(pi.PID1624nct * (OR.l - 1) + 1)
gamma.u.1624nct <- (pi.PID1624nct * (OR.u - 1)) / 
(pi.PID1624nct * (OR.u - 1) + 1)
gamma.l.2544nct <- (pi.PID2544nct * (OR.l - 1)) /
(pi.PID2544nct * (OR.l - 1) + 1)
gamma.u.2544nct <- (pi.PID2544nct * (OR.u - 1)) /
(pi.PID2544nct * (OR.u - 1) + 1)
gamma.l.1644nct <- (pi.PID1644nct * (OR.l - 1)) /
(pi.PID1644nct * (OR.l - 1) + 1)
gamma.u.1644nct <- (pi.PID1644nct * (OR.u - 1)) /
(pi.PID1644nct * (OR.u - 1) + 1)
gamma.l.1624ct <- gamma.l.1624 - gamma.l.1624nct
gamma.u.1624ct <- gamma.u.1624 - gamma.u.1624nct
gamma.l.2544ct <- gamma.l.2544 - gamma.l.2544nct
gamma.u.2544ct <- gamma.u.2544 - gamma.u.2544nct
gamma.l.1644ct <- gamma.l.1644 - gamma.l.1644nct
gamma.u.1644ct <- gamma.u.1644 - gamma.u.1644nct
numEPSduePID.l <- gamma.l.1644 * sum(r.HESEP[ ])
numEPSduePID.u <- gamma.u.1644 * sum(r.HESEP[ ])
numEPSdueCT.l <- gamma.l.1644 * sum(r.HESEP[ ]) * propCTofPIDEPs.tot2
numEPSdueCT.u <- gamma.u.1644 * sum(r.HESEP[ ]) * propCTofPIDEPs.tot2
# Proportion of conceptions that are Ectopic - 2002
for (a in 1:4) {
propEP[a] <- HESEP[a] / conc[a]
}
propEP.1624 <- (propEP[1] * sum(N[16:19]) + propEP[2] * 
sum(N[20:24])) /
sum(N[16:24])
propEP.2544 <- (propEP[3] * sum(N[25:34]) + propEP[4] * 
sum(N[35:44])) /
sum(N[25:44])
propEP.tot <- (propEP[1] * sum(N[16:19]) +
propEP[2] * sum(N[20:24]) + 
propEP[3] * sum(N[25:34]) + 
propEP[4] * sum(N[35:44])) / 
sum(N[16:44])
# Retrospective estimate of prop EPS due to PID - 2002
for (a in 1:4) {
retroEPfromPID.l[a] <- propEP[a] * gamma.l[a]
retroEPfromPID.u[a] <- propEP[a] * gamma.u[a]
}
retroEPfromPID.l.tot <- propEP.tot * gamma.l.1644
retroEPfromPID.u.tot <- propEP.tot * gamma.u.1644
# Proportion due to PID and CT - 2002
for (a in 1:4) {
propPID[a] <- EPbyage[a] / propEP[a]
propifnoct[a] <- EPbyagenct[a] / propEP[a]
propnct[a] <- propPID[a] - propifnoct[a]
}
propPID.tot <- (propPID[1] * sum(N[16:19]) +
propPID[2] * sum(N[20:24]) +
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propPID[3] * sum(N[25:34]) + 
propPID[4] * sum(N[35:44])) / 
sum(N[16:44])
propifnoct.tot <- (propifnoct[1] * sum(N[16:19]) +
propifnoct[2] * sum(N[20:24]) + 
propifnoct[3] * sum(N[25:34]) + 
propifnoct[4] * sum(N[35:44])) / 
sum(N[16:44])
propnct.tot <- (propnct[1] * sum(N[16:19]) +
propnct[2] * sum(N[20:24]) + 
propnct[3] * sum(N[25:34]) + 
propnct[4] * sum(N[35:44])) / 
sum(N[16:44])
}
# Data
list(
# PID incidence, r-infection rate, Etological fractions and re-infection rate
mu = c(-3.865, -3.595, -3.964, -4.402, -0.5856, 0.7104, 0.4815, 0.3117, 0.3277, 
1.919),
Omega = structure(.Data =c(
573.855, -49.264, -10.817, -3.992, 323.371, 97.687, -112.351, -30.198, -5.401, -2.713,
-49.264, 301.419, -14.194, -3.299, 147.591, -78.069, 176.480, -72.284, -11.551, 2.012,
-10.817, -14.194, 105.908, -20.063, 37.684, -13.275, -46.636, 236.305, -118.245,
0.515,
-3.992, -3.299, -20.063, 57.687, 19.172, -2.664, -8.418, -125.677, 138.728, 0.088,
323.371, 147.591, 37.684, 19.172, 351.620, 1.363, -1.443, -1.164, 1.537, 0.030,
97.687, -78.069, -13.275, -2.664, 1.363, 285.706, -324.389, -85.846, -16.864, -7.957,
-112.351, 176.480, -46.636, -8.418, -1.443, -324.389, 734.182, -295.254, -50.046,
8.090,
-30.198, -72.284, 236.305, -125.677, -1.164, -85.846, -295.254, 1512.713, -758.618,
3.088,
-5.401, -11.551, -118.245, 138.728, 1.537, -16.864, -50.046, -758.618, 839.634, 0.705,
-2.713, 2.012, 0.515, 0.088, 0.030, -7.957, 8.090, 3.088, 0.705, 13.711),
.Dim = c(10,10)),
r.phi = 26, n.phi = 115,
# Population sizes from census, age =1...44 - 2002
N=c(NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, 
305500,306300,296400,291400,294800,
310100,313900,305600,294700,295000,
304100,317000,329600,349600,370300,
380900,376900,387800,390900,399400,
401200,402600,398700,391900,381900, 370900,356200,349000,343800),
# Routine PID data 
# HES PID data - 2002
r.HESPID = c(1233,3101,9756,10526), # 16-19, 20-24, 25-34, 35-44
# KC-60 PID data 
r.kc602008 = c(2900,3972,3538,1253), #16-19, 20-24, 25-34, 35-44
# predicted GPRD data - 2002
r.GPRDPID = c(5083,8842,14932,9609), # 16-19, 20-24, 25-34, 35-44
# Prospective PID to EP data (Westrom 560238) 
# NB data are for first pregnancy
# results by number of episodes
r.EPnum = c(6,61,24,15),      # 0,1,2,3 diagnosed PIDs
n.EPnum = c(439,912,148,39),  # 0,1,2,3 diagnosed PIDs
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# number by severity, in women with one PID episode only - read from 
# graph!
r.EPsev = c(7,19,35),      # mild, moderate, severe
n.EPsev = c(309,420,183),  # mild, moderate, severe
# number by age group, in women with one PID episode only
r.EPage = c(39,22),     # <25, 25-35 at index?
n.EPage = c(713,199),   # <25, 25-35 at index?
# HES EP data - 2002
r.HESEP = c(291,1154,4340,1840), # 16-19, 20-24, 25-34, 35-44
# Conceptions data - 2002
# 13-15, 15-17, 15-19, 20-24, 25-29, 30-34, 35-39, 40+
#conc = c(7900,42000,97100,167800,199400,204300,98900,19600),
# 16-19, 20-24, 25-34, 35-44 - Guessed!
concdata = c(90000,167800,403700,113900)
)
# Initial values 1
list(
Y = c(-5,-5,-5,-5,-1,-5,-5,-5,-5,-1),
HESPID = c(0.01,0.01,0.01,0.01),
kc602008 = c(0.01,0.01,0.01,0.01),
GPRDPID = c(0.01,0.01,0.01,0.01),
alpha = -2,
beta0 = -2,
beta1 = c(NA,NA,0.5,0.5),
beta2 = c(NA,0.05,0.05),
beta3 = c(NA,0.5),
HESEP = c(0.01,0.01,0.01,0.01),
conc = c(0.01,0.01,0.01,0.01),
philap = 0.3
)
# Initial values 2
list(
Y = c(-1,-1,-1,-1,-1,-1,-1,-1,-1,-1),
HESPID = c(0.1,0.1,0.1,0.1),
kc602008 = c(0.1,0.1,0.1,0.1),
GPRDPID = c(0.1,0.1,0.1,0.1),
alpha = -5,
beta0 = -5,
beta1 = c(NA,NA,0.05,0.05),
beta2 = c(NA,0.5,0.5),
beta3 = c(NA,0.05),
HESEP = c(0.1,0.1,0.1,0.1),
conc = c(0.1,0.1,0.1,0.1),
philap = 0.6
)
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Appendix 13 Overestimation of prevalence of
infertility (see Chapter 10)
I f we took the case of a 34-year-old woman who has been infertile for unknown reasons for 2 years, shewould have an approximately 50% chance of conceiving by the age of 44 years.125 If 50% are sterile,
and the remaining 50% could have 0.65 probability of conceiving in any 12-month period, given that they
have not yet conceived,293 then in women who have been infertile for exactly 2 years, one would observe a
56.1% infertility rate, rather than 50%, a 12% multiplicative overestimation.
By the end of 3 years, the overestimation would be down to 4.3%, and by 4 years, only 1.5%. The exact
distribution of duration of secondary infertility in surveys of women aged 41–55 years is not known. In
estimating the prevalence of secondary infertility in women aged 44 years, we have used a uniform
distribution from 0% to 12% to represent this overestimation.
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Appendix 14 WinBUGS code and data files for
prediction of tubal factor infertility prevalence
(see Chapter 10)
The following WinBUGS code processes the survey data on infertility (see Table 37) and deliversestimates of the prevalence on primary, secondary, and total infertility, and the prevalence of TFI (see
Table 38). The data input for the Oakley et al.129 study is based on a WinBUGs simulation exercise, shown
later in this appendix.
for (i in 1:4) { 
Model { 
p[i] ~ dbeta(x[1],x[2]) # common beta for pr(1ary infertility)
}
for (i in 5:7) {
p[i] ~ dbeta(x[3],x[4]) # common beta for pr(2ndary infertility)
}
for (i in 8:8) {
p[i] ~ dbeta(.5,.5) # Jeffreys priors p[8]
}
f ~ dunif(0.89,1)        # adjustment for length of follow-up
for (i in 1:4) {
x[i] ~ dexp(.001)       # priors for beta parameters
}
for (i in 1:8) {
r[i] ~ dbin(p[i],n[i])  # likelihood 
rhat[i] <- p[i] * n[i]  # expected value of the numerators
dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i])) + (n[i]-r[i]) * 
(log(n[i]- r[i]) - log(n[i]-rhat[i]))) # Deviance 
# contribution
}
x[5] <- x[1]/sum(x[1:2]) # estimate of pr(1ary infertility)
x[6] <- x[3]/sum(x[3:4]) # estimate of pr(2ndary infertility)
x[7] <- x[6] * f         # adjusted pr(2ndary)
x[8] <- x[5] + x[7]      # total infertility
x[9] <- x[8] * p[8]      #  total TFI
dev[9] <- sum(dev[1:8])  # total residual deviance
dev[10] <- sum(dev[1:7]) # totall res dev for fertility data
}
# Initial Values 1
list(x=c(4,6,4,6,NA,NA,NA,NA,NA),p=c(.4,.4,.4,.4,.4,.4,.4,.4),f=.92))
# Initial values 2
list(x=c(20,20,20,20,NA,NA,NA,NA,NA),p=c(.2,.2,.2,.2,.2,.2,.2,.2),
f=0.96))
# Data
# primary (Bhattacharya, Templeton, Gunnell, Oakley (adjusted))
# secondary ( Bhattacharya, Templeton, Gunnell)
# Proportion of total infertility (including males) due to TFI
# (Maheshwari)
list(r=c(79, 27, 31, 158.3, 5, 17, 41, 442), 
n=c(2347, 766, 1609, 6128, 2347, 766, 1609, 1782))
Simulation model to adjust the Oakley % primary infertility data for the 
proportion of women who were involuntarily childless.
model {
for (i in 1:2) {
p[i] ~ dbeta(.5,.5)
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r[i] ~ dbin(p[i],n[i]) }
p[3] <- p[1]/p[2]
}
# Initial values
list(p=c(.5,.5,NA))
# Data
list(r=c(159,2910),n=c(6584,3113))
Results:
node mean     sd MC error 2.5% median 97.5% start sample
p[1] 0.02422 0.001891 7.665E-6 0.02068 0.02418 0.02806 10001 60000
p[2] 0.9347 0.004425 1.77E-5 0.9257 0.9348 0.943 10001 60000
p[3] 0.02592 0.002027 8.251E-6 0.02211 0.02587 0.03004 10001 60000
The output is used as follows: the probability of primary infertility from the Oakley et al.129 study
is taken to be the reported probability divided by the proportion who were not involuntarily childless:
(159/6584) / (2910/3113)= 0.02583. The variance of this estimate, taken from the posterior estimate
of p[3] is 0.0020272. The effective denominator is therefore the solution to n in 0.0025834 ×
(1 – 0.0025834) / n= 0.0020272, which gives n= 6128, with numerator 158.3. These figures are
used as ‘data’ in the previous code.
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Appendix 15 WinBUGS code for the predictions
from prospective models (see Table 40, Chapter 10)
# TFI analysis
model {
# Population (disecrete time) model - 2 year higher rate
# PID incidence and ct GP re-infection rate ratio informative priors
Y[1:10] ~ dmnorm(mu[], Omega[ , ]) 
for (ag in 1:4) {
log(lambda.PID[ag]) <- Y[ag]
EF[ag] <- Y[ag+5] * Y[ag+5]
}
logit(psi) <- Y[5]
log(eta1) <- Y[10]
# WBDEV call
for (ag in 1:4) {
input1[ag] <- lambda.PID[ag]
input1[ag+6] <- EF[ag]
}
input1[5] <- psi
input1[6] <- eta1
philap ~ dbeta(12,16)
input1[11] <- philap
for (i in 1:29) {
input2[i] <- N[i+15]
}
solution[1:609] <- cumulativePIDlap(input1[1:11],input2[1:29])
# number of previous PIDs [n,a] n = number: 0,1,2,3; a = age-group
for (i in 1:4) { 
numPIDs[2,i] <- solution[i]
numPIDs[3,i] <- solution[i+4]
numPIDs[4,i] <- solution[i+8]
numPIDsnct[2,i] <- solution[i+12]
numPIDsnct[3,i] <- solution[i+16]
numPIDsnct[4,i] <- solution[i+20]
}
# number of previous PIDs in women aged 44, n = number: 0,1,2,3; 
num44[2] <- solution[58]
num44[3] <- solution[87]
num44[4] <- solution[116]
num44nct[2] <- solution[145]
num44nct[3] <- solution[174]
num44nct[4] <- solution[203]
# population denominators - 2002
N1619 <- sum(N[16:19])
N2024 <- sum(N[20:24])
N2534 <- sum(N[25:34])
N3544 <- sum(N[35:44])
N1644 <- sum(N[16:44])
N1617 <- sum(N[16:17])
N1820 <- sum(N[18:20])
N2124 <- sum(N[21:24])
N2529 <- sum(N[25:29])
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N3044 <- sum(N[30:44])
N1819 <- sum(N[18:19])
N3034 <- sum(N[30:34])
# Distribution of PID severity - 2002
# hospital
r.HESPID[1] ~ dbin(HESPID[1],N1619) 
r.HESPID[2] ~ dbin(HESPID[2],N2024) 
r.HESPID[3] ~ dbin(HESPID[3],N2534) 
r.HESPID[4] ~ dbin(HESPID[4],N3544) 
# priors
for (a in 1:4) {
HESPID[a] ~ dbeta(1,1)
}
# kc60
r.kc602008[1] ~ dbin(kc602008[1],N1619)
r.kc602008[2] ~ dbin(kc602008[2],N2024)
r.kc602008[3] ~ dbin(kc602008[3],N2534)
r.kc602008[4] ~ dbin(kc602008[4],N3544)
# priors
for (a in 1:4) {
kc602008[a] ~ dbeta(1,1)
}
# data by age not available until 2008
# 13421 / 12117 is the ratio of totals for 2002 and GUMCAD data for 
# 2008
# assumes GUMCAD data representative of all kc60
# assumes age distribution is the same in 2002 as 2008
for (a in 1:4) { 
kc60[a] <- kc602008[a] * 13421 / 12117
}
# GPRD
r.GPRDPID[1] ~ dbin(GPRDPID[1],N1619) 
r.GPRDPID[2] ~ dbin(GPRDPID[2],N2024) 
r.GPRDPID[3] ~ dbin(GPRDPID[3],N2534) 
r.GPRDPID[4] ~ dbin(GPRDPID[4],N3544) 
# priors
for (a in 1:4) {
GPRDPID[a] ~ dbeta(1,1)
}
# Distribution
for (a in 1:4) {
pmin[a] <- kc60[a] + max(HESPID[a],GPRDPID[a])
pmax[a] <- kc60[a] + HESPID[a] + GPRDPID[a]
X[a] ~ dunif(pmin[a],pmax[a])
hospdiag[a] <- psi * HESPID[a] / X[a] 
milddiag[a] <- 1 - hospdiag[a] - undiag[a]
undiag[a] <- (1 - psi)
}
# proportion with PIDs by each age, severity, and number 
# all PID
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# n = 1
for (s in 1:3) {
for (a in 1:4) {
PIDcat[1,s,a] <- 1 - (PIDcat[2,s,a] + PIDcat[3,s,a] + 
PIDcat[4,s,a])
}
PIDcat44[1,s] <- 1 - (PIDcat44[2,s] + PIDcat44[3,s] + PIDcat44[4,s])
}
# n = 2-4
for (n in 2:4) {
for (a in 1:4) {
PIDcat[n,1,a] <- numPIDs[n,a] * undiag[a]
PIDcat[n,2,a] <- numPIDs[n,a] * milddiag[a]
PIDcat[n,3,a] <- numPIDs[n,a] * hospdiag[a]
}
PIDcat44[n,1] <- num44[n] * undiag[4]
PIDcat44[n,2] <- num44[n] * milddiag[4]
PIDcat44[n,3] <- num44[n] * hospdiag[4]
}
# non-CT related PID
# n = 1
for (s in 1:3) {
for (a in 1:4) {
PIDcatnct[1,s,a] <- 1 - (PIDcatnct[2,s,a] + PIDcatnct[3,s,a] +
PIDcatnct[4,s,a])
}
PIDcat44nct[1,s] <- 1 - (PIDcat44nct[2,s] + PIDcat44nct[3,s] +
PIDcat44nct[4,s])
}
# n = 2-4
for (n in 2:4) {
for (a in 1:4) {
PIDcatnct[n,1,a] <- numPIDsnct[n,a] * undiag[a]
PIDcatnct[n,2,a] <- numPIDsnct[n,a] * milddiag[a]
PIDcatnct[n,3,a] <- numPIDsnct[n,a] * hospdiag[a]
}
PIDcat44nct[n,1] <- num44nct[n] * undiag[4]
PIDcat44nct[n,2] <- num44nct[n] * milddiag[4]
PIDcat44nct[n,3] <- num44nct[n] * hospdiag[4]
}
# Probability of TFI given PID by age, severity, number of PIDs-
# Westrom
# Likelihood
for (a in 1:2) {
for (s in 1:3) {
onePIDsev[a,s] <- p[a,s,1]
r.onePIDsev[a,s] ~ dbin(onePIDsev[a,s],n.onePIDsev[a,s])
}
twoPID[a] <- (p[a,1,2] * n.onePIDsev[a,1] +
p[a,2,2] * n.onePIDsev[a,2] +
p[a,3,2] * n.onePIDsev[a,3]) / sum(n.onePIDsev[a, ])
r.twoPID[a] ~ dbin(twoPID[a],n.twoPID[a])
threePID[a] <- (p[a,1,3] * n.onePIDsev[a,1] +
p[a,2,3] * n.onePIDsev[a,2] +
p[a,3,3] * n.onePIDsev[a,3]) / sum(n.onePIDsev[a, ])
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r.threePID[a] ~ dbin(threePID[a],n.threePID[a])
}
# model
for (a in 1:2) {
for (s in 1:3) {
for (n in 1:3) {
logit(p[a,s,n]) <- beta0 + beta1[a] + beta2[s] + beta3[n]
PIDtoTFI[n+1,a,s] <- p[a,s,n]
}
}
}
for (a in 1:2) {
onePID[a] <- (onePIDsev[a,1] * n.onePIDsev[a,1] +
onePIDsev[a,2] * n.onePIDsev[a,2] +
onePIDsev[a,3] * n.onePIDsev[a,3]) /
sum(n.onePIDsev[a, ])
}
# priors
beta0 ~ dnorm(0,0.0001)
beta1[1] <- 0
beta1[2] ~ dnorm(0,0.0001)
beta2[1] <- 0
beta2[2] ~ dnorm(0,0.0001)
beta2[3] ~ dnorm(0,0.0001)
beta3[1] <- 0
beta3[2] ~ dnorm(0,0.0001)
beta3[3] ~ dnorm(0,0.0001)
# RESIDUAL DEVIANCE
for (a in 1:2) {
for (s in 1:3) {
dev1[a,s] <- 2 * (r.onePIDsev[a,s] * log(r.onePIDsev[a,s] / 
(onePIDsev[a,s] * n.onePIDsev[a,s])) +
(n.onePIDsev[a,s] - r.onePIDsev[a,s]) * 
log((n.onePIDsev[a,s] - r.onePIDsev[a,s]) /
(n.onePIDsev[a,s] - (n.onePIDsev[a,s] * 
onePIDsev[a,s]))))
}
dev2[a] <- 2 * (r.twoPID[a] * log(r.twoPID[a] / 
(twoPID[a] * n.twoPID[a])) +
(n.twoPID[a] - r.twoPID[a]) * 
log((n.twoPID[a] - r.twoPID[a]) /
(n.twoPID[a] - (n.twoPID[a] * twoPID[a]))))
dev3[a] <- 2 * (r.threePID[a] * log(r.threePID[a] / 
(threePID[a] * n.threePID[a])) +
(n.threePID[a] - r.threePID[a]) * 
log((n.threePID[a] - r.threePID[a]) /
(n.threePID[a] - (n.threePID[a] * 
threePID[a]))))
}
sumdev1 <- sum(dev1[ , ])
sumdev2 <- sum(dev2[])
sumdev3 <- sum(dev3[])
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sumdev.tot <- sumdev1 + sumdev2 + sumdev3
# Progression probabilities by age, diagnostic status, and number
# progress[n,s,a] n: number of PIDs 0,1,2,3+, 
# 1: undiagnosed (mild), 
# 2: diagnosed outside of Hospital (mild), 
# 3: hospital diagnosed(overall Westrom)
# a: age<=29, 30+
# model 1
for (n in 1:3) {
for (a in 1:2) {
PIDtoTFI2[n,1,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
sum(n.onePIDsev[a, ])
PIDtoTFI2[n,2,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
sum(n.onePIDsev[a, ])
PIDtoTFI2[n,3,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
sum(n.onePIDsev[a, ])
}
}
# model 2
#for (n in 1:3) {
# for (a in 1:2) {
#  PIDtoTFI2[n,1,a] <- PIDtoTFI[2,a,1]
#  PIDtoTFI2[n,2,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
#                       PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
# PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
# sum(n.onePIDsev[a, ])
#  PIDtoTFI2[n,3,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
#                       PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
# PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
# sum(n.onePIDsev[a, ])
#  }
# }
# model 3
#for (n in 1:3) {
# for (a in 1:2) {
#  PIDtoTFI2[n,1,a] <- PIDtoTFI[2,a,1]
#  PIDtoTFI2[n,2,a] <- PIDtoTFI[2,a,1]
#  PIDtoTFI2[n,3,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
#                       PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
# PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
# sum(n.onePIDsev[a, ])
#  }
# }
# model 4
#for (n in 1:3) {
# for (a in 1:2) {
#  A[n,a] ~ dunif(0,PIDtoTFI[2,a,1])
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#  PIDtoTFI2[n,1,a] <- A[n,a]
#  PIDtoTFI2[n,2,a] <- PIDtoTFI[2,a,1]
#  PIDtoTFI2[n,3,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
#                       PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
# PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
# sum(n.onePIDsev[a, ])
#  }
# }
# model 5
#for (n in 1:3) {
# for (a in 1:2) {
#  PIDtoTFI2[n,1,a] <- 0
#  PIDtoTFI2[n,2,a] <- PIDtoTFI[2,a,1]
#  PIDtoTFI2[n,3,a] <- (PIDtoTFI[2,a,1] * n.onePIDsev[a,1] +
#                       PIDtoTFI[2,a,2] * n.onePIDsev[a,2] +
# PIDtoTFI[2,a,3] * n.onePIDsev[a,3]) / 
# sum(n.onePIDsev[a, ])
#  }
# }
# TFIs by age
# all PID
for (n in 2:4) {
for (s in 1:3) {
TFIs[n,s,1] <- PIDcat[n,s,1] * PIDtoTFI2[n-1,s,1]
TFIs[n,s,2] <- PIDcat[n,s,2] * PIDtoTFI2[n-1,s,1]
TFIs[n,s,3] <- PIDcat[n,s,3] * 
(PIDtoTFI2[n-1,s,1] * N2529 + PIDtoTFI2[n-1,s,2] * 
N3034) /
N2534
TFIs[n,s,4] <- PIDcat[n,s,4] * PIDtoTFI2[n-1,s,2]
TFI44[n,s] <- PIDcat44[n,s] * PIDtoTFI2[n-1,s,2]
}
}
for (a in 1:4) {
TFIbyage[a] <- sum(TFIs[2:4 , ,a])
}
TFI44tot <- sum(TFI44[2:4 , ])
TFIbyage.tot <- (TFIbyage[1] * sum(N[16:19]) +
TFIbyage[2] * sum(N[20:24]) + 
TFIbyage[3] * sum(N[25:34]) + 
TFIbyage[4] * sum(N[35:44])) / 
sum(N[16:44])
# non-CT related PID
for (n in 2:4) {
for (s in 1:3) {
TFIsnct[n,s,1] <- PIDcatnct[n,s,1] * PIDtoTFI2[n-1,s,1]
TFIsnct[n,s,2] <- PIDcatnct[n,s,2] * PIDtoTFI2[n-1,s,1]
TFIsnct[n,s,3] <- PIDcatnct[n,s,3] * 
(PIDtoTFI2[n-1,s,1] * N2529 + PIDtoTFI2[n-1,s,2] * 
N3034) / N2534
TFIsnct[n,s,4] <- PIDcatnct[n,s,4] * PIDtoTFI2[n-1,s,2]
TFI44nct[n,s] <- PIDcat44nct[n,s] * PIDtoTFI2[n-1,s,2]
}
}
for (a in 1:4) {
TFIbyagenct[a] <- sum(TFIsnct[2:4 , ,a])
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}
TFI44totnct <- sum(TFI44nct[2:4 , ])
TFIbyagenct.tot <- (TFIbyagenct[1] * sum(N[16:19]) +
TFIbyagenct[2] * sum(N[20:24]) + 
TFIbyagenct[3] * sum(N[25:34]) + 
TFIbyagenct[4] * sum(N[35:44])) / 
sum(N[16:44])
for (a in 1:4) {
TFIduetoCTbyage[a] <- TFIbyage[a] - TFIbyagenct[a]
}
TFIduetoCTbyage.tot <- (TFIduetoCTbyage[1] * sum(N[16:19]) +
TFIduetoCTbyage[2] * sum(N[20:24]) + 
TFIduetoCTbyage[3] * sum(N[25:34]) + 
TFIduetoCTbyage[4] * sum(N[35:44])) / 
sum(N[16:44])
# proportion of PID related TFIs due to CT
for (a in 1:4) {
propCTofPIDTFIs[a] <- 1 - (TFIbyagenct[a] / TFIbyage[a])
}
propCTofPIDTFIs44 <- 1 - (TFI44totnct / TFI44tot)
propCTofPIDTFIs.tot <- (propCTofPIDTFIs[1] * sum(N[16:19]) +
propCTofPIDTFIs[2] * sum(N[20:24]) + 
propCTofPIDTFIs[3] * sum(N[25:34]) + 
propCTofPIDTFIs[4] * sum(N[35:44])) / 
sum(N[16:44])
}
# Data
list(
# PID incidence, r-infection rate, Etological fractions and re-
infection #rate
mu = c(-3.865, -3.595, -3.964, -4.402, -0.5856, 0.7104, 0.4815, 0.3117, 0.3277, 
1.919),
Omega = structure(.Data =c(
573.855, -49.264, -10.817, -3.992, 323.371, 97.687, -112.351, -30.198, -5.401, -2.713,
-49.264, 301.419, -14.194, -3.299, 147.591, -78.069, 176.480, -72.284, -11.551, 2.012,
-10.817, -14.194, 105.908, -20.063, 37.684, -13.275, -46.636, 236.305, -118.245,
0.515,
-3.992, -3.299, -20.063, 57.687, 19.172, -2.664, -8.418, -125.677, 138.728, 0.088,
323.371, 147.591, 37.684, 19.172, 351.620, 1.363, -1.443, -1.164, 1.537, 0.030,
97.687, -78.069, -13.275, -2.664, 1.363, 285.706, -324.389, -85.846, -16.864, -7.957,
-112.351, 176.480, -46.636, -8.418, -1.443, -324.389, 734.182, -295.254, -50.046,
8.090,
-30.198, -72.284, 236.305, -125.677, -1.164, -85.846, -295.254, 1512.713, -758.618,
3.088,
-5.401, -11.551, -118.245, 138.728, 1.537, -16.864, -50.046, -758.618, 839.634, 0.705,
-2.713, 2.012, 0.515, 0.088, 0.030, -7.957, 8.090, 3.088, 0.705, 13.711),
.Dim = c(10,10)),
# Population sizes from census, age =1...44 - 2002
N=c(NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, NA,NA,NA,NA,NA, 
305500,306300,296400,291400,294800,
310100,313900,305600,294700,295000,
304100,317000,329600,349600,370300,
380900,376900,387800,390900,399400,
401200,402600,398700,391900,381900, 370900,356200,349000,343800),
# Routine PID data 
# HES PID data - 2002
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r.HESPID = c(1233,3101,9756,10526), # 16-19, 20-24, 25-34, 35-44
# KC-60 PID data 
r.kc602008 = c(2900,3972,3538,1253), #16-19, 20-24, 25-34, 35-44
# predicted GPRD data - 2002
r.GPRDPID = c(5083,8842,14932,9609), # 16-19, 20-24, 25-34, 35-44
# Westrom Progression data (A cohort study of 1,844)-assumes a=1 goes 
# to 29
r.onePIDsev = structure(.Data =c(
2,23,34,
0,5,15
),
.Dim = c(2,3)),
n.onePIDsev = structure(.Data =c(
241,361,169,
71,89,60
),
.Dim = c(2,3)),
r.twoPID = c(29,7), n.twoPID = c(158,27),
r.threePID = c(23,3), n.threePID = c(61,4),
# Note: 0 TFIs in 451 control women so assume zero.
)
# Initial values 1
list(
Y = c(-5,-5,-5,-5,-1,-5,-5,-5,-5,-1),
HESPID = c(0.01,0.01,0.01,0.01),
kc602008 = c(0.01,0.01,0.01,0.01),
GPRDPID = c(0.01,0.01,0.01,0.01),
philap = 0.3,
beta0 = -2,
beta1 = c(NA,0.5),
beta2 = c(NA,0.05,0.05),
beta3 = c(NA,0.5,0.5)
)
A = structure(.Data =c(
0.01,0.01,
0.01,0.01,
0.01,0.01
),
.Dim = c(3,2)),
)
# Initial values 2
list(
Y = c(-1,-1,-1,-1,-1,-1,-1,-1,-1,-1),
HESPID = c(0.1,0.1,0.1,0.1),
kc602008 = c(0.1,0.1,0.1,0.1),
GPRDPID = c(0.1,0.1,0.1,0.1),
philap = 0.6,
beta0 = -5,
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beta1 = c(NA,0.05),
beta2 = c(NA,0.5,0.5),
beta3 = c(NA,0.05,0.05),
)
A = structure(.Data =c(
0.1,0.1,
0.1,0.1,
0.1,0.1
),
.Dim = c(3,2)),
)
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Appendix 16 Sensitivity, specificity and
resolution of assays (see Chapter 11)
Analyses of the Wills et al.,269 Morre et al.265 and Narvanen et al.268 data on test performance, accordingto our model for Test Resolution, are set out in Table 48.
Wills et al.269 examined four assays in 164 female NAAT-positive patients attending STD clinics who had
been infected for at least 1 month, and in 747 children aged 2–13 years. Twenty-five of the 747 paediatric
samples were positive on MIF, and seven of these were positive on Western blot and were excluded. In our
analysis, we assign the remaining 18 MIF-positive samples a uniform prior probability of between zero and
one as being true positive. The estimates of test resolution varied from 3.0 to 4.9 (mean= 4.1, SD= 0.83).
Morre et al.265 describe a ‘discrepancy analysis’ of MIF and three peptide-based assays in 149 STI clinic
attenders identified through screening. Women were counted as ‘true positive’ if they were positive on
two peptide assays, or MIF on two occasions. ‘Grey’ samples were included in our analysis and assigned a
uniform prior probability of being true positive between zero and one. Values of R range from 4.7 to 6.4
(mean= 5.9, SD= 0.79).
Narvanen et al.268 tested 82 culture-positive infected women and 152 paediatric control subjects with a CT
enzyme immunoassay (CT-EIA). Resolution was 6.29.
TABLE 48 Estimates of sensitivity, false-positive rate and resolution RT from serological studies
Study Assay TP FN TN(a) FP(a) TN(b) FP(b) Grey
SeT%
(95% CI)
FpT%
(95% CI) RT
Morre265 CT-EIA 61 11 72 1 4 82.5
(72.7 to 90.7)
1.4
(0 –5)
6.4
(4.4 to 9.4)
SeroCT 61 11 69 1 7 81.2
(70.6 to 90.2)
1.4
(0 to 5)
6.3
(4.3 to 9.3)
CT
pELISA
50 20 72 2 5 69.3
(57.9 to 79.6)
2.6
(0.3 to 7)
4.7
(3.3 to 6.6)
MIF 57 15 74 1 2 78.1
(67.9 to 86.9)
1.4
(0 to 4.9)
6.1
(4.2 to 9.2)
Wills269 Pgp3 121 43 29 711 17 705 73.8
(66.8 to 80.2)
3.1
(1.9 to 4.6)
4.5
(3.9 to 5.1
Ani
labs
98 66 8 587 6 574 59.8
(52.1 to 67.3)
1.2
(0.6 to 2.0)
4.9
(4.2 to 5.6)
SeroCT 91 73 22 718 20 702 55.5
(47.8 to 63.0)
2.9
(2.0 to 3.9)
3.8
(3.3 to 4.2)
CT
pELISA
75 89 31 709 29 693 45.7
(38.2 to 55.3)
4.1
(3.0 to 5.4)
3.0
(2.6 to 3.4)
Narvanen268 CT-EIA 69 13 150 2 84.2
(75.5 to 91.2)
1.3
(0.2 to 3.6)
6.3
(4.8 to 8.2)
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
The analysis of the Morre study assumes that ‘grey‘ samples were equally likely to be TPs or TNs. The analysis of the
Wills et al.269 study assumes that 18 paediatric samples that were either included (a) or excluded (b) from the calculation of
FP rate were equally likely to be TPs or TNs.
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Appendix 17 WinBUGS code applied to
serology data
model {
# cycles through the different combinations of input parameters
for (a in 1:numcombs) { 
for (i in 1:17) {
for (g in 1:2) {
r[i,a,g] ~ dbin(p[g,a,i],n[i,a,g])
rhat[i,a,g] <- p[g,a,i]*n[i,a,g]
dev[i,a,g] <- 2 * (r[i,a,g] * (log(r[i,a,g])-log(rhat[i,a,g])) +
(n[i,a,g]-r[i,a,g]) * (log(n[i,a,g]-r[i,a,g]) -
log(n[i,a,g]-rhat[i,a,g])))
}
sumdev1[i,a] <- sum(dev[i,a,])
p[1,a,i] <- pi[1,a] * se[i,a] + (1-pi[1,a]) * fp[i,a] 
p[2,a,i] <- pi[3,a]*sec[i,a] + pi[2,a] * se[i,a] + pi[4,a] * 
fp[i,a]
logit(se[i,a]) <- lse[i,a]
logit(sec[i,a]) <- lse[i,a] + dse[a]
lse[i,a] ~ dnorm(0,.01)
lfp[i,a] <- lse[i,a] - res[test[i],a]
logit(fp[i,a]) <- lfp[i,a]
}
for (j in 1:5) {
res[j,a] ~ dnorm(mean[a],prec[a])I(0,)
}
z[a] ~ dbeta(1,1)
x[a] ~ dbeta(1,1)
# Ever exposed in control group
pi[1,a] <- ctprev[a]
# Ever exposed in Non CT caused TFI
pi[2,a] <- (1 - pi[3,a]) * (pi[1,a] + z[a] * (1 - pi[1,a]))
# Proportion of TFI caused by C
pi[3,a] <- x[a]
# the negatices in the tfi group
pi[4,a] <- (1 - pi[3,a]) * ((1 - z[a]) * (1 - pi[1,a]))
# sum check
pi[5,a] <- pi[2,a] + pi[3,a] + pi[4,a]
sumdev2[a] <- sum(sumdev1[,a])
}
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